Cancer theranostics: multifunctional gold nanoparticles for diagnostics and therapy by Conde, João Diogo Osório de Castro
 
 
Universidade Nova de Lisboa 
& 
Universidad de Zaragoza 
 
 
 
 
CANCER THERANOSTICS:  
MULTIFUNCTIONAL GOLD NANOPARTICLES 
FOR DIAGNOSTICS AND THERAPY 
 
 
João Diogo Osório de Castro Conde 
 
 
 
Doctorate in Biology 
 
Specialty in Biotechnology 
 
 
 
 
Lisbon 2013 
 
 
 
CANCER THERANOSTICS:  
MULTIFUNCTIONAL GOLD NANOPARTICLES 
FOR DIAGNOSTICS AND THERAPY 
 
 
João Diogo Osório de Castro Conde 
 
 
Thesis supervised by 
 
Prof. Pedro V. Baptista 
Prof. Jesus M. de la Fuente 
 
 
Doctorate in Biology 
Specialty in Biotechnology 
 
 
 
All the statements expressed in this document are the sole responsibility of its author.  
 
Todas as afirmações presentes no seguinte documento são da exclusiva responsabilidade do 
seu autor. 
 
 
 
 
 
 
 
COPYRIGHT 
 
Autorizo os direitos de copyright da presente tese de doutoramento, denominada “Cancer 
Theranostics: multifunctional gold nanoparticles for diagnostics and therapy”. 
 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, 
perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de 
exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio 
conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e 
de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não 
comerciais, desde que seja dado crédito ao autor e editor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Para as minhas princesas, 
Catarina e Ritinha  
Todo o meu Amor! 
 
 
 
 
 
 
i 
 
TABLE OF CONTENTS 
 
Acknowledgements ............................................................................................................ ..... ii 
Preface ............................................................................................................................. ........ iv 
Publications published during the PhD Grant .................................................................. ... v 
Sumário ................................................................................................................................. viii 
Abstract .................................................................................................................................... x 
Symbols and notations ....................................................................................................... ... xii 
 Introduction .….………...................................................................................................... 1 
1. General considerations on Gold Nanoparticles………………………………….... 2 
1.1.Gold Nanoparticle synthesis …………………………………………………….6 
1.2.Stabilization against aggregation ………………………………………………. 6 
1.3.Biological applications ….………………………………………………………8 
2. NanoDiagnostics …………………………………………………………………... 10 
2.1.Nanocarriers in Cancer diagnosis …………………………………………….. 12 
3. NanoTherapy ……………………………………………………………………… 13 
3.1.Tumour targeting ……………………………………………………………... 14 
3.2.Gene therapy ………………………………………………………………….. 15 
4. NanoToxicity ……………………………………………………………………… 17 
References ………………………………………………………………………………19 
5. Review articles and book chapter……………………………………………….... 24 
6. General objectives…………………………………………………………………129 
 
 Gold Nanoparticles as Nanosensors for Diagnostic …................................................. 131 
Overview .............................................................................................................................. 132 
Articles ................................................................................................................................. 133 
 
 Gold nanoparticles as Nanovectors for Therapy ......................................................... 169 
Overview .............................................................................................................................. 170 
Articles ................................................................................................................................. 173 
 
 Gold nanoparticles for Theranostics …………............................................................ 266 
Overview .............................................................................................................................. 267 
Articles ................................................................................................................................. 269 
 
 Final Conclusions ……………………………………………………………………… 355 
ii 
 
ACKNOWLEDGEMENTS 
 
“Fortune favours the audacious” – Desiderius Erasmus 
 
This project has required the input from many people to acquire some of the “amazing” 
results we could achieved. Although the following words will never be enough to express all 
my appreciation to them, I would like here to present my admiration for all their support 
during this long passage. Hence, I would like to thanks: 
 
My supervisor, Professor Pedro V. Baptista for giving me the opportunity to be a member 
of his working group. I would like to thanks for his never ending, dedicated and thoughtful 
scientific and personal input during my work. I owe him immensely. For his help, guidance, 
proof reading and scientific contributions with all publications, oral presentations and of 
course this doctoral thesis. 
 
My co-supervisor, Professor Jesus M. de la Fuente, I am especially thankful for his 
guidance and magnanimity that allowed me to work independently.  I would like to thanks for 
his support. I always enjoyed his commitment to achieve and foster a great working 
experience at his chair.  
 
Professor João C. Lima for the numerous enthusiastic and successful scientific discussions. 
You are a great scientist. I want to be like you, someday! 
 
Vanesa Sanz for all the things that I learned from you... and all the funny moments in the lab. 
 
My Thesis Committee members, Prof. Jorge Gaspar (Faculdade de Ciências Médicas) and 
Prof. Ricardo Franco (REQUIMTE) for taking some time in evaluating my progress. 
 
I would like to thanks Fundação para a Ciência e Tecnologia, for the financial support 
(SFRH/BD/62957/2009) provided to conduct this thesis and for the projects where I 
participate: Sensitive and selective detection of DNA/RNA based on functionalised gold 
nanoparticles - application to pathogen detection; mutation detection and RNA quantification 
- PTDC/BIO/66514/2006 ; NANOLIGHT - Nanosystems for delivery of caged compounds - 
iii 
 
PTDC/QUI-QUI/112597/2009; and Silence is golden (siAu) - Silencing the silencers via 
multifunctional gold nanoconjugates towards cancer therapy - PTDC/BBB-NAN/1812/2012. 
 
The members of the lab 315 for the great time in the lab. I believe I have every reason to 
convey my appreciation to all of you for the cooperation I have received from each and every 
one of you individually. 
 
A special thanks to a colleague and friend, Leticia Giestas. I will always remember the talks 
on our joys and sorrows about the lab. Your support and judgment always kept me “in line”. 
Thank you for everything. 
 
A todos os meus Amigos por estarem sempre lá…. Porque sempre me guiaram, porque 
sempre me apoiaram, porque sempre me fizeram sorrir… 
 
Um agradecimento muito especial aos meus Pais, porque sempre acreditaram que seria 
possível… porque sempre acreditaram em mim. Pelo apoio incondicional nos melhores e nos 
piores momentos, especialmente quando achamos que não somos capazes. Muito obrigado. 
Sem vocês nada teria sido possível. 
 
Por ultimo, não tenho palavras para descrever a gratidão e orgulho que tenho pela minha 
mulher, Catarina. Muito obrigado por todo o amor e carinho. Por todo o apoio e 
compreensão mesmo quando roubava um pouco do nosso tempo. Obrigado por fazeres de 
mim um homem melhor… uma pessoa melhor. E um obrigado do tamanho do mundo à nossa 
princesinha linda, Ritinha, que veio unir-nos ainda mais. Amo-vos muito…. 
 
 
 
 
 
 
iv 
 
Preface 
 
This Thesis compiles the work done during my doctoral studies that I started after invitation 
by Prof. Pedro V. Baptista for a PhD position at the Research Centre for Human Molecular 
Genetics, Dept. of Life Sciences at Science and Technology Faculty, New University of 
Lisbon. In 2010, I was awarded with a PhD Grant funded by the Portuguese Foundation for 
Science and Technology under the topic “Cancer Theranostics − Multifunctional gold 
nanoparticles for diagnostics and therapy” (part of the European project NanoScieE+ - 
NANOTRUCK). Prof. Pedro V. Baptista is an Associate Professor of Molecular Genetics & 
Nanomedicine at Dept. of Life Sciences, Science and Technology Faculty, New University of 
Lisbon.  
From June 2010 to March 2011, the fellow carried out a part of the PhD Project at the 
Biofunctional Nanoparticles and Surfaces Group, IUI of Nanoscience of Aragon (INA), 
Zaragoza, Spain, under supervision of Prof. J.M. de la Fuente. Prof. J.M. de la Fuente 
established a multidisciplinary Nanotherapy and Nanodiagnostics Group at IUI of 
Nanoscience of Aragon, University of Zaragoza (Spain) after receiving an ERC Starting 
Grant.  
The NANOTRUCK project intends to develop an innovative kind of multifunctional gold 
nanoparticles loaded with fluorescent, tumoral markers, cell penetrating peptides and RNAi 
complementary to the proto-oncogene c-Myc for cancer diagnosis and treatment. The fellow 
worked on the synthesis and functionalization of the multifunctional gold nanoparticles and 
on the in vitro studies for the silencing of c-Myc gene in human cells. From this work, he has 
broadened his experience in techniques in the molecular genetics field such as the cloning of 
constructs for applications in gene therapy and techniques related with the small interfering 
RNA approach for gene silencing. This project implies the collaboration with different groups 
in Europe with expertise in different subfields: Centre for Cell Engineering (University of 
Glasgow, UK), Instituto di Cibernetica “E. Caianiello” (Pozzuoli, Italy), Helmholtz Zentrum 
München (München, Germany), Science and Technology Faculty, New University of Lisbon 
(Lisbon, Portugal) and IUI of Nanoscience of Aragon at the University of Zaragoza 
(Zaragoza, Spain). Thanks to these collaborations, the interaction between nanoparticles and 
biological systems, ranging from in vitro cultured human cells to in vivo animal models 
(primitive Hydra and complex vertebrate mouse) were studied. From this work, the fellow 
acquired experience in the diagnostics and therapy fields, as can be seen from his publications 
on the development of nanosystems for the combined diagnostics/therapeutics (theranostics) 
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involving DNA/RNA detection with strong impact in genetic diagnostics and for gene 
delivery and silencing systems of relevance for therapy strategies, with particular focus on 
enabling the development of safer, more efficient, and specific platforms to human disease.  
During the PhD the fellow has acquired experience in molecular biology techniques useful for 
the biomedical applications of nanoparticles (Human Cell culture, Microbiology, Confocal 
Microscopy, Electrophoresis, Real-Time PCR, etc), and skills useful in the development of 
applications of nanoparticles in gene therapy (plasmid DNA cloning, Antisense and RNA 
interference methodologies, work with reporter vectors such as EGFP and luciferase gene 
expression) and different techniques for nanoparticle characterization (Atomic Force 
Microscopy, Scanning Electron Microscopy, Transmission Electron Microscopy, Light-
Scattering microscopy, Fluorescence, UV-VIS molecular absorption, etc). With a strong 
background in nanodiagnostics, nanotherapy and nanotoxicology fields, as can be seen from 
publications on the development of nanosystems (with ssDNA/ssRNA, siRNA, antibodies, 
peptides, tumoral markers, polymers and fluorescent dyes) for the combined 
diagnostics/therapeutics (theranostics) systems. These platforms involves DNA/RNA 
detection with strong impact in genetic diagnostics and in gene delivery/silencing and tumour 
targeting systems, with particular focus on enabling the development of safer, more efficient, 
and specific methods to human disease. 
 
Overall, my doctoral studies have resulted in the following peer-reviewed publications with 
more than 200 citations: 
 
1. “Gold Nanoparticle-mediated oncogene knockdown in human cancer cells: From cell 
proliferation to cell-cycle and apoptosis.” H.W. Child, Y. Hernandez, João Conde, 
P.V. Baptista, J.M. de la Fuente, C.C. Berry. (Submitted) 
 
2. “Multifunctional Gold Nanocarriers for Cancer Theranostics – From bench to bedside 
and back again?” João Conde*, F. Tian, P.V. Baptista and J.M. de la Fuente 
(Accepted, Invited Book Chapter) (* Corresponding-author). 
 
3. “In vivo tumour targeting via nanoparticle-mediated therapeutic siRNA coupled to 
inflammatory response in lung cancer mouse models.” João Conde*, F. Tian*, Y. 
Hernández, C. Bao, D. Cui, K.P. Janssene, M.R. Ibarra, P.V. Baptista, T. Stoëger and 
J.M. de la Fuente. (* Co-first authors). Biomaterials (2013), Vol. 34, pp. 7744–7753. 
Research article (IF=7.604) 
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4. “A Gold-nanobeacon system for Gene therapy: evaluation of Genotoxicity, Cell 
toxicity and Proteome profiling analysis” João Conde, M. Larguinho, A. Cordeiro, 
L.R. Raposo, P.M. Costa, S. Santos, M.S. Diniz, A.R. Fernandes and P.V. Baptista. 
Nanotoxicology (2013). Research article (IF=7.844) 
 
5. “Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking 
of the silencing events.” João Conde, J. Rosa, J.M. de la Fuente and P.V. Baptista. 
Biomaterials (2013), Vol. 34, pp. 2516–2523. Research article (IF=7.604) 
 
6. “Design of Multifunctional Gold Nanoparticles for In vitro and In vivo Gene 
Silencing.” João Conde*, A. Ambrosone*, V. Sanz, Y. Hernández, V. Marchesano, F. 
Tian, H. Child, C.C. Berry, M.R. Ibarra, P.V. Baptista, C. Tortiglione and J.M. de la 
Fuente. (* Co-first authors). ACS Nano (2012), Vol. 6, pp. 8316–8324. Research 
article (IF=12.062) 
 
7. “RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of 
Several Different mRNA Targets Using Colour Multiplexing and Application to 
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Nanoparticles in Biology and Medicine: Methods and Protocols Series. Methods in 
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8. “Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on Gold 
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SUMÁRIO 
 
O uso de nanopartículas de ouro tem ganho terreno em diagnóstico molecular, devido às suas 
propriedades físico-químicas únicas, apresentando inúmeras vantagens, tais como aumento da 
sensibilidade e especificidade, e do potencial para caracterizar sistemas “single molecule”. 
Devido à sua versatilidade, bem como fácil síntese e funcionalização, nanopartículas de ouro 
multifuncionais têm, também, sido propostas como sistemas ideais de “delivery” para terapia 
(nanovectores). Ser capaz de produzir tais sistemas significa o início de uma nova era na área 
de teragnóstico (diagnóstico e terapia), impulsionada pela criação de veículos fantásticos à 
nanoescala. 
De facto, a Nanotecnologia tem a capacidade de explorar novos sistemas para teragnóstico em 
cancro, através do desenvolvimento de métodos de diagnóstico, tais como colorimetria e 
imunoensaios, e em abordagens terapêuticas por meio de terapia génica, “delivery” de 
fármacos e/ou no “targeting” de tumores. 
As características únicas das nanopartículas à nanoescala, tais como a elevada relação de 
superfície/volume ou as propriedades ópticas dependentes de tamanho e forma, que são 
radicalmente diferentes das dos seus materiais à macroescala, constituem as principais 
vantagens para a criação de sistemas utilizados em ensaios clínicos. 
Este projecto de doutoramento pretende optimizar a síntese e funcionalização de 
nanopartículas de ouro para a detecção de transcritos de oncogenes (c-Myc e BCR-ABL), 
podendo ser utilizado para a avaliação do perfil de expressão em células cancerígenas e, 
simultaneamente, o desenvolvimento de uma plataforma inovadora de nanopartículas de ouro 
multifuncionais, funcionalizadas com marcadores tumorais, péptidos de internalização celular, 
marcadores fluorescentes e siRNAs capazes de silenciar determinados genes, de forma a 
avaliar o nível de expressão e determinar a eficiência de silenciamento. Este trabalho é parte 
de uma colaboração entre o Centro de Investigação em Genética Molecular Humana, 
Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal e o Instituto de 
Nanociencia de Aragón, Espanha no âmbito de um projecto europeu [NanoScieE
+
 - 
NanoTruck]. 
Por forma a atingir este objetivo, desenvolveram-se estratégias eficazes de conjugação para 
combinar, de uma forma altamente controlada, biomoléculas à superfície de nanopartículas de 
ouro com funções específicas, tais como: oligos ssDNA para detectar sequências específicas e 
para a quantificação de RNA mensageiro; Polímeros biofuncionais: poli(etilenoglicol) (PEG) 
utilizados para aumentar a solubilidade e biocompatibilidade, conferindo também uma 
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funcionalidade química através da introdução de um grupo funcional; Péptidos de 
internalização celular (por exemplo, péptido TAT): usados para superar de forma mais 
eficiente a barreira lipofílica das membranas celulares, por forma a alcançar mais facilmente o 
citoplasma das células alvo; amónios quaternários: para introduzir cargas positivas na 
superfície das nanopartículas de ouro (para fazer ligar/adsorver os RNAs); e siRNA 
complementar a um proto-oncogene, c-Myc, implicado no crescimento celular, proliferação, 
perda de diferenciação e morte celular programada. 
A fim de estabelecer que estas nanopartículas são alternativas viáveis para os métodos 
disponíveis, estes sistemas inovadores foram extensivamente caracterizados na sua 
funcionalização química, nível de internalização celular, toxicidade celular e inflamação, e o 
“knockdown” da expressão da proteína MYC em várias linhagens celulares de cancro e em 
modelos in vivo. 
 
Palavras-chave: Nanomedicina, Terapia, Diagnóstico, Teragnóstico, Cancro, Nanopartículas 
de ouro.  
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ABSTRACT  
 
The use of gold nanoparticles (AuNPs) has been gaining momentum in molecular diagnostics 
due to their unique physico-chemical properties these systems present huge advantages, such 
as increased sensitivity, reduced cost and potential for single-molecule characterisation. 
Because of their versatility and easy of functionalisation, multifunctional AuNPs have also 
been proposed as optimal delivery systems for therapy (nanovectors). Being able to produce 
such systems would mean the dawn of a new age in theranostics (diagnostics and therapy) 
driven by nanotechnology vehicles. 
Nanotechnology can be exploit for cancer theranostics via the development of diagnostics 
systems such as colorimetric and imunoassays, and in therapy approaches through gene 
therapy, drug delivery and tumour targeting systems. 
The unique characteristics of nanoparticles in the nanometre range, such as high surface-to-
volume ratio or shape/size-dependent optical properties, are drastically different from those of 
their bulk materials and hold pledge in the clinical field for disease therapeutics 
This PhD project intends to optimise a gold-nanoparticle based technique for the detection of 
oncogenes’ transcripts (c-Myc and BCR-ABL) that can be used for the evaluation of the 
expression profile in cancer cells, while simultaneously developing an innovative platform of 
multifunctional gold nanoparticles (tumour markers, cell penetrating peptides, fluorescent 
dyes)  loaded with siRNA capable of silencing the selected proto-oncogenes, which can be 
used to evaluate the level of expression and determine the efficiency of silencing. This work 
is a part of an ongoing collaboration between Research Centre for Human Molecular 
Genetics, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal and 
Biofunctional Nanoparticles and Surfaces Group, Instituto de Nanociencia de Aragón, Spain 
within a European project [NanoScieE
+
 - NANOTRUCK]. 
In order to achieve this goal we developed effective conjugation strategies to combine, in a 
highly controlled way, biomolecules to the surface of AuNPs with specific functions such as: 
ssDNA oligos to detect specific sequences and for mRNA quantification; Biofunctional 
spacers: Poly(ethylene glycol) (PEG) spacers used to increase solubility and biocompatibility 
and confer chemical functionality; Cell penetrating peptides: to overcome the lipophilic 
barrier of the cellular membranes and deliver molecules into cells using TAT peptide to 
achieve cytoplasm and nucleus; Quaternary ammonium: to introduce stable positively charged 
in gold nanoparticles surface; and RNA interference: siRNA complementary to a master 
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regulator gene, the proto-oncogene c-Myc, that is implicated in cell growth, proliferation, loss 
of differentiation, and cell death. 
In order to establish that they are viable alternatives to the available methods, these innovative 
nanoparticles were extensively characterized on their chemical functionalization, ease of 
uptake, cellular toxicity and inflammation, and knockdown of MYC protein expression in 
several cancer cell lines and in in vivo models. 
 
Keywords: Nanomedicine, Therapy, Diagnostics, Theranostics, Cancer, Gold Nanoparticles.  
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SYMBOLS AND NOTATIONS 
 
AuNPs - gold nanoparticles 
cDNA - complementary DNA (DNA synthesized from mRNA template) 
CML - chronic myelogenous leukemia 
CPPs - Cell penetrating peptides 
DEPC - Diethylpyrocarbonate 
DLS - Dynamic Light Scattering 
DNA - Deoxyribonucleic Acid 
dNTPs - Deoxyribonucleotide Triphosphate 
dsDNA - double-stranded DNA 
DTNB - 5,5’-dithio-bis(2-nitrobenzoic) acid 
DTT - Dithiothreitol 
EDC - 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGFP - Enhanced Green Fluorescent Protein 
FRET - Förster’s or fluorescence resonance energy transfer  
GST - Glutathione 
LSPR - localized surface plasmon resonance 
MDR - multiple-drug resistance 
mRNA - Messenger RNA 
miRNA - micro RNA 
MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
NIR - near-infrared 
NPs - nanoparticles 
NHS - N-hydroxysuccinimide 
NTP - Ribonucleotide Triphosphate 
PBS - Phosphate Buffer Saline 
PCR - Polymerase Chain Reaction 
PEG - Poly(ethylene glycol)  
Prot - Protamine 
RGD Arginine-Glycine-Aspartic Acid (peptide) 
RNA - Ribonucleic Acid 
RNAi - RNA interference 
RISC - RNA-Induced Silencing Complex 
xiii 
 
RT-PCR - Reverse Transcriptase-Polymerase Chain Reaction 
SDS - Sodium Dodecyl Sulfate 
SEM - Scanning electron microscopy 
SERS - Surface-Enhanced Raman Scattering 
siRNA - Small interfering RNA 
ssDNA - Single-stranded DNA 
ssRNA - single-stranded RNA 
TAT - Transactivator of transcription (peptide) 
TEM - Transmission electron microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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1. GENERAL CONSIDERATIONS ON GOLD NANOPARTICLES 
Gold has been regarded as precious for as long as humans have existed, and has been 
associated with gods, kings and immortality. Already synthesized of gold at the times of 
Faraday, they generated ever-increasing interest since the ability to synthesize those particles 
in a controlled fashion way and their application in diverse nanosystems have come up in the 
last few decades [20;21]. Today, nanotechnology is enabling gold to help address critical 
global problems from cancer treatment to climate change. Although nanotechnology is 
thought of as a new branch of science that has only emerged over the past decade, gold 
nanoparticles (AuNPs) have been used, even though unintentionally, for several thousand 
years [1] (see Figure 1). 
Gold nanoparticles have gained increasing interest due to their special features, such as 
extraordinary optical and electronic properties, high stability and biological compatibility, 
controllable morphology and size dispersion and shapes (see Figure 2), and easy surface 
functionalization.  
 
 
Figure 1. (a) Golden burial mask of Egyptian Pharaoh Tutankhamun (King Tut) of the 18
th
 Dynasty 
(ca. 1323 BC). (b) A gold medal presented at the Games of the II Olympiad (Paris, France; 1900). 
While bulk gold is highly un-reactive and predominantly reflects light, nanoscale gold can be highly 
reactive, exhibiting pharmacologic properties and the ability to absorb, transfer, and convert light 
energy into heat. The mask in (a), discovered in 1922 by Howard Cater, consists of solid gold with 
inlaid glass and stone (21 cm high and ca. 11 kg). Prior to the 1900 Olympics in (b), athletes received 
only silver and copper medals which easily oxidize. The winged goddess Nike is shown on the front in 
(b); a victorious athlete holding a laurel branch is shown on the back with The Acropolis in the 
background [2]. 
2
 
Figure 2. Gold nanoparticles of various size and shape with potential applications in biomedicine. 
Small (a) and large (b) nanospheres, (c) nanorods, (d) sharpened nanorods, (e) nanoshells, (f) 
nanocages/frames, (g) hollow nanospheres, (h) tetrahedra/octahedra/ cubes/icosahedra, (i) rhombic 
dodecahedra, (j) octahedra, (k) concave nanocubes, (l) tetrahexahedra, (m) rhombic dodecahedra, (n) 
obtuse triangular bipyramids, (o) trisoctahedra, and (p) nanoprisms [2].  
 
The main characteristics include the electrical, chemical, and optical properties. The optical 
properties of AuNPs are significant because its adsorption and emission of the wavelength are 
within the visible range of light and because of their size- and shape-dependent properties [3]. 
Of particular interest is the light extinction process in the UV-visible range, which occurs 
when an electromagnetic wave passes through a metal particle exciting its electronic or 
3
vibrational states [4]. This phenomenon induces dipole moments that oscillate at the 
respective frequency of the incident wave, and therefore disperse secondary radiation in all 
directions. This collective oscillation of the free conduction electrons is called localized 
surface plasmon resonance (LSPR). Surface plasmons are collective charge oscillations that 
occur at the interface between conductors and dielectrics (Figure 3). The oscillation 
frequency is usually in the visible region giving rise to the strong surface plasmon resonance 
absorption [25-28]. They can take various forms, ranging from freely propagating electron 
density waves along metal surfaces to localized electron oscillations on metal nanoparticles 
(NPs) [4;5]. When light passes through a metal nanoparticle induces dipole moments that 
oscillate at the respective frequency of the incident wave, consequently dispersing secondary 
radiation in all directions. Light on NP induces the conduction electrons to oscillate 
collectively with a resonant frequency that depends on the nanoparticles’ size, shape, 
composition, inter-particle distance and environment (dielectric properties) [30-32;58]. As a 
result of these SPR modes, the nanoparticles absorb and scatter light so intensely that single 
NPs are easily observed by eye using dark-field (optical scattering) microscopy. 
 
Figure 3. Localized surface plasmon resonance. Schematic representation of how the interaction of 
the electromagnetic waves with the metal NPs surface electrons generates a surface plasmon 
resonance [4]. 
 
Size provides important control over many of the physical and chemical properties, including 
luminescence, conductivity, and catalytic activity. AuNPs give rise to both absorption and 
scattering whose proportions depend on the AuNP size, shell thickness, aspect ratio and 
percentage of gold [6] (see Figure 4). AuNPs with a diameter smaller than 20 nm essentially 
show absorption, but when the size increase to 80 nm also increases the ratio of scattering to 
absorption. As the size of the AuNP increases, light can no longer polarize the nanoparticles 
4
homogeneously, and higher order modes at lower energy dominate. This causes a red-shift 
and broadening of the surface plasmon band. Small AuNPs like the ones with 13 nm of 
diameter absorb green light, which corresponds to a strong absorption band at 520 nm in the 
visible light spectrum. However, solutions of AuNPs appear red in colour. For smaller AuNPs 
(i.e. 5 nm diameter), surface electrons are oscillated by the incoming light in a dipole mode, 
but the SPR it is very sensitive to the composition, size, shape, inter-particle distance and 
environment (dielectric properties) of the AuNPs [30-32]. For example, for citrate stabilised 
particles, the addition of NaCl shields the surface charge and leads to a concomitant decrease 
in the inter-particle distance and eventual particle aggregation [7]. For instance, 5 nm AuNPs 
are orange-red, but they turn blue-purple upon aggregation (network formation) to larger 
AuNPs. 
 
 
Figure 4. Gold nanoparticles commonly applied in biomedical applications. (a) Gold nanorods, (b) 
silica–gold core–shell nanoparticles, and (c) gold nanocages. The intense colour of these nanoparticles 
arises from the collective excitation of their conduction electrons, or surface plasmon resonance 
modes, which results in photon absorption at wavelengths which varies with (a) aspect ratio, (b) shell 
thickness, and/or (c) galvanic displacement by gold. 
 
This also explains the corresponding surface plasmon band shifts (red shift), which results in 
colour changes (red-to-purple) that are observed during the aggregation of small AuNPs. 
When AuNPs aggregate, their surface plasmons combine (interparticle plasmon coupling), 
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and the aggregate could be considered as a single large particle, although the detailed 
interparticle plasmon coupling is rather complex and dependent on many factors, such as 
aggregate morphology and nanoparticles density [31;32;34]. 
 
1.1. GOLD NANOPARTICLE SYNTHESIS  
Gold nanoparticles, also known as colloidal gold, is a suspension of sub-micrometre-sized 
gold metal particles in a fluid and can be obtained in sizes between 3 and 200 nm in diameter. 
As a colloidal particle is much larger than its constituent atoms, its typical shape mainly 
results from its surface energy, whose minimization decreases the surface area and favours the 
formation of spherical objects [8]. 
The most common methods for the synthesis of spherical gold colloidal particles involve the 
chemical reduction of Au ions.  
Since the pioneering work of Turkevich [9] and the modification by G. Frens [10], the most 
widely studied reductant is sodium citrate [37;38]. The method of citrate reduction of Au(III) 
to Au(0) in water is still used nowadays to subsequently replace the citrate ligand of these 
AuNPs by appropriate ligands of biological interest. 
In the citrate reduction method, sodium citrate reduces the gold cations in hydrogen 
tetrachloroaurate (HAuCl4). As the gold metal forms, anions coat the outside of the particles 
preventing them from forming larger particles.  The small gold nanoparticles that are formed 
stay in solution because their coatings are negatively charged and repel each other, preventing 
aggregation. By other words, the particles are stabilized by citrate ions bound to the surface of 
the nanoparticles, resulting in negatively charged particles that repel each other by 
electrostatic repulsion [11]. 
Recent modifications of the Turkevitch method have allowed better size distribution and size 
control within the 9–120 nm range [32;39;40]. It is now well known that, by varying the 
citrate/Au ratio, colloidal particles with diameters ranging from 10 to 150 nm may be 
generated. 
The synthesis of gold nanoparticles by reducing agents such as sodium borohydride [12], 
ascorbic acid in presence of cetyltrimethylammonium bromide (CTAB) [13], sugars (glucose, 
fructose and sucrose) [14] have also been reported. 
 
1.2. STABILIZATION AGAINST AGGREGATION 
In typical synthesis, AuNPs are produced by reduction of gold salts. Usually a stabilizing 
agent is also added to prevent the particles from aggregating. Because thiol groups bind to 
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gold surfaces with high affinity, most frequently thiol modified ligands are used as stabilizing 
agents which bind to the surface of the AuNPs by formation of Au-sulfur bonds [15]. 
Although AuNPs can be stabilized by a large variety of stabilizers (ligands, surfactants, 
polymers, dendrimers, biomolecules, etc.), [16] the most robust AuNPs were disclosed by 
Giersig and Mulvaney to be stabilized by thiolates using the strong Au–S bond between the 
soft acid Au and the soft thiolate base [17]. 
After synthesis, the stabilizing agents surrounding the AuNPs can be replaced by other 
molecules by ligand exchange reactions [18]. In addition, ligands can also be linked to the 
shell of stabilizing agents. One of the most common applications is the linkage of amino 
groups in biological molecules with carboxyl groups at the free ends of the stabilizing agents 
[19]. 
Functionalization of AuNPs makes it possible to adjust the surface properties and attach 
different kinds of molecules to the particles. This has encouraged the development of new 
forms and modifications of nanoparticles for biomedical, biological and treatment/diagnostic 
applications, as well as the use of these nanoparticles in self assembly paradigms using 
biomolecules such as DNA/RNA, oligonucleotides (i.e. siRNA, ssDNA), peptides and 
antibodies, fluorescent dyes, polymers, drugs, tumoral markers, PEGs, various enzymes and 
other proteins, that are easily attached to the nanoparticles’s surface (Figure 5). 
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Figure 5. Schematic representation of a multifunctional nanocarrier. These innovative NPs 
comprise nucleic acids such as RNA and DNA used for gene silencing approaches and in colorimetric 
assays, respectively. Aptamers and anticancer drug molecules are also used for delivery to the target 
tissue. Carbohydrates may be useful as sensitive colorimetric probes. PEG is used to improve 
solubility and decrease immunogenicity. Responsive nanocarriers can also trigger reaction upon 
external stimuli through the functionality of valuable tumor markers, peptides, carbohydrates, 
polymers and antibodies that can be used to improve nanocarrier circulation, effectiveness and 
selectivity. Multifunctional systems can also carry fluorescent dyes that are used as reporter molecules 
tethered to the particle surface and employed as tracking and/or contrast agents. 
 
1.3. BIOLOGICAL APPLICATIONS 
Nanoparticle-based delivery systems in Theranostics (Diagnostics & Therapy) provide better 
penetration of therapeutic and diagnostic substances within the body at a reduced risk in 
comparison to conventional therapies [49;50].  
Limitations in medical practice are closely associated with the fact that diagnostics, therapy 
and therapy guidance are three discrete and isolated stages. In order to overcome some of the 
sensitivity and specificity of current medicines, theranostics unites the three above stages in 
one single process, supporting early-stage diagnosis and treatment [51-53]. Nowadays, there 
is an ever-increasing need to enhance the capability of theranostics procedures where 
nanoparticle-based sensors may provide for the simultaneous detection of several gene-
associated conditions and nanodevices with the ability to monitor real-time drug action. 
The unique characteristics of nanoparticles in the nanometre range, such as high surface-to-
volume ratio or size-dependent optical and magnetic properties, are drastically different from 
those of their bulk materials and hold pledge in the clinical field for disease therapeutics 
[54;55]. 
In spite of these advantages, nanoparticles do have limitations. For example, their small size 
and large surface area can lead to particle-particle aggregation and may result in limited 
loading of functional components and burst release. 
In fact, only nanoparticles with the appropriate size (and surface chemistry) are not 
immediately recognized by our immune system and show increased circulation times. The 
size plays an important role to avoid clearance. Hydrophilic nanoparticles with an effective 
size in the range of 10 to 100 nm are small enough to slow down activation of the 
mononuclear phagocyte system and are big enough to avoid renal filtration [20]. 
However, nanoparticles with unique and broad-based optical properties, ease of synthesis and 
facile surface chemistry and functionalization, and appropriate size scale are generating much 
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eagerness in clinical diagnostics and therapy. The most common applications in which gold 
nanoparticles have been used so far are labelling, delivering, heating, sensing and detection 
[21] (Figure 6). 
 
 
Figure 6. Nanoparticles for Theranostics. Nanoparticles-based strategies can be used for biosensing 
using plasmonic nanosensors, such as metal nanoparticles functionalized with nucleic acid strand for 
colorimetric assays; Biobar-codes for protein detection or intense labels for immunoassays (1). Some 
nanoparticle systems can also be used for sensing by exploring a typical FRET system (2) or can be 
surrounded with Raman reporters (3) in order to provide in vivo detection (8), tumour targeting (4) and 
drug delivery (7). In fact, NPs symbolize an important class of materials with unique features suitable 
for biomedical imaging applications (8) such as increased sensitivity in detection and high quantum 
yields for fluorescence. Alternatively, NPs can survey near/far-field enhancing qualities that hold 
promise for a bounty of novel applications in optics and photonics. Engineered NPs can also act as 
phototherapeutic agents that can be attached to specific targets for selective gene silencing (5) or 
damage to cancer cells (6). 
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2. NANODIAGNOSTICS 
Nanodiagnostics can be defined as the use of nano-sized materials, devices or systems for 
diagnostics purposes. It is a burgeoning field as more and improved techniques are becoming 
available for clinical diagnostics with increased sensitivity at lower costs [3-6].  
The use of the colloidal gold colour change upon aggregation is the best characterized 
example for diagnostic systems using AuNPs.  In fact, AuNPs functionalized with ssDNA 
capable of specifically hybridizing to a complementary target for the detection of specific 
nucleic acid sequences in biological samples have been extensively used [3;5;61;63-
68;70;71].   
Other approaches are the use of AuNPs as a core/seed that can be tailored with a wide variety 
of surface functionalities to provide highly selective nanoprobes for diagnosis [22]; the 
utilization of Surface Plasmon resonance (SPR) scattering imaging or SPR absorption 
spectroscopy generated from antibody conjugated AuNPs in molecular biosensor techniques 
for the diagnosis and investigation of oral epithelial living cancer cells in vivo and in vitro 
[211]; the use of multifunctional AuNPs which incorporate both cytosolic delivery and 
targeting moieties on the same particle functioning  as intracellular sensors to monitoring 
actin rearrangement in live fibroblasts [23]; and the employment of AuNPs in electrochemical 
based methods that can be coupled with metal deposition for signal enhancement [24]. 
Consequently, the use of thiol-linked ssDNA-modified gold nanoparticles (herein designated 
Au-nanoprobes) for the colorimetric detection of gene targets represents an inexpensive and 
easy to perform alternative to fluorescence or radioactivity-based assays [25]. In 1996, Mirkin 
et al. [26] described the use of a cross-linking method that relies on the detection of single-
stranded oligonucleotide targets using two different Au-nanoprobes, each of them 
functionalized with a DNA-oligonucleotide complementary to one half of the given target 
[60;71].  
On the other hand, in 2005 Baptista et al. introduced a non-cross linking method where thiol-
linked DNA-gold nanoparticles were used in a novel colorimetric method to detect the 
presence of specific mRNA from a total RNA extract of yeast cells [27]. The method consists 
in visual and/or spectrophotometric comparison of solutions before and after salt induced Au-
nanoprobe aggregation (see Figure 7) – the presence of a complementary target prevents 
aggregation and the solution remains red and has a strong absorbance at ±520 nm; non-
complementary/mismatched targets do not prevent Au-nanoprobe aggregation, resulting in a 
visible change of colour from red to blue and therefore a shift in the surface plasmon 
absorbance to 600-650 nm. This method has been successfully applied to detect eukaryotic 
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gene expression without retro-transcription or PCR amplification steps [4;7]; to distinguish 
fully complementary from mismatched sequences, with a single base mismatch i.e. to detect 
common mutations within the β-globin gene [28]; and in a fast and straightforward assay for 
Mycobacterium tuberculosis DNA detection in clinical samples [6;62]. 
 
 
Figure 7. RNA detection using DNA-gold nanoparticles. Detection and quantification of the mRNA 
using DNA thiol-modified gold nanoparticles. The assay is based on the increased stability of the Au-
nanoprobes upon hybridization with the complementary target in solution, while non-hybridized Au-
nanoprobes easily aggregate once the solution’s ionic strength is increased. This method can be 
successfully applied to detect eukaryotic gene expression without retro-transcription or PCR 
amplification steps. Positive: sample in the presence of complementary target (solution remains red); 
Negative: sample in the presence of non-complementary target (solution turns blue). 
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To further improve the detection flexibility, simplicity and efficiency, and reduce the cost, 
advance molecular diagnosis assay that utilizes gold nanoparticles derivatized with thiol 
modified oligonucleotides is the most simple, rapid and with a great efficiency nanodiagnostic 
system.  
NP-based biosensors provide a new horizon for novel functions with a variety of applications 
in clinical diagnostics and biological research. Gold NPs have already proven to be one of the 
most important groups of nanomaterials for biosensing approaches. Highly sensitive and 
specific biosensors based on AuNPs have open up the possibility of creating new diagnostic 
platforms for disease markers, biological and infectious agents in the early-stage detection of 
disease and threats, especially in cancer. [143;213]  
 
2.1. NANOCARRIERS IN CANCER DIAGNOSIS  
Cancer is the one of first leading causes of mortality in the modern world, with more than 10 
million new cases every year [29]. However, advances in diagnosis and treating this disease 
that kills millions of people each year worldwide, have not been as effective as for other 
chronic diseases, and only for some types of cancer there are effective methods of detection 
[30]. Thus, the main challenge is to find new and more effective diagnostic agents for the 
monitorization of predictive cell molecular changes that are involved in tumour development. 
The key to the efficient and ultimately triumphant treatment of cancer is early and accurate 
diagnosis [31]. 
It’s here that nanotechnology enters the fray in the technological leap of controlling materials 
at nanoscale by offering a “big revolution” in new medical and healthcare diagnostic systems 
[20]. In fact, nanotechnology combined with biology and medicine is the most advanced 
technology both from an academic point-of-view and for commercial applications, producing 
major advances in cancer diagnostics and bioengineering [22;217]. 
Nanotechnology can be exploit for cancer theranostics via the development of diagnostics 
systems such as colorimetric and imunoassays, and in therapy approaches through gene 
therapy, drug delivery and tumour targeting systems [32]. 
The unique characteristics of nanoparticles in the nanometre range, such as high surface-to-
volume ratio or size-dependent optical properties, are drastically different from those of their 
bulk materials and hold pledge in the clinical field for disease therapeutics [54;55].  
Molecular nanodiagnostics applied to cancer may provide rapid and sensitive detection of 
cancer related molecular alterations, which would enable early detection even when those 
alterations occur only in a small percentage of cells. When referring to cancer therapy, 
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targeting and localized delivery are of utmost importance to enhance the therapeutic effect 
and decrease undesirable distribution to healthy organs and tissues. Multifunctional gold 
nanocarriers may potentiate the development of individualized cancer therapy based on the 
individual’s biological information within the tumour (biomolecular profiling). Gold 
nanocarriers can be modified with multiple cell-targeting and membrane translocating 
peptides, loaded with DNA/RNA and used as nanovectors [12;13]. 
A great effort has been applied to the detection of microorganisms and/or virus using gold 
SPR biosensors but very few were used for the detection of chronic diseases, such as asthma, 
Alzheimer's disease, diabetes, epilepsy, heart disease and specially cancer. Actually, 
molecular nanodiagnostics applied to cancer may provide rapid and sensitive detection of 
cancer related molecular alterations, which would enable early detection even when those 
alterations occur only in a small percentage of cells. 
The high mortality rate in cancer is commonly attributed to the difficulties in detecting the 
disease at an early treatable stage. Therefore new synthesis, fabrication, and characterization 
methods are needed for developing highly advanced AuNPs capable of use in sensitive and 
multiple detection methods with negligible toxicity and high sensitivity. In the future, it might 
be possible to apply all AuNPs properties together and evolve new chemistry for synthesis of 
smart materials for diagnostic applications and clinical trials. 
 
3. NANOTHERAPY 
In medical term a therapeutic effect is a consequence of a medical treatment of any kind, the 
results of which are judged to be desirable and beneficial. Conventional therapy methods, for 
example in cancer, involve the employment of anticancer agents that do not greatly 
differentiate between cancerous and normal cells. Efficient in vivo targeting to heterogeneous 
population of cancer cells and tissue still requires better selectivity and non-cytotoxicity to 
surrounding normal cells. This fact leads to systemic toxicity, adverse effects and severe side 
effects [33].  
In another way, universally targeting cells within a tumour is not always feasible because 
some drugs cannot diffuse efficiently and the random nature of the approach makes it difficult 
to control the process and may induce multiple-drug resistance (MDR), a situation where 
chemotherapy treatments fail patients owing to resistance of cancer cells towards one or more 
drugs [34]. Consequently, nanotechnology could offer a less invasive alternative, enhancing 
the life expectancy and quality of life of the patient [35]. 
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At the moment, it is expected that the greatest gains in therapeutic selectivity will be achieved 
by synergistic combinations of several multicomponent targeting strategies. Currently, it is 
imperative to develop technology for targeting and delivery of multiple therapeutic agents, 
and for the simultaneous capability of avoiding biological and biophysical barriers. For 
example, nanoparticles can extravasate into the tumour stroma through the fenestrations of the 
angiogenic vasculature, demonstrating targeting by enhanced permeation and retention. These 
particles are able to carry multiple antibodies, which further target them to epitopes on cancer 
cells, and direct antitumor action, leading to cell death. Irradiation might be use to activate the 
nanoparticles and set up the release of their cytotoxic action [36]. 
 
3.1. TUMOR TARGETING 
It is expected that the greatest gains in therapeutic selectivity will be achieved by synergistic 
combinations of several multicomponent targeting strategies, i.e. capable of simultaneously 
target and deliver multiple therapeutic agents, while avoiding the organism’s biological and 
biophysiscal barriers. NPs targeting strategies to cancerous tissues have focused on passive 
and active targeting. In passive targeting, because numerous tumours present defective 
vasculature and poor lymphatic drainage due to the rapid growth of solid tumours, noble 
metal NPs can extravasate into the tumour stroma through the fenestrations of the angiogenic 
vasculature, demonstrating targeting by enhanced permeation and retention, thus 
accumulation at the tumour site [12;19;109]. Additionally, functionalization of the NP’s 
surface with hydrophilic molecules, such as PEG, can also greatly increase their solubility, 
help evading macrophage-mediated uptake and, thus, avoid removal from the systemic 
circulation and protect their carriers from enzymatic degradation when used in vivo [16]. For 
active targeting, NPs can be easily functionalized with a wide variety of biological moieties, 
such as antibodies, peptides and/or DNA/RNA to specifically target extracellular and 
intracellular receptors or pathways [16]. The use of NPs functionalized with multiple peptides 
or antibodies, such as monoclonal antibodies, have been described to successfully target 
specific cell surface proteins or receptors on cancer cells and further direct their antitumor 
action, leading to tumour cell death with minimal damage to collateral healthy cells [110-
113]. In nucleic-acid functionalized NPs, DNA and RNA macromolecules can be used to 
simultaneously target specific sequences and exert their genetic-based therapy [114;115]. 
To help tracking nanoparticles in vivo and enhance the imaging properties of such moieties, 
leading to more efficient control of their therapeutic properties, they can also be 
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functionalized with chemical moieties, such as Raman [116;117] or fluorescent [92;118] 
reporters.  
 
3.2. GENE THERAPY 
We are in the dawn of a new age in gene therapy driven by nanotechnology vehicles. 
Although there are technical challenges associated with the therapeutic application of 
nanoparticles, the integration of therapy with diagnostic profiling has accelerated the pace of 
discovery of new nanotechnology methods. The development of a safe, efficient, specific and 
nonpathogenic vehicle for gene delivery is highly attractive [17;18].  
Gene therapy is receiving increasing attention and, in particular, small-interference RNA 
(siRNA) shows significant potential in new molecular approaches to down-regulate specific 
gene expression in cancerous cells. In fact, this non-viral-vector-mediated delivery of 
therapeutic siRNAs is highly desirable and constitutes an important challenge to gene therapy 
[14-16].   
In fact, antisense DNA [119;120] and RNA interference (RNAi) via the use of small-
interfering RNA [121-124] have emerged as powerful and useful tools to block gene function 
and for sequence-specific posttranscriptional gene silencing, playing an important role in 
downregulation of specific gene expression in cancer cells.  
siRNAs are 21-23 nucleotide double strand nucleic acid molecules (dsRNA), with symmetric 
2-3 nt 3’ overhangs and 5’-phosphate and 3’-hydroxyl groups, that mediate the cleavage of 
complementary mRNA sequences and thus regulate gene expression [121;129;347;348].  
The RNA silencing pathway (Figure 8) begins with long dsRNA precursors that are 
processed to siRNA duplexes by the RNase-III-like enzyme Dicer. These short dsRNAs are 
subsequently unwound and assembled into an effector complex, RNA Induced Silencing 
Complex (RISC), which can direct RNA cleavage, mediate translational repression or induce 
chromatin modification. The antisense strand then binds to its complementary/target mRNA. 
The strand antisense to the targeted mRNA is often referred to as the guide strand, and its 
base-paired sense strand is known as the passenger strand, which is destroyed upon 
incorporation of the guide strand into RISC. The catalytic RISC recognizes mRNAs 
containing perfect or near-perfect complementary sequence to the guide siRNA and cleaves 
the mRNAs at a site precisely 10 nucleotides from the 5’-end of the guide strand. Finally, 
mRNA degradation is achieved by endo- and exonucleases, resulting in knockdown of the 
expression of the corresponding genes [349-351]. 
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Figure 8. The RNA interference pathway, defined as a gene silencing pathway that is triggered by 
double-stranded RNA (dsRNA). Gene silencing can be the result of nucleolytic degradation of the 
mRNA, or by translational suppression. 
 
siRNAs can be transfected into mammalian cells by a variety of methods [125-128] that 
influence the strength and duration of the silencing response, which in turn is affected by the 
amount of siRNA that is delivered and on the potential of each siRNA to suppress its target.  
Thus, one drawback of using naked siRNAs is that they show extremely short half-lives, weak 
protection against action by RNases, poor chemical stability, and common dissociation from 
vector [37]. In fact, the major obstacle to clinical application is the uncertainty about how to 
deliver therapeutic RNAs (e.g., miRNA and/or siRNA) with maximal therapeutic impact. 
Nanotechnology offers an unprecedented opportunity to overcome these problems, as 
nanoscale devices, due to their small size, can readily interact with biomolecules on both the 
surface of cells and inside of cells for longer periods of time [38]. AuNPs have shown 
potential as intracellular delivery vehicles for antisense oligonucleotides [39] and for 
therapeutic siRNA by providing protection against RNAses and ease of functionalization for 
selective targeting [114;115]. For example, Mirkin and coworkers showed that AuNPs 
attached to single-stranded oligodeoxynucleotides can be used for gene therapy, providing a 
highly efficient gene regulator in terms of high loading of the antisense DNA with no toxicity 
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at the concentrations studied [39]. They have also shown that polyvalent RNA-AuNP 
conjugates are readily taken up by cells and that the particle bound siRNA could effectively 
regulate genes in the context of RNA interference [40]. AuNPs modified with the hydrophilic 
PEG polymer, siRNAs and then coated with poly(β-aminoester)s have been shown to 
facilitate high levels of in vitro siRNA delivery and gene silencing in human cells [41]. Also, 
Braun et al. developed an Au-nanoshell functionalized with TAT-lipid layer for transfection 
and selective release of siRNA [42], where the TAT-lipid coating was used to efficiently 
mediate the cellular uptake of the nanoconjugates and the siRNA release was dependent on 
near-infrared (NIR) laser pulses. The authors demonstrated that this NIR strategy for siRNA 
release was proficient and time dependent. Several other studies using engineered NPs 
modified with siRNA have demonstrated a cytoplasmic delivery system of siRNA and 
efficient gene silencing using AuNPs [114;131;133;134]. However, almost all nanoconjugates 
using siRNA have exclusively been tested in cell cultures targeting only reporter genes. 
Further research into the fundamental mechanisms of gene therapy in vivo using nanodevices 
could unveil new dimensions of nanoparticle-mediated gene silencing that will have profound 
implications for understanding gene regulation, and which could also affect the development 
of functional genomics and therapeutic applications. 
 
4. NANOTOXICITY 
The AuNPs have a proclivity in vivo and in vitro to bioaccumulate within various types of 
cells with a special affinity for macrophage-type cells (both histiocytes and blood phagocytic 
cells), and reticuloendothelial cells throughout the body). They also produce varying degrees 
of bioaccumulation in such tissues as lymph nodes, bone marrow, spleen, adrenals, liver and 
kidneys [297-299].  
Research shows that nanoparticles can stimulate and/or suppress the immune responses, and 
that their compatibility with the immune system is largely determined by their surface 
chemistry. In fact, is well known the influence of size, solubility and surface modification on 
the biocompatibility of nanoparticles and their use in biological applications [43]. 
AuNPs are generally considered to be benign. However, the size similarity of AuNPs to 
biological matters could provide “camouflage” to cellular barriers, leading to undesired 
cellular entry which might be detrimental to normal cellular function [44]. 
Pan and colleagues recently conducted a systematic investigation of the size-dependent 
cytotoxicity of AuNPs against four cell lines [45]. They found that AuNPs 1 to 2 nm in size 
displayed cell-type dependent cyotoxicity with high micromolar IC50s. In contrast, AuNPs 15 
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nm in size were nontoxic to cells at concentrations 60-fold higher than the IC50 of the smaller 
AuNPs. These results seemed to confirm size dependent toxicity of AuNPs [277;303-306], an 
inference that has been somewhat ambivalent. 
Now the most imperative question rises up. Are the gold nanoparticles cytotoxic or 
biocompatible? And how can the gold nanoparticles be design to avoid these effects? 
There does not seem to have a simple answer. Even though there is not any general 
mechanism for making nanoparticles universally ‘non-toxic’ to all living cells and all 
organisms, there are important findings that can be applied for increasing nanoparticle 
biocompatibility and reducing cytotoxic interactions in vivo and in vitro.  
Using the lowest nanoparticle dose to get the desired response for the shortest period of time, 
in general, seems to promote biocompatibility as well as coating a nanoparticle if the outer 
coating completely covers the nanoparticle reactive surface (a non-continuous covering, the 
presence of cracks, roughness or interruptions could lead to complement or antibody 
attachment, or dissolution of the coating by cell digestion), and cannot be removed and 
utilized by the living cell [46].  
It is essential to test nanoparticle/biological interactions experimentally and modify the 
nanoparticles for best biocompatibility with the cell in order to eliminate membrane lipid 
peroxidation; reduce the generation of reactive oxygen species; prevent acute and chronic 
release of inflammatory factors (and ‘complement’ activation); guard against alterations in 
genetic cellular function; and reduce the possibility of nanoparticles becoming ‘stuck’ during 
filtration or passage through pores and fenestrations [308] due to size, inflexibility of the 
nanoparticle core, or protein adsorption and agglomeration [46]. 
When interpreting nanoparticle interactions with biological cells and organisms, it is 
important to remember that living systems may appear normal and be capable of growth and 
function, but they may be genetically altered in subtle ways following nanoparticle exposure, 
which can produce serious consequences at some time in the distant future. Conversely, other 
cells that seem to be damaged may, in time, recover from nanoparticle exposure and function 
normally in the absence of the nanoparticles [46].  
In conclusion, the only weapon that we have to insure that these new materials are well 
designed and safely used is to question and test each new nanoparticle to make sure that it has 
been designed for safety (with maximum biocompatibility) during handling, use and disposal.  
 
These concepts were extensively reviewed in the Review Articles A, B and C and Book 
Chapter A at the end of this Introduction section. 
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5. REVIEW ARTICLES AND BOOK CHAPTER 
 
In order to complement this introduction, we present three review articles and one book 
chapter on the application of noble metal nanoparticles in cancer diagnostics and therapy.  
 
Review Article A 
“Noble Metal Nanoparticles Applications in Cancer.” João Conde, G. Doria and P.V. 
Baptista. Journal of Drug Delivery (2012), Vol. 2012, pp. 1-12. Review article 
 
Book Chapter A 
“Multifunctional Gold Nanocarriers for Cancer Theranostics – From bench to bedside and 
back again?” João Conde, F. Tian, P.V. Baptista and J.M. de la Fuente (Submitted, Invited 
Book Chapter) 
 
Review Article B 
“Noble Metal Nanoparticles for Biosensing Applications.” G. Doria, João Conde, B. Veigas, 
L. Giestas, C. Almeida, M. Assunção, J. Rosa and P.V. Baptista. Sensors (Basel) (2012), Vol. 
12, pp. 1657-1687. Review article (IF= 1.953) 
 
Review Article C 
“Nanophotonics for Molecular Diagnostics and Therapy Applications.” João Conde, J. Rosa, 
J.C. Lima and P.V. Baptista. International Journal of Photoenergy (2012), Vol. 2012, pp. 
1-11. Review article (IF= 2.663) 
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Nanotechnology has prompted new and improved materials for biomedical applications with particular emphasis in therapy
and diagnostics. Special interest has been directed at providing enhanced molecular therapeutics for cancer, where conventional
approaches do not effectively differentiate between cancerous and normal cells; that is, they lack specificity. This normally
causes systemic toxicity and severe and adverse side effects with concomitant loss of quality of life. Because of their small size,
nanoparticles can readily interact with biomolecules both at surface and inside cells, yielding better signals and target specificity for
diagnostics and therapeutics. This way, a variety of nanoparticles with the possibility of diversified modification with biomolecules
have been investigated for biomedical applications including their use in highly sensitive imaging assays, thermal ablation, and
radiotherapy enhancement as well as drug and gene delivery and silencing. Here, we review the available noble metal nanoparticles
for cancer therapy, with particular focus on those already being translated into clinical settings.
1. Introduction
Cancer is one of the leading causes of mortality in the
modern world, with more than 10 million new cases every
year [1]. It is well established that cancer is a multifacto-
rial disease caused by a complex mixture of genetic and
environmental factors [2–4], where considerable advances
have led to a more comprehensive understanding of cancer
at the genetic, molecular, and cellular levels providing new
targets and strategies for therapy [5]. Nevertheless, these
advances have yet to be effectively translated into functioning
diagnostics and therapy. For example, the effectiveness of
many anticancer drugs is limited due to the inability to reach
the target site in sufficient concentrations and efficiently
exert the pharmacological effect without causing irreversible
unwanted injury to healthy tissues and cells [6, 7].
The technological leap of controlling materials at nano-
scale provides for a “big revolution” in medical and health-
care treatments and therapies [8, 9]. Nanotechnology offers
a wealth of tools to diagnose and treat cancer—new imaging
agents, multifunctional, targeted devices capable of bypass-
ing biological barriers to deliver therapeutic agents directly
to cells and tissues involved in cancer growth and metastasis,
monitor predictive molecular changes allowing preventive
action against precancerous cells, and minimizing costs and
side effects [5, 10, 11]. Nanotechnology-based therapies for
cancer with minimal side effects and high specificity are on
the surge, where the main challenge is to develop a system
for molecular therapy capable of circulating in the blood
stream undetected by the immune system and recognize
the desirable target, signaling it for effective drug delivery
or gene silencing with minimum collateral cell damage—
nanovectorization. As a result, personalized medicine could
become a reality in cancer patient management.
Nanoparticles (NPs), and noble metal NPs in particular,
are versatile agents with a variety of biomedical applications
including their use in highly sensitive diagnostic assays [12,
13], thermal ablation, and radiotherapy enhancement [14–
17], as well as drug and gene delivery [18–21]. Moreover,
noble metal NPs have been proposed as nontoxic carriers
for dru and gene-delivery applications [22–24]. Additionally,
the nanoparticle-based systems can provide simultaneous
diagnostic and therapy, that is, Theranostics, exploring
their unique properties for better penetration of therapeutic
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Figure 1: Noble metal NPs for cancer therapy. Once the tumor is directly connected to the main blood circulation system, NPs can exploit
several characteristics of the newly formed vasculature and efficiently target tumors. Tumor cells are supplied by blood capillaries that perfuse
the cells of the tissue where NPs can (i) passively accumulate or (ii) anchor through targeting moieties to biomarkers overexpress by tumor
cells. NPs can act simultaneously as therapeutic agents, inducing hyperthermia, enhancing radiotherapy, silencing genes, and/or delivering
drugs to induce tumor cell death, and as imaging enhancers or contrast agents, to help tracking the therapeutic effects in real time.
moieties and tracking within the body, allowing a more
efficient therapy with a reduced risk in comparison to
conventional therapies [25]—see Figure 1.
The unique characteristics of noble metal NPs, such
as high surface-to-volume ratio, broad optical properties,
ease of synthesis, and facile surface chemistry and func-
tionalization hold pledge in the clinical field for cancer
therapeutics [22, 26, 27]. Noble metal NPs (e.g., gold,
silver, or a combination of both) present highly tunable
optical properties, which can be easily tuned to desirable
wavelengths according to their shape (e.g., nanoparticles,
nanoshells, nanorods, etc.), size (e.g., 1 to 100 nm), and
composition (e.g., core/shell or alloy noble metals), enabling
their imaging and photothermal applications under native
tissue [28, 29]. These NPs can also be easily functionalized
with various moieties, such as antibodies, peptides, and/or
DNA/RNA to specifically target different cells [30] and with
biocompatible polymers (e.g., polyethylene glycol and PEG)
to prolong their in vivo circulation for drug and gene delivery
applications [23, 24]. Moreover, they can efficiently convert
light or radiofrequencies into heat, thus enabling thermal
ablation of targeted cancer cells [31, 32].
In this paper, we will focus on the application of noble
metal NPs for cancer therapy with particular emphasis on
their use in vivo and their potential to be translated into
clinical settings.
2. Therapy
In medical terms, a therapeutic effect is a consequence of
a medical treatment of any kind, the results of which are
judged to be desirable and beneficial [33]. Conventional
therapy methods in cancer involve the employment of agents
that do not greatly differentiate between cancerous and
normal cells, leading to systemic toxicity and adverse and
severe side effects [34]. Efficient in vivo targeting to hetero-
geneous population of cancer cells and tissue still requires
better selectivity and noncytotoxicity to surrounding healthy
cells. However, universally targeting cells within a tumor
is not always feasible, because some drugs cannot diffuse
efficiently and the random nature of the approach makes
it difficult to control the process and may induce multiple-
drug resistance—a situation where chemotherapy treatments
fail due to resistance of cancer cells towards one or more
drugs [7]. Making use of their extraordinary properties,
nanotechnology-based systems could offer a less-invasive
alternative, enhancing the life expectancy and quality of life
of the patient [35]. Among these, the potential therapeutic
application of noble metal NPs represents an attractive
platform for cancer therapy in a wide variety of targets and
clinical settings [36, 37].
2.1. Tumor Targeting. It is expected that the greatest gains
in therapeutic selectivity will be achieved by synergistic
combinations of several multicomponent targeting strate-
gies that is capable of simultaneously target and deliver
multiple therapeutic agents while avoiding the organism’s
biological and biophysical barriers. NPs targeting strategies
to cancerous tissues have focused on passive and active
targeting. In passive targeting, because numerous tumors
present defective vasculature and poor lymphatic drainage
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due to the rapid growth of solid tumors, noble metal NPs can
extravasate into the tumor stroma through the fenestrations
of the angiogenic vasculature, demonstrating targeting by
enhanced permeation and retention, thus accumulation at
the tumor site [6, 8, 38]. Additionally, functionalization
of the NP’s surface with hydrophilic molecules, such as
PEG, can also greatly increase their solubility, help evading
macrophage-mediated uptake and, thus, avoid removal from
the systemic circulation and protect their carriers from
enzymatic degradation when used in vivo [30]. For active
targeting, NPs can be easily functionalized with a wide
variety of biological moieties, such as antibodies, peptides,
and/or DNA/RNA to specifically target extracellular and
intracellular receptors or pathways [30]. The use of NPs
functionalized with multiple peptides or antibodies, such as
monoclonal antibodies, have been described to successfully
target specific cell surface proteins or receptors on cancer
cells and further direct their antitumor action, leading to
tumor cell death with minimal damage to collateral healthy
cells [36, 39–41]. In nucleic-acid functionalized NPs, DNA
and RNA macromolecules can be used to simultaneously tar-
get specific sequences and exert their genetic-based therapy
[42, 43].
To help tracking noble metal NPs in vivo and enhance
the imaging properties of such moieties, leading to more
efficient control of their therapeutic properties, they can also
be functionalized with chemical moieties, such as Raman
[44, 45] or fluorescent [46, 47] reporters.
2.2. Gene Silencing. Antisense DNA [48, 49] and RNA
interference (RNAi) via the use of small-interfering RNA
[50–53] have emerged as a powerful and useful tools to block
gene function and for sequence-specific posttranscriptional
gene silencing, playing an important role in downregulation
of specific gene expression in cancer cells.
Small interfering RNAs (siRNAs) can be transfected into
mammalian cells by a variety of methods that influence the
strength and duration of the silencing response, which in
turn is affected by the amount of siRNA that is delivered
and on the potential of each siRNA to suppress its target.
Thus, one drawback of using naked siRNAs is that they show
extremely short half-lives, weak protection against action by
RNases, poor chemical stability, and common dissociation
from vector [54]. In fact, the major obstacle to clinical appli-
cation is the uncertainty about how to deliver therapeutic
RNAs (e.g., miRNA and/or siRNA) with maximal therapeu-
tic impact. Nanotechnology offers an unprecedented oppor-
tunity to overcome these problems, as nanoscale devices, due
to their small size, can readily interact with biomolecules on
both the surface of cells and inside of cells for longer periods
of time [10]. Gold NPs (AuNPs) have shown potential as
intracellular delivery vehicles for antisense oligonucleotides
[55] and for therapeutic siRNA by providing protection
against RNAses and ease of functionalization for selective tar-
geting [42, 43]. For example, Mirkin and coworkers showed
that AuNPs attached to single-stranded oligodeoxynu-
cleotides can be used for gene therapy, providing a highly effi-
cient gene regulator in terms of high loading of the antisense
DNA with no toxicity at the concentrations studied [55].
They have also shown that polyvalent RNA-AuNP conjugates
are readily taken up by cells and that the particle bound
siRNA could effectively regulate genes in the context of RNA
interference [42]. AuNPs modified with the hydrophilic PEG
polymer, siRNAs and then coated with poly(β-aminoester)s
have been shown to facilitate high levels of in vitro siRNA
delivery and gene silencing in human cells [56]. Also, Braun
et al. developed an Au-nanoshell functionalized with TAT-
lipid layer for transfection and selective release of siRNA [57],
where the TAT-lipid coating was used to efficiently mediate
the cellular uptake of the nanoconjugates and the siRNA
release was dependent on near-infrared (NIR) laser pulses.
The authors demonstrated that this NIR strategy for siRNA
release was proficient and time dependent.
Several other studies using engineered NPs modified with
siRNA have demonstrated a cytoplasmic delivery system of
siRNA and efficient gene silencing using AuNPs [42, 56, 58–
60].
2.3. Hyperthermia. Hyperthermia is based on the effect
increasing temperatures have on living cells, and it is
commonly accepted that above 42◦C cell viability is strongly
reduced. In fact, hyperthermia effects can range from
moderate denaturation of blood and extracellular proteins
to induction of apoptosis and, above 50◦C, to cell death
and tissue ablation [61]. Hyperthermia therapy in cancer
has been widely used either via direct irradiation or suitable
temperature vectors, such as metal NPs [62]. In nanoparticle-
mediated hyperthermia for cancer, NPs heat up cancerous
cells beyond their temperature tolerance limits, which are
lower than normal healthy tissue due to their poor blood
supply, killing them selectively. This can be achieved by
exposing the entire patient or the targeted area to an
alternating current magnetic field, an intense light source
or radiofrequencies which will cause the NPs to heat up
and induce thermal ablation of the tumor. One of the
most widespread examples of hyperthermia mediated by
NPs, magnetic NPs have been introduced in the body
through magnetic delivery systems or local injection to the
affected area [63]. The first in vivo Phase II clinical trials
of magnetic NP hyperthermia were undertaken in Germany
in 2005 [64] by injecting the prostate of cancer patients
with biocompatible magnetite NPs. Successful results were
obtained using minimally invasive ablation of the tumor in
an AC magnetic field after several sessions.
Noble metal NPs have thoroughly been used as pho-
tothermal agents for in vivo therapy as a less invasive experi-
mental technique that holds great promise for the treatment
of cancer [65]. It combines two key components: (i) light
source, such as lasers with a spectral range of 650–900 nm
[66] for deep tissue penetration and (ii) optical absorbing
NPs which efficiently transforms the optical irradiation into
heat on a picosecond time scale, thus inducing photothermal
ablation [67, 68]. For example, Huang and coworkers
demonstrated that Au-nanorods are effective photothermal
agents due to their longitudinal absorption band in the NIR
on account of their SPR oscillations [65, 66, 69]. Small diam-
eter Au-nanorods are being used as photothermal converters
of near infrared radiation (NIR) for in vivo applications due
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to their high absorption cross-sections beyond the tissue
absorption spectra. Since NIR light transmits readily through
human skin and tissue, these nanorods can be used as
ablation components for cancer [70, 71]. Other gold nanos-
tructures such as Au-nanoshells [72–74], Au-nanocages
[67, 75, 76], and spherical AuNPs [77] have also demon-
strated effective photothermal destruction of cancer cells and
tissue. PEG-modified Au-nanoshells (Silica/Au core/shell
NPs) injected intravenously in tumor-bearing mice showed
to passively accumulate in the tumor tissue due to the
leakiness of the tumor vasculature. The rapid heating of Au-
nanoshells upon NIR laser irradiation allowed for effective
photothermal ablation of tumor in the mouse [78]. A similar
approach was used by Terentyuk et al., where plasmonic sil-
ica/gold nanoshells were used to produce a controllable laser
hyperthermia in tissues, thus enhancing the photothermal
effect in cancer cells [79]. Sirotkina et al. described the use of
AuNPs for skin tumor therapy based on local laser-inducing
hyperthermia. After intravenous injection, the AuNPs accu-
mulated in the skin tumor cells after 4-5 hours and induced
apoptotic death of tumor cells, completely inhibiting the
tumor growth after just five days of treatment [80].
The photothermal properties of AuNPs can also be used
to generate transient vapor nanobubbles in order to produce
a tunable nanoscale theranostic agent, described as plas-
monic nanobubbles [81]. These nanobubbles are generated
when the AuNPs are locally overheated with short laser
pulses, due to the evaporation of a very thin volume of
the surrounding medium, which in turn creates a vapor
nanobubble that expands and collapses within nanoseconds.
Plasmonic nanobubbles have been successfully applied as an
in vivo tunable theranostic cellular agent in zebrafish hosting
prostate cancer xenografts and in leukemia cells of human
bone marrow specimens, presenting higher therapeutic
selectivity when compared with AuNPs alone [82, 83]. The
use of noninvasive radiowaves at 13.56 MHz have also been
shown to induce heat in AuNPs and thermally destroy tumor
tissue [84]. In vivo rat exposures to 35 Watts using direct
AuNPs injections resulted in significant thermal injury at
subcutaneous injection sites. Radio waves have the advantage
of presenting significantly better penetration on tissue than
NIR light, making them more efficient for deeper solid
tumors [85]. Nonetheless, despite their greater depth of
penetration, there is also greater energy attenuation by tissue.
Gold-silver-(AuAg-) nanorods labeled with molecular
aptamers proved to require up to six orders of lower laser
power irradiation to induce cell death when compared to Au-
nanoshells or Au-nanorods [86]. These aptamer Scg8-AuAg-
nanorods conjugates presented excellent hyperthermia effi-
ciency and selectivity to CEM cells, exceeding the affinity of
the original aptamer probes alone. Bimetallic AuAg-nano-
structures with a dendrite morphology and hollow interior
have also been developed as photothermal absorbers to
destroy A549 lung cancer cells [87]. The photothermal per-
formance of such dendrites required lower NP concentra-
tions and laser power for efficient cancer cell damage when
compared to Au-nanorods photothermal therapeutic agents.
Likewise, Cheng and coworkers evaluated the photothermal
efficiencies of three Au-based nanomaterials (silica@Au-
nanoshells, hollow Au/Ag nanospheres and Au-nanorods) at
killing three types of malignant cells (A549 lung cancer cells,
HeLa cervix cancer cells, and TCC bladder cancer cells) using
a CW NIR laser [88]. Silica@Au-nanoshells needed the low-
est NP concentration for effective photo-ablation, whereas
hollow Au/Ag nanospheres and Au-nanorods needed incre-
asingly higher concentrations.
Gold has also been used together with magnetic or para-
magnetic materials to enhance the photothermal effect and,
thus, increase cancer cell death [89, 90].
2.4. Drug Delivery. The vast majority of clinically used drugs
for cancer are low molecular-weight compounds that diffuse
rapidly into healthy tissues being evenly distributed within
the body, exhibit a short half-life in the blood stream and a
high overall clearance rate. As a consequence, relatively small
amounts of the drug reach the target site, and distribution
into healthy tissues leads to severe side effects. Poor drug
delivery and residence at the target site leads to significant
complications, such as multidrug resistance [91]. As seen
above, nanoparticles can be used as vectors for targeting
cancer tissue/cells so as to optimize biodistribution of drugs.
The NPs’ performance as drug vectors depends on the size
and surface functionalities of the particles, drug release rate,
and particle disintegration. These systems show evidence of
enhanced delivery of unstable drugs, more targeted distribu-
tion and capability to evade/bypass biological barriers.
AuNPs have already been used as vehicles for the delivery
of anticancer drugs, such as paclitaxel- [92] or Platinum-
(Pt-) based drugs (e.g., cisplatin, oxaliplatin, etc.) [93, 94].
Gibson et al. described the first example of 2 nm AuNPs cova-
lently functionalized with the chemotherapeutic drug pacli-
taxel [92]. The administrations of hydrophobic drugs require
molecular encapsulation, and it is found that nanosized
particles are particularly efficient in evading the reticuloen-
dothelial system [95]. Gold-gold sulfide nanoshells covered
by a thermosensitive hydrogel matrix have been developed as
a photothermal modulated drug-delivery system [96]. These
nanoshell-composite hydrogels were designed to strongly
absorb NIR light and release multiple bursts of any soluble
material held within the hydrogel matrix in response to
repeated NIR irradiation. More recently, Yavuz and cowork-
ers developed a similar approach using 50-nm hollow Au-
nanocubes (nanocages) with eight lopped-off porous corners
covered by a thermosensitive polymer containing a preloaded
effector that can be later released in a controllable fashion
using an NIR laser [18].
2.5. Radiotherapy. Radiotherapy uses ionizing radiation for
cancer treatment to control the proliferation of malignant
cells. Nonetheless, the delivery of a lethal dose of radiation to
a tumor while sparing nearby healthy tissues remains the
greatest challenge in radiation therapy. Noble metal NPs
can act as antennas, providing enhanced radiation targeting
with lower radiation doses, consequently avoiding damage
to healthy tissues. The irradiation may also be used to acti-
vate the NPs and set up the release of their cytotoxic action.
AuNPs, upon X-ray irradiation, can act as dose enhancers
and/or generate radicals that damage cancer cells and induce
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Figure 2: Multifunctional NP-based systems for tumor targeting, delivery and imaging. These innovative NPs comprise nucleic acids,
aptamers and anticancer drug molecules for delivery to the target tissue. Depending on the targeting mechanism, they can be on the surface
or inside the NPs. Responsive NPs/molecules can also trigger reaction upon external stimuli through the functionality of valuable tumor
markers, peptides, polymers and antibodies that can used to improve NP circulation, effectiveness and selectivity. Multifunctional systems
can carry reporter molecules tethered to the particle surface and employed as tracking and/or contrast agents.
cell apoptosis and have been proposed as potential radiosen-
sitizers for X-ray cancer therapy [97]. The use of this strategy
has led to improvement in the treatment on cancer cells
with little or no increase in harm to normal surrounding
tissues in mice models [15] and also in breast cancer [98].
More recently, Xu and coworkers studied the potential effects
on radiation-induced killing of glioma cells mediated by
10, 20, and 40 nm AuNPs and 20, 50, and 100 nm silver
nanoparticles (AgNPs), all modified with proteins from fetal
bovine serum [99]. Treating glioma cells with AgNPs led
to radiation dose-dependent cytotoxicity, with smaller size
particles (20 and 50 nm) being the most cytotoxic at relatively
harmless radiation doses. In this study, AuNPs showed little
effect on cell survival across different doses of ionizing
radiation, which contrasted with the results of previous
studies performed with AuNPs coated with PEG or amino
acids in mice colorectal adenocarcinoma and breast cancer
cells [15, 98]. Hypothetically, the different coatings of the
AuNPs used may be responsible for the different outcomes
observed.
The use of platinum NPs (PtNPs) as prominent radiation
sensitizers in radiotherapy cancer treatment showed strong
enhancement of the biological efficiency of radiations, lead-
ing to amplified lethal damage in DNA from tumor cells,
when compared to metal atoms [37].
3. Imaging
Along with their therapeutic capabilities, most noble metal
NPs can be used for the simultaneous actuation and tracking
in vivo—see Figure 2. Because light absorption from biologic
tissue components is minimized at near infrared (NIR)
wavelengths, most noble metal NPs for in vivo imaging and
therapy have been designed to strongly absorb in the NIR
so as to be used as effective contrast agents [100]. However,
noble metal nanomaterials, such as NPs, nanoshells, nan-
oclusters, nanocages, and nanorods, have showed widespread
application as contrast agents for in vivo cancer imaging:
those presenting a significant absorbance and scattering in
the NIR region [46, 101] or surface-enhanced Raman scat-
tering (SERS) [102], or as contrast agents for computed
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tomography (CT) [103], magnetic resonance imaging (MRI)
[104], optical coherence tomography (OCT) [105–107], and
photoacoustic imaging (PAI) [108]. Moreover, most noble
metal nanomaterials are capable of combining multiple
imaging modalities that can yield complementary informa-
tion and offer synergistic advantages over any single imaging
technique [109, 110].
Three-dimensional imaging can be achieved by com-
puted tomography (CT), where a series of plane-cross-secti-
onal images along an axis are interlinked by computer to
create a 3D image. Typically, the cross-sectional images are
acquired using X-ray radiation involving larger radiation
doses than the conventional X-ray imaging procedures,
which could lead to increased risk to public health [111].
The use of ∼30 nm PEG-coated AuNPs for in vivo CT con-
trast agent was shown to increase image contrast, which
allows to reduce the radiation dosage needed, allow to
overcome the limitations of conventional contrast agents
(e.g., iodine-based compounds), such as short imaging times
due to rapid renal clearance, renal toxicity, and vascular
permeation [103]. Hybrid NPs with a super-paramagnetic
iron oxide/silica core and a gold nanoshell, with significant
absorbance and scattering in the NIR region, have been used
in vivo as dual contrast agents for CT and magnetic resonance
imaging (MRI) presenting high CT attenuation and a good
MR signal in hepatoma, compensating for the weakness of
each modality [112].
Optical coherence tomography (OCT) is an imaging
modality that provides cross-sectional subsurface imaging of
biological tissue with micrometer scale resolution. The extra
scattering achieved by using Au-nanoshells has been shown
to provide an enhanced optical contrast and brightness for
improved diagnostic imaging of tumors in mice due to the
preferential accumulation of the nanoshells in the tumor.
[78]. Tseng et al. developed nanorings with a localized
surface plasmon resonance covering a spectral range of
1300 nm that produced both photothermal and image
contrast enhancement effects in OCT when delivered into
pig adipose samples [113]. Moreover, the image contrast
enhancement effect could be isolated by continuously
scanning the sample with a lower scan frequency, allowing to
effectively control the therapeutic modality. Similarly, gold
capped nanoroses have been used in photothermal OCT to
detect macrophages in ex vivo rabbit arteries [114].
Photoacoustic imaging (PAI) and photoacoustic tomog-
raphy (PAT) are noninvasive imaging techniques capable of
resolving the optical absorption map of tissue at penetration
depths akin with ultrasound imaging. Wang and coworkers
have used this technique to image the distribution of Au-
nanoshells circulating in the vasculature of a rat brain by
achieving a gradual enhancement of the NIR optical absorp-
tion in the brain vessels [115]. These Au-nanocages enhanced
the contrast between blood and the surrounding tissues
by up to 81%, allowing a more detailed image of vascular
structures at greater depths. Additionally, these nanocages
were shown to be better suited for in vivo applications,
specially due to their more compact size (<50 nm compared
to >100 nm for Au-nanoshells) and larger optical absorption
cross sections when compared to Au-nanoshells. Gold-nano-
rods show the maximum of the plasmon resonance tuned
further into the NIR that allowed Motamedi et al. to develop
a contrast agent for a laser optoacoustic imaging system
for in vivo detection of gold nanorods and to enhance the
diagnostic power of optoacoustic imaging [116]. Song et al.
proposed a noninvasive in vivo spectroscopic photoacoustic
sentinel lymph node mapping using gold nanorods as lymph
node tracers in a rat model [117].
Also, noble metal NP probes can be used for in situ
diagnostics of cancer. For example, NP-based NIR probes can
overcome several limitations of conventional NIR organic
dyes, such as poor hydrophilicity and photostability, low
quantum yield and detection sensitivity, insufficient sta-
bility in biological systems, and weak multiplexing capa-
bility. Additionally, the high scattering properties of these
NPs can enhance contrast of imaging systems based on
microscopy, such as dark-field or dual-photon lumines-
cence microscopy. Zhang et al. developed fluorescent metal
nanoshells as molecular imaging agents to detect single
microRNA (miRNA) molecules in lung cancer cells [47].
These metal nanoshells were composed of silica spheres
with encapsulated Ru(bpy)3
2+ complexes as core and thin
silver layers as shell. The silver shell allowed to enhance
emission intensity up to 6-fold and photostability by 2-fold,
as well as to achieve longer lifetime emission signals that
overcome cellular autofluorescence interference. Loo et al.
demonstrated the use of NIR scattering Au-nanoshells as a
contrast agent in dark-field microscopy to target antihuman
epidermal growth factor receptor 2 (HER2), a clinically
significant breast cancer molecular marker [72]. These Au-
nanoshells were also used by Bickford et al. for imaging
live HER2-overexpressing cancer cells using two-photon
microscopy [118].
Surface-enhanced Raman scattering (SERS) using Au-
or AgNPs with an attached reporter species with a Raman
signature can be explored to highlight cellular structures
and provide molecular structural information on the cellular
environment in live cells [119, 120]. The use of such NPs
allows for higher spectral specificity, multiplex capabili-
ties, improved contrast and photostability to Raman-based
imaging techniques. In situ monitoring of photothermal
nanotherapy of LNCaP human prostate cancer cells by SERS
was a significant enhancement of the Raman signal intensity
by several orders of magnitude that have been observed [44].
4. Toxicity
Both in vivo and in vitro, nanoparticles have a tendency to
accumulate within various types of cells with special affinity
for macrophage-type cells (both histiocytes and blood
phagocytic cells) and reticuloendothelial cells throughout the
body. They also produce varying degrees of bioaccumulation
in such tissues as lymph nodes, bone marrow, spleen,
adrenals, liver, and kidneys [121–123]. The NPs size plays
an important role in avoiding immune activation and
renal clearance, thus enhancing their circulating time and
availability for effective therapy. For example, hydrophilic
NPs ranging in size between 10 and 100 nm are small enough
to slow down activation of the mononuclear phagocyte
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system but are big enough to avoid renal filtration [8].
Research shows that NPs can stimulate and/or suppress
the immune responses and that their compatibility with
the immune system is largely determined by their surface
chemistry. In fact, the influence of size, solubility, and surface
modification on the biocompatibility of NPs and their use in
biological applications is well known [122]. In terms of acute
toxic effects to cells, noble metal NPs have been shown to
induce DNA damage and oxidative damage [124–126].
Generally, AuNPs are considered to be benign, but the
size similarity to biological molecules could provide “cam-
ouflage” to cellular barriers, leading to undesired cellular
entry which might be detrimental to normal cellular function
[127]. A systematic investigation of the size-dependent
cytotoxicity of AuNPs against four cell lines found that 1
to 2 nm AuNPs displayed cell-type-dependent cytotoxicity
with high micromolar IC50s, whereas 15 nm AuNPs were
nontoxic to cells at concentrations 60-fold higher than the
IC50 of the smaller AuNPs [128]. These results seemed
to confirm size-dependent toxicity of AuNPs, an inference
that has hitherto been shown to be somewhat ambivalent
[129–134]. In fact, Yen et al. showed that AuNPs, especially
those of smaller sizes, dramatically led to a decrease in the
population of the macrophages and upregulated the expres-
sions of proinflammatory genes interlukin-1, interlukin-6,
and tumor necrosis factor alpha [135]. Sun et al. studied
the in vivo toxicity of AuNPs according to their shape in
KM mice showing that rod-shaped AuNPs were the most
toxic, followed by cube-shaped AuNPs, while sphere-shaped
AuNPs displayed the best biocompatibility, revealing that
toxicity is shape dependent. Moreover, this study revealed
that all AuNPs accumulated preferentially in the liver and
spleen organs [136]. Nonetheless, it is worth pointing out
that CTAB (a cationic surfactant commonly used for Au-
nanorods synthesis) was also recently pointed out as the
source of Au-nanorods’ cytotoxicity, which may explain their
toxicity in the previous studies [137].
Silver NPs are generally considered more toxic than
AuNPs, with several studies showing that cell exposure
to AgNPs induced significant cytotoxicity [138–141]. Con-
versely, Yen et al. determined a lower cytotoxicity of AgNPs
than that of the AuNPs and attributed this difference to
the surface charges between NPs, which can explain the
discrepancy with other studies related to AgNPs cytotoxicity
[135].
As for platinum, the cytotoxicity of 5–8 nm PtNPs capped
with polyvinyl alcohol (PVA) has been addressed in human
cells, where PtNPs were shown to enter the cells through dif-
fusion, leading to an increase in DNA damage, proliferating
cell nuclear antigen-mediated growth arrest and apoptosis
[126]. Asharani et al. performed a comparison between
toxicity of 3–10 nm Pt-, 5–35 nm Ag-, and 15–35 nm AuNPs
capped with PVA in developing zebrafish embryos, conclud-
ing that AgNPs were the most toxic, followed by PtNPs, while
AuNPs presented no indication of toxicity [142].
Even though we have focused our attention on the toxi-
city aspects of the different noble metal nanoparticles based
mainly on size and metal, attention should also be brought
upon other properties of the nanoconjugates, such as surface
chemistry, shape, and administration pathways. In fact,
surface chemistry (e.g., functionalization with biomolecules,
stabilizers, etc.) constitutes another interface of interaction
with the organism’s proteins and cells, which in term may be
associated with unspecific adsorption or specific recognition
by the immune system, thus contributing to the overall
effects of the use of the nanoparticles. The interaction with
the immune system contributes not only for the specificity
of the targeting (passive and/or active), but also towards
the toxicological effect of nanoconjugates (see [122] and
references therein).
5. Conclusions
Nanotechnology has provided for novel and powerful sys-
tems that may be used treatment and diagnostic of cancer. In
vivo demonstrations of noble metal NPs as theranostic agents
are now emerging and serve as important milestones towards
clinical application. Nonetheless, the majority of products,
reagents and drugs being used for the development of these
nanoscale theranostic agents have still to be approved by the
main supervising agencies, such as the FDA and EMA. Thus
far, there are some questions whose answers still provide
no clear understanding about the design and application
of NPs, such as pharmacokinetics, biodistribution and side
effects of the nanotherapy, and safety profile of NPs before
and after conjugation and toxicity [10]. Are noble metal
NPs cytotoxic or biocompatible? And how can the NPs be
design to avoid these effects? These seem to question more
difficult to answer than previously believed. Most therapeutic
and imaging approaches based on noble metal NPs rely
on AuNPs, mostly due to their higher level of nontoxicity.
Nonetheless, a more comprehensive application of core/shell
or alloy noble metal NPs, that may allow combination of
the benefits of each noble metal into a single carrier, is still
to be thoroughly addressed. Even though there is not any
general mechanism for making NPs universally “nontoxic”
to all living cells and all organisms, there are important
findings that can be applied for increasing nanoparticle
biocompatibility and reducing cytotoxic interactions in vivo
and in vitro. In general, using the lowest NP dose to
get the desired response for the shortest period of time
seems to promote biocompatibility. The coating/capping
of a nanoparticle is also of the utmost relevance, since a
noncontinuous covering, the presence of cracks, roughness,
or interruptions could lead to complement or antibody
attachment, or dissolution of the coating by cell digestion,
decreasing bioavailability at target cell [143]. It is essential to
test nanoparticle/biological interactions experimentally and
modify the NPs for best biocompatibility with the cell in
order to eliminate damage to healthy tissue, guarding against
alterations in genetic/molecular function while killing the
abnormal cells. When interpreting NPs interactions with
biological cells and organisms, it is important to remember
that living systems may appear normal and be capable of
growth and function, but they may be genetically altered
in subtle ways following NP exposure, which can produce
serious consequences at some time in the distant future, such
as cancer itself.
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Noble metal nanoparticles have shown to be powerful
tools against cancer though still in need of further optimiza-
tion and characterization for full understanding of their
whole potential. It is now time to start translating these pro-
mising platforms to the clinical settings towards widespread
effective therapy strategies in the fight against cancer.
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Abstract 
After a quarter of century of rapid technological advances, research has revealed the complexity of 
cancer, a disease intimately related to the dynamic transformation of the genome. However, the full 
understanding of the molecular onset of this disease is still far from achieved and the search for 
mechanisms of treatment will follow closely. 
It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. 
It is indisputable that the use of gold nanocarriers has been gaining momentum as vectors for therapy 
and diagnostic strategies, combining the AuNPs‟ ease of functionalization with numerous 
biomolecules, high loading capacity and fast uptake by target cells. In fact, over the last decade 
nearly 12.000 research papers focusing on multifunctional gold nanocarriers have been published in 
peer-reviewed journals. Some of the described nanosystems will most likely revolutionize our 
understanding of biological mechanisms and push forward the clinical practice through their 
integration in future diagnostics platforms. Nevertheless, very little gave fruitful results in order to 
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improve a bench-to-bedside approach to translational research. On the basis of theoretical and 
experimental results obtained so far are we or not at the point: from bench to bedside and back 
again? As you will see, the answers to this question are complex, but one thing is clear: Translation 
into clinics is a tortuous and difficult path. Here, we provide a critical review about the available 
multifunctional gold nanocarriers for in vitro application and in vivo cancer targeting on 
nanodiagnostics and therapy. Finally, the correct choices of chemical modifications to incorporate 
into the multifunctional gold nanocarriers to avoid activation off-target, side effects and toxicity are 
illustrated toward the development of new clinical strategies. 
 
Keywords: cancer; gold nanoparticles; nanomedicine; nanotheranostics; nanotoxicity. 
 
1. Introduction 
The National Cancer Institute predicts that over the next years, nanotechnology will result in 
important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, 
prevention and control of cancer [1]. Nanotechnology offers numerous tools to diagnose and treat 
cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers 
to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, 
and devices capable of predicting molecular changes to prevent action against precancerous cells [2].  
Nanoparticle-based delivery systems in Theranostics (Diagnostics & Therapy) provide better 
penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison 
to conventional therapies [3;4]. Limitations in medical practice are intimately associated with the fact 
that diagnostics, therapy and therapy guidance are mostly separate from each other. It is here that 
theranostics unites the three stages in one single process, supporting early-stage diagnosis and 
treatment, overcoming some of the sensitivity and specificity of current medicines [5-7]. At the 
present time, there is a growing need to enhance the capability of theranostics procedures where 
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nanoparticle-based sensors may provide for the simultaneous detection of several gene-associated 
conditions and nanodevices with the ability to monitor real-time drug action. These innovative 
multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics 
systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, 
drug delivery and tumor targeting systems (Figure 1). 
 
Figure 1. Nanocarriers for Cancer Theranostics. Nanoparticles-based strategies can be used for 
biosensing using plasmonic nanosensors for colorimetric assays and bio-bar codes for protein 
detection or intense labels for immunoassays. Moreover, the use of metal surfaces to enhance the 
Raman scattering signal of target molecules may be used for cancer diagnostics. Engineered 
nanocarriers can also act as therapeutic agents via gene silencing and drug delivery systems. Some 
nanocarriers can be attached to specific targets for selective damage to cancer cells through tumor 
targeting approaches. 
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Nowadays the main challenge is to develop a system for molecular therapy capable of circulating in 
the blood stream undetected by the immune system and capable to recognize the desirable target and 
signal it for effective drug delivery or gene silencing. As a result, nanotechnology is playing a role in 
providing new types of nanotherapeutics for cancer that have the potential to provide effective 
therapies with minimal side effects and with high specificity [8]. The interdisciplinary and vibrant 
field of nanotechnology continues giving us hope of a personalized medicine as a part of cancer 
patient management. Gold nanoparticles (AuNPs) are one of those nanosystems that provide non-
toxic carriers for drug and gene delivery applications [9;10]. They are versatile agents with a variety 
of biomedical applications including use in highly sensitive diagnostic assays [11], thermal ablation 
and radiotherapy enhancement [12-14], as well as drug and gene delivery [15;16]. 
The unique characteristics of AuNPs in the nanometer range, such as high surface-to-volume ratio or 
size-dependent optical properties, are drastically different from those of their bulk materials and hold 
pledge in the clinical field for disease therapeutics [8;17]. Nanoparticles (NPs) exhibiting these 
unique and broad-based optical properties, ease of synthesis and facile surface chemistry and 
functionalization, and appropriate size scale are generating much eagerness in clinical diagnostics 
and therapy. The most common applications in which gold nanocarriers have been used so far are 
labeling, delivering, heating, sensing and detection [18]. 
In spite of these advantages, nanoparticles show some limitations, such as their small size and large 
surface area can lead to particle-particle aggregation and may result in limited loading of functional 
components and burst release. In fact, only NPs with the appropriate size (and surface chemistry) 
will not be immediately recognized by our immune system and committed to removal from the 
organism, thus showing increased circulation times. Also, size and surface properties play an 
important role to avoid clearance [19]. For example, hydrophilic nanoparticles with an effective size 
in the range of 10 to 100 nm are small enough to slow down activation of the mononuclear 
phagocyte system and are big enough to avoid renal filtration [20]. The unique characteristics of 
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nanoparticles (NPs) in the nanometer range, such as high surface-to-volume ratio or size-dependent 
optical properties, are drastically different from those of their bulk materials and hold pledge in the 
clinical field for disease therapeutics [21]. 
When referring to cancer therapy, targeting and localized delivery are of utmost importance to 
enhance the therapeutic effect and decrease an adverse distribution to healthy organs and tissues. 
Multifunctional gold nanocarriers may potentiate the development of individualized cancer therapy 
based on the individual‟s biological information within the tumor (i.e. biomolecular profiling). Gold 
nanocarriers can be modified with multiple cell-targeting and membrane translocating peptides, 
loaded with DNA/RNA and used as nanovectors [20;22]. 
In this paper, we will focus on the exciting new methods and applications of AuNPs for cancer 
diagnosis and therapy with particular emphasis on their use in vivo and their potential to be 
translated into clinical settings.  
 
1. Nanodiagnostics 
Nanodiagnostics can be defined as the use of nano-sized materials, devices or systems for 
diagnostics purposes [23]. It is a promising field as more and improved techniques are becoming 
available for clinical diagnostics with increased sensitivity at lower costs [24-27].  
The use of the colloidal gold color change upon aggregation is the best characterized example for 
diagnostic systems using AuNPs.  In fact, AuNPs functionalized with ssDNA capable of specifically 
hybridizing to a complementary target for the detection of specific nucleic acid sequences in 
biological samples have been extensively used [24;26;28-36].   
The use of thiol-linked ssDNA-modified gold nanoparticles for the colorimetric detection of gene 
targets represents an inexpensive and easy to perform alternative to fluorescence or radioactivity-
based assays [37]. In 1996, Mirkin et al. [29] described the use of a cross-linking method that relies 
on the detection of single-stranded oligonucleotide targets using two different Au-nanoprobes, each 
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of them functionalized with a DNA-oligonucleotide complementary to one half of the given target. A 
mixture of gold nanoparticles with surface-immobilized non-complementary DNA sequences 
appears red in color and has a strong absorbance at 520 nm. When a complementary DNA sequence 
is added, the nanoparticles are reversibly aggregated causing a red shift in the surface plasmon 
absorbance to 574 nm, and the solution becomes purple in color. Consequently, these AuNPs 
reversibly assemble by the formation of the DNA duplex, linking the particles together. These 
pioneer work gave the research community the idea of an easy method to sensitized oligonucleotide–
AuNP conjugates, with intense and highly tunable optical properties, ease of conjugation though the 
gold–thiol bond, catalytic properties, and relative biocompatibility [30;38].  
On the other hand, in 2005 Baptista et al. introduced a non-cross linking method where thiol-linked 
DNA-gold nanoparticles were used in a novel colorimetric method to detect the presence of specific 
mRNA from a total RNA extract of yeast cells [25]. The method consists in visual and/or 
spectrophotometric comparison of solutions before and after salt induced Au-nanoprobe aggregation 
(see Figure 2) – the presence of a complementary target prevents aggregation and the solution 
remains red and has a strong absorbance at ±520 nm; non-complementary/mismatched targets do not 
prevent Au-nanoprobe aggregation, resulting in a visible change of color from red to blue and 
therefore a shift in the surface plasmon absorbance to 600-650 nm. This method has been 
successfully applied to detect eukaryotic gene expression without retro-transcription or PCR 
amplification steps [25;39]; to distinguish fully complementary from mismatched sequences, with a 
single base mismatch i.e. to detect common mutations within the β-globin gene [26]; and in a fast 
and straightforward assay for Mycobacterium tuberculosis DNA detection in clinical samples 
[27;40]. 
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Figure 2. The colorimetric assay. (A) Oligonucleotide probe and target sequences designed for 
BCR-ABL b3a2 (e14a2) junction and for BCR and ABL genes. Complementary and non-
complementary target sequences were used to study the level of specific interaction between the 
target and the Au-nanoprobes. BCR-ABL fusion positive (100% complementary); BCR and ABL 
gene sequences were used as controls (50% non-complementary); and a completely unrelated 
sequence (100% non-complementary) was used as negative control. (B) The assay is based on the 
increased stability of the Au-nanoprobes upon hybridization with the complementary target in 
solution, while non-hybridized Au-nanoprobes easily aggregate once the solution‟s ionic strength is 
increased. The absence of full complementarity is revealed by a change of color from red to blue due 
to A-nanoprobe aggregation which is corroborated by naked eye and UV/vis spectroscopy. BCR-
ABL Positive: sample in the presence of complementary target (solution remains red); BCR-ABL 
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Negative: sample in the presence of non-complementary target (solution turns blue). (C) 
Spectrophotometry relative to the detection of synthetic BCR-ABL oligonucleotide target. 
Oligonucleotides with BCR or ABL sequence only (showing 50% complementarity) were used as 
controls and an unrelated target (showing 100% non-complementarity to the Au-nanoprobe) as 
negative control. (D) Detection of BCR-ABL in total RNA from K562 cell line, HL-60 cell line and 
human PBMC (harboring 50% complementary targets to the nanoprobe) and S. cerevisiae cells 
(100% non-complementary). Nanoprobe aggregation as measured by ratio of area under the curve 
AUC500 nm-560 nm/AUC570 nm-630 nm. The dashed line represents the threshold of 1 considered 
for discrimination between Positive and Negative. 
 
 
Other approaches are the use of AuNPs as a core/seed that can be tailored with a wide variety of 
surface functionalities to provide highly selective nanoprobes for diagnosis [41]; the utilization of 
Surface Plasmon resonance (SPR) scattering imaging or SPR absorption spectroscopy generated 
from antibody conjugated AuNPs in molecular biosensor techniques for the diagnosis and 
investigation of oral epithelial living cancer cells in vivo and in vitro [42]; the use of multifunctional 
AuNPs which incorporate both cytosolic delivery and targeting moieties on the same particle 
functioning  as intracellular sensors to monitoring actin rearrangement in live fibroblasts [43]; and 
the employment of AuNPs in electrochemical based methods that can be coupled with metal 
deposition for signal enhancement [44]. 
Gold NPs have already proven to be one of the most important groups of nanomaterials for 
biosensing approaches. Highly sensitive and specific biosensors based on AuNPs have open up the 
possibility of creating new diagnostic platforms for disease markers, biological and infectious agents 
in the early-stage detection of disease and threats, especially in cancer [21;45]. 
 
1.1. Gold nanocarriers in Cancer Diagnosis  
Cancer is the one of first leading causes of mortality in the modern world, with more than 10 million 
new cases every year [46;47]. Some continue to argue that the search for the origin and treatment of 
this disease will continue through the next quarter of century, adding successive layers of complexity 
to an investigation that per se is very complex. In fact, advances in diagnosis and treating this disease 
that kills millions of people each year worldwide, have not been as effective as for other chronic 
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diseases, and only for some types of cancer there are effective methods of detection [46]. The high 
mortality rate in cancer is commonly attributed to the difficulties in detecting the disease at an early 
treatable stage. The main challenge is to find new and more effective diagnostic agents for the 
monitorization of predictive cell molecular changes that are involved in tumor development as the 
key to the efficient and ultimately triumphant treatment of cancer is early and accurate diagnosis 
[48].  
It is here that nanotechnology enters the fight in the technological leap of controlling materials at 
nanoscale by offering a “big revolution” in new medical and healthcare diagnostic systems [20]. In 
fact, nanotechnology combined with biology and medicine is the most advanced technology both 
from an academic point-of-view and for commercial applications, producing major advances in 
molecular diagnostics and bioengineering [49;50]. AuNPs are one of those nanosystems that provide 
non-toxic carriers with a variety of biomedical applications including use in highly sensitive 
diagnostic assays [21;45]. 
In reality the multiplexed marker protein assays are critical in the diagnosis of complex diseases like 
cancer. In fact, AuNP probes barcoded with reporter DNAs and a capture antibody have been 
extensively used with great promise [51;52]. For instance, AuNP imunoassays are one of the most 
used nanosystems in cancer detection. Mirkin and co-workers developed an ultrasensitive method for 
detecting protein analytes. This facile immunoassay was used for the detection of prostate specific 
antigen (PSA, a valuable biomarker for prostate cancer screening) and had an almost one million-
fold higher sensitivity than a conventional ELISA-based assay [53]. This study was the first step to 
use six years later the AuNP bio-barcode assay probe for the detection of PSA in a clinical pilot 
study with 18 men who have undergone radical prostatectomy for prostate cancer. This new bio-
barcode PSA assay is approximately 300 times more sensitive than commercial immunoassays [54].  
Also, Huang et al. have reported a PSA immunoassay on a commercially available surface plasmon 
resonance biosensor. This sandwich assay with AuNPs was used for a major enhancement in 
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sensitivity of PSA detection at clinical relevant concentrations [55]. Other study demonstrated a 
highly sensitive organic electrochemical transistor based immunosensor with secondary antibody-
conjugated AuNPs with a low detection limit for PSA. These sensor performances were particularly 
improved in the lower concentration range where the detection is clinically important for the 
preoperative diagnosis and screening of prostate cancer [55]. 
Additionally, AuNP probes coupled with dynamic light scattering (DLS) measurements can also be 
used for the development of a one-step homogeneous immunoassay for the detection of free-PSA. 
The light scattering intensity of nanoparticles and nanoparticle oligomers is several orders of 
magnitude higher than proteins, making it possible to detect nanoparticle probes in the low 
picomolar concentration range [56]. 
AuNPs scatter light intensely at or near their surface plasmon wavelength region and when coupled 
with DLS detection can be very useful for serum protein biomarker detection and analysis. Huo et al. 
reported the use of citrate-AuNP to absorb proteins from the serum and form a protein corona on the 
nanoparticle surface. The protein corona formation and the subsequent binding of antibody to the 
target proteins in the protein corona were detected by DLS. Using this simple assay, the authors 
discovered multiple molecular aberrations associated with prostate cancer from both mice and human 
blood serum samples [57;58]. 
Other authors have taken a different approach to addressing the use of AuNPs in cancer biomarker 
detection by employing the biological applications of antibody-conjugated AuNPs in several types of 
cancer, such as breast cancer [59;60], pancreatic adenocarcinoma [61], cervical cancer [62], 
epithelial cancer [63], liver cancer [64], prostate cancer [65] and oral cancer [42]. 
The mechanism of selectivity and all these immunoassay's response open up a new possibility of 
rapid, simple, clean, easy, economically very cheap, non-toxic and reliable diagnosis of cancer. In 
fact, antibody-conjugated AuNPs are one of the most used nanosystems in cancer diagnostics, being 
useful in molecular biosensor techniques for the diagnosis and investigation of cancer cells in vivo 
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and in vitro. The importance of these nanosystems can be demonstrated by a significant number of 
companies involved in the synthesis and applications of antibody-conjugated nanoparticles, such as 
Magnisense SAS, Diagnostic Biosensors, LLC, Alnis Biosciences Inc. and Invitrogen Corp [66]. 
Direct detection of cancer cells using colorimetric assays with AuNPs has been extensively used due 
to their simplicity and versatility, among which those based on LSPR. LSPR is the collective 
oscillation of the electrons in the conduction band, which is usually in the visible region giving rise 
to the strong surface plasmon resonance absorption [67]. These AuNPs are commonly functionalized 
with biomolecules (e.g., DNA, RNA, peptides, enzymes) and capable of recognizing molecular 
events associated with cancer development down to femtomolar level with single base discrimination 
resolution [68-70]. Molecular nanodiagnostics applied to cancer may provide rapid and sensitive 
detection of cancer related molecular alterations, which would enable early detection even when 
those alterations occur only in a small percentage of cells. For instance, Conde et al. present an 
AuNPs based approach for the molecular recognition and quantification of the BCR-ABL fusion 
transcript, which is responsible for chronic myeloid leukemia (CML). This inexpensive and very 
easy to perform method allows quantification of unamplified total human RNA and specific 
detection of the oncogene transcript. This assay may constitute a promising tool in early diagnosis of 
CML and could easily be extended to further target genes with proven involvement in cancer 
development [39;71]. The sensitivity settled by the Au-nanoprobes allows differential gene 
expression from 10 ng/μl of total RNA and takes less than 30 minutes to complete after total RNA 
extraction, minimizing RNA degradation (see Figure 2).  
Also, aptamer-conjugated AuNPs have become a powerful tool for point of care diagnostics [72]. 
Most of the common aptamer-AuNP assays are able to differentiate between different types of target 
and control cells based on the aptamer used in the assay, indicating the wide applicability for cancer 
cell detection. For instance, Liu et al. reported the use of an aptamer-nanoparticle strip biosensor for 
the rapid, specific, sensitive, and low-cost detection of circulating cancer cells in human blood, 
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showing great promise for in-field and point-of-care cancer diagnosis and therapy [73]. In another 
study, Medley et al. have developed a colorimetric assay for the direct detection of diseased cells and 
thus capable of distinguish between cancer cells and noncancerous cells. This assay combines the 
selectivity and affinity of aptamers and the spectroscopic advantages of AuNPs to allow for the 
sensitive detection of cancer cells with both the naked eye and based on absorbance measurements 
[70]. Another important aspect correlated with disease state in cancer patients is the presence of 
circulating tumor cells in the bloodstream. In order to induce optical contrast in non-pigmented 
cancer cells, Viator et al. attached AuNPs to a prostate cancer cell line, using optical absorption to 
detect such cells in a photoacoustic flowmeter designed to find circulating tumor cells in blood 
samples [74].  
Another application of AuNPs in cancer is their capability to target and provide in vivo tumor 
detection using Surface-enhanced Raman scattering - SERS. Actually, Lin et al. described the 
tremendous potential of using AuNP based-SERS to obtain blood serum biochemical information for 
non-invasive colorectal cancer detection [75]. Raman reporters when combined with AuNPs can 
elicit an optical contrast to discriminate between cancerous and normal cells and their conjugation 
with antibodies allowed them to map the expression of relevant biomarkers for molecular imaging 
[76], as well as detect and characterized circulating tumor cells. These SERS nanoparticles constitute 
an important tool for clinical research once they can successfully identified circulating tumor cells in 
the peripheral blood of 19 patients with squamous cell carcinoma of the head and neck [77]. 
The papers discussed earlier report the development of nanoscale devices and platforms that can be 
used for improved biomarker detection, such as nucleic acids (DNA or RNA) or proteins. However, 
the development of molecular diagnosis of cancer and at the same time the selective delivery of a 
specific anticancer agent by joining diagnostics and therapy (theranostics) on a single nanodevice 
will most definitely revolutionizing the way we manage cancer [78]. 
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Table 1 summarizes the latest types of AuNP-based biosensors for cancer dignostics, according to 
their methodology principle. Some of the described nanosystems will most likely revolutionize our 
understanding of biological mechanisms and push forward the clinical practice through their 
integration in future diagnostics platforms. Nevertheless, very little gave successful results or went to 
clinical trials. Therefore new synthesis, fabrication, and characterization methods are needed for 
developing highly advanced AuNPs capable of use in sensitive and multiple detection methods with 
negligible toxicity and high sensitivity. In the future, it might be possible to apply all AuNPs 
properties together and evolve new chemistry for synthesis of smart materials for diagnostic 
applications and clinical trials. 
 
Table 1. Summary of the latest AuNP-based biosensors used in cancer diagnostics according to the 
type of NP, surface modification, type of cancer and explored methodology principle. 
 
Method 
Type 
of NP 
Surface 
modification 
Target/Cells/ 
Samples 
Type of 
Cancer 
Comments 
[Reference] 
Colorimetric 
 
Scanometric 
40 nm 
spherical 
dA-tailed probe 
applied to the strip, 
which contains 
oligo(dT)-
conjugated AuNPs 
in dry form 
Fusion genes in 
K562 cell line 
acute and 
chronic 
leukemia 
Dry-reagent, disposable, 
dipstick test for molecular 
screening of seven 
chromosomal translocations 
associated with acute and 
chronic leukemia [79] 
13 nm 
spherical 
ssDNA 
BCR-ABL b3a2 
(e14a2) fusion 
transcript 
Chronic 
myeloid 
leukemia 
Detection and quantification 
of the 
BCR-ABL gene fusion using 
thiol-DNA modified AuNPs 
[39] 
30 nm 
spherical 
thiol-terminated 
DNA barcodes; 
anti-PSA antibodies 
Prostate-specific 
antigen PSA 
(biomarker for 
prostate cancer 
screening) 
Prostate cancer 
Nanoparticle based bio-
barcode for PSA detection 
[54] 
15 nm 
spherical 
antibody anti-
CA15-3−HRP 
(horseradish 
peroxidase) 
CA15-3 breast 
cancer biomarker 
in human serum 
Breast cancer 
Enhanced AuNP based 
ELISA for a breast cancer 
biomarker detection [59] 
oval-
shaped 
monoclonal anti-
HER2/c-erb-2 
antibody; S6 RNA 
aptamer-conjugated 
SK-BR-3 cells Breast cancer 
Colorimetric and highly 
sensitive two-photon 
scattering assay for highly 
selective and sensitive 
detection of breast cancer 
[60] 
Immunoassays 
15 nm 
spherical 
dithiol-PEG-
COOH; F19 
monoclonal 
antibodies 
Tissues from 
cancerous and 
healthy human 
pancreas (patients 
Pancreatic 
adenocarcinoma 
pancreatic adenocarcinoma 
[61] 
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undergoing 
pancreatic 
resection) 
25 nm 
spherical 
anti-EGFR and 
non-specific IgG 
antibodies 
SiHa cervical 
cancer cells 
Cervical cancer 
Optical imaging of cervical 
pre-cancers using AuNPs 
and CdSe QDs for 
reflectance and fluorescence 
imaging [62] 
10 nm 
spherical 
antibody 
(Cetuximab) 
epidermal growth 
factor receptor 
(EGFR) in A431 
cells 
Liver cancer 
High-performance probes 
based on AuNPs for 
detection of live cancer cell 
[63] 
16 nm 
spherical 
NHS-PEG; mouse 
anti-human AFP 
antibodies 
(antibody-1 and 
antibody-2) 
liver cancer 
biomarker alpha-
fetoprotein (AFP) 
Liver cancer 
One-step homogeneous 
detection of cancer marker 
using antibody-AuNP probes 
[64] 
60 nm 
spherical 
PSMA (prostate 
specific membrane 
antigen); C225 
(Erbitux, the 
antibody raised 
against human EGF 
receptor) 
living bone 
metastatic prostate 
cancer (C4-2B); 
human bone 
marrow stromal 
(HS-5) cells 
Prostate cancer 
Tunable plasmonic 
nanoprobes for theranostics 
of prostate Cancer [65] 
35 nm 
spherical 
monoclonal anti-
epidermal growth 
factor receptor 
(anti-EGFR) 
nonmalignant 
epithelial cells 
(HaCaT); 
malignant oral 
epithelial cells 
(HOC 313 clone 8 
and HSC 3) 
Oral cancer 
Surface plasmon resonance 
scattering and absorption of 
antibody-AuNPs in oral 
cancer diagnostics [42] 
Surface-
enhanced 
Raman 
scattering - 
SERS 
30 nm 
spherical 
mouse anti-human 
free PSA clone 
PSA-F65 and clone 
PSA-66 
Prostate-specific 
antigen (PSA) in 
human serum 
Prostate cancer 
Detection of PSA with an 
immunoassay based on 
SERS and immunogold 
labels [80] 
43 nm 
spherical 
human serum human serum 
Colorectal 
cancer 
AuNP based-SERS to obtain 
blood serum biochemical 
information for non-invasive 
colorectal cancer detection 
[75] 
60 nm 
spherical 
QSY reporter 
molecules; thiol-
PEG-COOH; 
epidermal growth 
factor (EGF) 
peptide 
epidermal growth 
factor (EGF) 
Squamous cell 
carcinoma of 
the head and 
neck 
SERS AuNPs identified 
circulating tumor cells in the 
peripheral blood of cancer 
patients [77]. 
35-50 nm 
spherical 
Thiol-DNA hairpin 
tagged with a 
Raman label 
BRCA1 SNPs Breast cancer 
Plasmonic 
nanoprobes for detection of 
SNPs in breast cancer 
BRCA1 gene [81] 
Electrochemical 
5 nm 
spherical 
Glutathione (GSH); 
primary antibodies 
for human 
Interleukin-8 
Interleukin-8 (IL-8) 
cancer biomarker 
in human serum 
Cancer 
biomarker 
Ultrasensitive 
immunosensor based on a 
glutathione-protected 
AuNP sensor surface [82] 
4 nm 
spherical 
antibodies for IL-6; 
biotinylated 
secondary antibody 
with 16-18 
horseradish 
peroxidase labels 
Interleukin-6 (IL-6) 
cancer biomarker 
in calf serum 
Cancer 
biomarker 
Inkjet printed AuNP 
electrochemical arrays for 
immunodetection of a cancer 
biomarker protein [83] 
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13 nm 
spherical 
Alkaline 
phosphatase; poly 
(styrene-co-acrylic 
acid); TNF-α 
antibody 
Tumor necrosis 
factor α (TNF-α) in 
human serum 
Tumor necrosis 
factor 
Electrochemical 
immunosensor of tumor 
necrosis factor based on 
alkaline phosphatase 
functionalized NPs [84] 
 
 
2. NanoBioimaging 
Nanoparticles are within the same size domain as many biomaterials including: enzymes, antibodies 
and protein receptors. This combined with the unique properties of materials in the nano-size range 
provides scope for making measurements more efficiently than existing molecular materials.  
Because light absorption from biologic tissue components is minimized at near infrared (NIR) 
wavelengths, most NPs for in vivo imaging have been designed to strongly absorb in the NIR 
so as to be used as effective contrast agents [45]. 
Gold nanoparticles have been used as exceptional contrast agents in vivo, giving a higher contrast 
when compared to traditional agents [85]. Ji et al. described the characterization of hybrid 
nanoparticles with a superparamagnetic iron oxide (SPIO)−silica core and a gold nanoshell, that 
displayed superparamagnetic characteristics and a significant absorbance in the near-infrared (NIR) 
region of the electromagnetic spectrum [86]. Examples include a superparamagnetic magnetite core 
with a layer of silica, before gold en-capsulation and the poly(ethylene glycol) (PEG) coating of 
magnetite/gold NPs to ensure biocompatibility. These poly(ethylene glycol) (PEG) coated hybrid 
nanoparticles comprising an iron oxide nanoparticle core and a thin gold layered shell show a 
potential as Computed tomography/Magnetic resonance imaging dual contrast agents [87]. 
Recently, the exploit of the high scattering ability of gold nanoshells as a contrast agent in vivo has 
been used by Optical Coherence Tomography (OCT) [88]. OCT is an imaging modality that provides 
cross-sectional subsurface imaging of biological tissue with micrometerscale resolution. The extra 
scattering achieved using a gold nanoshell, which possess both absorption and scattering properties 
in the NIR, provide optical contrast for improved diagnostic imaging and, at higher light intensity. 
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This property has been used to increase the contrast of tumours in mice. The gold nanoshells 
accumulated preferentially in the tumour and increased the contrast more than in other tissue [88]. 
PEG-coated gold nanoshells have been used as a contrast agent to image their distribution circulating 
in the vasculature in rat brain using photoacoustic imaging [89]. In this study, the images of the 
distribution of nanoshells circulating in the vasculature of a rat brain achieved by deep penetrating 
near-infrared light present a gradual enhancement of the optical absorption in the brain vessels (see 
Figure 3). Gold-nanorods and gold-nanoprisms have also been extensively used in bioimaging due 
to their ability to have the maximum of the plasmon resonance tuned further into the near infrared 
(NIR). Actually Motamedi et al. reported a contrast agent for a laser optoacoustic imaging system for 
in vivo detection of gold nanorods as well as to enhance the diagnostic power of photoacoustic 
imaging [90]. Song et al. also proposed a noninvasive in vivo spectroscopic photoacoustic sentinel 
lymph node mapping in a rat model using gold nanorods as lymph node tracers [91]. More recently, 
Daxiang Cui and co-workers reported the use of gold-nanoprisms a novel contrast agent for the 
hybrid technique of optoacoustic imaging. The authors demonstrated an in silico electron 
tomographic reconstruction of such gold nanostructures, which show promise for application in 
biomedical imaging, drug delivery, and photothermal therapy [92]. 
Some of the studies reported here can be useful for in situ diagnostics of cancer, by overcoming 
several limitations of conventional dyes, such as poor hydrophilicity and photostability, low quantum 
yield and detection sensitivity, insufficient stability in biological systems, and weak multiplexing 
capability. Additionally, the high scattering properties of these kind of  NPs can enhance contrast of 
imaging systems based on microscopy. 
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Figure 3. NanoBioimaging. Poly(ethylene glycol)-coated Au nanocages as a potential near-infrared 
(NIR) contrast agent for photoacoustic tomography (PAT). (A) SEM image of the as-synthesized 
silver nanocubes and (B) SEM image of gold nanocages. (C) Absorption spectra of Ag nanocubes 
and Au nanocages. The insets in panels A and B show TEM images of the nanocubes and nanocages, 
respectively (scale bars, 25 nm). Noninvasive PAT imaging of a rat‟s cerebral cortex (D) before the 
injection of nanocages and (E) about 2 h after the final injection of nanocages, which is the peak 
enhancement point. (F) A pixelwise differential image (image D - image E). (G) An openskull 
photograph of the rat‟s cerebral cortex. 
 
3. Nanotherapy 
In medical terms, a therapeutic effect is a consequence of a medical treatment of any kind, the results 
of which are judged to be desirable and beneficial. Conventional therapy methods in cancer involve 
the employment of anticancer agents that do not greatly differentiate between cancerous and normal 
cells [93]. Efficient in vivo targeting to heterogeneous population of cancer cells and tissue still 
requires better selectivity and decreased toxicity to surrounding normal cells, towards a decrease of 
systemic toxicity, adverse and severe side effects [94].  
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In another way, universally targeting cells within a tumor is not always feasible because some drugs 
cannot diffuse efficiently and the random nature of the approach makes it difficult to control the 
process and may induce multiple-drug resistance (MDR)  a situation where chemotherapy 
treatments fail patients owing to resistance of cancer cells towards one or more drugs [22]. 
Consequently, nanotechnology could offer a less invasive alternative, enhancing the life expectancy 
and quality of life of the patient [95]. 
At the moment, it is expected that the greatest gains in therapeutic selectivity will be achieved by 
synergistic combinations of several multicomponent targeting strategies. Currently, it is essential to 
develop technology for target and delivery of multiple therapeutic agents, and for the simultaneous 
capability of avoiding biological and biophysiscal barriers. For example, nanoparticles can 
extravasate into the tumor stroma through the fenestrations of the angiogenic vasculature, 
demonstrating targeting by enhanced permeation and retention. These particles are able to carry 
multiple antibodies, which further target them to epitopes on cancer cells, and direct antitumor 
action, leading to cell death. Irradiation might be use to activate the nanoparticles and set up the 
release of their cytotoxic action [96]. 
Due to advances in nanobiotechnology, potential therapeutic application of gold nanocarriers 
represent are an attractive platform for cancer therapy and has been investigated by different 
coworkers and used in a broad range of applications [95]. Table 2 summarizes the latest progresses 
and general considerations for AuNP delivery and targeting in cancer therapy, according to their 
methodology principle, type of incubation/exposure and target organs.  
 
Table 2. Summary of AuNPs used in cancer therapy according to the type of NP, surface 
modification, type of cancer, target cells/organs/organisms and explored methodology principle. 
 
Method 
Type of 
AuNP 
Surface modification 
Target 
cells/organs/organisms 
Comments [Reference] 
Gene 
therapy 
13 nm 
spherical 
thiol-ssDNA 
RAW 264.7 
(macrophage); HeLa cells 
(cervical carcinoma); NIH-
3T3 (fibroblast); MDCK 
In vitro intracellular gene 
Regulation; control of protein 
expression in cells [97] 
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cells (kidney) 
13 nm 
spherical 
PEG-block-poly(2-(N,N-
dimethylamino)ethyl 
methacrylate) copolymer 
(PEG-PAMA); siRNA 
HuH-7 cells 
(hepatocarcinoma) 
Smart PEGylated AuNPs for 
the in vitro delivery of siRNA 
and to induce gene silencing [98] 
13 nm 
spherical 
thiol-siRNA 
HeLa cells (cervical 
carcinoma) 
Polyvalent RNA-nanoparticle 
conjugates for in vitro luciferase 
knockdown [99] 
14 nm 
spherical 
thiol-siRNA; naked 
siRNA; PEG-COOH; PEG-
N3; HIV-derived TAT 
peptide; RGD peptide; 
quaternary ammonium. 
HeLa cells (cervical 
carcinoma); (freshwater 
polyp, Hydra); mice 
(C57BL/6j) 
In vitro and in vivo RNAi 
triggering using hierarchical 
approach with three 
biological systems of increasing 
complexity [100] 
15 nm 
spherical 
cationic polymers: PEI; 
charge-reversal 
PAH-Cit; MUA 
(mercaptoundecanoic acid) 
HeLa cells (cervical 
carcinoma) 
Charge-reversal functional 
AuNPs to deliver siRNA and 
plasmid DNA into cancer cells 
(in vitro) [101] 
14 nm 
spherical 
Cy3 labeled hairpin-DNA 
HCT-116 cells (carcinoma 
of colon) 
Au-nanobeacons capable of 
intersecting both pathways of in 
vitro RNA interference, blocking 
exogenous siRNA and 
endogenous microRNA [102] 
13 nm 
spherical 
PEG-NH2; siRNA; poly(β-
amino 
ester)s (PBAEs) 
HeLa cells (cervical 
carcinoma) 
gold, Poly(β-amino ester) 
nanoparticles that facilitate 
high levels of in vitro siRNA 
delivery [103] 
40 nm 
spherical 
Protease-degradable poly-
L-lysine (PLL); siRNA 
MDA-MB231-luc cells 
(breast cancer; LNCaP-luc 
cells (prostate 
adenocarcinoma) 
multilayer siRNA coated AuNPs 
using siRNA and PLL as the 
charged polyelectrolytes for in 
vitro luciferase knockdown [104] 
Au-
nanospheres 
Folate receptor; siRNA 
nude mice bearing HeLa 
cervical cancer xenografts 
near-IR light-inducible NF-
kappaB in vivo downregulation 
through folate receptor-targeted 
hollow Au-nanospheres carrying 
siRNA recognizing NF-kappaB 
p65 subunit [105] 
40 nm Au-
nanoshells 
PEG-NH2; TAT-lipid; 
Cy3-siRNA 
mouse endothelial cells 
NIR laser-induced release of 
siRNA from the nanoshells and 
in vitro GFP silencing [106] 
spherical 
nucleic acid 
NP 
siRNA 
HeLa cells (cervical 
carcinoma); SKH-1E and 
C57BL/6J mice 
In vitro and in vivo topical 
delivery of siRNA-based 
spherical nucleic acid AuNP 
conjugates for gene regulation 
[107] 
Tumor 
targeting 
spherical 
pH Low Insertion Peptide 
(pHLIP) 
Mouse model 
nanogold-pHLIP conjugates used 
in vivo to target tumors [108] 
6 nm 
spherical 
amine-terminated 
generation 5 (G5) 
poly(amidoamine) 
(PAMAM) dendrimers pre-
functionalized with folic 
acid (FA) and fluorescein 
isothiocyanate (FI) 
KB-HFAR cells (human 
epithelial carcinoma) 
multifunctional dendrimer-
stabilized AuNPs can 
specifically target cancer cells 
expressing high-affinity FA 
receptors in vitro [109] 
30 nm 
spherical 
PEGylated trastuzumab 
(Herceptin) 
MDA-MB-361 (breast 
cancer) tumors 
Human Epidermal Growth 
Factor Receptor-2 (HER-2)-
targeted AuNPs that enhance the 
radiation response of in vitro 
breast cancer cells and in vivo 
tumor xenografts to X-radiation 
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[110] 
4 nm 
spherical 
VEGF antibody (AbVF) 
CLL B cells (B-Chronic 
Lymphocytic Leukemia) 
AuNPs enhance in vitro 
apoptosis in B-chronic 
lymphocytic leukemia [111] 
60 nm 
spherical 
PEG-COOH; malachite 
green isothiocyanate 
(MGITC); ScFv B10 
(antibody fragment for 
human EGFR) 
Tu686 and H520 cells 
(EGFR-positive cancer 
cells); nude mouse 
xenografted with Tu686 
cells 
Pegylated SERS AuNPs for in 
vitro and in vivo tumor targeting 
and detection [112] 
Ultra-small 
Au-
nanoclusters 
folic acid (FA); near-
infrared fluorescent dye 
(MPA); Doxorubicin 
(DOX) 
A549 cells (lung cancer); 
HepG-2 (liver cancer); 
MDA-MB-231 (breast 
cancer); HTC116 
(carcinoma of colon) 
Cellular and in vivo studies with 
Au-FA-MPA and Au-FA-DOX 
show high affinity and anti-
tumor activity to different tumors 
[113] 
30 nm 
spherical 
PEGylated trastuzumab 
(FDA-approved 
humanized monoclonal 
antibody); radiolabeled 
polymer 
MDA-MB-361 cells (breast 
cancer); athymic CD-1 mice 
bearing MDA-MB-
361tumors 
AuNPs that enhance tumor 
uptake and intracellular delivery 
(in vitro and in vivo) while 
reducing the systemic exposure 
by evaluation of the impact of 
targeting and route of 
administration on organ 
distribution [114] 
Drug 
delivery 
2.5 nm 
spherical 
hydrophobic drugs: 
tamoxifen (TAF) 
and β-lapachone (LAP); 
Bodipy (fluorescent probe) 
MCF-7 cells (breast cancer) 
Entrapment of hydrophobic 
drugs in AuNP monolayers with 
efficient in vitro release into 
cancer cells [115] 
30 nm 
spherical 
prostate-specific membrane 
antigen (PSMA) RNA 
aptamer; Doxorubicin 
(DOX) 
LNCaP cells (prostate 
adenocarcinoma) 
A drug-loaded aptamer−AuNP 
bioconjugate for in vitro imaging 
and therapy of prostate cancer 
[116] 
25 nm 
spherical 
thiol-PEGylated; 
tamoxifen (TAM) 
MDA-MB-361 cells (breast 
cancer); MCF-7 cells (breast 
cancer) 
Tamoxifen−poly(ethylene 
glycol)−thiol AuNPs that 
enhance potency and selective 
delivery for in vitro breast cancer 
treatment [117] 
180 nm 
spherical 
PEG; Oxaliplatin 
A549 cells (lung epithelial 
cancer); HCT116, HCT15, 
HT29, RKO cells (all for 
colon cancer) 
AuNPs for the improved 
anticancer drug delivery in vitro 
of the active component of 
oxaliplatin [118] 
13 nm 
spherical 
cisplatin 
A549 cells (lung cancer); 
tumor-bearing SCID mice 
In vitro and in vivo antitumoral 
drugs conjugated to AuNPs [119] 
spherical Cyclic peptide 
CCRF-CEM cells (human 
leukemic lymphoblasts); 
SK-OV-3 cells (human 
ovarian adenocarcinoma) 
Cyclic peptide-capped AuNPs 
for in vitro drug delivery [120] 
40 nm Au-
nanospheres 
NH2-PEG-COOH; 
Doxorubicin (DOX); 
Cyclic peptide c(TNYL-
RAW), a second-
generation EphB4-binding 
antagonist 
mice bearing Hey tumors 
In vivo photothermal 
chemotherapy using 
doxorubicin-loaded Au-
nanospheres that target EphB4 
receptors in tumors [121] 
plasmonic 
vesicles 
assembled 
from 14 nm 
spherical 
AuNPs 
Raman reporter; PEG;  
hydrophobic copolymer 
(PMMAVP) of methyl 
methacrylate (MMA) and 
4-vinylpyridine (4VP) 
SKBR-3 cells (breast 
adenocarcinoma) 
Self-assembled plasmonic 
vesicles of SERS-encoded 
amphiphilic AuNPs for in vitro 
cancer cell targeting and 
traceable intracellular drug 
delivery [122] 
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In this panorama we can see that over the last 10 years, the majority (approximately 80%) of gold 
nanoformulations for gene therapy, tumor targeting and drug delivery in cancer have been tested in 
cell cultures and normally targeting reporter genes, such as luciferase or GFP. In the future, it is 
imperative to develop new therapy vehicles and extensive testing in animal models in order to 
develop the next-generation nanoparticle translation into the clinics. There is only one active clinical 
trial reporting the use of AuNPs. This phase I trial is studying the side effects and best dose of TNF-
bound colloidal gold in treating patients with advanced solid tumors (clinical trial number 
NCT00356980), sponsored by the National Institutes of Health Clinical Center (CC) and National 
Cancer Institute (NCI). As it can be seen in Figure 4 there is a disproportional level between 
nanoparticle production and their translation into clinics.  
In fact, clinical trials require the coordinated effort of interdisciplinary research groups, institutes and 
pharmaceuticals. Clinical-stage programs will probably have to deal with more and more human data 
and financial investment, before they can be viewed as a mainstream proposition for resourceful 
nanotherapy vehicle developers. The current generation of nanoparticles varies widely in size, 
chemical composition, surface charge, tissue tropism and sensitivity that makes difficult to translate 
them into the manufacturing process. The community has to learn how to deal with all the dat 
produced so far. The rules for understanding how nanoparticles interact with different organs and 
organisms are starting to emerge, although most of the valuable evidences has to come from animal 
models. 
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Figure 4. Disproportional level between nanoparticle production and their translation into 
clinics. Thousands of systems were published describing different synthesis, biofunctionalization and 
characterization methods that will most likely revolutionize our understanding of chemical and 
biological mechanisms and push forward efficient diagnostics and therapeutic platforms. 
Nevertheless, very few were produced to improve a bench-to-bedside approach to translational 
research. Outcomes like this must be followed by extensive laboratory work, which results in 
improved screening procedures and a new therapy of great potential, although the final product 
should always be part of a two way interaction between laboratory scientists and clinicians. 
 
 
3.1.Gene therapy 
We are in the dawn of a new age in gene therapy driven by nanotechnology vehicles. Although there 
are technical challenges associated with the therapeutic application of nanoparticles, the integration 
of therapy with diagnostic profiling has accelerated the pace of discovery of new nanotechnology 
methods. The development of a safe, efficient, specific and nonpathogenic vehicle for gene delivery 
is highly attractive [123;124].  
Gene therapy is receiving increasing attention and, in particular, small-interference RNA (siRNA) 
shows importance in novel molecular approaches in the knockdown of specific gene expression in 
cancerous cells (see Figure 5). In fact, this non-viral-vector-mediated delivery of therapeutic siRNAs 
is highly desirable and constitutes an important challenge to gene therapy [125-127].   
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Figure 5. Regulation of gene expression via siRNA-gold nanoparticles. Engineered nanoparticles 
modified with siRNA can represent a delivery system of siRNA and a useful tool to block gene 
function and for sequence-specific post-transcriptional gene silencing. siRNA-modified nanocarriers 
can enter cells and  subsequently unwound siRNA strands and assembled into an effector complex, 
RNA Induced Silencing Complex (RISC), which can direct RNA cleavage, mediate translational 
repression or induce chromatin modification. The antisense strand then binds to its 
complementary/target mRNA (activated RISC/mRNA complex). The catalytic RISC recognizes 
mRNAs containing perfect or near-perfect complementary sequence to the guide siRNA and cleaves 
the mRNAs at a site precisely 10 nucleotides from the 5‟-end of the guide strand. Finally, mRNA 
degradation is achieved by endo- and exonucleases, resulting in knockdown of the expression of the 
corresponding genes. 
 
 
In fact, antisense DNA [128;129] and RNA interference (RNAi) via the use of small-interfering 
RNA [130-133] have emerged as powerful and useful tools to block gene function and for sequence-
specific posttranscriptional gene silencing, playing an important role in downregulation of specific 
gene expression in cancer cells. Thus, one drawback of using naked siRNAs is that they show 
extremely short half-lives, weak protection against action by RNases, poor chemical stability, and 
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common dissociation from vector [134]. In fact, the major obstacle to clinical application is the 
uncertainty about how to deliver therapeutic RNAs (e.g., miRNA and/or siRNA) with maximal 
therapeutic impact. AuNPs have shown potential as intracellular delivery vehicles for antisense 
oligonucleotides [97] and for therapeutic siRNA by providing protection against RNAses and ease of 
functionalization for selective targeting [99;135]. For example, Mirkin and coworkers reported the 
use of polyvalent RNA-AuNP conjugates that are readily taken up by cells and that the particle 
bound siRNA can effectively regulate genes in the context of RNA interference [99].  
Several other studies using engineered NPs modified with siRNA have demonstrated a cytoplasmic 
delivery system of siRNA and efficient gene silencing using AuNPs [99;101;103;136]. However, 
almost all nanoconjugates using siRNA have exclusively been tested in cell cultures targeting only 
reporter genes. 
Recently, Conde et al. provided evidence of in vitro and in vivo RNAi triggering via the synthesis of 
a library of novel multifunctional AuNPs, using a hierarchical approach including three biological 
systems of increasing complexity: in vitro cultured human cells, in vivo freshwater polyp (Hydra 
vulgaris), and in vivo mice models [100]. The authors developed effective conjugation strategies to 
combine, in a highly controlled way, specific biomolecules to the surface of AuNPs such as: (a) 
biofunctional spacers: Poly(ethylene glycol) (PEG) spacers used to increase solubility and 
biocompatibility; (b) cell penetrating peptides such as TAT and RGD peptides: A novel class of 
membrane translocating agents named cell penetrating peptides (CPPs) that exploit more than one 
mechanism of endocytosis to overcome the lipophilic barrier of the cellular membranes and deliver 
large molecules and even small particles inside the cell for their biological actions; and (c) siRNA 
complementary to a master regulator gene, the protooncogene c-myc, were bond covalently (SH-
siRNA) and ionically (naked siRNA) to AuNPs [100]. 
However, efforts to target siRNA-nanoparticles to organs are less advanced. Some organs need 
smaller and novel NPs to access different kinds of tissue. Another challenge, which also requires 
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novel materials, is the endosomal release of siRNA, once it is transported across the cell membrane. 
Most of the described systems also get trapped by the the lysosomes and their siRNA cargo gets 
compromised. Probably the endosomal escape or siRNA accessibility to form the RNA-induced 
silencing complex (RISC) requires substantially more circulation time. 
While the AuNPs for gene therapy discussed thus far employ the load of siRNA to nanoparticles, 
AuNPs have also shown potential as intracellular delivery vehicles for antisense oligonucleotides 
(ssDNA,dsDNA) by providing protection against intracellular nucleases and ease of 
functionalization for selective targeting [99;135]. So far, several strategies for gene delivery systems 
have been developed, including mixed monolayer protected AuNPs [137;138], polymer-AuNPs 
complexes [139;140] and dsDNA and ssDNA functionalized AuNPs [141;142]. 
Recently, Conde et al developed a new theranostic system capable of intersecting all RNA pathways: 
from gene specific downregulation to silencing the silencers, i.e. siRNA and miRNA pathways. The 
authors reported the development AuNPs functionalized with a fluorophore labeled hairpin-DNA, 
i.e. Gold nanobeacons, capable of efficiently silencing single gene expression, exogenous siRNA and 
endogenous miRNAs while yielding a quantifiable fluorescence signal directly proportional to the 
level of silencing [102].  
From a synthetic point of view it is still unclear the differences between DNA–AuNPs and siRNA–
AuNPs. From the papers reported so far the siRNA and DNA gold nanoconjuates are almost from 
the same size and charge, and show similar efficiencies. Nevertheless siRNA–AuNP conjugates 
require functionalization with thiol-PEG molecules to achieve equivalent stability to DNA–AuNPs, 
which may have something to do with the capacity loading of the different molecules due to singular 
hydrophobicity and/or hydrophilicity, molecular weight and charge density properties between RNA 
and DNA [143]. However, this fact needs additional clarification.  
Further research into the fundamental mechanisms of in vivo gene therapy using nanodevices could 
unveil new dimensions of nanoparticle-mediated gene silencing that will have profound implications 
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for understanding gene regulation, and which could also affect the development of functional 
genomics and therapeutic applications. One of the most important issues that is still unclear is how 
biocompatible AuNPs will be following intraveneous injection, in particular when the ultimate 
destination is the cytoplasm and/or nucleus inside cells. Future in vivo work will need to cautiously 
consider the accurate option of chemical modifications to incorporate into the nanoparticles to avoid 
off-target effects. Though nanoparticles‟ potential against cancer is still in need of further 
optimization and characterization, it is now time to start translating these promising platforms to the 
clinical settings towards widespread effective therapy strategies in the fight against cancer. 
 
3.2. Tumor targeting 
Nanoparticles are excellent tumor-targeting vehicles because of a unique inherent property of solid 
tumors. Numerous tumors present with defective vasculature and poor lymphatic drainage, due to the 
rapid growth of solid tumors, resulting in an enhanced permeability and retention effect. This effect 
allows nanoparticles to accumulate specifically at the tumor site [20;93]. Once the tumor is directly 
connected to the main blood circulation system, multifunctional nanocarriers can exploit several 
characteristics of the newly formed vasculature and efficiently target tumors. Tumor cells are 
supplied by blood capillaries that perfuse the cells of the tissue where nanocarriers can passively 
accumulate or anchor through targeting moieties to biomarkers overexpress by tumor cells (see 
Figure 6) [45]. 
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Figure 6. Tumor targeting via multifunctional nanocarriers. Cancer cells reduce adhesion to 
neighboring cells and migrate into the vasculature-rich stroma. Once at the vasculature, cells can 
freely enter the bloodstream (A). Once the tumor is directly connected to the main blood circulation 
system, multifunctional nanocarriers can interact directly with cancer cells and effectively target 
tumors. Engineered NPs maybe also administered directly to bronchial airways (B). These 
nanocarriers may bind to unique moieties that are presented by the cancer cell that can upregulate 
certain cell-surface molecules and secreted factors. 
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Shi et al. developed a simple system with multifunctional amine terminated poly(amidoamine) 
(PAMAM) dendrimers, folic acid (FA) and fluorescein isothiocyanate functionalized in gold 
nanoparticles. This approach can specifically target cancer cells expressing high-affinity FA 
receptors in vitro [109]. 
Further work in tumor targeting was reported in a subcutaneous model of colon cancer, where it was 
demonstrated that systemically delivered AuNPs (size, approximately 33 nm) conjugated to tumor 
necrosis factor (TNF) accumulated in tumors [144]. This study outlines the development of a 
colloidal gold nanoparticle vector that targets the delivery of tumor necrosis factor (TNF) to a solid 
tumor growing in mice. 
Mukherjee et al. studied B-Chronic Lymphocytic Leukemia (CLL) which is characterized by 
apoptosis resistance. They found induction of significantly more apoptosis in CLL B cells by co-
culture with an anti-VEGF antibody. To increase the efficacy of these agents in CLL therapy they 
focused on the use of AuNPs, by attaching VEGF antibody to the nanoparticle‟s surface. The 
AuNPVEGF antibody treated cells showed significant down regulation of anti-apoptotic proteins 
[111].   
In cancer research, colloidal gold can be used to target tumors and provide detection using SERS 
(Surface Enhanced Raman Spectroscopy) in vivo. These AuNPs are surrounded with Raman 
reporters which provide light emission that is over 200 times brighter than quantum dots [145;146]. 
It was found that the Raman reporters were stabilized when the nanoparticles were encapsulated with 
a thiol-modified polyethylene glycol coat and gave large optical enhancements. This allows for 
compatibility and circulation in vivo. When conjugated to tumor-targeting ligands, these conjugated 
SERS nanoparticles were able to target tumor markers such as epidermal growth factor receptor 
(EGFR), which is sometimes overexpressed in cells of certain cancer types, [42;147] and then detect 
the location of the tumor on human cancer cells and in xenograft tumor models [112]. Qian et al. 
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described biocompatible and nontoxic nanoparticles for in vivo tumor targeting and detection based 
on pegylated gold nanoparticles and surface-enhanced Raman scattering. These conjugated 
nanoparticles were able to target tumor biomarkers such as epidermal growth factor receptors on 
human cancer cells and in xenograft tumor models [112]. 
Although cancer therapies are improving, some formulations are not reaching with high efficiency 
tumor cells or tissues, and countless doubts remains over the efficacy of those that do. To efficiently 
target a cancer cell, either a circulation cell or a cell from the primary tumor or one hidden within a 
population of normal cells, represents an exceptional challenge. In fact, there are a lot of limitations 
for tumor targeting as some nanocarriers can also target normal proteins which are not exclusively 
expressed by the cancer cell. Targeting specific cells may be completely different to target the organ. 
The most important aspects that the researchers need to take into account are the specificity of the 
nanoparticle to the target molecules, as well as toxicological and immunological effects [148]. For 
example, the combination of small size nanoparticles with their special thermal, imaging, drug/gene 
carrier, or optical characteristics with the specific and selective recognition abilities of antibodies 
will definitely produce a hybrid product that shows versatility and specificity. Therefore, 
multifunctional nanocarriers have the potential to join numerous therapeutic functions into a single 
platform, by targeting specific tumor cells, tissues and organs. 
 
3.3. Drug delivery 
The vast majority of FDA approved used drugs exhibit a short half-life in the blood stream and a 
high overall clearance rate. In fact, the major obstacles/limitations in drug delivery are: cytoplasmic 
and systemically delivery of the drug, renal clearance, target site accumulation after administration 
and heterogeneous vascular perfusion and diffusion. Actually, these small drug molecules usuaaly 
diffuse rapidly into healthy tissues and are dispersed consistently within the body. As a consequence, 
just a small amount of the drug can reach the target site, which often leads to side effects. These 
66
BOOK CHAPTER: “Nano-oncologicals: new targeting and delivery approaches” 
30 
 
obstacles usually occur with drugs that exhibit a narrow therapeutic index, such as anticancer 
biomolecules, immunosuppressive agents, as well as antirheumatic medicines. Poor drug delivery 
and accumulation at the target site frequently leads to significant limitations, such as multi-drug 
resistance, which leads many cancers to develop severe resistance to chemotherapy drugs [149]. 
Nanocarriers can also be used to optimize the biodistribution of drugs to diseased organs, tissues or 
cells, in order to improve and target drug delivery [150].  
It is important to realize that the nanoparticle-mediated drug delivery is feasible only if the drug 
distribution is otherwise inadequate. These cases include drug targeting of difficult, unstable 
molecules (proteins, siRNA, DNA), delivery to the difficult sites (brain, retina, tumors, intracellular 
organelles) and drugs with serious side effects (e.g. anti-cancer agents). The performance of the 
nanoparticles depends on the size and surface functionalities in the particles. Also, the drug release 
and particle disintegration can vary depending on the system (eg. biodegradable polymers sensitive 
to pH). An optimal nanodrug delivery system ensures that the active drug is available at the site of 
action for the correct time and duration, and their concentration should be above the minimal 
effective concentration (MEC) and below the minimal toxic concentration (MTC) [151;152].  
AuNPs are also being investigated as vehicles for drug delivery such as paclitaxel [153]. Gibson et 
al. describe the first example of 2 nm AuNPs covalently functionalized with the chemotherapeutic 
drug paclitaxel. The administrations of hydrophobic drugs require molecular encapsulation and it is 
found that nanosized particles are particularly efficient in evading the reticuloendothelial system. 
This approach gives a rare opportunity to prepare hybrid particles with a well-defined amount of 
drug and offers a new alternative for the design of nanosized drug-delivery systems [115;153;154] 
(see Figure 7) 
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Figure 7. Drug delivery. Entrapment of hydrophobic drugs in nanoparticle monolayers with 
efficient release into cancer cells (A) Delivery of payload to cell through monolayer-membrane 
interactions. (B) Structure of particles and guest compounds: Bodipy, TAF, and LAP, the number of 
encapsulated guests per particle, and log P of the guests. (C) Release of Bodipy from AuNPZwit 
Bodipy in DCM-aqueous solution two-phase systems (λex=499 nm, (λem=517 nm). (D) PL intensity 
of AuNPZwit-Bodipy in cell culture medium and 100% serum, indicating little or no release relative 
to AuNPZwit-Bodipy in PBS after NaCN induced release of guest molecules (λex=499 nm, 
λem=510 nm). 
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Nanotechnology has provided for novel and powerful systems that may be used treatment of human 
diseases. However the majority of products, reagents and drugs being used for the development of 
these nanoscale systems have to be approved by the main supervising agencies, such as the FDA and 
EMA [2].  
Thus far, some limitations for the correct design and application of nanoparticles, such as 
pharmacokinetics, biodistribution, and side effects of the nanotherapy; safety profile of nanoparticles 
before and after conjugation and  toxicity, needs to be clarified to validate efficient clinical appliance 
[2]. 
 
4. NanoToxicity 
The AuNPs have a proclivity in vivo and in vitro to bioaccumulate within various types of cells with 
a special affinity for macrophage-type cells (both histiocytes and blood phagocytic cells), and 
reticuloendothelial cells throughout the body). They also produce varying degrees of 
bioaccumulation in such tissues as lymph nodes, bone marrow, spleen, adrenals, liver and kidneys 
[155-157].  
Research shows that nanoparticles can stimulate and/or suppress the immune responses, and that 
their compatibility with the immune system is largely determined by their surface chemistry. In fact, 
is well known the influence of size, solubility and surface modification on the biocompatibility of 
nanoparticles and their use in biological applications [158] (see Figure 8). 
AuNPs are generally considered to be benign. However, the size similarity of AuNPs to biological 
matters could provide “camouflage” to cellular barriers, leading to undesired cellular entry which 
might be detrimental to normal cellular function [159]. 
Pan and colleagues recently conducted a systematic investigation of the size-dependent cytotoxicity 
of AuNPs against four cell lines [160]. They found that AuNPs 1 to 2 nm in size displayed cell-type 
dependent cyotoxicity with high micromolar IC50s. In contrast, AuNPs 15 nm in size were nontoxic 
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to cells at concentrations 60-fold higher than the IC50 of the smaller AuNPs. These results seemed to 
confirm size dependent toxicity of AuNPs [115;144;161-163], an inference that has hitherto been 
somewhat ambivalent. On the other hand, found that the presence of sodium citrate residues on 
AuNPs impaired the viability in the alveolar type-II cell lines A549 and NCIH441. Interestingly, the 
presence of an excess of sodium citrate on the surface of NPs not only reduced the in vitro viability 
of A549 and NCIH441cell lines, but also affected cellular proliferation and increased the release of 
lactate dehydrogenase (marker for apoptotic cell degradation) [164].  
 
 
Figure 8. NanoToxicity: Causes and Effects. Nanoparticles biocompatibility/effects and their use 
in biological applications can be influenced by size, shape, solubility, composition and surface 
charge and modification/chemistry. 
 
 
Although AuNPs are generally considered as highly biocompatible, previous in vitro studies have 
also shown that cytotoxicity of AuNPs in certain human epithelial cells was observed [165;166]. 
70
BOOK CHAPTER: “Nano-oncologicals: new targeting and delivery approaches” 
34 
 
Now the most imperative question rises up. Are the gold nanoparticles cytotoxic or biocompatible? 
And how can the gold nanoparticles be design to avoid these effects? 
There does not seem to have a simple answer. Even though there is not any general mechanism for 
making nanoparticles universally „non-toxic‟ to all living cells and all organisms, there are important 
findings that can be applied for increasing nanoparticle biocompatibility and reducing cytotoxic 
interactions in vivo and in vitro.  
Using the lowest nanoparticle dose to get the desired response for the shortest period of time, in 
general, seems to promote biocompatibility as well as nanoparticle´s coating. For example, if the 
outer coating does not completely covers the nanoparticle reactive surface, the presence of cracks, 
roughness or interruptions could lead to complement or antibody attachment, or dissolution of the 
coating by cell digestion [167].  
It is essential to test nanoparticle/biological interactions experimentally and modify the nanoparticles 
for best biocompatibility with the cell in order to eliminate some obstacle, like the peroxidation of 
membrane lipids, the generation of reactive oxygen species, the acute and chronic release of pro-
inflammatory factors, modification in genetic cellular function, and the possibility of nanoparticles 
becoming inactive/unavailable during filtration or passage through pores and fenestrations [168,169] 
due to size, inflexibility of the nanoparticle core, or protein adsorption and agglomeration [167]. 
When interpreting nanoparticle interactions with cells and organisms, it is important to remember 
that living systems may appear normal and be capable of growth and function, but they may be 
genetically altered in subtle ways following nanoparticle exposure, which can produce serious 
consequences at some time in the distant future. Conversely, other cells that seem to be damaged 
may, in time, recover from nanoparticle exposure and function normally in the absence of the 
nanoparticles [167,169].  
In conclusion, the only weapon that we have to insure that these new materials are well designed and 
safely used is to question and test each new nanoparticle to make sure that it has been designed for 
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safety (with maximum biocompatibility) during handling, use and disposal. Evaluating the 
biocompatibility of nanomaterials is imperative. In fact, it is important to carefully characterize the 
biocompatibility and safety of the nanomaterials if they are to be used for medical purposes. Despite 
the major scientific advances made in the field of molecular and cell biology and biotechnology, the 
basic concepts of regulatory toxicology have hardly changed over the past decades [158]. Actually, 
the vast majority of studies report the biocompatibility of nanomaterials only trough the study of cell 
viability. Almost no importance is given when testing nanomaterials in the detection of genetic 
damages (DNA strand breaks and the formation of nuclear abnormalities), or in identifying protein 
markers of toxicity, or measuring the level of oxidative stress. For example, when using gene 
silencing technologies, the function of specific genes and proteins in toxicity pathways could be 
identified, once DNA-damage response (DNA repair, cell-cycle regulation and apoptosis) 
encompasses gene-expression regulation at the transcriptional and post-translational levels.  
In fact, Conde et al. reported a gold-nanobeacon system [102] used for gene therapy that was 
extensively evaluated for the genotoxic, cytotoxic and proteomic effects after incubation in cancer 
cells [170]. The exposure was evaluated by two-dimensional protein electrophoresis followed by 
mass spectrometry to perform a proteomic profile and MTT assay, glutathione-S-transferase assay, 
micronucleus test and comet assay to assess the genotoxicity. An assessment of genome-related 
toxicity revealed no significant DNA damage increase, as well as no potential mutagenic or 
clastogenic consequences to the cell [170]. 
 
5. Conclusions and Future perspectives 
Over the last decade, thousands of different gold nanocarriers were developed and published. Almost 
20% of these papers were published in 2010 alone. It is indisputable that the use of gold nanocarriers 
has been gaining momentum as vectors for therapy and diagnostic strategies, combining the AuNPs‟ 
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ease of functionalization with numerous biomolecules, high loading capacity and fast uptake by 
target cells. 
Here, we have reviewed part of this exciting progress and research advances within the context of 
multifunctional gold nanocarriers for cancer theranostics. Despite the significant efforts towards the 
use of gold nanocarriers in biologically relevant research, more in vivo studies are needed to assess 
the applicability of these materials as delivery agents. In fact, only a few went through feasible 
clinical trials. Nanoparticles have to serve as the norm rather than an exception in the future 
conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice 
of chemical modifications to incorporate into the multifunctional gold nanocarriers to avoid 
activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do 
not consider the final application to guide the design and functionalization of NP. Instead, the focus 
is predominantly on engineering materials with specific physical or chemical properties.  
To improve medicine, scientific discoveries must be translated into clinical applications. Such 
discoveries typically begin at “the bench” with basic/fundamental research in which scientists study 
disease at a molecular or cellular level then progress to the clinical level, which is the patient's 
“bedside”. Scientists and clinicians are increasingly aware that this bench-to-bedside approach to 
translational research is really a two-way interaction. However, an additional effort should appear 
towards the development of new clinical strategies. 
For that reason, it is imperative to learn how advances in nanosystem‟s capabilities are being used to 
identify new diagnostic and therapy tools driving the development of personalized medicine in 
oncology; discover how integrating cancer research and nanotechnology modeling can help patient 
diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical 
strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on 
current research efforts; and last but not least, learn what approaches are proving fruitful in turning 
promising clinical data into treatment realities. 
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Although all studies described here provide a baseline level of data in support of the effectiveness 
and safety of nanomaterials, we wonder how useful the data generated will be in successfully 
predicting and preventing scientists from jeopardizing the safety of the future patients? 
With chemists, biologists and materials scientists working together with clinicians and engineers, but 
especially with “translational innovators” new solutions to crucial nanobiomedical problems will 
hopefully be found. 
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Abstract: In the last decade the use of nanomaterials has been having a great impact in 
biosensing. In particular, the unique properties of noble metal nanoparticles have allowed 
for the development of new biosensing platforms with enhanced capabilities in the specific 
detection of bioanalytes. Noble metal nanoparticles show unique physicochemical properties 
(such as ease of functionalization via simple chemistry and high surface-to-volume ratios) 
that allied with their unique spectral and optical properties have prompted the development 
of a plethora of biosensing platforms. Additionally, they also provide an additional or 
enhanced layer of application for commonly used techniques, such as fluorescence, 
infrared and Raman spectroscopy. Herein we review the use of noble metal nanoparticles 
for biosensing strategies—from synthesis and functionalization to integration in molecular 
diagnostics platforms, with special focus on those that have made their way into the 
diagnostics laboratory. 
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1. Introduction 
In the era of nanotechnology, noble metal nanoparticles (NPs) have played an important role in the 
development of new biosensors and/or in the enhancement of existing biosensing techniques to fulfill 
the demand for more specific and highly sensitive biomolecular diagnostics. The unique 
physicochemical properties of such metals at the nanoscale have led to the development of a wide 
variety of biosensors, such as: (i) nanobiosensors for point of care disease diagnosis, (ii) nanoprobes 
for in vivo sensing/imaging, cell tracking and monitoring disease pathogenesis or therapy monitoring 
and (iii) other nanotechnology-based tools that benefit scientific research on basic biology [1–5]. In 
fact, NPs are, in general, one of the most common nanotechnology-based approaches for developing 
biosensors, due to their simplicity, physiochemical malleability and high surface areas [6]. They can 
measure between 1 to 100 nm in diameter, have different shapes and can be composed of one or more 
inorganic compounds, such as noble metals, heavy metals, iron, etc. The majority of them exhibit  
size-related properties that differ significantly from those observed in microparticles or bulk materials. 
Depending on their size and composition we can observe peculiar properties, such as quantum 
confinement in semiconductor nanocrystals, surface plasmon resonance in some metal NPs and 
superparamagnetism in magnetic materials. Noble metal NPs, in particular gold and silver NPs, are 
among the most extensively studied nanomaterials and have led to the development of innumerous 
techniques and methods for molecular diagnostics, imaging, drug delivery and therapeutics. Most of 
their unique physicochemical properties at the nanoscale, such as Localized Surface Plasmon 
Resonance (LSPR), have been explored for the development of new biosensors. This review will focus 
on these unique physicochemical properties of noble metal NPs that have thus far been explored for 
the development of new highly sensitive and specific biosensing techniques, favoring those that have 
already been successfully tested with biological samples. While some recent reports have addressed 
specific bio-application for noble metal NPs, such as molecular diagnostics and therapy [5,7] or cancer 
applications [8], and others have focused on the bio-applications of a specific type of noble metal NP, 
mostly gold NPs [9], here we aim at presenting an overview on the general principals and up to date 
applications of all noble metal NPs used for the development of biosensors. 
2. Noble Metal Nanoparticles for Biosensing 
2.1. Synthesis and Functionalization of Noble Metal Nanoparticles 
Numerous techniques have been developed to synthesize noble metal NPs, including chemical 
methods (e.g., chemical reduction, photochemical reduction, co-precipitation, thermal decomposition, 
hydrolysis, etc.) and physical methods (e.g., vapor deposition, laser ablation, grinding, etc.), whose 
ultimate goal is to obtain NPs with a good level of homogeneity and provide fine control over size, 
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shape and surface properties, in order to better take advantage of their unique physicochemical 
properties for biosensing [10]. 
The majority of the biosensing applications based on NPs that have been developed thus far are 
based on gold NPs, due to their unique optical properties and ease of derivatization with different 
biomarkers in aqueous solution [11–13]. These gold NPs, also known as colloidal gold, can be easily 
synthesized in sizes ranging between 3 and 200 nm in diameter and in different shapes, being the most 
common the quasi-spherical shape, mainly due to their surface energy that favors the formation of 
spherical particles. Generally, the method of choice to synthesize quasi-spherical gold NPs is the 
chemical reduction of Au(III) to Au(0) ions using sodium citrate as a reducing agent, a method first 
developed by Turkevich [14] and latter optimized by Frens [15]. In this approach, the citrate acts both 
as reducing agent and as capping agent which, as the gold NPs form, prevents the NPs from forming 
larger particles and simultaneously conferring them a mild stability due to electrostatic repulsion 
between citrate-capped gold NPs [16]. Recent modifications of the Turkevich method have allowed a 
better distribution and control over the size of the gold NPs, where a range between 9–120 nm can be 
achieved just by varying the citrate/Au ratio [17–19]. Alternatively, many other aqueous- and organic-
based methodologies have been developed for the controlled synthesis of different noble metal NPs, 
including spherical or non-spherical, pure, alloy or core/shell NPs of gold, silver, platinum, palladium 
and/or rhodium [20–22]. The development of new biosensing and therapeutic applications based on 
noble metal NPs has been pushing forward the chemistry for their functionalization with different 
moieties such as nucleic acids, antibodies, biocompatible polymers, enzymes and other proteins, in a 
quest for an increased biocompatibility and targeting specificity [10,23]. 
Table 1. Types of conjugations between biomolecules and noble metal NPs. 
Type of conjugation Pros Cons 
Electrostatic interactions 
(e.g., adsorption of 
negative charged DNA to 
positive charged gold NP) 
- Very simple and 
straightforward to perform. 
- Restricted to opposite charged biomolecules 
and NPs; 
- Very sensitive to environmental properties 
(e.g., pH, ionic strength, etc.); 
- Weak functionalization. 
Chemisorption 
(e.g., quasi-covalent 
binding of thiol-
functionalized 
biomolecule to gold NP) 
- Allows oriented 
functionalization; 
- Very robust 
functionalization. 
- Requires NPs with capping agents with 
weaker adsorption than the derivatization 
moiety; 
- Usually requires modification of the 
biomolecule; 
- Subject to interference by other chemical 
groups available for adsorption within the 
biomolecule; 
- Affected by chemical degradation and 
surface oxidation of some NPs (e.g., silver). 
Affinity-based 
(e.g., His-tag protein 
binding to Ni-NTA 
derivatized gold NP) 
- Allows oriented 
functionalization; 
- Very straightforward binding 
between affinity pairs. 
- Requires modification of both NPs and 
biomolecules with an affinity pair; 
- Limited to availability of suitable binding 
affinity pairs. 
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Table 1 summarizes the different approaches for the biofunctionalization of noble metal NPs, 
including the main pros and cons of each approach, which can be consulted in more detail in the 
excellent review made by Sperling et al. [10]. 
A range of highly sensitive biosensing methods for nucleic acids, proteins, antibodies, enzymes and 
other biological molecules have been developed by exploring different physicochemical properties of 
the noble metal NPs, such as LSPR, fluorescence enhancement/quenching, surface-enhanced Raman 
scattering (SERS), electrochemical activity, etc. Among these biosensing methods, the colorimetric 
approaches have been the most explored and, due to their simplicity and portability, are one the most 
promising for future diagnostic methods at point-of-care. For this reason also, most methods have been 
based on silver and gold NPs, since these present unique optical properties within the visible 
wavelength range and are easy to synthesize and functionalize, with gold NPs being the most explored 
of all noble metal NPs. Nonetheless, even though in much less extension than silver and gold NPs, 
other noble metal NPs, such as platinum NPs, have also been used in biosensing applications, mostly 
by exploring their unique electrochemical properties. 
2.2. Localized Surface Plasmon Resonance 
One of the most explored characteristic of noble metal NPs for biosensing is their LSPR arising 
from the electromagnetic waves that propagate along the surface of the conductive metal [24]. When 
excited with an electromagnetic wave, such as light, most noble metal NPs produce an intense 
absorption and scattering due to the collective oscillation of the conduction electrons located at the 
NPs’ surface. In the particular case of gold and silver NPs, the LSPR yields exceptionally high 
absorption coefficients and scattering properties within the UV/visible wavelength range that allows 
them to have a higher sensitivity in optical detection methods than conventional organic dyes, making 
them the perfect candidates for colorimetric biosensing applications [25,26]. Moreover, their LSPR 
properties can be easily modulated according to their size, shape and composition [22,27]. Figure 1 
illustrates the effect of nanoparticle composition in LSPR that has been already demonstrated 
beneficial for the development of new and highly sensitive biosensing methods [28,29]. 
Typically, colloidal solutions of spherical gold NPs (<40 nm) present a red color with their LSPR 
band centered at ca. 520 nm, while spherical silver NPs present a yellow color with their LSPR band 
centered at ca. 420 nm [25]. Both metals can also be combined in an alloy or core-shell conformation, 
presenting a LSPR band that can vary within the wavelength limits of pure metal NPs LSPR bands. In 
the case of the core-shell conformation, a dual LSPR peak characteristic of each pure metal can be 
observed, depending on the thickness of the metallic shell [27]. These LSPR bands are usually weakly 
dependent on the size of the NPs and the refractive index of the surrounding media, but strongly 
change with inter-particle distance, for example aggregation of NPs leads to a pronounced color 
change as a consequence of the plasmon coupling between NPs and a concomitant red-shift of the 
LSPR absorption band peak [30]. Most of the colorimetric biosensors based on gold and/or silver NPs 
have been developed considering these changes in color generated by the plasmon coupling between 
NPs upon aggregation, while other methods have used the LSPR properties of the noble metal NPs just 
as a colorful reporter (i.e., making use of their superb scattering and/or absorbance properties). Some 
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are based on the unspecific adsorption of biomolecules to non-functionalized noble metal NPs, while 
others are based on functionalized noble metal NPs for increased specificity. 
Figure 1. Example of LSPR modulation through different NP compositions. The LSPR 
absorption band of gold/silver alloy NPs increases to longer wavelengths with increasing 
amounts of gold. 
 
In the case of the non-functionalized NPs, Li et al. took advantage of the differential propensity of 
ssDNA and dsDNA adsorption to gold NPs to develop a biosensor for DNA detection [31]. The free 
bases of ssDNA molecules interact electrostatically with the negatively charged surface of gold NPs 
harboring a citrate capping, which confers an increased stability to the NPs upon increasing ionic 
strength. On the other hand, dsDNA molecules adsorb much less to the NPs’ surface and do not provide 
stability to increasing ionic strength induced aggregation of the NPs. Based on these observations, Li 
and co-workers combined gold NPs with citrate capping with a polymerase chain reaction (PCR) 
procedure, using ssDNA probes complementary to the amplicon. Whenever the template of the PCR is 
amplified, the ssDNA probes hybridize with the amplicon and consequently become unavailable to 
adsorb to the gold NPs’ surface and confers them with increased stability to salt induced aggregation. 
This way, a positive result (i.e., target amplification) yields a colorimetric change from red to blue 
upon salt addition, while in a negative result the color remains unchanged. This approach has also been 
successfully explored for the detection of SNPs [32,33], ultraviolet (UV)-induced mutagenic or 
carcinogenic DNA dimers [34], or to directly detect unamplified hepatitis C virus RNA isolated from 
clinical specimens [35]. Similarly, Xia and co-workers used the same approach to develop a nearly 
“universal” biosensor to detect a broad range of targets including nucleic acids, proteins, small 
molecules and inorganic ions, using conjugated polyelectrolytes and different ssDNA aptamers or 
probe molecules that mediated the target detection [36]. Ma et al. used gold nanorods in a CTAB 
solution to achieve a DNA target detection limit down to 0.1 pM [37] and Kanjanawarut et al. used 
peptide nucleic acids instead of ssDNA oligonucleotide probes to improve the differential aggregation 
between complementary and non-complementary targets [38]. Non-functionalized citrate-capped NPs 
have also been used to develop colorimetric biosensors for thiourea and melamine [39,40]. In these 
approaches, the presence of thiourea or melamine in the colloidal solution reduced the overall surface 
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charges of silver or gold NPs, respectively, resulting in their aggregation and a colorimetric response 
correlating with the concentration of the targets (up to 0.8 nM for thiourea and 40 ppb for melamine). 
Other approaches have used noble metal NPs functionalized with different biosensing molecules 
(e.g., ssDNA, antibodies, proteins or enzymes) in order to increase specificity of the methods. In 1996, 
Mirkin et al. described the use gold NPs functionalized with thiol-modified ssDNA probes (i.e., gold 
nanoprobes) that would form a cross-linking network upon detection of a complementary ssDNA 
target by both gold nanoprobes [41]. This cross-linking network lead to the aggregation of the gold 
NPs causing a red-shift in the LSPR absorbance band to 574 nm. It was also possible to detect a single 
base mismatch through this cross-linking approach by controlling the temperature of denaturation of 
the cross-linked network, which presents a sharp melting transition [42]. This cross-linking approach 
has also been combined with a rolling circle amplification technique allowing the detection of single 
point mutations with 1 fM sensitivity [43]. Other methods for specific nucleic acid detection using 
gold NPs functionalized with ssDNA probes have been developed based on their differential  
non-cross-linking aggregation mediated by the increasing ionic strength of the solution [44–50]. In the 
case of the non-cross-linking method developed by Baptista and co-workers, the differential 
aggregation of the gold nanoprobes is evaluated upon salt addition to discriminate the presence of 
complementary, mismatched and non-complementary targets in solution [45–50]. Only the presence of 
a fully complementary target provides stability to the gold nanoprobes, while mismatched and  
non-complementary targets allow the nanoprobes to aggregate upon salt addition. This method has 
been thus far successfully applied to the detection of pathogenic agents [46,48] and single-nucleotide 
polymorphism (SNP)/single point mutations [50,28], as well as in gene expression analysis without the 
need for retro-transcription [47,49]. Moreover, the use of different gold/silver alloy nanoprobes in 
combination with the pure gold nanoprobes has allowed to create a multiplex DNA biosensor 
following this non-cross-linking approach [28,29]. Jian and co-workers also developed a non-cross-
linking assay for the specific detection of a gene associated with sickle-cell anemia using fibrinogen-
functionalized 56 nm gold NPs and a thrombin-binding aptamer assembled on gold NPs [51]. The 
detection was mediated through thrombin-induced aggregation of the fibrinogen-functionalized gold 
NPs allowing to achieve a limit of detection of 12 pM. The potency of the inhibition mediated by the 
thrombin-binding aptamer conjugated with gold NPs relative to thrombin also demonstrated to be 
highly dependent on the concentration of fully complementary DNA targets presenting a linear 
sensitivity in the concentration range of 20–500 pM. 
Apart from the methods based on colorimetric alterations, other colorimetric methods have been 
developed using the noble metal NPs as a reporter. One example is the method for detecting nucleic 
acid sequences through the hybridization with gold nanoprobes in a chromatographic strip, also known 
as dipstick, as described by Kalogianni et al. [52]. In this approach, similarly to current pregnancy 
tests, biotinylated PCR products are hybridized to a specific oligo(dA)-tailed probe and loaded on the 
chromatographic stripe. As the buffer migrates through the stripe, the biotinylated PCR products are 
immobilized by streptavidin spotted in a specific location of the stripe. Finally, to detect the presence 
of the DNA target in the streptavidin spot, poly-dT gold nanoprobes are used to hybridize with the 
poly-dA probe. Other variants of this technique have also been described by Kalogianni et al. to fit a 
specific application (e.g., SNP detection, multiplex analysis) [53–55] and by Fan et al. to monitor 
protein-protein interactions using silver NPs instead of gold NPs [56]. Using a high-throughput 
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microarray approach, Mirkin’s group used gold nanoprobes to substitute the conventional 
fluorescence-labeled probes usually used to report target hybridization [57]. In this approach, the 
scattered light incident on the gold NPs reported complementary target hybridization. Moreover, using 
an additional step of silver(I) reduction over the gold nanoprobes surface, the scattering intensity 
increased and up to 200 fM of genomic DNA target was successfully detected [58]. The detection of 
single base mismatches was also possible at controlled temperatures with increased selectivity when 
compared to standard fluorescent probes. Zhou et al. added a biomineralization-assisted amplification 
methodology to this approach that allowed to discriminate single-base mismatches upon a salt-based 
stringency wash using a target concentration as low as 50 aM [59]. The assay involves two types of 
derivatized gold NPs: one simultaneously functionalized with both target-recognition oligonucleotide 
and biomineralization-capable silicatein (probe A) and the other derivatized with an oligo(ethylene 
glycol) derivative (probe B). These two probes allowed detection of DNA through a cascade signal 
amplification process: first, a transparent solid support surface modified with a capture oligonucleotide 
was used to hybridize to both target and probe A in a sandwich manner; then, the silicatein from probe 
A catalyzes the synthesis of silica simultaneously allowing for the entrapment of probe B and yielding 
the first signal amplification. The signal can be further enhanced by selective deposition of silver 
metals on both probes. 
Mirkin’s group also developed the microarray approach to detect protein cancer markers using 
antibody microarrays and gold NPs functionalized with antibodies [60]. This time, they used an 
electroless gold deposition as a light scattering signal enhancer allowing to detect as low as 300 aM 
(9,000 copies) of prostate specific antigen in buffer and 3 fM in 10% serum. They have also developed 
a bio-barcode assay high sensitivity for nucleic acid or protein targets, by combining such microarray 
approaches with magnetic microparticles holding recognition elements (antibodies or DNA) for 
specific targets and gold nanoprobes that harbored a secondary recognition agent and hundreds of 
ssDNA barcodes strands [61,62]. Through this approach they have been able to successfully detected 
prostate-specific antigen (PSA) in clinical samples with 300 times more sensitivity than commercial 
PSA immunoassays [63]. In fact, the microarray approach developed by Mirkin’s group is already 
being commercialized by Nanosphere, Inc. (known as Verigene® system) and was one of the first 
nanotechnology-based diagnostic platforms to be approved by U.S. Food and Drug Administration 
(FDA). 
Gold NPs functionalized with an antibody anti-CA15-3-HRP were also implemented in a traditional 
ELISA immunoassay to detect a breast cancer biomarker present in blood (i.e., CA15-3 antigen) such 
as to improve the optical signal of the assay [64]. When compared to classical ELISA procedures, the 
gold NPs based ELISA presented a higher sensitivity and shorter assay time allowing to detect a target 
within the 0–60 U/mL range. Zhang et al. also developed a human serum albumin (HSA) immunosensor 
based on a chitosan-modified glass slide harboring a polymer with amino groups that served as linking 
sites (using glutaraldehyde) for anti-HAS antibody [65]. The antigen (HSA) and gold NP-labeled  
anti-HSA were then added to complete the sandwich-type immunocomplex and a linear correlation 
was obtained between the logarithm of HSA concentration and the absorbance intensity, as measured 
by UV-visible spectroscopy. Mayer et al. have also explored the shifts in the LSPR spectral extinction 
peak of gold nanorods and bipyramids NPs conjugated with antibodies to monitor real-time dynamic 
interactions with a specific secondary antibody [66,67]. 
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2.3. Infrared Imaging and Enhanced-Spectroscopy 
Noble metal NPs presenting a significant absorbance and scattering in the near infrared (NIR) 
region, such as gold nanoshells, nanorods or silver NPs, have found wide application as contrast agents 
for in vivo imaging [68–70] and also as nanostructures for surface-enhanced infrared absorption 
spectroscopy (SEIRAS)-mediated biosensing [71]. 
Several authors have taken advantage of the high permeability of human skin and tissue to NIR 
radiation to develop minimally invasive deep tissue diagnostic imaging techniques using such NPs as 
contrast agents. In general, the use of such noble metal NPs in in vivo imaging applications allows one 
to overcome several limitations of conventional NIR organic dyes, such as rapid photobleaching, 
detection sensitivity, insufficient stability in biological systems and weak multiplexing capability [69]. 
The high scattering properties of these NPs permits to enhance the contrast of imaging systems based 
on microscopy, such as dark-field or dual-photon luminescence microscopy, and even combine multiple 
imaging modalities such as to explore synergistic advantages over single imaging techniques [72,73]. 
Additionally, the synergy of such biosensing aptitudes with their intrinsic therapeutical capabilities, 
i.e., theranostics, can provide for more efficient and focused therapies of different diseases, such as 
cancer [4]. These noble NPs, with a LSPR located within the NIR region, have been applied to 
different imaging techniques, such as Photoacoustic Imaging (PAI), Photoacoustic Tomography 
(PAT), dark-field microscopy and two-photon microscopy. PAI and PAT techniques allow 
noninvasive imaging with the capacity of resolving the optical absorption map of tissue at penetration 
depths akin with ultrasound imaging. For example, Agarwal and co-workers combined antibody 
functionalized gold nanorods tuned to the NIR region with PAI to effectively target and image early 
stage prostate cancer cells. These gold nanorods allowed them to produce high contrast images 
between targeted tissue and non-targeted tissue [74]. Similarly, Eghtedari et al. used gold nanorods as 
a contrast agent for in vivo detection using a laser based PAI system [75], while Pan et al. used NIR 
absorbing 2−4 nm gold nanobeacons (i.e., gold NP functionalized with ssDNA strands that form a 
hairpin structure) to detect sentinel lymph nodes through PAI in ex vivo tissue samples [76]. On the 
other hand, Wang’s group has used PAT technique to image the distribution of gold nanoshells 
circulating in the vasculature of a rat brain by achieving a gradual enhancement of the NIR optical 
absorption in the brain vessels [77,78]. They concluded that these NPs presented a high spatial resolution 
and enhanced sensitivity with an increased photoacoustic contrast up to 81% greater than blood, in 
their latest report. Lu et al. have also observed this increase in contrast by using similar NIR absorbing 
40 nm gold nanoshells functionalized with thiolated-PEG as contrast agents for PAT in nude mice [79]. 
NIR scattering gold nanoshells were used by Loo and co-workers as a contrast agent in dark-field 
microscopy to target human epidermal growth factor receptor 2 (HER2), a clinically significant breast 
cancer molecular marker [80]. Similarly, Bickford et al. also used these type of gold nanoshells to 
image live HER2-overexpressing cancer cells using two-photon microscopy [81]. 
The LSPR of noble metal NPs when tuned into the NIR part of the spectrum can also be exploited 
for surface enhanced infrared absorption (SEIRA) spectroscopy, taking advantage of the direct NIR 
excitation of molecules adsorbed to metal NPs’ surface. Some applications have benefited from 
SEIRA, namely in chemical analysis and biochemical sensing [82]. Mostly, gold and silver NPs have 
been used for the development of SEIRA based biosensors. As an example, by depositing gold NPs 
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functionalized with specific antibodies over a SiO2/Si wafer surface, Enders and co-workers were able 
to detect antibody-antigen coupling with a 25-fold enhancement over a SiO2/Si wafer surfaces’ lacking 
the gold NP layer [71]. The IR transmission spectra (normal incidence) of non-specific antibody–antigen 
coupling and of specific antibody–antigen coupling was studied using a monolayer of anti-rabbit 
antibodies from goat immobilized on gold NP/(aminopropyl)-triethoxysilane/SiO2/Si wafer as reference. 
The specific antibody–antigen reaction could clearly be detected via the characteristic absorption bands 
of proteins that are not coupled to the non-specific antigens. 
2.4. Raman-Spectroscopy and Imaging 
In 1974, Fleishmann and co-workers demonstrated for the first time that Raman signals from 
different types of molecules could be dramatically enhanced by their adsorption to silver surfaces [83], 
as well as on other metals, as later demonstrated. Since then, the use of metal NPs for  
surface-enhanced Raman scattering (SERS), mostly gold and silver NPs, has led to the development of 
a wide variety of new biosensors for the detection of nucleic acids, antibodies, proteins and other 
biological molecules [84,85]. Raman scattering arises from the inelastic scattering of photons that hit 
the analyte molecule and either gain or lose energy from the molecule’s vibrational and rotation 
motion. This interaction generates a very narrow spectrum of bands that is unique for each analyte, and 
which can be greatly enhanced by metal nanostructures in the order of 105 to 106 times more than  
non-SERS Raman signals [86]. This enhancement is mainly attributed to the LSPR of the metal 
nanostructures and can be greater enhanced when the analyte molecules are placed in “hot spots” 
where LSPR fields overlap, such as junctions between aggregates of noble metal NPs [87]. 
The SERS detection of specific biomolecules mediated by noble metal NPs can be either 
accomplished directly or indirectly, through the association with a molecule with an intense and 
characteristic Raman signature, typically a fluorescent dye. Most of the methods based on SERS have 
taken similar approaches to those already described in colorimetric and fluorescent assays. For 
example, by exploring the electrostatic adsorption of some biomolecules to the NPs’ metal surface 
some groups have created a metallic layer made of gold or silver NP aggregates to perform the 
detection of biomolecules and metabolites by SERS. Gogotsi et al. developed a SERS label-free 
biosensor based on a glass coated with gold NPs to detect and quantify nicotinic acid adenine 
dinucleotide phosphate (NAADP) molecules, which is a calcium secondary messenger that plays a 
crucial role for intracellular Ca2+ release [88]. This system allowed for the rapid detection of 100 μM 
NAADP without any special sample purification or labeling, making it an important tool for the study 
of normal cell function and cancer development. Ozaky’s group used a similar approach using a 
surface covered with silver NPs instead of gold to detect bombesin, a neurotransmitter tumor marker, 
and its modified analogues by SERS [89]. They have also developed a protocol to monitor  
protein-protein and protein-small molecule interactions employing colloidal silver staining of the 
samples for producing active substrates for SERS [90,91]. Similarly, Van Duyne’s group used SERS 
to detect and monitor glucose levels by adding a self-assembled monolayer of decanethiol over an 
aggregated silver NPs film in order to increase glucose adsorption which is minimal for bare-SERS 
active substrates, such as roughened silver [92,93]. The initial glucose detection limit of this system 
was lower than 5 mM, but was subsequently improved by the use of mixed decanethiol and 
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mercaptohexanol or (1-mercaptoundeca-11-yl)tri(ethylene glycol) layers and use of gold NPs instead 
of silver [94–96].The detection of ssDNA using SERS was carried out by Fabris and co-workers using 
a slide derivatized with uncharged peptide nucleic acids (PNAs) that recognized specific negatively 
charged ssDNA targets, which upon hybridization mediated the adsorption of positively charged silver 
NP [97]. A further addition of rhodamine6G dye to this system gave rise to SERS signals that allowed 
monitoring the hybridization event. 
The use of conjugated noble metal NPs was also explored in SERS-based biosensors for a more 
versatile and specific detection of biomolecules. In most cases, a probe (e.g., DNA, antibody) is 
functionalized to the NP or an aggregated layer of NPs such as to create a sandwich conjugation with a 
Raman-labeled probe upon target detection, thus generating the SERS signal. Some variations of this 
cross-linking approach (Figure 2) have been explored by (i) Bonham et al. in the detection of  
DNA-binding proteins through the use of DNA functionalized gold NPs and an electroless silver 
plating of the conjugates to enhance the output signal [98]; (ii) Ryu et al., to detect a specific Anthrax 
biomarker by means of peptide derivatized gold NPs [99] (iii) Vo-Dinh and co-workers for the 
detection of specific DNA sequences, such as HIV DNA, using Raman-active dye-labeled DNA on 
silver or gold NPs [100–103]; (iv) Ozaki’s group to detect hepatitis B virus antigen using surface 
immobilized antibodies and gold NPs conjugated to antibodies and 4-mercaptobenzoic acid (MBA), 
acting as a Raman-active probe. In this case the signal was further enhanced by silver staining allowing 
to detect as low as 0.5 µg/mL of target [104]; (v) Driskell et al. in the detection of viral pathogens, 
such as feline calicivirus, using gold NP conjugated with a monoclonal antibody and a Raman reporter 
moiety, namely 5,5'-dithiobis(succinimidyl-2-nitrobenzoate) [105]; among others [106–108]. 
Figure 2. Examples of different variations of cross-linking approaches for SERS. The 
schematics depicts different approaches to the use of Raman-active moieties to enhance 
SERS signal output via cross-linking strategies: the Raman-active moiety can be bond to 
the target (two illustrations to the left) or to the surface of the film and/or NP (two 
illustrations to the right). Signal enhancement will occur upon cross-linking of the involved 
moieties derived from target recognition and binding. 
 
The cross-linking approach can also be used to entrap the Raman reporter moiety in “hot-spots” 
between NPs upon target detection, benefiting from an additional enhancement of SERS signal. For 
example, ssDNA functionalized silver [109] or gold [110,111] Raman dye-labeled NPs were used to 
detect the presence of a complementary ssDNA target that would generate a cross-linked nanostructure 
of NPs and, therefore, entrap the Raman-dye within it. 
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Vo-Dinh’s group also explored a molecular nanobeacon approach using a Raman dye-labeled DNA 
functionalized on silver NPs where the presence of a complementary target would decrease SERS 
signal. This decrease was a consequence of the disruption of the hairpin structure that, otherwise, leads 
the Raman dye to the proximity of NPs’ metallic surface [112]. Through this approach they were able 
to detect and quantify a gag gene sequence of the human immunodeficiency virus type 1 (HIV-1) 
within the range of 0.5 and 2 µM of DNA target. They have also expanded this method for multiplexing 
capability using two different Raman dyes-labeled gold nanobeacons to successfully detect the presence 
of the erbB-2 and ki-67 breast cancer biomarkers [113]. 
Other multiplex SERS methods have also been developed for biosensing based on a  
microarray approach [114,115], multiple dye-labeling [116,117], or even on “bar-coded” noble metal 
NPs [118–120]. An example of the latter, are the gold barcode nanodisks fabricated by Mirkin’s group 
using on-wire lithography to create a barcode with 2 nm separated patterns of nanodisks over nickel 
wires [119]. The gaps located between the gold nanodisks acted both as “hot-spots”, to enhance the 
SERS signal from the Raman-active dyes, and as a physical encoded “barcode” pattern, for multiplex 
detection of biomolecules using confocal Raman spectroscopy. As proof-of-concept, they demonstrated 
that multiplexing detection of DNA was possible with targets concentrations as low as 100 fM.  
More recently, the group also developed silver nanorods with etched gaps for multiplex biosensing by 
SERS [120]. 
The application of SERS mediated by noble metal NPs has also been described for in situ detection 
of specific reactions and intracellular molecular imaging of living cells and tissues. As an example, 
Qian and co-workers derivatized 60-80 nm gold NPs with PEG and a tumor targeting ligand, namely 
single-chain variable fragment antibodies, to detect tumors both in vitro and in vivo through SERS 
imaging [121]. These NPs were able to detect tumor biomarkers, such as epidermal growth factor 
receptors on human cancer cells and in xenograft tumor models, being more than 200 times brighter 
than NIR-emitting quantum dots (QDs). They were able to detect tumors up to 2 cm below the skin of 
live animals, mainly due to the fact that the LSPR peaks of such NPs was tuned within the 630–785 nm 
region, where the optical absorption of water is minimal. Specific cancer markers (phopholipase Cg1 
biomarker proteins—PCg1) were also imaged in live human embryonic kidney cells (HEK293) by 
SERS microscopy using derivatized gold/silver core/shell NPs with R6G Raman tags and IgG 
antibodies [122]. Multiplexed SERS imaging has also been demonstrated in living mouse upon the 
injection of five different 60 nm gold NPs derivatized with a silica shell and a unique Raman active 
moiety for each NP (making up a total of 120 nm NP in diameter) [123]. These conjugated SERS-NPs 
naturally accumulated in the liver 24 h after the injection and presented five distinguishable SERS 
spectra signals up to 5 mm of tissue depth, which limited the mapping of the total liver for deeper 
tissue levels. 
2.5. Fluorescence Spectroscopy 
The exceptional quenching of fluorescent dyes mediated by noble metal NPs has allowed increased 
sensitivity and efficiency of Förster resonance energy transfer (FRET)-based biosensors. Two 
approaches have been used thus far: the so called molecular beacons that rely on NPs functionalized 
with fluorescent-labeled ssDNA strands that form a hairpin structure; and noble metal nanoprobes 
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consisting of NPs functionalized with single strand nucleic acid strands that are hybridized to another 
fluorescent-labeled single strand nucleic acid probe (Figure 3). 
Figure 3. Different approaches for fluorescent-based noble metal NPs biosensing.  
(A) molecular nanobeacons and (B) other nanoprobes. Distance to the nanoparticle determine 
the fluorescence signal that is observed. Distances are not represented to the scale. 
 
In the case of the molecular beacons, the hairpin structure leads the fluorescent dye moiety to the 
proximity of the NP’s surface and, consequently, to the quenching of fluorescence due to Nanoparticle 
Surface Energy Transfer (NSET) occurring between the dye (donor molecule) and the NP’s surface 
(acceptor)—a phenomenon that has been described to permit energy transfer for distances nearly twice 
as far as FRET [124,125]. In the presence of a complementary DNA/RNA target, the hairpin structure 
is disrupted by target hybridization and fluorescence is restored. Several methods have been developed 
based on this approach to monitor specific nucleic acid hybridizations as well as cleavage processes 
mediated by nucleases, mainly using gold NPs [126]. For example, Dubertret and co-workers reported 
the use of molecular nanobeacons based on 1.4 nm gold NPs to detect single-base mismatches in DNA 
with a 100-fold increase in sensitivity when compared to conventional molecular beacons [127]. 
Similarly, Benia et al. used molecular nanobeacons based on 13 nm gold NPs to successfully detect a 
mutation associated to cystic fibrosis using just 1 nM of target [128]. They have also shown that the 
use of gold NPs larger than 13 nm for molecular nanobeacons is not recommended due to the fact that 
larger NPs present relevant quenching efficiency even at large fluorophore–NP separation lengths, 
despite the fact that they could carry a higher number of molecular beacons. 
On another approach, noble metal nanoprobes can be combined with dye-labeled ssDNA probes to 
detect specific nucleic acid targets by FRET/NSET mediated mechanisms. One method is to design 
such probes to harbor complementary and contiguous sequences to the target, in such way that upon 
target hybridization the dye is forced to approach the NP’s surface and the fluorescent signal 
consequently decreases [129]. Another method is to hybridize the dye-labeled ssDNA directly to the 
nanoprobes and detect specific target DNA sequences based on strand displacement of the fluorescent 
probe [130]. For example, in the presence of a fully complementary long ssDNA targets, the short  
dye-labeled DNA strand is displaced and, as a result, the fluorescence that was initially quenched by 
the NP is restored. Through this approach, the signal-to-noise ratio and detection limit of 50 pM is 
significantly improved when compared with similar probes using organic acceptors as reported by Mo 
and co-workers [130]. A similar approach was used by Wang and co-workers to detect proteins using 
the dye-labeled ssDNA hybridized to an aptamer that is immobilized on gold NPs [131]. Whenever a 
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protein binds to the aptamer, the dye-labeled ssDNA is released and fluorescence is restored, allowing 
to detect proteins with high sensitivity and specificity. Similarly, Ray and co-workers demonstrated 
that the DNA cleavage by specific nucleases can also be easily and quickly monitored using  
Au-nanoprobes hybridized with complementary Cy3-labeled nucleic acid strands with a sensitivity 
several orders of magnitude greater than the conventional gel electrophoresis or HPLC techniques, or 
even a few orders of magnitude greater than UV assays [132]. The presence of a S1 nuclease leads to 
the cleavage of the dye-labeled dsDNA bound to the NP and consequently to an enhancement of the 
fluorescence signal by a factor of 120. Jennings et al. also developed a method based on this approach 
using NSET to measure Mg2+-induced conformational changes and kinetics of a hammerhead 
ribozyme using a fluorescent labeled RNA that hybridized with a complementary strand attached to  
1.4 nm gold NPs and formed the hammerhead structure [133]. Mayilo et al. described a sandwich 
immunoassay using gold NPs quenching upon detecting a cardiac troponin T protein by its interaction 
with two different antibodies, one attached to gold NPs and the other labeled with fluorescent  
dyes [134]. Guirgis and co-workers developed an immunoassay to detect malaria based on the 
fluorescence quenching of Cy3B-labeled recombinant Plasmodium falciparum heat shock protein  
70 (PfHsp70) upon binding to gold NPs functionalized with an anti-Hsp70 monoclonal antibody [135]. 
Upon competition with the free antigen, the Cy3B-labeled recombinant PfHsp70 is released to solution 
resulting in an increase of fluorescence intensity. The interaction of human blood proteins with gold 
NPs has also been studied by letting the proteins interact with fluorescent gold NPs and performing the 
detection through quenching [136]. 
The combination of noble metal NPs and semiconductor QDs as a FRET donor–acceptor couple has 
also been explored by several authors to develop fluorescence competition assays for nucleic acid, 
protein and antibody/antigen detection following the same approaches described above, simply by 
substituting the dye with QDs [137–139]. Additionally, more than one dye can also be simultaneously 
used to develop multiplexing approaches of all the previously described methods by tracking the 
specific emission of each dye, since the quenching effectiveness of noble metal NPs is widespread 
across the UV/visible spectra. Namely multiplex methods for DNA detection [140,141], endonucleases 
monitoring [142], small analytes detection (adenosine, potassium and cocaine) using aptamers [143] 
have been described. 
The use of noble metal NPs to enhance the fluorescence signal of dyes used in a DNA assay has 
been reported by Dragan et al. [144]. A 2-color DNA assay based on the combination of the  
Metal-Enhanced Fluorescence (MEF) effect and microwave-accelerated DNA hybridization allowed to 
detect dye-labeled targets in a microarray format. The microarray ssDNA probes are functionalized 
over a monolayer film of silver NPs which contributed for the large enhancement of the target’s 
fluorescent label due to a short-range (0–30 nm) coupling effect of a dye’s excited state electronic 
system with NPs plasmons. 
Different noble metal NPs with inherent fluorescent properties or directly functionalized with 
fluorescent dyes have also been used for in vivo biosensing. Zhang and co-workers have developed 
fluorescent metal nanoshells composed of silica spheres with encapsulated [Ru(bpy)3]2+ complexes as 
cores and thin silver layers as shells to detect single microRNA molecules in cells positive to lung 
cancer [145]. These nanoshells harbored a covalently bound ssDNA probe that recognized the micro 
RNA (miRNA) target in the cells and presented highly contrast images against cellular autofluorescence, 
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mainly due to their strong intensity emission and longer lifetimes. The same authors have also reported 
similar fluorescence enhancements of different fluorophores when functionalized to different silver 
NPs, which were used to target different receptors within cell membranes [146,147]. Using a different 
approach, Phillips and co-workers developed an array of gold NP–conjugated polymer constructs for 
bacterial sensing [148]. The efficient quenching ability of gold NPs coupled with the molecular-wire 
effect of conjugated polymer compounds generated a pronounced fluorescence response mediated by 
the binding strength of the bacterium to the gold NP. Through this approach, the authors successfully 
differentiated twelve different bacteria using only three systems. 
2.6. Electric and Electrochemical Approaches 
The unique physicochemical properties of noble metal NPs, such as high surface area, high 
mechanical strength, rich electronic and catalytic properties, have been explored to detect biological 
recognition events through electrical signals or electrochemical transductions and design a new 
generation of electronic biosensor devices [149,150]. These electrical and electrochemical approaches 
generally rely on the changes in the ohmic response of an electrical circuit or the flow of electrons 
arising from faradaic processes (i.e., oxidation or reduction) near the surface of an electrode, 
respectively, to achieve biosensing. Although the direct electrical and electrochemical detection of 
biomolecules is possible, many have benefited from the electroactive or catalytic properties of NPs as 
reporters for biosensing with unprecedented levels of sensitivity [151]. 
The key aspect of electrical biosensors is the generation or modulation of electrical current in an 
electronic circuit by molecular binding of the biomolecule of interest, such as the completion of a 
broken circuit or altering the electrical properties of an electro-mechanical sensor (e.g., piezoelectric 
sensor). An example of the latter case, is the piezoelectric biosensor developed by Chen and  
co-workers using gold NP functionalized with DNA probes for the detection of the foodborne 
pathogen Escherichia coli O157:H7 [152]. In this application, the authors used gold nanoprobes as a 
mass enhancer and, thus, further amplify the changes in the signal and the sensitivity of the 
piezoelectric sensor, as well as increase the specificity of the method. The oscillation frequency of the 
piezoelectric sensor decreased in real-time as the weight at the sensor's surface increased due to  
the sandwich hybridization occurring between the target oligonucleotide, the sensor’s probe 
oligonucleotides and the circulating DNA functionalized gold NP. Similarly, Pang et al. used this 
piezoelectric approach to detect a DNA single-base mutation within an artificial codon CD17 of the  
β-thalassemia gene, complementing the method with a DNA ligase reaction [153]. Immunoassays  
were also developed using piezoelectric sensors in which the specific agglutination of antigen-coated 
gold NPs causes a frequency change in the signal when in the presence of the corresponding  
antibody [154,155]. 
Another electrical approach for biosensing is to explore the conductivity of noble metal NPs and 
use them as conductive tags to act as a “switch” on an electrical circuit. Following this idea, several 
groups developed DNA sensors based on electrode gaps in which the binding of noble metal NPs 
functionalized with oligonucleotides leaded to conductivity changes associated with target-probe 
binding events [156–160]. In the case of the Mirkin’s group approach [156], the presence of a 
complementary target allowed the gold nanoprobes to form a sandwich hybridization with the probes 
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functionalized within the electrode gaps, thus filling the gaps and facilitating silver deposition to 
further increase conductivity between electrodes, allowing to detect DNA concentrations as low as 500 
fM with a single base resolution. 
In general, electrochemical biosensors employ potentiometric, amperometric or impedimetric 
transducers to convert the biosensing information into a measurable signal. Some authors have 
described the use of potentiometric stripping analysis to detect and quantify gold, silver or gold/silver 
NPs that worked as tags for biosensing DNA [161–164], antibodies [165–167] or aptamers [168], with 
sensitivities of down to 600 aM, 3 fM and 1 nM, respectively. Others have described the use of cyclic 
voltammetry [169,170], differential pulse voltammetry [171], chronocoulometry [172] electrochemical 
methods to perform biosensing of DNA and proteins mediated by noble metal NPs acting as 
electrochemical labels. Ozsoz and co-workers described an electrochemical genosensor based on gold 
NP and disposable pencil graphite electrodes for the detection of a Factor V Leiden mutation in PCR 
products amplified from clinical samples [173]. The method allowed detection of as little as 0.78 fmol 
of PCR amplicons using the oxidation signal of colloidal gold nanoprobes that hybridized to the 
complementary DNA targets. More recently, Yu et al. used gold NP in combination with apoferrition 
NPs to further increase the sensitivity of electrochemical DNA biosensing down to 51 aM [174]. 
Several authors have described the development of amperometric-based biosensors, which are 
usually more suited for mass production than potentiometric biosensors [175]. In this approach the 
working electrode is usually a noble metal NP covered by the biorecognition component, which 
enables the amperometric signal. Namely, using this amperometric approach: Polsky and co-workers 
used platinum NPs functionalized with nucleic acid aptamers to detect thrombin with a sensitivity limit 
corresponding to 1 nM [176]; Munge et al. developed an immunosensor to detect attomoles of the 
cancer biomarker interleukin-8 using glutathione derivatized gold NPs [177]; Jensen and co-workers 
used inkjet printed arrays with gold NPs to detect the cancer biomarker interleukin-6 directly in  
serum with a detection limit of 20 pg/mL [178]; Yin et al. used gold NPs over a surface of 
poly(styrene-acrylic acid) nanospheres, that served as a matrix to conjugate alkaline phosphatase, to 
detect the tumor necrosis factor α up to 0.01 ng/mL [179]; Meng et al. used gold NPs combined with 
ferric oxide NPs and carbon nanotubes to detect up to 0.04 ng/mL of the tumor biomarker alpha 
fetoprotein [180]; Sharma and co-workers used gold NPs and screen printed electrodes modified with 
multiwall carbon nanotubes to detect Plasmodium falciparum histidine-rich protein 2 in serum of 
humans with malaria [181]. In this case, the authors compared the method with a commercial kit, 
Paracheck Pf test (Orchid Biomedical Systems, Goa, India), and determined that their method was 
more sensitive and specific than the kit, having a detection limit of 8 ng/mL; Merkoçi’s group  
used gold NP and magnetic beads to develop a magneto-immunosensor for the detection of  
anti-hepatitis B virus antibodies and human IgG in human serum [182,183]; Che and co-workers used 
gold NPs with multi-walled carbon nanotube-silver composites to detect down to 0.08 ng/mL of  
alpha-1-fetoprotein [184]; Scodeller et al. used gold-silver core-shell NPs to develop a system 
responsive to glucose based on the enzymatic reduction of FAD by glucose [185]. 
Some impedimetric based electrochemical biosensors have also been reported, following either 
impedance (Z) or its components resistance (R), capacitance (C) and inductance (L). Mahmoud and 
co-workers developed an assay based on a modified gold electrode with single-walled carbon 
nanotube/gold NPs derivatized with thiol terminated ferrocene-pepstatin conjugates able to detect 
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picomolar levels of HIV-1 protease and screen its potent inhibitors using electrochemical impedance 
spectroscopy [186]. Yang et al. fabricated a capacitive immunosensor based on grafted ethylene 
diamine and self-assembled gold NPs monolayer on glassy carbon electrode for the detection of 
Salmonella spp. using also electrochemical impedance spectroscopy [187]. This assay was successfully 
used for the detection of Salmonella spp. in lab-processed commercial pork samples and presented a 
detection limit of 100 CFU/mL. 
Recently, Tian and co-workers developed an electrochemiluminescence biosensor using luminol 
functionalized gold NPs as labels [188,189]. The electrochemiluminescence of luminol is enhanced  
2 to 3-orders of magnitude on gold NPs when compared to bare gold electrodes and allowed this 
sandwich-type immunocomplex sensor to achieve a detection limit of 1 pg/mL for human IgG in 
human sera. 
Multiplex approaches based on some of the methods previously described have also been described. 
Li and co-workers used gold surface DNA arrays functionalized with multiple probes in combination 
with reporting probes made of silver NPs to detect herpes simplex virus (HSV), Epstein-Barr virus 
(EBV) and cytomegalovirus (CMV) sequences by differential pulse voltammetry [190]. The silver 
NPs-based tag allowed for the detection down to 5 aM of target DNA by producing a 103-fold 
amplification in the differential pulse voltammetry signal, due to the excellent electroactive properties 
of silver NPs. 
Enzyme-functionalized gold NPs harboring specific DNA sequences were also used as catalytic 
labels for multiplex DNA detection [191]. A sandwich hybridization strategy was used in this  
method, involving DNA probes functionalized on a glassy carbon electrode which registered the 
electrochemical signals generated by the enzymatic products produced from the substrates catalyzed 
by the functionalized enzymes, namely horseradish peroxidase (HRP) and alkaline phosphatase (ALP), 
upon complementary target recognition. This method allowed to detect two distinct targets in a one-pot 
solution with a detection limit of 0.1 and 12 fM using HRP–gold NPs and ALP–gold NPs as labels, 
respectively. Zhang et al. explored anodic stripping voltammetry using a screen-printed carbon 
electrode chip in combination with bio-barcoded gold NPs, as electrochemical reporters, and magnetic 
NPs, for easy and clean separation from the sample, to detect multiple pathogens (e.g., Bacillus anthracis 
and Salmonella enteritidis) [192]. A multiplex immunoassay was also developed using screen-printed 
array of carbon electrodes and gold NPs as electrochemical labels [193]. This immunoassay is performed 
using a sandwich approach between the electrode array probes and gold NPs labeled with antibodies, 
mediated by the target analytes (i.e., human and goat IgG). Under optimal conditions the method 
allowed to detect a minimum target concentration of 1.1 and 1.6 ng/mL, respectively, using differential 
pulse voltammetry. 
3. Application in Biosensing Platforms—Future Perspectives 
Noble metal NP-based biosensors provide a new horizon for novel functions with a variety of 
applications in clinical diagnostics and biological research. This review has provided a summary of the 
various biosensing strategies developed thus far, that explored the unique physicochemical properties 
of noble metal NPs, towards their potential applications in clinical and point-of-care diagnostics.  
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Table 2 summarizes the different types of real biological samples that have been tested with these 
noble metal NP-based biosensors, according to their methodology principle. 
Table 2. Summary of real biological samples tested with noble metal NP-based biosensors 
according to the type of NP and explored methodology principle. 
Method Type of NP Target/Samples [reference] 
Colorimetric/ 
scanometric 
Gold 
• SNP (rs2131877) in human DNA [32] 
• Mutations in EGFR gene in genomic DNA [33] 
• SNP associated with long QT syndrome in genomic DNA [31] 
• SNPs in β-thalassemia gene in genomic DNA—mediated by  
PCR [43,45] 
• SNPs in MBL2 gene in genomic DNA—mediated by PCR [53,54] 
• Fusion genes in K562 cell line [55] 
• Hepatitis C virus RNA [35] 
• M. tuberculosis DNA and associated drug-resistance SNPs in 
clinical samples [46,48,50] 
• BCR-ABL fusion transcript in clinical samples [47] 
• FSY1 mRNA in total RNA [49] 
 Gold 
• Melamine in whole milk [40] 
• Prostate specific antigen (PSA) in human serum [63] 
• CA15-3 breast cancer biomarker in human serum [64] 
• Genetically modified organisms [52] 
• Mutations associated to methicillin resistance in S. aureus & Factor 
V Leiden mutants [58] 
 
Gold/silver 
alloy 
• TP53 gene [28] 
• BCR-ABL fusion genes [29] 
NIR Gold 
• Prostate cancer cells in mouse [74] 
• Lymph nodes in mouse [76] 
• Brain vessels in mouse [77–79] 
• HER2 cancer biomarker in breast adenocarcinoma cells [80,81] 
SERS Gold 
• Nicotinic acid adenine dinucleotide phosphate (NAADP) in cell 
extracts [88] 
• Glucose in rat [96] 
• Multiple pathogen DNA in clinical specimens (cerebrospinal fluid, 
stool, pus, and sputum) [118] 
• Feline calicivirus (FCV) antibody from cell culture media [105] 
• Prostate-specific antigen in human serum [194] 
• Deep-tissue imaging in living mouse [123] 
 Silver 
• HIV-1 DNA in genomic DNA - PCR mediated [112] 
• Glucose in rat [93] 
 
Gold/silver 
core/shell 
• Phospholipase Cγ1 biomarker protein in cancer cells [122] 
Fluorescence-
based 
Gold 
• Plasmodium falciparum heat shock protein in infected blood 
cultures [135] 
 Silver 
• miRNA-486 expression levels in lung cancer cells [145] 
• Cell membrane imaging in cell lines [146,147] 
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Table 2. Cont. 
Method Type of NP Target/Samples [reference] 
Electric/ 
Electrochemical 
Gold 
• Factor V Leiden DNA mutation in genomic DNA – mediated by 
PCR [173] 
• E. coli O157:H7 in food samples [152] 
 Gold 
• Anti-Toxoplasma gondii immunoglobulins in rabbit blood and 
serum [154] 
• Human and mouse IgG antibody in human and mouse serum [166] 
• Interleukin-8 (IL-8) cancer biomarker in human serum [177] 
• Interleukin-6 (IL-6) cancer biomarker in calf serum [178] 
• Tumor necrosis factor α (TNF-α) in human serum [179] 
• Plasmodium falciparum histidine-rich protein 2 in serum [181] 
• Anti-hepatitis B virus antibodies and human IgG in human serum 
[182,183] 
• HIV-1 protease and inhibitors in human serum [186] 
• Salmonella spp. in pork samples [187] 
• Human IgG in human serum [188,189] 
• Human and goat IgG in serum [193] 
 Silver • α-1-Fetoprotein (AFP) in human serum [184] 
Noble metal NPs have already proven to be one of the most important groups of nanomaterials for 
biosensing approaches, as well as in other biomedical applications (e.g., therapy). Highly sensitive and 
specific biosensors based on noble metal NPs have open up the possibility of creating new diagnostic 
platforms for disease markers, biological and infectious agents in the early-stage detection of disease 
and threats. Among the different approaches explored thus far, such as colorimetric, NIR imaging, 
fluorescence quenching/enhancement, SERS, electric and electrochemical sensing, there are, as 
always, advantages and disadvantages associated to each approach towards the ultimate diagnostic 
application in real samples. In most cases, the proof-of-concept for such approaches has been reported 
using controlled synthetic bioanalytes and/or samples, while validation of these biosensors with a 
statistically larger population of real samples still remains to be addressed as to further prove the 
potential application in clinical and point-of-care diagnostics. Apart from that, one key issue to take 
into consideration in biosensing platform integration is the increasing demand for higher sensitivity 
and selectivity at minimal costs, and the possibility to monitor biosensing in real-time, especially for 
point-of-care platforms, for which simplicity should also be considered. Considering this, colorimetric 
and electrochemical approaches are the most promising due to their simplicity, high sensitivity and 
specificity, in addition to the fact that in most cases they simply do not require expensive and complex 
instrumentations to achieve a sample-in/answer-out biosensing platform. Moreover, such approaches 
allow for multiplexing biosensing enabling their application in a range from low- to high-throughput 
diagnostics. In fact, some of these approaches have already reached commercialization, as is the case 
of Verigene® system by Nanosphere, Inc. (Northbrook, IL, USA) which explores the scattering 
capabilities of gold NPs in a microarray platform providing a diagnostic platform for DNA/RNA and 
protein sensing. 
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On the other hand, the use of NIR active noble metal NPs as contrast agents for PAI or PAT is one 
of the most promising platforms for in vivo imaging, provided that aspects concerning the toxicology 
of such nanomaterials are carefully addressed. Moreover, in most cases, the use of such NP in in vivo 
imaging allows also to simultaneously carry out therapeutic procedures (i.e., theranostics), such as 
photothermal therapy, enabling a more precise and efficient treatment of diseases, such as cancer. As 
an example of this potential, Nanospectra Biosciences (Houston, TX, USA) is already carrying out 
clinical trials for its AuroLase® Therapy approach, which combines gold nanoshells with photothermal 
ablation technology for in vivo imaging and therapy. 
Other developed methodologies using noble metal NPs, such as SERS and fluorescent 
quenching/enhancement approaches, can still find great application in research laboratories, allowing 
to unveil current paradigms and emerging challenges of biology and medicine. That said, some of the 
described noble metal NP-based biosensors that are currently under development will most likely 
revolutionize our understanding of biological mechanisms and push forward the clinical practice through 
their integration in future diagnostics platforms. As nanotechnology is becoming increasingly accessible 
to research laboratories and, most recently, to clinical laboratories, significant advances in the area of 
noble metal NP-based biosensors will certainly occur in the near future, pushed by the intervention of a 
cross-disciplinary team, consisting of a variety of researchers with diverse backgrounds, that will make 
the prospect of widespread use of noble metal NPs in clinical and point-of-care diagnostics a reality. 
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Light has always fascinated mankind and since the beginning of recorded history it has been both a subject of research and a tool
for investigation of other phenomena. Today, with the advent of nanotechnology, the use of light has reached its own dimension
where light-matter interactions take place at wavelength and subwavelength scales and where the physical/chemical nature of
nanostructures controls the interactions. This is the field of nanophotonics which allows for the exploration and manipulation
of light in and around nanostructures, single molecules, and molecular complexes. What is more is the use of nanophotonics in
biomolecular interactions—nanobiophotonics—has prompt for a plethora of molecular diagnostics and therapeutics making use
of the remarkable nanoscale properties. In this paper, we shall focus on the uses of nanobiophotonics for molecular diagnostics
involving specific sequence characterization of nucleic acids and for gene delivery systems of relevance for therapy strategies. The
use of nanobiophotonics for the combined diagnostics/therapeutics (theranostics) will also be addressed, with particular focus on
those systems enabling the development of safer, more efficient, and specific platforms. Finally, the translation of nanophotonics
for theranostics into the clinical setting will be discussed.
1. Introduction
Nanophotonics deals with the interaction of light with
matter at a nanometer scale, providing challenges for fun-
damental research and opportunities for new technologies,
encompassing the study of new optical interactions, materi-
als, fabrication techniques, and architectures, including the
exploration of natural and synthetic, or artificially engi-
neered, structures such as photonic crystals, holey fibers,
quantum dots, subwavelength structures, and plasmonics
[1, 2]. The use of photonic nanotechnologies in medicine
is a rapidly emerging and potentially powerful approach
for disease protection, detection, and treatment. The high
speed of light manipulation and the remote nature of optical
methods suggest that light may successfully connect diag-
nostics, treatment, and even the guidance of the treatment
in one theranostic procedure combination of therapeutics
with diagnostics (including patient prescreening and therapy
monitoring).
Limitations in medical practice are closely associated
with the fact that diagnostics, therapy, and therapy guidance
are three discrete and isolated stages. In order to overcome
some of the sensitivity and specificity of current medicines,
theranostics unites the three above stages in one single
process, supporting early-stage diagnosis and treatment [3,
4]. Nowadays, there is an ever increasing need to enhance the
capability of theranostics procedures where nanophotonics-
based sensors may provide for the simultaneous detection of
several gene-associated conditions and nanodevices utilizing
light-guided and light-activated therapy with the ability to
monitor real-time drug action (see Figure 1).
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Figure 1: Nanophotonics for theranostics. Nanoparticles-based strategies can be used for biosensing using plasmonic nanosensors, such as
metal nanoparticles functionalized with nucleic acid strand for colorimetric assays and biobar codes for protein detection or intense labels for
immunoassays. Some nanoparticle systems can also be used for sensing by exploring a typical FRET system or can be surrounded with Raman
reporters in order to provide in vivo detection and tumour targeting. In fact, NPs symbolize an important class of materials with unique
features suitable for biomedical imaging applications such as increased sensitivity in detection and high quantum yields for fluorescence.
Alternatively, NPs can survey near/far field enhancing qualities that hold promise for a bounty of novel applications in optics and photonics.
Engineered NPs can also act as phototherapeutic agents that can be attached to specific targets for selective damage to cancer cells.
2. Nanophotonics For Diagnostics
2.1. Surface Plasmons on Nanoparticles and Surfaces. Surface
plasmons are collective charge oscillations that occur at
the interface between conductors and dielectrics. They can
take various forms, ranging from freely propagating electron
density waves along metal surfaces to localized electron
oscillations on metal nanoparticles (NPs) [5, 6]. When
light passes through a metal nanoparticle, it induces dipole
moments that oscillate at the respective frequency of the
incident wave, consequently dispersing secondary radiation
in all directions. This collective oscillation of the free conduc-
tion electrons is called localized surface plasmon resonance
(LSPR). Light on NP induces the conduction electrons to
oscillate collectively with a resonant frequency that depends
on the nanoparticles’ size, shape, composition, interparticle
distance, and environment (dielectric properties) [7–10]. As
a result of these SPR modes, the nanoparticles absorb and
scatter light so intensely that single NPs are easily observed
by eye using dark-field (optical scattering) microscopy.
Plasmonic NPs provide a nearly unlimited photon resource
for observing molecular binding for longer periods of time,
once they do not blink or bleach like fluorophores [11].
Nanoparticle-based colorimetric assays for diagnostics
have been a subject of intensive research, where LSPR can
be used to detect DNA or proteins by the changes in the
local index of refraction upon adsorption of the target
molecule to the metal surface. Due to the intense SPR in
the visible yielding extremely bright colors, gold nanoparticle
colloids have been widely used of molecular diagnostics. In
fact, gold nanoparticles (AuNPs) functionalized with ssDNA
capable of specifically hybridizing to a complementary target
for the detection of specific nucleic acid sequences in
biological samples have been extensively used [12–27]. Other
approaches use the AuNPs’ plasmonic as a core/seed that can
be tailored with a wide variety of surface functionalities to
provide highly selective nanoprobes for diagnostics [28] or
the SPR scattering imaging or SPR absorption spectroscopy
generated from antibody-conjugated AuNPs in molecular
biosensor techniques for the diagnosis of oral epithelial living
cancer cells in vivo and in vitro [29] and the use of multi-
functional AuNPs which incorporate both cytosolic delivery
and targeting moieties on the same particle functioning as
intracellular sensors to monitor actin rearrangement in live
fibroblasts [30].
Plasmonic NPs have also been used as extremely intense
labels for immunoassays [31–34] and biochemical sensors
[19, 35–37]. Also, the use of colloidal silver plasmon resonant
particles (PRPs) coated with standard ligands as target-
specific labels has been reported for in situ hybridization and
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immunocytology assays [34]. Most notably, a nanoparticle-
based Biobar code has been developed for the detection
of proteins that relies on magnetic microparticle probes
with antibodies that specifically bind a target of interest
and nanoparticle probes that are encoded with DNA that
is unique to the protein target of interest and antibodies
that can sandwich the target captured by the microparticle
probes [33]. Haes and coworkers have reported on an optical
biosensor based on localized surface plasmon resonance
spectroscopy developed to monitor the interaction between
the antigen, amyloid-β-derived diffusible ligands (ADDLs),
and specific anti-ADDL antibodies, used in the detection of
a biomarker for Alzheimer’s Disease [35].
2.2. Raman-Spectroscopy-Based Systems. When light inter-
acts with a substance, it can be absorbed, transmitted, or
scattered. Scattered radiation can result from an elastic col-
lision (Rayleigh scattering) or inelastic (Raman scattering).
Raman spectroscopy is based on a change of frequency
when light is inelastically scattered by molecules or atoms
resulting in a molecular fingerprint information on molec-
ular structure or intermolecular interaction of a specific
process or molecule. The potential of Raman spectroscopy as
biomedical diagnostics tool is rather low due to its low cross-
section (∼10−30 cm2) that results in low sensitivity [38].
However, in 1977, two groups independently described the
use of noble metal surfaces to enhance the Raman scattering
signal of target molecules [39, 40]—Surface enhancement
raman spectroscopy (SERS). Jeanmaire and Van Duyne
proposed a twofold electromagnetic field enhancement that
was later associated with the interaction between the incident
and scattered photons with the nanostructure’s LSPR [41].
Simultaneously, Albrecht and Creighton suggested the source
of the enhancement to be caused by a specific interaction
between an adsorbate and the nanoparticle surface, briefly, a
charge transfer from the adsorbate into the empty energetic
levels on the metal surface or from the occupied levels of the
nanoparticle’s surface to the adsorbate [42–44].
Generally, SERS requires that the biological analyte
reaches a suitable surface where the substrates are treated as
two-dimensional macroscopic surfaces onto which adsorbed
molecules suffer a local-field enhancement. Despite direct
adsorption not being a good solution because of its depen-
dence on the affinity between substrate and analyte,
a method to identify and distinguish different strains of virus
based on signal differences generated by the surface amino-
acids using silver nanorods has been successfully developed
[45]. Using a similar approach of direct adsorption, Pı̂nzary
et al. used naked silver nanoparticles to differentiate in situ
healthy colon from carcinoma colon tissue [46]. Nanotags
have been widely employed to address the lack of specificity
[47, 48]. These nanotags usually possess a metallic colloidal
core functionalized with a Raman reporting molecule and
the specific molecule used to capture the analyte and have
been used to directly detect DNA sequences [49, 50] and
amplified DNA products of epizootic pathogens using com-
plementary DNA strands so that only the complementary
target hybridizes with the probes [51]. Using a similar
system, but exploring the distance-dependent enhancement
of the electromagnetic field with a hairpin probe molecule,
Wabuyele has also been used to distinguish single nucleotide
polymorphisms in cancer-related genes [52]. Combining
nanotags with other nanoparticles or binding surfaces that
target the same analyte in a sandwich conformation proved
useful to detect antibodies in serum [53]. A similar approach
using a flat substrate instead of NPs had already been
proposed to detect DNA, RNA, and proteins [54, 55].
However, in this approach, the substrate is used only to
immobilize the analyte; a gold-nanoparticle-based nanotag
is used to identify the analyte and the surface enhancement
is obtained by silver coating of the nanotag. miRNA profiling
has also been pursued via a slightly different approach based
on the hybridization of the target molecules with a thiolated
oligonucleotide and subsequent functionalization on a silver
substrate [56]. SERS have also been explored to identify
changes in the analyzed system such as interaction between
DNA and xenobiotic molecules like cisplatin [57] or DNA-
binding proteins [58, 59]. The combination of magnetic
iron/gold core-shell nanoparticles with gold nanorods has
also been used to specifically enumerate E. coli in water
samples in a rapid and sensitive test [60]. In this case,
the magnetic nanoparticles are used to concentrate the
bacteria, improving the Raman signal by concentration and
the posteriorly added gold nanorods serve as Raman signal
enhancers.
SERS can also be used in conjunction with colloidal
gold to detect and target tumors in vivo, where the AuNPs
are surrounded with Raman reporters that provide light
emission 200 times brighter than quantum dots [61, 62].
It was also found that the Raman reporters became more
stable and yielded larger optical enhancements when NPs
were encapsulated with a thiol-modified polyethylene glycol
coat, which also allows for increased biocompatibility and
circulation times in vivo. When conjugated to tumor-
targeting ligands, these conjugated SERS-NPs were able to
target tumor markers at surface of malignant cells, such as
epidermal growth factor receptor (EGFR) that is sometimes
overexpressed in cells of certain cancer types [29] and used
to locate the tumor in xenograft tumor models [50].
2.3. Fluorescence-Based Systems. Quantum dots (QDs) are
semiconductor nanoparticles with narrow, tunable, symmet-
rical emission spectra, and high quantum yields [63–65],
and together with compatibility with DNA and proteins,
make QDs exceptional substitutes as fluorescence labels.
The use of QDs for nucleic acid characterization has
long been proposed, for example, CdSe/ZnS QDs for SNP
identification on human TP53 gene, multiallele detection
of hepatitis B and C viruses [66], and in situ detection of
chromosome abnormalities and mutations [67]. QDs have
also been used as chemical sensors by exploring a typical
FRET system where a dark quencher is placed at a protein-
binding site attached to a QD surface. The quantum dots
emission is quenched in presence of the analyte and upon
analyte displacement the emission is restored [68]. A simpler
approach was used to detect adenine using fluorescent
ZnS nanoparticles at pH7, making use of capability of
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adenine itself to quench emission of the quantum-dot-like
nanoparticles [69].
Several studies report on the modulation of fluorophores
at the vicinity of nanoparticles (e.g., gold, silver, and quan-
tum dots) [70, 71], an interaction that has found application
in a variety of systems to detect biologically relevant targets
with particular focus upon AuNPs due to their ease in func-
tionalization with biomolecules [72–75]. Several methods
based on the quenching of fluorescence have been proposed
for DNA detection consisting of fluorophore-labeled ssDNA
electrostatically adsorbed onto gold nanoparticles [76], car-
bon nanotubes [77], and carbon nanoclots [78], where the
presence of a complementary target triggers desadsorption
of the newly formed dsDNA from the nanostructures due
to the electrostatic variation between ssDNA and dsDNA,
and fluorescence emission is restored. Also, fluorescence
quenching of fluorophores close to metal nanoparticles
functionalized with thiol-modified oligonucleotides has been
explored in different conformations. Tang and co-workers
proposed a method to probe hydroxyl radicals using an
AuNP-oligonucleotide-FAM system where the hydroxyl rad-
ical promotes strand breakage and consequent release of
FAM, restoring the previously quenched fluorescence [79].
The same quenching mechanism was used to detect specific
DNA strands using two probes (one with an AuNP label and
another labeled with TAMRA) that hybridize to two DNA
sequences near each other [80], bringing the fluorophore and
AuNP close enough to quench fluorescence emission.
Proteins have also been probed through nanoparticle-
fluorescence-mediated systems, for example, human blood
proteins have been let to interact with fluorescent AuNPs
and detected through quenching [81]. In another example,
a sandwich immunoassay using AuNPs quenching has been
proposed for the detection of the protein cardiac troponin T
by its interaction with two different antibodies, one attached
to AuNPs and the other labeled with fluorescent dyes [82].
By means of an opposite modulation, infrared fluorescent
nanoparticles showed enhanced fluorescence when interact-
ing with protein [83].
A popular application of fluorescence modulation by
nanoparticles has been specific ion sensing. Su and co-
workers developed a copper sensor by covering fluores-
cent DNA-Cu/Ag nanoclusters with mercaptopropionic acid
which quenches the intrinsic fluorescence of the nanopar-
ticle; in the presence of Cu2+, the capping agent is oxi-
dized to form a disulfide compound resulting in release
of the nanoparticle and restoration of emission suitable
for quantification between 5 and 200 nM [84]. A very
specific colorimetric and fluorimetric method to detect
Hg2+ ions was developed with porphyrin-modified Au@SiO2
nanoparticles, where the intensively fluorescent red complex
turns green and weakly fluorescent in presence of Hg2+ [85].
Another examples include sensing of Pb2+ and adenosine
by combining an adenosine aptamer and a DNAzyme
with an abasic site where 2-amino-5,6,7-trimethyl-1,8-
naphthyridine is trapped to quench its fluorescence [86].
When in solution, Pb2+ enables the DNAzyme to cleave its
substrate thus removing the fluorescent compound from the
abasic site restoring its fluorescence. Similarly, the presence
of adenosine induces structural change of the aptamer,
resulting in the release of the fluorescent molecule from the
DNA duplex and a subsequent fluorescence enhancement.
2.4. Nanophotonics Bioimaging. Nanoparticles show unique
features suitable for biomedical imaging applications, such
as an increased sensitivity in detection through amplification
of signal changes (e.g., magnetic resonance imaging); high
fluorescence quantum yields and large magnetic moments;
properties that induce phagocytosis and selective uptake
by macrophages (e.g., liposomes); physicochemical manip-
ulations of energy (i.e., quantum dots); among others
[87]. Because light absorption from biologic tissue com-
ponents is minimized at near infrared (NIR) wavelengths,
most nanoparticles (e.g., noble metal and magnetic NPs,
nanoshells, nanoclusters, nanocages, nanorods and quantum
dots) for in vivo imaging and therapy have been designed to
strongly absorb in the NIR and used for in vivo diagnostics
[83, 88, 89]. Ex vivo and in vivo imaging applications of
nanoparticles have included their use as contrast agents for
magnetic resonance imaging (MRI) [90], optical coherence
tomography (OCT) [91–93], photoacoustic imaging (PAI)
[94], and two-photon luminescence (TPL) spectroscopy
[95].
2.4.1. Magnetic Resonance Imaging. Magnetic resonance
imaging (MRI) is based heavily on nuclear magnetic reso-
nance (NMR), first described by R. Damadian. Magnetic res-
onance measurements cause no obvious deleterious effects
on biological tissue, and the incident radiation consists
of common radio frequencies at right angles to a static
magnetic field [96]. Iron oxide nanoparticles show super-
paramagnetism, allowing for the facile alignment of the
magnetic moments to an applied magnetic field, thus of
great interest as contrast agents for MRI [97]. Presently,
magnetic iron oxide nanoparticles are routinely used as
contrast agents to enhance an MRI image, providing sharper
contrast between soft and hard tissue in the body (e.g.
liver and spleen or lymph nodes) [98]. Jun et al. pre-
sented a synthetically controlled magnetic nanocrystal model
system that led to the improvement of high-performance
nanocrystal—antibody probe systems for the diagnosis of
breast cancer cells via magnetic resonance imaging [99].
Also, MnFe2O4 nanocrystals functionalized with an antibody
conjugate (herceptin) capable of specific targeting of can-
cerous cells was successfully used for in vivo MRI in mice
[88]. Driehuysb et al. developed an imaging method to detect
submillimeter-sized metastases with molecular specificity
by targeting cancer cells with iron oxide nanoparticles
functionalized with cancer-binding ligands, demonstrating
in vivo detection of pulmonary micrometastases in mice
injected with breast adenocarcinoma cells [100]. Hybrid NPs
with a superparamagnetic iron oxide/silica core and a gold
nanoshell, with significant absorbance and scattering in the
NIR region, have been used in vivo as contrast agents for
MRI presenting a good MR signal in hepatoma, each moiety
providing for a distinct signal that enhanced detection
[101].
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2.4.2. Optical Coherence Tomography. Optical Coherence
Tomography (OCT) is an imaging modality that provides
cross-sectional subsurface imaging of biological tissue with
micrometer scale resolution which is based on a broadband
light source and a fiber-optic interferometer. It captures
three-dimensional images from within optical scattering
media, typically employing near-infrared light. The use
of relatively long wavelength light allows it to penetrate
into the scattering medium [102–104]. The extra scattering
provided by Au-nanoshells enhances optical contrast and
brightness for improved diagnostic imaging of tumors in
mice due to the preferential accumulation of the nanoshells
in the tumor [105]. Tseng et al. developed nanorings with
a localized surface plasmon resonance covering a spectral
range of 1300 nm that produced both photothermal and
image contrast enhancement effects in OCT when delivered
into pig adipose samples [106]. Additionally, the image con-
trast enhancement effect could be isolated by continuously
scanning the sample with a lower scan frequency, allowing to
effectively control the therapeutic modality. In the same way,
gold capped nanoroses have been used in photothermal OCT
to detect macrophages in ex vivo rabbit arteries [107].
2.4.3. Photoacoustic Imaging. In photoacoustic imaging
(PAI) and photoacoustic tomography (PAT), a pulse of
NIR laser light, typically 757 nm, is used in resonance with
the surface plasmon instead of a continuous NIR source.
With this technique causing rapid thermal expansion of
the surrounding media, the generated sound wave can be
detected on the surface of the subject. NIR reduces the
amount of absorption that occurs, but absorption of light
by various other organs is unavoidable [108, 109]. Yang
et al. demonstrated the feasibility of using poly(ethylene
glycol)-coated Au nanocages as a new in vivo NIR contrast-
enhancing agent for photoacoustic tomography and image
their distribution in the vasculature of rat brain. These Au-
nanocages enhanced the contrast between blood and the
surrounding tissues by up to 81%, achieving a more detailed
image of vascular structures at greater depths. Additionally,
they were shown to present slight advantages over Au-
nanoshells, being better suited for in vivo applications,
specially due to their more compact size (<50 nm compared
to >100 nm for Au-nanoshells) and larger optical absorption
cross-sections [110]. Due to the ability of gold-nanorods
to have the maximum of the plasmon resonance tuned
further into the NIR, Motamedi et al. reported a contrast
agent for a laser optoacoustic imaging system for in vivo
detection of gold nanorods and to enhance the diagnostic
power of optoacoustic imaging [111]. Song et al. proposed
a noninvasive in vivo spectroscopic photoacoustic sentinel
lymph node mapping in a rat model using gold nanorods as
lymph node tracers [112].
2.4.4. Two-Photon Luminescence. In two-photon lumines-
cence (TPL) spectroscopy, an electron is excited from
the conductance band to the valence band of the metal
nanoparticles using two photons. As the electron relaxes
to the conductance band, light is released and amplified
due to a resonant coupling with localized surface plasmons,
enhancing a variety of linear and nonlinear optical prop-
erties [113, 114]. TPL was first described by Boyd et al.
that found that roughened metal surfaces exhibited much
higher induced luminescence efficiency than smooth surfaces
[115]. In fact, TPL is a potentially powerful technique
for noninvasive imaging at the micron scale hundreds of
microns deep into scattering tissue. This way, it ought to be
possible to discriminate cancerous and healthy tissue based
on two-photon imaging from endogenous fluorophores. For
enhanced imaging, two-photon contrast agents have been
developed showing the ability to increase signal-to-noise
ratio and targeted to molecular signatures of interest that are
not fluorescent. Because imaging of intrinsic fluorophores
is often difficult due to their relatively weak signals, the use
of such a bright contrast agent holds the promise to enable
in vivo applications of two photon imaging in a clinical
setting [113, 116, 117]. Wang et al. collected images of single
gold nanorods flowing in the mouse ear blood vessels with
luminescence three times stronger than background [114].
It is worth mentioning that the TPL signal from a single
nanorod is 58 times that of the two-photon fluorescence
signal from a single rhodamine molecule.
2.4.5. QDs for In Vivo Imaging. In the last decade, water
soluble bioconjugated QDs have been increasingly applied
for imaging [63, 64, 118] However, QD probes for imaging
show poor stability once inside cytosolic environment and
reduced biocompatibility in living organisms [119], which
constitutes a serious drawback for widespread in vivo
application.
Despite the serious concerns related to the in vivo use of
QDs, these nanocrystals show remarkable imaging properties
that may be judged of value for improved diagnostics. In
fact, QDs have proven of great value when imaging vascular
networks of mammals such as lymphatic and cardiovascular
systems [120–124]. Also, Kim et al. demonstrated that quan-
tum dots allowed a major cancer surgery to be performed
in large animals (mice and pigs) under complete image
guidance, by locating the position of sentinel lymph nodes
[125]. With similar potential to that observed when imaging
the lymph system, the imaging of cardiovascular systems
has also been achieved using QDs [126, 127]. Larson et
al. demonstrated that QDs retained their fluorescence after
injection and could be detected in the capillaries of skin and
adipose tissue of a mouse [128]. The fluorescent emission
and multiplexing capabilities of QDs are being exploited to
improve the sensitivity and selectivity in the early detection
of tumors [61, 129, 130]. Åkerman et al. described for the
first time the application of targeted cancer imaging by
using ZnS-capped CdSe QDs coated with a lung-targeting
peptide that accumulate in the lungs of mice, whereas two
other peptides specifically direct QDs to blood vessels or
lymphatic vessels in tumors [131]. Later, Gao et al. described
the development of multifunctional nanoparticle probes
based on QDs with a copolymer linked to tumor-targeting
ligands and drug-delivery functionalities for cancer targeting
and imaging in living animals [132]. Once the toxicological
aspects associated with QDs have been clarified, such studies
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demonstrate the potential of QDs for ultrasensitive and
multiplexed imaging of molecular targets in vivo.
3. Nanophotonics for Therapy
Nanophototerapy uses pulsed lasers and absorbing nanopar-
ticles attached to specific targets for selective damage to
cancer cells. Plasmonic photothermal therapy (PPTT) and
photodynamic therapy (PDT) are two of the main techniques
that take advantage of the selective absorbance of the surface
plasmon resonance and the fact that the nanoparticles relax
by liberating heat into their surrounding environment.
3.1. Plasmonic Photothermal Therapy. Plasmonic photother-
mal therapy is a less invasive experimental technique that
holds great promise for the treatment of cell malignancies
and, in particular, of cancer. It combines two key compo-
nents: (i) light source, specifically lasers with a spectral range
of 650–900 nm for deep tissue penetration and (ii) optical
absorption of AuNPs which release the optical irradiation
as heat in the picoseconds time scale, thereby inducing
photothermal ablation [133–135]. Kirui et al. reported the
use of gold and iron oxide hybrid nanoparticles in targeting,
imaging, and selective thermal killing of colorectal cancer
cells [136]. Huang and colleagues have demonstrated that
gold nanorods have a longitudinal absorption band in the
NIR on account of SPR oscillations and are effective as
photothermal agents [137]. Gold nanorods aspect ratios
allow tuning the SPR band from the visible to the NIR
(transmits readily through human skin and tissue), mak-
ing them suitable for photothermal converters of near
infrared light for in vivo applications [138, 139]. Effective
photothermal destruction of cancer cells and tissue have
been demonstrated for other gold nanostructures, such as
branched gold nanoparticles [140], gold nanoshells [141–
143], gold nanocages [134], and gold nanospheres [144].
3.2. Photodynamic Therapy. Photodynamic therapy employs
chemical photosensitizers that generate reactive oxygen
species (ROS), such as a singlet oxygen (1O2), capable of
tumor destruction [145, 146]. This technique is noninvasive
and can be applied locally or systemically without noticeable
cumulative toxicity effects without high costs. To attain
maximal killing efficiency of tumor cells, the photosensitizer
must be in close proximity to the tumor cells, thus requiring
specific targeting when administered systemically. One of
the major limitations is the poor tissue penetration of high-
energy light and the systemic dispersal of the photosensitizer
[147, 148].
Aiming at circumventing some of the limitations of pho-
todynamic therapy, Zhang et al. reported a new type of pho-
tosensitizers based on photon upconverting nanoparticles (a
process where low energy light, usually near-infrared (NIR)
or infrared (IR), is converted to higher energies, ultraviolet
(UV), or visible, via multiple absorptions or energy transfer
steps) [149, 150]. One year later, Yong et al. reported the
use of NPs modified with zinc phthalocyanin photosensitizer
that produce green/red emission on near-infrared (NIR)
excitation and is capable of singlet oxygen sensitization; upon
targeted binding to cancer cells, significant cell destruction
was induced [151]. Recently, Qian et al. published similar
results with the use of zinc phthalocyanine nanocrystals
coated with a uniform layer of mesoporous silica [152].
4. Conclusions
Light is an amazing intermediate with a gargantuan capacity
for carrying multiple information and functions. Instinc-
tively, we view light as rays, which propagate in a single direc-
tion, either being absorbed or reflected to some extent by any
object on which it impinges. However, the propagation of
light through a material is itself a quantum effect, involving
the excitation and relaxation of electrons in the material.
It is well known that light has the facility to act through
biological, chemical, mechanical, and thermal pathways
at molecular/cellular levels in diagnostic and therapeutic
applications.
Currently, we are in the dawn of a new age in therapy
driven by nanotechnology vehicles. Although there are tech-
nical challenges associated with the therapeutic application
of nanodevices, the integration of therapy with diagnostic
profiling has accelerated the pace of discovery of new
nanotechnology methods. In addition to continuing to push
forward on the above challenges, nanotechnology together
with photonics can be used both for identifying useful target
candidates and for validating their importance in disease
states. Nanophotonics may present new opportunities for
personalized medicine in which diagnosis and treatment
are based on each individual’s molecular profile. Further
research into the fundamental mechanisms that efficiently
control light using nanodevices could unveil new dimensions
of nanoparticle-mediated theranostic systems.
Here, we have attempted to give the reader a limited
overview of some aspects of the current state of research into
the fascinating aspects and control over nanophotonics in
molecular diagnostics and therapy applications.
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6. GENERAL OBJECTIVES 
 
The studies presented in this Thesis aim to optimise an Au-nanoprobe based technique for the 
detection of oncogenes’ transcripts (c-Myc and BCR-ABL) that can be used for the evaluation 
of the expression profile in cancer cells, while simultaneously developing an innovative 
platform of multifunctional gold nanoparticles loaded with, cell penetrating peptides, tumoral 
marker, polymers and siRNA capable of silencing the selected proto-oncogenes, which can be 
used to evaluate the level of expression and determine the efficiency of silencing.  
 
This work is a part of an ongoing collaboration between Faculdade de Ciência e Technologia-
Universidade Nova de Lisboa and IUI of Nanoscience of Aragon at the University of 
Zaragoza within a European project [NanoScieE+ - Nanotruck]. 
The NANOTRUCK project intends to develop an innovative kind of multifunctional gold 
nanoparticles loaded with fluorescent, tumoral markers, cell penetrating peptides and RNAi 
complementary to the proto-oncogene c-Myc for cancer diagnosis and treatment. The fellow 
worked on the synthesis and functionalization of the multifunctional gold nanoparticles and 
on the in vitro studies for the silencing of c-Myc gene in human cells. From this work, he has 
broadened his experience in techniques in the molecular genetics field such as the cloning of 
constructs for applications in gene therapy and techniques related with the small interfering 
RNA approach for gene silencing.  
 
This project implies the collaboration with different groups in Europe with expertise in 
different subfields: Centre for Cell Engineering (University of Glasgow, UK), Instituto di 
Cibernetica “E. Caianiello” (Pozzuoli, Italy), Helmholtz Zentrum München (München, 
Germany), Science and Technology Faculty, New University of Lisbon (Lisbon, Portugal) 
and IUI of Nanoscience of Aragon at the University of Zaragoza (Zaragoza, Spain). Thanks to 
these collaborations, the interaction between nanoparticles and biological systems, ranging 
from in vitro cultured human cells to in vivo animal models (primitive Hydra and complex 
vertebrate mouse) were studied. From this work, the fellow acquired experience in the 
diagnostics and therapy fields, as can be seen from his publications on the development of 
nanosystems for the combined diagnostics/therapeutics (theranostics) involving DNA/RNA 
detection with strong impact in genetic diagnostics and for gene delivery and silencing 
systems of relevance for therapy strategies, with particular focus on enabling the development 
of safer, more efficient, and specific platforms to human disease. 
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Overall, the objectives of this Thesis are: 
 
 
 Synthesis and characterisation of thiol-modified ssDNA gold nanoparticles   
Au-nanoprobes suitable for the specific detection of the oncogenes’ mRNA sequences 
via non-cross-linking method.  
 
 Optimisation of the Au-nanoprobe system for evaluation of levels of expression  
quantitative and/or semi-quantitative. 
 
 Evaluate efficiency of ssDNA-gold nanoparticles for the inhibition of in vitro 
transcription and in vitro translation. 
 
 To use multifunctional gold nanoparticles (tumour markers, cell penetrating peptides, 
polymers) as vectors for siRNA delivery into tumour cells - evaluation of siRNA load 
by means of standard spectrophotometry and fluorescence labelled oligonucleotides. 
 
 To evaluate the transfection level of siRNA-nanoconjugates by fluorescence 
techniques (i.e. fluorescence and confocal microscopy) 
 
 To evaluate the silencing efficiency by the previously optimised siRNA-
nanoconjugates system in comparison to qRT-PCR. 
 
For this, we used several molecular biology techniques useful for the biomedical applications 
of nanoparticles (Human Cell culture, Microbiology, Confocal Microscopy, Electrophoresis, 
Real-Time PCR, etc), and skills useful in the development of applications of nanoparticles in 
gene therapy (plasmid DNA cloning, Antisense and RNA interference methodologies, work 
with reporter vectors such as EGFP and luciferase gene expression) and different techniques 
for nanoparticle characterization (Atomic Force Microscopy, Scanning Electron Microscopy, 
Transmission Electron Microscopy, Light-Scattering microscopy, FT-IR, Zeta potential, 
Dynamic Light Scattering, Fluorescence, UV-VIS molecular absorption, etc). 
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 
Gold Nanoparticles as 
Nanosensors for Diagnostics 
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OVERVIEW 
 
This section presents 3 articles related to the studies on noble metal nanoparticles as 
nanosensors for cancer diagnostics. 
Article A describes the detection and quantification of the BCR-ABL gene fusion using DNA 
thiol-modified gold nanoparticles. In a proof-of-concept experiment we developed an Au-
nanoprobe based approach for the molecular recognition of BCR-ABL b3a2 fusion that 
constitute a promising tool in early diagnosis of chronic myelogenous leukemia (CML). The 
detection procedure is an application of the non-cross-linking Au-nanoprobe method that 
makes use of the gold nanoparticles’ optical properties.  
These studies were extended to the simultaneous identification of different mRNA targets in 
CML using colour multiplexing with other noble metal nanoparticles like gold-silver alloy 
nanoparticles in Article B and Article C. In Article B we extensively described the protocol 
for synthesis and functionalization of gold and gold-silver alloy nanoparticles for diagnostic 
applications. 
 
All these studies were performed at the Research Centre for Human Molecular Genetics, 
Dept. of Life Sciences at Science and Technology Faculty, New University of Lisbon. 
 
Article A 
“RNA Quantification using Gold Nanoprobes - application to Cancer Diagnostics.” João 
Conde, J.M. de la Fuente and P.V. Baptista. Journal of Nanobiotechnology (2010), Vol. 8, 
pp. 1-8. Research article IF=not yet determined by ISI (unofficial=5.09) 
 
Article B 
“RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of Several 
Different mRNA Targets Using Colour Multiplexing and Application to Cancer Diagnostics.” 
João Conde, G. Doria, J.M. de la Fuente and P.V. Baptista. Nanoparticles in Biology and 
Medicine: Methods and Protocols Series. Methods in Molecular Biology (2012), Vol. 906, 
pp. 71-87. Humana Press, Springer Protocols.  
 
Article C  
“Alloy Metal Nanoparticles for Multicolour Cancer Diagnostics.” P.V. Baptista, G. Doria, 
João Conde. Proceedings of SPIE (2011), Vol. 7909, 79090K-1, Colloidal Quantum 
Dots/Nanocrystals for Biomedical Applications VI. Proceedings article 
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RNA quantification using gold nanoprobes -
application to cancer diagnostics
João Conde1, Jesús M de la Fuente2, Pedro V Baptista1*
Abstract
Molecular nanodiagnostics applied to cancer may provide rapid and sensitive detection of cancer related molecular
alterations, which would enable early detection even when those alterations occur only in a small percentage of
cells. The use of gold nanoparticles derivatized with thiol modified oligonucleotides (Au-nanoprobes) for the detec-
tion of specific nucleic acid targets has been gaining momentum as an alternative to more traditional methodolo-
gies. Here, we present an Au-nanoparticles based approach for the molecular recognition and quantification of the
BCR-ABL fusion transcript (mRNA), which is responsible for chronic myeloid leukemia (CML), and to the best of our
knowledge it is the first time quantification of a specific mRNA directly in cancer cells is reported. This inexpensive
and very easy to perform Au-nanoprobe based method allows quantification of unamplified total human RNA and
specific detection of the oncogene transcript. The sensitivity settled by the Au-nanoprobes allows differential gene
expression from 10 ng/μl of total RNA and takes less than 30 min to complete after total RNA extraction, minimiz-
ing RNA degradation. Also, at later stages, accumulation of malignant mutations may lead to resistance to che-
motherapy and consequently poor outcome. Such a method, allowing for fast and direct detection and
quantification of the chimeric BCR-ABL mRNA, could speed up diagnostics and, if appropriate, revision of therapy.
This assay may constitute a promising tool in early diagnosis of CML and could easily be extended to further tar-
get genes with proven involvement in cancer development.
Background
The National Cancer Institute envisions that over the
next years, nanotechnology will result in significant
advances in early detection, molecular imaging, targeted
and multifunctional therapeutics, prevention and control
of cancer [1]. Nanodiagnostics is a burgeoning field as
more and improved techniques are becoming available
for clinical diagnostics with increased sensitivity at lower
costs [2-10]. Due to their optical properties, gold nano-
particles (AuNPs) have been used for DNA/RNA
screening approaches, namely via functionalization with
thiolated oligonucleotides (Au-nanoprobes), capable of
specifically hybridizing with a complementary oligonu-
cleotide sequence [9].
The surface plasmon resonance (SPR) of AuNPs is
responsible for the intense colors - monodisperse Au-
nanoprobes (≈ 13 nm) appear red and exhibit a narrow
SPR band centered around 520 nm; a solution
containing aggregated Au-nanoprobes appears blue, due
to a red shift of the SPR. Our method relies on visual
and/or spectroscopy comparison of solutions before and
after salt induced Au-nanoprobe aggregation -presence
of complementary target prevents aggregation and the
solution remains red (SPR peak at ± 520 nm); non-com-
plementary targets do not prevent Au-nanoprobe aggre-
gation, resulting in a visible change of color from red to
blue (red-shift of the SPR peak to 600-650 nm) [5-7].
The principle of gold nanoparticles assay method detec-
tion of RNA hybridization is depicted in Figure 1. This
non-cross-linking method has already been successfully
applied for detection of eukaryotic gene expression with-
out reverse transcription or PCR amplification steps [6],
and for Mycobacterium tuberculosis detection [7,8].
Chronic myeloid leukemia (CML) is a clonal neoplas-
tic disease of the hematopoietic stem cell, whose hall-
mark molecular event is the genetic t(9;22)(q34;q11)
translocation known as the Philadelphia (Ph) chromo-
some [11,12]. This translocation - ABL gene (chromo-
some 9) and BCR gene (chromosome 22) - originates a
BCR-ABL fusion gene, leading to the expression of a
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chimeric BCR-ABL protein with tyrosine-kinase activity
[13-15]. The most commonly used procedures for the
initial diagnosis and management of CML patients are
expensive and time consuming, e.g karyotype analysis,
reverse transcriptase polymerase chain reaction analyses
(RT-PCR) and fluorescence in-situ hybridization (FISH)
[16-18]. Therefore, there is a need for molecular meth-
ods able to detect and quantify the BCR-ABL fusion
transcripts, which is of paramount relevance when mon-
itoring minimal residual disease and genetic recurrence
in patients known to harbor the translocation [19,20].
Here we present an Au-nanoprobe based approach for
the molecular recognition and quantification of BCR-
ABL b3a2 (e14a2) fusion for the early diagnosis of CML,
which is inexpensive very easy to perform and uses total
human RNA as target without reverse transcription
and/or amplification.
Methods
Probe design and Au-nanoprobe synthesis
The probe sequence 5’-thiol-CGCTGAAGGGCTTTT-
GAACT-3’ and the complementary target derive from
the BCR-ABL b3a2 (e14a2) chimeric protein mRNA
(Gene-Bank accession no. AJ 131466.1: 5’-TGGATT-
TAAGCAGAGTTCAAAAGCCCTTCAGCGGCCA
GTA-3’), and the control oligonucleotide target
sequences: BCR (Gene-Bank accession no. NM
021574.2: 5’-TGGATTTAAGCAGAGTTCAAATCTG-
TACTGCACCCTGGAG-3’), ABL (Gene-Bank accession
no. NM 005157.3: 5’-CTCCAGCTGTTATCTGGAAG
AAGCCCTTCAGCGGCCAGTA-3’) and an unrelated
target (5’-AGGAAAACGATTCCTTCTAACAGAAATG
TCCTGAGCAATC-3’). The way these sequences relate
to each other is illustrated in Figure 2.
The 13 nm gold nanoparticles were prepared by the
citrate reduction method described by Lee and Meisel
[21]. The thiolated oligonucleotide was dissolved in 1 ml
of 0.1 M DTT, extracted three times with ethyl acetate,
and further purified through a desalting NAP-5 column
(Pharmacia Biotech, Sweden) according to the manufac-
turer’s instructions. The Au-nanoprobe was prepared as
described in Baptista et al [5]. Briefly, 500 μl of 10 μM
thiol modified oligonucleotide was initially incubated
with 6 ml of an aqueous solution of AuNPs (≈8.55 nM)
for at least 16 h. After centrifugation (20 min at 14500
G), the oily precipitate was washed with 5 ml of 10 mM
phosphate buffer (pH 8.0), 0.1 M NaCl, recentrifuged
and redispersed in 5 ml of the same buffer to a final
concentration in AuNPs of 8.5 nM. The resulting Au-
nanoprobe was stored in the dark at 4°C.
Cell culture and total RNA isolation
K562 erythroleukemic cells (BCR-ABL positive cell line
derived from CML patients in blast crisis) and HL-60
cell line, a human leukemic promyelocytic cell line
(BCR-ABL negative) were cultured in 90% RPMI 1640
and 10% FBS at 37°C with 5% CO2. Saccharomyces cere-
visae cells were grown in YPD medium at 30°C
Figure 1 Schematic representation of Au-nanoprobe assay method. The assay is based on the increased stability of the Au-nanoprobes
upon hybridization with the complementary RNA target in solution, while non-hybridized Au-nanoprobes easily aggregate once the solution’s
ionic strength is increased. Positive: sample in the presence of complementary RNA; Negative: sample in the presence of non-complementary
RNA; Blank: Au-nanoprobe alone (no target).
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overnight. Human peripheral blood mononuclear cells
(PBMC) from control individuals were separated from
3 ml of heparinized peripheral venous blood by Ficoll
gradient (Histopaque®-1077, Sigma-Aldrich, St. Louis,
USA) according to manufacturer’s specifications. Isola-
tion of total RNA was performed using a High Pure
RNA Isolation Kit (Roche Applied Science) according to
the manufacturer’s protocol. RNA concentration was
determined by UV photometry and the RNA was stored
at -80°C until use. RNA integrity was evaluated on a 1%
agarose gel stained by GelRed™.
Reverse transcription (RT) and PCR amplification
Total RNA extracted from K562 cells was subjected to
RT with Revert-AidTM M-MuLV Reverse Transcriptase
(Fermentas, Vilnius, Lithuania) according to the manu-
facturer’s specifications, using 20 μM of BCR-ABLre-
verse primer, annealing at 42°C for 1 h and 70°C for 10
min to inactivate the reverse transcriptase. The reverse
transcription reaction product, a 273-bp fragment of the
human BCR-ABL fusion gene (b3a2 junction), was PCR
amplified using primers BCR-ABLforward (18 nt): 5’-
AGTCTCCGGGGCTCTATG-3’ and BCR-ABLreverse
(20 nt): 5’-GATTATAGCCTAAGACCCGG-3’. PCR
amplification of the b3a2 region was carried out in 25 μl
using 0.25 μM of primers, 0.2 mM dNTPs with 1 U Taq
DNA polymerase (Amersham Biosciences, GE Health-
care, Europe, GmbH). The PCR reactions were
performed in duplicate on a MyCycler Thermocycler
(Bio-rad). Thermal cycling conditions consisted of dena-
turation at 95°C for 5 min and 30 cycles of amplifica-
tion, each cycle consisting of denaturation of 95°C for
30 s, annealing at 52°C for 30 s, elongation was at 72°C
for 30 s and final elongation at 72°C for 5 min and cool-
ing at 4°C. The sequence of the PCR products was con-
firmed by sequencing.
Real-Time RT-PCR assay
The Real-Time PCR amplification was performed in a
Corbett Research Rotor-Gene RG3000 using SYBR
GreenER Real-Time PCR Kit (Invitrogen, Karlsbad, CA,
USA) according to manufacturer’s specifications in 50 μl
reactions containing cDNA from K562 and HL-60 cell-
lines, 1× SYBR Green SuperMix and 200 nM of BCR-
ABLforward and BCR-ABLreverse. The amplification
conditions consisted of 50°C for 2 min hold, 95°C dur-
ing 10 min hold, followed by 40 cycles consisting of
denaturation at 95°C for 30 s, annealing at 52°C for
30 s, extension at 72°C for 30 s, with a final extension
step at 72°C for 5 min. All the results were originated
from three independent experiments.
Au-nanoprobe hybridization and color detection
The Au-nanoprobe assay was performed in a total
volume of 30 μl containing the Au-nanoprobe at a
final concentration of 2.5 nM, the appropriate targets
Figure 2 Oligonucleotide probe and target sequences designed for BCR-ABL b3a2 (e14a2) junction and for BCR and ABL genes.
Complementary and non-complementary target sequences were used to study the level of specific interaction between the target and the Au-
nanoprobes. BCR-ABL fusion positive (100% complementary); BCR and ABL gene sequences were used as controls (50% non-complementary);
and a completely unrelated sequence (100% non-complementary) was used as negative control.
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at a final concentration of 100 fmol/μl (100% comple-
mentary BCR-ABL target; 50% complementary BCR
and ABL targets, and 100% non-complementary target)
in 10 mM phosphate buffer (pH 8.0). Total RNA was
used at a final concentration 10-60 ng/μl [100% com-
plementary K562 cells RNA (BCR-ABL Positive); non-
complementary HL-60 cells RNA (BCR-ABL Nega-
tive)]. Blank measurements were made in exactly
the same conditions but replacing target or total RNA
for an equivalent volume of 10 mM phosphate buffer
(pH 8.0).
Following 5 min of denaturation at 95°C, the mixtures
were allowed to stand for 30 min at 25°C and 0.3 M
MgCl2 was added at a final concentration of 0.16 M.
After 15 min at room temperature for color development,
photographs were taken and assayed by UV-visible spec-
troscopic measurements of the SPR band. Absorption
spectra were performed in a UNICAM, model UV2, UV-
visible spectrophotometer with Ultra-Micro quartz cells
(Hellma, Germany), using 10 mM phosphate buffer (pH
8.0), 0.1 M NaCl as reference. The areas under the curve
(AUC500 nm-560 nm/AUC570 nm-630 nm) were calculated
with the values for absorbance for 500 nm-600 nm/570
nm-630 nm using the trapezoidal rule.
Results and Discussion
Gold nanoprobe assay for target detection
First, we used thiolated ssDNA, complementary to the
fusion site of the BCR-ABL mRNA, to functionalize
gold nanoparticles and produce specific Au-nanop-
robes. These nanoprobes were assessed in terms of
specificity by means of total RNA mixtures spiked in
with synthetic oligonucleotides harboring the fusion
site BCR-ABL b3a2. It should be noted that, in reality,
patients may only harbor one copy of the fusion gene
and the remaining copies of normal ABL and BCR
should be still functional, thus expressing the normal
mRNA sequence. Two oligonucleotides, each harboring
the normal sequence of the BCR and ABL genes
respectively, were used to evaluate the probe’s capabil-
ity to discriminate from similar sequences. Following
salt addition, the presence of the respective comple-
mentary synthesized target, protected the Au-nanop-
robes from aggregation and the solution remained red;
whereas the presence of non-complementary targets
does not protect from aggregation and the solution
turned blue (BCR and ABL controls only 50% comple-
mentary to the Au-nanoprobe) - Figure 3A. Absence
of any target results in extensive aggregation (Blank).
Only full hybridization of the Au-nanoprobe to a fully
complementary synthetic sequence (BCR-ABL fusion
sequence) avoids aggregation, whereas semi-comple-
mentary targets (normal ABL and BCR gene sequence)
do not show the same capability.
Based on the UV/Vis spectra (see Figure 4) obtained
after inducing aggregation, Au-nanoprobe aggregation
was evaluated in terms of SPR variation, i.e. a ratio
between the free and aggregated fractions after 15 min
incubation with [MgCl2] = 0.16 M. The ratio between
the areas under the curve of the SPR was calculated
using the trapezoidal rule - AUC500 nm-560 nm/AUC570
nm-630 nm. A ratio of 1 may be considered as the point
of equilibrium between non-aggregated and aggregated
nanoprobe, hence the threshold to respectively consider
the positive and negative discrimination of sequences
(positive identification of complementary target ratio
>1). Commonly, for discriminating between two signifi-
cantly different aggregation levels, as for example in a
YES/NO for identification of a given target, the ratio
between the peaks at 520 nm and 600 nm is usually
used. However, for identifying small differences in
aggregation levels between two quantities for the same
target, there is a need to decrease the noise level in the
spectra. When establishing a ratio between two absor-
bance values, the error increases mainly due the noise in
the spectra, which can be overcome (i.e. strongly
reduced) by using an integral of the signal, i.e. the area
under the curve.
The Au-nanoprobes were then used for the detection of
the BCR-ABL b3a2 fusion mRNA in total RNA extracted
from K562 cells (BCR-ABL positive cell line), HL-60 cells
(BCR-ABL negative cell line), human peripheral blood
mononuclear cells (PBMC) and S. cerevisiae cells - Figure
3B. Total RNA from HL-60 cell line and PBMC only
express the normal BCR and ABL transcripts, which are
50% complementary to the probe sequence. Total RNA
from an unrelated organism (S. cerevisae) was used to con-
firm specificity of the detection method. The results origi-
nate from a minimum of three individual parallel
hybridization experiments. BCR-ABL fusion discrimination
was observed only for samples containing the complemen-
tary RNA target (K562 cells). Samples containing the nor-
mal BCR and ABL genes showed a minor stabilization of
the Au-nanoprobe, yet below the threshold for positive
identification of the target (ratio <1).
Gold nanoprobe assay for RNA quantification
Once the specific identification of the target sequence
was achieved, the Au-nanoprobes were used to evalu-
ate both the limit of detection and quantification
potential. For this purpose, different concentrations of
the specific synthetic oligonucleotide target were used
to spike in 20 ng/μl of total RNA extracted from the
BCR-ABL negative cell line HL-60. Our data indicate a
linear correlation (R2 = 0.9966) between the AUC500
nm-560 nm/AUC570 nm-630 nm for target concentration
range between 33 and 133 fmol/μl (Figure 5). A non-
complementary target was used in a parallel spike in
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Figure 3 Au-nanoprobe detection of the BCR-ABL fusion gene sequence. (A) Colorimetric assay (above) and respective spectrophotometry
(below) relative to the detection of synthetic BCR-ABL oligonucleotide target. Oligonucleotides with BCR or ABL sequence only (showing 50%
complementarity) were used as controls and an unrelated target (showing 100% non-complementarity to the Au-nanoprobe) as negative
control. (B) Detection of BCR-ABL in total RNA from K562 cell line, HL-60 cell line and human PBMC (harboring 50% complementary targets to
the nanoprobe) and S. cerevisiae cells (100% non-complementary). Nanoprobe aggregation as measured by ratio of AUC500 nm-560 nm/AUC570 nm-
630 nm. The dashed line represents the threshold of 1 considered for discrimination between Positive and Negative. The error bars represent the
standard deviation from three independent assays.
Conde et al. Journal of Nanobiotechnology 2010, 8:5
http://www.jnanobiotechnology.com/content/8/1/5
Page 5 of 8
138
experiment, where extensive aggregation of the Au-
nanoprobe was observed for all tested concentrations.
In order to validate the detection and quantification
potential of the Au-nanoprobes in the positive cell line
(K562), Real-time RT-PCR was used. Our method
showed a linear correlation for BCR-ABL detection
within the range of 10-60 ng/μl of total RNA (see Figure
6). A linear association (R2 = 0.9171) was found between
the two methods, Real-Time RT-PCR and Au-nanoprobe,
for BCR-ABL detection (inset in Figure 6). Real-Time
RT-PCR is a more robust and sensitive technique but
time consuming, more expensive and requiring expensive
equipment and highly trained personnel.
Conclusions
In conclusion, we demonstrated the potential of an Au-
nanoprobe based assay for the specific identification and
quantification of aberrant expression of genes involved
Figure 4 Au-nanoprobe UV/Vis spectra obtained after inducing aggregation. (A) UV/Vis spectra in absence (Blank) and in presence of
target (BCR-ABL target). (B) UV/Vis spectra for the detection of the BCR-ABL b3a2 fusion mRNA in total RNA from K562 cells (BCR-ABL positive cell
line), HL-60 cells (BCR-ABL negative cell line), human PBMC and S. cerevisiae cells; Au-nanoprobe alone before (Au-nanoprobe + buffer) and after
(Blank) salt addition. All samples in 10 mM phosphate buffer (pH 8.0). Also, spectral data from untreated Au-nanoparticles in sodium citrate.
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Figure 5 Quantification of BCR-ABL by Au-nanoprobe. Ratio AUC500 nm-560 nm/AUC570 nm-630 nm as function of specific target concentration in
mixtures of 20 ng/μl total RNA from BCR-ABL negative cell line HL-60 spiked in with increasing concentrations of the synthetic oligonucleotide
(black diamond’s - complementary target; blank squares - non-complementary target). The error bars represent the standard deviation from
three independent assays.
Figure 6 Au-nanoprobe based quantification of BRC-ABL fusion mRNA directly in total RNA extracted from K562 cell line. Nanoprobe
aggregation as measured by ratio of AUC500 nm-560 nm/AUC570 nm-630 nm for increasing concentrations of total RNA from a BCR-ABL positive cell
line (K562) - 10 to 60 ng/μl. (Inset) Real-Time RT-PCR vs. Au-Nanoprobe Assays. A linear association (R2 = 0.9171) was found between the two
methods. The error bars represent the standard deviation from three independent assays.
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in cancer development. This Au-nanoprobe strategy
allowed for detection of less than 100 fmol/μl of a speci-
fic RNA target, with the possibility of discriminating
between a positive and negative from as little as 10 ng/
μl of total RNA. As proof-of-concept we used the BCR-
ABL fusion product that is of paramount importance in
chronic myeloid leukemia, showing the application
potential in cancer diagnosis. To our knowledge, this is
the first report on quantification of human mRNA
directly from total RNA without reverse transcription or
amplification. The assay has a total work-up time of less
than 45 minutes with comparable sensitivity to those
demonstrated by traditional molecular biology
methodologies.
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 Chapter 6 
 RNA Quanti fi cation Using Noble Metal Nanoprobes: 
Simultaneous Identi fi cation of Several Different mRNA 
Targets Using Color Multiplexing and Application 
to Cancer Diagnostics 
 João  Conde ,  Gonçalo  Doria ,  Jesus  M.  de la  Fuente , 
and  Pedro  Viana  Baptista  
 Abstract 
 Nanotechnology provides new tools for gene expression analysis that allow for sensitive and speci fi c 
characterization of prognostic signatures related to cancer. Cancer is a multigenic complex disease where 
multiple gene  loci contribute to the phenotype. The ability to simultaneously monitor differential expres-
sion originating from each  locus allows for a more accurate indication of degree of cancerous activity than 
either  locus alone. Metal nanoparticles have been widely used as labels for in vitro identi fi cation and 
quanti fi cation of target sequences. 
 Here we describe the synthesis of nanoparticles with different noble metal compositions in an alloy 
format that are then functionalized with thiol-modi fi ed ssDNA (nanoprobes). We also show how to use 
such nanoprobes in a non-cross-linking colorimetric method for the direct detection and quanti fi cation of 
speci fi c mRNA targets, without the need for enzymatic ampli fi cation or reverse transcription steps. The 
different metals in the alloy provide for distinct absorption spectra due to their characteristic plasmon reso-
nance peaks. The color multiplexing allows for simultaneous identi fi cation of several different mRNA tar-
gets involved in cancer development. Comparison of the absorption spectra of the nanoprobes mixtures 
taken before and after induced aggregation of metal nanoparticles allows to both identify and quantify 
each mRNA target. We describe the use of gold and gold:silver-alloy nanoprobes for the development of 
the non-cross-linking method to detect a speci fi c  BCR–ABL fusion gene (e.g., e1a2 and e14a2) mRNA 
target associated with chronic myeloid leukemia (CML) using 10 ng  μ L −1 of unampli fi ed total human 
RNA. This simple methodology takes less than 50 min to complete after total RNA extraction with com-
parable speci fi city and sensitivity to the more commonly used methods. 
 Key words:  Gold nanoparticles ,  Gold:silver alloy nanoparticles ,  Nanoprobes ,  Colorimetric method , 
 mRNA detection ,  Gene expression ,  Cancer 
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 Gene expression detection can provide powerful insights into the 
chemistry and physiology of biological systems. Cancer cells exhibit 
deregulation of the cell cycle resulting in uncontrolled growth and 
they are resistant to programmed death as a result of abnormalities 
in one or more proteins that inhibit apoptosis. Moreover, alterna-
tively and abnormally expressed mRNAs (e.g., alternatively spliced 
mRNAs, fusion gene products) are considered as triggers of tumor 
development. Better understanding of the molecular mechanisms 
underlying biological processes can be achieved by comparing gene 
expression between cells in different states or between cells from 
different tissues, using techniques such as reverse transcription-
polymerase chain reaction (RT-PCR)  ( 1– 3 ) . However, methods 
based on reverse transcription are actually based on detection 
of ampli fi ed cDNAs instead of the RNA itself. Direct detection of 
RNA, especially mRNA, has remained a challenge. 
 The National Cancer Institute envisions that over the next 
years, nanotechnology will result in signi fi cant advances in early 
detection, molecular imaging, targeted and multifunctional 
therapeutics, prevention and control of cancer  ( 4 ) . The use of nan-
otechnology (materials, devices, or systems) for diagnostics pur-
poses, i.e., nanodiagnostics, has delivered improved techniques for 
clinical diagnostics with increased sensitivity at lower costs. Due to 
their optical properties, gold nanoparticles (AuNPs) have been 
used for DNA/RNA screening approaches, namely via functional-
ization with thiolated oligonucleotides (Au-nanoprobes), capable 
of speci fi cally hybridizing with a complementary oligonucleotide 
sequence  ( 5– 12 ) . These optical properties derive from the charac-
teristic surface plasmon resonance (SPR) band that can be easily 
tailored through the synthesis of NPs with different metal 
composition, either in an alloy or core–shell structure, e.g., differ-
ent gold:silver ratios  ( 13,  14 ) . 
 Baptista and co-workers  ( 15 ) developed a colorimetric non-
cross-linking method where Au-nanoprobes are used to detect the 
presence of speci fi c DNA and/or mRNA target sequence, which 
was successfully applied to tuberculosis diagnostics, gene expression 
studies, and cancer diagnostics  ( 16– 20 ) . The method consists in a 
visual and/or spectrophotometric comparison of solutions before 
and after salt induced Au-nanoprobe aggregation and the method 
is outlined in Fig.  1 . The presence of a complementary target pre-
vents aggregation and the solution remains red with a strong sur-
face plasmon absorbance peak at ±520 nm. Noncomplementary/
mismatched targets do not prevent Au-nanoprobe aggregation, 
resulting in a visible change of color from red to blue characterized 
by a concomitant shift in the surface plasmon absorbance from 520 
to 600–650 nm. More recently, the same group has developed an 
 1.  Introduction
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one-pot multiplex detection assay by using gold:silver-alloy 
nanoprobes in conjugation with the Au-nanoprobes  ( 21 ) . 
 Chronic myeloid leukemia (CML) is a clonal neoplastic disease 
of the hematopoietic stem cell, and the hallmark molecular event 
of CML is the genetic t(9;22)(q34;q11) translocation known as 
the Philadelphia chromosome that is present in >90 % of CML 
patients  ( 22,  23 ) . This translocation of ABL (chromosome 9) and 
BCR (chromosome 22) sequences form a BCR–ABL fusion gene, 
leading to the expression of a chimeric BCR–ABL protein with 
tyrosine-kinase activity  ( 24 ) . The BCR–ABL abnormal kinase 
activity is characterized by deregulation of cellular proliferation, 
decreased adherence of leukemic cells to the bone marrow stroma, 
and reduced apoptotic activity  ( 25 ) . 
 Here, we report on the use of gold and gold:silver-alloy nano-
probes for the development of the non-cross-linking method to 
detect a speci fi c  BCR–ABL fusion gene (e.g., e1a2 and e14a2) 
mRNA target associated with CML using 10 ng  μ L −1 of unampli fi ed 
total human RNA. This simple methodology takes less than 50 min 
to complete after total RNA extraction with comparable speci fi city 
and sensitivity to the more commonly used methods. 
 Fig. 1.  Schematic of the non-cross-linking assay for RNA quanti fi cation. The assay relies on visual comparison of test 
solutions before and after salt-induced nanoprobe aggregation. “Blank” denotes nanoprobe alone; “Pos” denotes a Positive 
sample containing complementary mRNA target; “Neg” denotes a Negative sample, where a noncomplementary mRNA is 
added to the nanoprobe. 
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 Prepare all solutions using ultrapure grade water, e.g., Milli-Q 
water (18.2 MΩ-cm at 25 °C) and use analytical grade reagents. 
  1.  Gold(III) chloride trihydrate (HAuCl 4 ·3H 2 O,  ³ 49.0 % Au 
basis). 
  2.  Silver nitrate (AgNO 3 ,  ³ 99.0 %). 
  3.  Sodium citrate tribasic dihydrate (HOC(COONa)
(CH 2 COONa) 2 ·2H 2 O,  ³ 99.0 %). 
  4.  4,500 and 250 mL two-neck round bottom  fl asks equipped 
with a water-cooled Liebig condenser. 
  5.  Hot plate with magnetic stirrer. 
  6.  100 and 250 mL Erlenmeyer amber  fl ask with a ground 
glass cap. 
  7.  Aqua regia : Mix three volumes of hydrochloric acid (37 % 
HCl) with one volume of nitric acid (70 % HNO 3 ). 
  1.  1 M DL-Dithiothreitol (DTT) solution, molecular biology 
grade. Store at 4 °C until use. 
  2.  Thiol-modi fi ed oligonucleotides (5 ¢ -thiol-(CH 2 ) 6 -ssDNA 
oligo) containing a complementary sequence to the target(s) 
of interest (see Note 1 for sequence design tips). The probes 
given in Table  1 are used to exemplify the speci fi c detection of 
BCR–ABL fusion gene (e14a2) mRNA, BCR–ABL fusion 
gene (e1a2) mRNA, and normal ABL gene mRNA. Resuspend 
the lyophilized thiol-modi fi ed oligonucleotides in 100  μ L of 
1 M DTT and incubate at room temperature for 1 h. Add 
900  μ L of ultrapure sterile water and mix gently. Store 
at −20 °C until use. 
  3.  10 mM phosphate buffer (pH8): 9.32 mM Na 2 HPO 4 , 
0.68 mM NaH 2 PO 4 . Sterilize by autoclaving and store at 4 °C 
until use. 
 2.  Materials
 2.1.  Noble Metal 
Nanoparticle 
Synthesis Components
 2.2.  Noble Metal 
Nanoprobes Synthesis 
Components
 Table 1 
 Oligonucleotide probes 
 Probes  Sequence (5 ¢ -3 ¢ ) 
 Gene-Bank 
acc. number 
 BCR–ABL (e14a2)  HS-(CH 2 ) 6 -CGCTGAAGGGCTTTTGAACT  AJ131466.1 
 BCR–ABL (e1a2)  HS-(CH 2 ) 6 -CGCTGAAGGGCTTCTGCGTC  AF113911.1 
 ABL (a1a2)  HS-(CH 2 ) 6 -CGCTGAAGGGCTTCTTCCAG  NM 005157.3 
145
756 RNA Quantifi cation Using Noble Metal Nanoprobes
  4.  AGEI solution: 2 % (w/v) SDS, 10 mM phosphate buffer 
(pH 8). Sterilize by  fi ltration (0.22  μ m) and store at 4 °C until 
use. Warm up to 25 °C before use. 
  5.  AGEII solution: 1.5 M NaCl, 0.01 % (w/v) SDS, 10 mM 
phosphate buffer (pH 8). Sterilize by  fi ltration (0.22  μ m) and 
store at 4 °C until use. Warm up to 25 °C before use. 
  6.  PBS solution: 0.1 M NaCl, 10 mM phosphate buffer (pH 8). 
  7.  Ethyl acetate (CH 3 COOC 2 H 5 ,  ³ 99.5 %). 
  8.  NAP-5 columns (GE Healthcare, Sweden). 
  9.  Ultrasound bath S10H (Elma, Germany) or equivalent sonica-
tor (ultrasonic effective power: 30 W; Ultrasonic frequency: 
37 kHz). 
  1.  DMEM: Dulbecco’s modi fi ed eagle medium. 
  2.  Fetal bovine serum: Heat inactivated. Store at −20 °C 
until use. 
  3.  CO 2 incubator MCO-96 (Sanyo, UK). 
  1.  TRIsure ® (Bioline, UK). 
  2.  DEPC-treated water: Add 0.1 mL Diethyl Pyrocarbonate 
(DEPC) for each 100 mL of water to be treated (i.e., 0.1 % 
(v/v) DEPC) and shake vigorously to bring the DEPC into 
solution. Incubate the solution at least 1 hour at 37 °C. 
Autoclave at least 15 min to inactivate any traces of DEPC. 
Store at 4 °C until use. 
  3.  75 % ethanol: Add 75 volumes of absolute ethanol to 25 vol-
umes of DEPC-treated water (see Note 2). Store at −20 °C 
until use. 
  4.  Chloroform. 
  5.  Isopropyl alcohol. 
  1.  MgCl 2 solution: 0.3 M MgCl 2 in deionized water. Store at 
room temperature. 
  2.  2.10 mM phosphate buffer (pH 8): as described in 
Subheading  2.2 , step 3. 
  3.  Ultra-Micro quartz cells (Hëllma, Germany) or 384 well small 
volume, LoBase Polystyrene microplates, black (Greiner Bio-
One, Germany). 
  4.  UV–Vis Spectrophotometer UV2 (UNICAM, UK) or 
Microplate reader In fi nite M200 with Absorbance module 
(Tecan, Switzerland) or equivalent instrument capable of scan-
ning wavelength range 400–800 nm. 
 2.3.  Cell Culture 
Components
 2.4.  Total RNA 
Isolation Components
 2.5.  Non-Cross-
Linking Assay 
Components
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  1.  K562 erythroleukemic cells (BCR–ABL positive cell line 
derived from CML patients in blast crisis, expressing the BCR–
ABL gene fusion e1a2 and e14a2 transcripts). 
  2.  2.HL-60cell line, a human leukemic promyelocytic cell line 
(BCR–ABL negative). 
  3.  Control oligonucleotide samples—see Table  2 . “BCR–ABL 
(e14a2) gene fusion” and “BCR–ABL (e1a2) gene fusion” oli-
gonucleotide control targets are derived from the reference 
sequences deposited in Gene Bank with accession no. 
AJ131466.1 and AF113911.1, respectively. “ABL gene” and 
“BCR gene” oligonucleotide control targets are derived from 
the reference sequences Gene Bank accession no. NM 005157.3 
and NM021574.2, respectively. The “Unrelated” oligonucle-
otide control target was randomly generated and checked to 
present no complementarity to the nanoprobes. The BCR–
ABL probes span over the region of fusion, i.e., breakpoint 
that is present in more than 90 % of CML patients. 
 
 Treat all glass materials with freshly prepared  aqua regia (see 
Note 4) by immersion for at least 1 h and wash vigorously after-
wards with ultrapure water. Cover all metal materials used during 
synthesis (e.g., metallic spatulas) with Te fl on to avoid metal corro-
sion and contamination. 
 2.6.  RNA and Control 
Samples ( See  Note 3 )
 3.  Methods
 3.1.  Noble Metal 
Nanoparticle 
Synthesis
 Table 2 
 Control targets 
 Targets  Sequence (5 ¢ -3 ¢ ) 
 Gene-Bank 
acc. number 
 BCR–ABL (e14a2) 
gene fusion 
 TGGATTTAAGCAGAGTTCAAAAGCCCTTCA
GCGGCCAGTA 
 AJ131466.1 
 BCR–ABL (e1a2) 
gene fusion 
 TCCATGGAGACGCAGAAGCCCTTCAGCGGC
CAGTAGCATC 
 AF113911.1 
 ABL gene  CTCCAGCTGTTATCTGGAAGAAGCCCTTCAG
CGGCCAGTA 
 NM 005157.3 
 BCR gene  TGGATTTAAGCAGAGTTCAAATCTGTACTGC
ACCCTGGAG 
 NM021574.2 
 Unrelated  GGCCGCTGCGGCGGGGCTCAGGGCACAAATT
GGAACGTTC 
 n.a. 
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  1.  In a 500 mL round bottom  fl ask, boil 225 mL of 1 mM 
HAuCl 4 (88.61 mg) until re fl ux with vigorous stirring. 
  2.  While in re fl ux, quickly add 25 mL of 38.8 mM sodium citrate 
(285 mg) and keep re fl ux for 15 min with vigorous stirring 
(see Note 5). 
  3.  Stop re fl ux maintaining the stirring and leave the colloidal 
solution to cool down to room temperature. 
  4.  Transfer the colloidal solution to a 250 mL Erlenmeyer amber 
 fl ask with a ground glass cap and store in the dark at room 
temperature until further use (see Note 6). 
  5.  The colloidal gold concentration should be determined by 
measuring the absorption (see Note 7) assuming a molar 
absorptivity for the plasmon resonance band maximum 
(520 nm) of 2.33 × 10 8 M −1 cm −1 . The expected typical yield 
(concentration) should be ~14 nM AuNPs (see Note 8). 
  1.  In a 250 mL round bottom  fl ask, boil 95 mL of 0.126 mM 
HAuCl 4 (4.71 mg) and 0.127 mM AgNO 3 (2.04 mg) (see 
Note 9) until re fl ux with vigorous stirring. 
  2.  While in re fl ux, quickly add 5 mL of 34 mM sodium citrate 
(50 mg) and keep re fl ux for 15 min with vigorous stirring. 
  3.  Stop re fl ux maintaining the stirring and leave the colloidal 
solution to cool down to room temperature. 
  4.  Centrifuge the colloidal solution at 233 ×  g for 20 min and 
decant the supernatant to a 100 mL Erlenmeyer amber  fl ask 
with a ground glass cap, to remove any silver precipitate that 
may have formed. 
  5.  Store in the dark at room temperature until further use. 
  6.  The colloidal alloy nanoparticle concentration can be deter-
mined by measuring the absorption (see Note 7) assuming a 
molar absorptivity 1.19 × 10 10 M −1 cm −1 for the typical plasmon 
resonance band maximum at 460 nm (see Note 9). The 
expected typical yield (concentration) should be ~0.1 nM alloy 
nanoparticles (50 % Ag: 50 % Au) (see Note 10). 
  1.  Extract one volume (100–500  μ L) of thiol-modi fi ed 
oligonucleotide resuspended in 0.1 M DTT with 2 volumes of 
ethyl acetate. Mix thoroughly. 
  2.  Centrifuge for 5 min at 21,460 ×  g and discard the organic 
phase (i.e., upper phase). 
  3.  Repeat the extraction of the aqueous phase 2 more times. 
  4.  Purify the remaining aqueous phase using a desalting NAP-5 
column, following the manufacturer’s instructions and using 
10 mM phosphate buffer (pH 8) as eluent. Typically, after col-
umn equilibration with the eluent, 500  μ L of the aqueous 
 3.1.1.  13 nm Gold 
Nanoparticle Synthesis
 3.1.2.  Alloy Gold:Silver 
Nanoparticles Synthesis
 3.2.  Noble Metal 
Nanoprobe Synthesis
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phase is added and let to enter the column. Afterwards, 
1,000  μ L of puri fi ed thiol-modi fi ed oligonucleotide can be 
collected by adding 1,000  μ L of the eluent to the column. 
  5.  Quantify the puri fi ed thiol-modi fi ed oligonucleotide by UV/
Vis spectroscopy using the extinction coef fi cient at 260 nm 
provided by the oligonucleotide manufacturer. An online 
Oligonucleotide Properties Calculator (e.g.,  http://www.
basic.northwestern.edu/biotools/oligocalc.html ) can be used 
if the extinction values are not known. 
  6.  Mix the puri fi ed thiol-modi fi ed oligonucleotide with the 
colloidal solution in a 1:200 [AuNPs]: oligonucleotide or 
1:62,000 [AuAg-alloy-NPs]:oligonucleotide ratio for the alloy 
nanoparticles. 
  7.  Add AGE I solution to achieve a  fi nal concentration of 10 mM 
phosphate buffer (pH 8), 0.01 % (w/v) SDS. Typically, 15.1  μ L 
of AGE I solution is added to a volume of 3 mL of the solution 
prepared in previous step. 
  8.  Sonicate the solution for 10 s using an ultrasound bath and 
incubate at room temperature for 20 min. 
  9.  Afterwards, sequentially increase the ionic strength of the solu-
tion by adding the respective volume of AGE II solution up to 
a  fi nal concentration of 10 mM phosphate buffer (pH 8), 
0.3 M NaCl, 0.01 % (w/v) SDS (see Note 11). Typically, 
104.1, 111.6, 119.8, 129.1, 139.4, and 151  μ L of AGE II 
solution is added sequentially to the 3,015.1  μ L of the solu-
tion prepared in step 7 to achieve 50 mM incremental increase 
in NaCl concentration. After each increment, sonicate the 
solution for 10 s and incubate at room temperature for 20 min 
before the next increment. 
  10.  Incubate the solution overnight at room temperature. 
  11.  Distribute the functionalized nanoparticles in 1.5 mL micro-
centrifuge tube and centrifuge for 20 min at 21,460 ×  g , dis-
card the supernatant. 
  12.  Wash the resulting oily pellet in microcentrifuge tubes by add-
ing 1 mL of 10 mM phosphate buffer (pH 8), centrifuge for 
20 min at 21,460 ×  g , discard the supernatant. 
  13.  Repeat the above washing step (two washes in total). 
  14.  Wash the pellet in microcentrifuge tubes by adding 1 mL of 
PBS solution and centrifuge for 20 min at 21,460 ×  g , discard 
the supernatant. 
  15.  Resuspend the pellet in 500  μ L of PBS solution. Transfer the 
resulting solutions of each microcentrifuge tube into a single 
polypropylene or glass vial with a conical skirted base. 
  16.  Determine the nanoprobe concentration via Lambert–Beer 
equation, using the absorbance (see Note 7) and the molar 
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absorptivity of the respective nanoparticles. Prepare aliquots of 
15 or 0.3 nM of Au- or AuAg-alloy-nanoprobes, respectively, 
using PBS as eluent. Normally, aliquots of 1,300  μ L should be 
suf fi cient. 
  17.  Store the nanoprobe stock solutions in the dark at 4 °C until 
further use. 
  1.  Grow K562 and HL-60 cells in Dulbecco’s modi fi ed Eagle’s 
medium (DMEM) with 10 % heat inactivated fetal bovine 
serum and maintain at 37 °C in 5 % CO 2 . 
  2.  After cells reach >80 % con fl uence level, collect 10 6 cells by 
centrifugation (1,500 rpm, 5 min at 4 °C). 
 Any suitable method can be used for total RNA extraction and 
puri fi cation. We have tried several commercially available puri fi cation 
kits with equivalent results. Currently, we are using a protocol 
based on the single step method developed by Chomczynski and 
Sacchi  ( 26,  27 ) .
  1.  Isolate Total RNA from K562 and HL-60 cell lines using 
TRIsure ® (use 1 mL of TRIsure per 5 × 10 6 cells). 
  2.  Lyse cells with 1 mL of TRIsure ® and pass the lysate several 
times through a pipette tip and vortex. 
  3.  Incubate samples for 5 min at room temperature. 
  4.  Add 0.2 mL of chloroform per 1 mL of TRIsure ® used. Cap 
tubes securely and shake vigorously by hand for 15 s. 
  5.  Incubate samples for 2–3 min at room temperature. Centrifuge 
samples at 12,000 ×  g for 15 min at 4 °C. The sample will sepa-
rate into a pale green, phenol–chloroform phase, an interphase, 
and a colorless upper aqueous phase that contains the RNA. 
  6.  Transfer the aqueous phase to another tube. Precipitate the 
RNA by mixing with 0.5 mL of isopropyl alcohol per 1 mL of 
TRIsure ® used. 
  7.  Incubate samples for 10 min at room temperature then centri-
fuge at 12,000 ×  g for 10 min at 4 °C. 
  8.  Remove the supernatant and wash the pellet once with 75 % 
ethanol, adding at least 1 mL of ethanol per 1 mL of TRIsure ® 
used. Vortex samples and centrifuge at 7,500 ×  g for 5 min 
at 4 °C. 
  9.  Air-dry the pellet for 10 min and dissolve in 25–50  μ L of 
DEPC-treated water (use 25  μ L per 10 6 cells) by pipetting the 
solution up and down, and incubating for 10 min at 55 °C. 
  10.  Store RNA at −80 °C. 
 3.3.  Cell Culture
 3.4.  Total RNA 
Isolation
150
80 J. Conde et al.
  1.  Prepare six solutions in 200  μ L polypropylene thermal- 
resistant reaction tubes by only mixing the nanoprobe stock 
solution with the 10 mM phosphate buffer, see Table  3 . Do 
not add MgCl 2 at this point! 
  2.  Incubate the solutions for 10 min at 95 °C. 
  3.  Allow the solutions to cool down at room temperature for 
30 min. 
  4.  Add the 0.3 M MgCl 2 according to Table  3 , mix well and spin 
down the solutions. 
  5.  Incubate the solutions for 15 min at room temperature and 
register their absorption spectra (350–800 nm) using a 
UV–visible spectrophotometer or microplate reader. 
  6.  Plot Abs peak /Abs 600nm vs. [MgCl 2 ] fi nal to determine the mini-
mum salt concentration needed for a complete nanoprobe 
aggregation, where Abs peak is the absorbance peak of the initial 
dispersed nanoprobe (see Note 12) . . For Abs peak /Abs 600nm ratios 
below 1, the nanoprobe is considered to be fully aggregated 
(see Note 13). . 
  1.  In 200  μ L polypropylene thermal-resistant reaction tubes, pre-
pare at least four assay solutions (Blank, Positive and Negative 
control, and sample) by mixing the total RNA sample ( fi nal 
concentration 10–60 ng  μ L −1 ) with the BCR–ABL (e14a2) 
Au-nanoprobe solution ( fi nal concentration of 2.5 nM) and an 
appropriate volume of 10 mM phosphate buffer (pH 8) to 
make up the total volume (total volume of 60  μ L, considering 
the volume of salt that will be added in step 5). If more than 
one sample is to be analyzed, more assay solutions can be pre-
pared accordingly. 
 3.5.  Colorimetric 
Non-Cross-Linking 
Assay
 3.5.1.  Noble Metal 
Nanoprobes 
Characterization
 3.5.2.  mRNA Detection 
and Quanti fi cation
 Table 3 
 Setup for characterization of nanoprobe aggregation 
 Tube  Nanoprobe a ( m L) 
 10 mM phosphate 
buffer (pH 8) ( m L) 
 300 mM 
MgCl 2 ( m L) 
 MgCl 2 concentration 
(mM) 
 1  10  50  –  0 
 2  10  48  2  10 
 3  10  46  4  20 
 4  10  44  6  30 
 5  10  42  8  40 
 6  10  40  10  50 
 a Nanoprobe stock solutions: 15 nM Au-nanoprobe or 0.3 nM alloy-nanoprobe (50 % Ag: 50 % Au) 
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  2.  As a Positive control use the complementary oligonucleotide 
BCR–ABL (e14a2) and as a Negative control use the BCR or 
ABL oligonucleotides ( fi nal concentration of 100 fmol  μ L −1 )—
see Table  1 for sequences. Additionally, prepare the blank solu-
tion by replacing the total RNA with an equivalent volume of 
10 mM phosphate buffer (pH 8). 
   For mRNA quanti fi cation, prepare  fi ve reference standard 
solutions using the complementary target ranging in concen-
tration from 0 to 100 fmol  μ L −1 . 
  3.  Incubate the solutions for 10 min at 95 °C. 
  4.  Allow the solutions to cool down for 30 min at room 
temperature. 
  5.  Add a predetermined volume of the concentrated MgCl 2 solution 
to attain the  fi nal concentration needed for aggregation of the 
nanoprobe as determined in Subheading  3.5.1 , step 6, Mix well. 
  6.  Spin down and incubate the solutions for 15 min at room 
temperature. 
  7.  Register the absorption spectra (350–800 nm) using a 
UV–visible spectrophotometer or a microplate reader. 
  8.  Determine the Abs peak /Abs 600nm ratio (for the described 13 nm 
gold nanoparticles, Abs peak is typically measured at 520 nm). 
Compare the ratios of the blank, positive and negative control 
with the ratios of the sample solutions. Typically, the blank 
sample, negative control, and negative samples yield ratios 
below 1, while positive control and positive samples yield ratios 
above 1 (see Fig.  2 ). 
 Fig. 2.  Characteristic detection assay results. UV/visible spectra of Au-nanoprobe alone 
(Blank); in the presence of a complementary target (Pos); and in the presence of a non-
complementary target (Neg), taken after 15 min incubation with salt. Inlet represents the 
Abs 520nm /Abs 600nm ratios of the presented UV/visible spectra. 
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  9.  For quanti fi cation, plot the Abs 520nm /Abs 600nm vs. mRNA con-
centration of the reference standard solutions and compare 
with the samples’ Abs 520nm /Abs 600nm ratio to determine their 
mRNA concentration (see Fig.  3 ) (see Note 14). 
  1.  In 200  μ L polypropylene thermal-resistant reaction tubes, 
prepare at least six assay solutions (blank, three positive and 
one negative control, and sample) by mixing the total RNA 
sample ( fi nal concentration 10–60 ng  μ l −1 ) with the ABL 
Au-nanoprobe solution ( fi nal concentration of 2.5 nM), the 
BCR–ABL (e1a2) AuAg-alloy-nanoprobe solution ( fi nal con-
centration of 0.05 nM), and an appropriate volume of 10 mM 
phosphate buffer (pH 8) to make up the total volume (total 
volume of 60  μ L, considering the volume of salt that will be 
added in step 5). If more than one sample is to be analyzed, 
more assay solutions can be prepared accordingly. 
  2.  Use the complementary oligonucleotides as Positive controls 
for each nanoprobe ABL (ABL Au-nanoprobe) and BCR–ABL 
(e1a2) (BCR–ABL (e1a2) AuAg-alloy-nanoprobe), both sepa-
rately and mixed. Use the unrelated oligonucleotide sequence 
as a negative control ( fi nal concentration of oligonucleotides at 
100 fmol  μ L −1 )—see Table  2 for sequences. Additionally, 
prepare the blank solution by replacing the total RNA with 
equivalent volume of 10 mM phosphate buffer (pH 8). 
  3.  Incubate all solutions for 10 min at 95 °C. 
 3.5.3.  One-Pot Multiplex 
Detection
 Fig. 3.  Characteristic quanti fi cation assay results. Typical Abs 520nm /Abs 600nm ratios obtained 
for a range of complementary target concentrations. Dashed line represents a linear  fi t of 
the experimental data points and the error bars represent the standard deviation ( n = 3). 
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  4.  Allow the solutions to cool down for 30 min at room 
temperature. 
  5.  Add a predetermined volume of the concentrated MgCl 2 solu-
tion to attain the  fi nal concentration needed for aggregation of 
the nanoprobes as determined in Subheading  3.5.1 , step 6 (see 
Note 15). 
  6.  Mix well, spin down, and incubate the solutions for 15 min at 
room temperature. 
  7.  Measure the absorption spectra (350–800 nm) using a 
UV–visible spectrophotometer or a microplate reader. 
  8.  Compare the spectra of the blank, positive and negative 
controls with the spectra of the sample(s)—as an example of 
typical multiplex results, see Fig.  4 . Typically, if only the 
complementary target to the Au-nanoprobe is present an 
 Fig. 4.  Representative one-pot assay results. UV/visible spectra and digital photography of AuAg-alloy- and Au-nanoprobe 
mix in the presence of a complementary targets to both the AuAg-alloy- and Au-nanoprobe – the solution retains the initial 
orange color (a), a complementary target to the AuAg-alloy-nanoprobe – the solution changes from orange to yellow (b), a 
complementary target to the Au-nanoprobe – the solution changes from orange to red (c) or a noncomplementary target 
to both AuAg-alloy- and Au-nanoprobes – the solution changes from orange to blue (d). Vertical dashed and solid lines 
represent the position of absorption peak of the AuAg-alloy-nanoprobes (460 nm) and Au-nanoprobe (520 nm), respec-
tively, when dispersed in solution. Schematics represent each nanoprobe and their complementary or noncomplementary 
targets. Reproduced from  ( 16 ) with permission from IOP. 
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absorbance peak at 520 and 600 nm can be observed. If only 
the complementary target to the AuAg-alloy-nanoprobe is 
present absorbance peaks at 460 and 600 nm can be observed. 
If both complementary targets are present absorbance peaks at 
460 and 520 nm can be observed. If only one absorbance peak 
at 600 nm can be observed, the target is either noncomple-
mentary or speci fi c RNA target concentration is below the 
method’s detection limit. 
 
  1.  Typical thiol-modi fi ed oligonucleotide probe sequences range 
between 15 and 25 nucleotides, according to speci fi city 
requirements. Check probe sequence speci fi city using NCBI 
nucleotide BLAST tool ( http://blast.ncbi.nlm.nih.gov/Blast.
cgi ). Increased nanoprobe speci fi city is achieved at the 
oligonucleotide’s 3 ¢ end, so consider any single nucleotide 
polymorphism at this position when designing the probe  ( 28 ) . 
  2.  Always measure the volume of ethanol and water separately 
and mix them subsequently. Do not prepare ethanol dilutions 
based on volumetric  fl asks, as the total volume of ethanol/
water will drop after mixing, leading to an erroneous dilution 
if the volumetric  fl ask mark is used as reference  ( 29 ) . 
  3.  Thiol-modi fi ed ssDNA, complementary to the fusion region 
of the BCR–ABL mRNA is used to functionalize the gold 
nanoparticles and produce speci fi c Au-nanoprobes to detect 
the fusion gene. These nanoprobes are assessed in terms of 
speci fi city by means of total RNA mixtures spiked in with syn-
thetic oligonucleotides (complementary target) harboring the 
fusion site BCR–ABL e14a2. It should be noted that, in reality, 
patients may only harbor one copy of the fusion gene and the 
remaining copies of normal ABL and BCR should be still func-
tional, thus expressing the normal mRNA sequence. Two oli-
gonucleotides harboring the normal sequence of the BCR or 
of the ABL genes are used to evaluate the probe’s capability to 
discriminate from similar sequences. 
  4.  Warning:  aqua regia is potentially hazardous and highly cor-
rosive. Always wear appropriate personal protective equipment 
(i.e., safety goggles, gloves, and laboratory coat) and work in a 
clean, well-ventilated chemical fume hood. Never store  aqua 
regia in a sealed container, as pressure may escalate and the 
container may burst or explode. Dispose  aqua regia adequately 
by dilution and neutralization. 
 4.  Notes
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  5.  After adding the citrate solution, the initial pale yellow color of 
the Au(III) solution should become instantly colorless and 
then gradually change to deep red due to the nanoparticle 
formation. The reduction process usually takes a few minutes 
to occur. During this process, a precursor called acetone dicar-
boxylic acid is formed as a result of the citrate oxidation. This 
precursor plays the roles of precursor, reducing and nucleating 
agents. The Au(III) ions are then reduced to Au(I) and when 
the solution becomes saturated of Au(I) atoms, they start to 
precipitate in the form of nanoparticles. The citrate acts as cap-
ping and stabilizing agent that sticks to the nanoparticle sur-
face avoiding the aggregation of the nanoparticles. 
  6.  The prepared nanoparticles are stable for months when stored 
in a clean container (glass or plastic) at room temperature. Do 
not freeze the nanoparticles as this may cause aggregation. 
  7.  The Lambert–Beer law states that the absorbance of a homo-
geneous substance becomes linear with its concentration accord-
ing to formula  A =  ε ×  l ×  C , where  A is the substance absorbance 
typically at its wavelength peak,  ε is the molar absorptivity for 
the wavelength of  A ,  l is the optical path length, and  C is the 
substance concentration. Care should be taken not to exceed 
an absorbance of 2 so as to avoid deviations to the Lambert–
Beer law. In case the measured absorbance exceeds this value, 
dilute the sample and consider the dilution factor when calcu-
lating the original stock concentration. 
  8.  Optionally, morphological characterization of the AuNPs can 
be performed by transmission electron microscopy (TEM) and 
dynamic light scattering (DLS). 
  9.  To obtain different AuAg alloy nanoparticles with different 
plasmon resonance peaks, the ratio of HAuCl 4 and AgNO 3 can 
be varied (e.g., the molar concentrations presented in the pro-
tocol refers to a 50%Au:50%Ag ratio, with a typical SRP band 
peak at 460 nm and a molar absorptivity of 1.19 × 10 10 M −1 cm −1 ). 
See Fig.  5 for typical SPR peak variation as function of the 
Au:Ag metal ratio. Nanoparticle size may also vary with the 
Au:Ag metal ratio. 
  10.  Optionally, morphological characterization of the alloy nano-
particles can be performed by TEM and DLS; the Au:Ag ratio 
can be determined by inductively coupled plasma (ICP) and/
or Energy-dispersive X-ray spectroscopy (EDX). 
  11.  Different degrees of nanoprobe functionalization (i.e., oligo-
nucleotide density) are attained by varying the  fi nal NaCl con-
centration during the aging process (e.g., 0.1, 0.5, 0.7 M). Be 
aware that nanoprobe hybridization ef fi ciency may decrease 
with increasing density due to steric hindrance. For further 
information, consult Doria et al .  ( 28 ) . 
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  12.  Abs peak is the absorbance maximum determined earlier for the 
particular nanoprobe peak of the initial dispersed nanoprobe. 
Typical values are 520 nm for Au-nanoprobes or 460 nm for 
alloy-nanoprobes: (50 % Ag: 50 % Au ). 
  13.  If the nanoprobes do not completely aggregate and change 
color within the suggested concentrations of MgCl 2 , use higher 
concentrations of MgCl 2. If the nanoprobe changes color and 
fully aggregates at a  fi nal MgCl 2 concentration of 10 mM, then 
derivatization of the nanoparticles with the thiol-modi fi ed oli-
gonucleotides may have not been effective. If so happens, 
repeat nanoprobe synthesis. 
  14.  To discriminate between two signi fi cantly different aggrega-
tion levels, as for example in a YES/NO identi fi cation of a 
given target, the ratio between the peaks at 520 and 600 nm is 
usually used for Au-nanoprobes. However, for identifying 
small differences in aggregation levels between two quantities 
for the same target, there is a need to decrease the background 
noise in the spectra. Such background noise may be strongly 
reduced and even solved if an integral of the signal is used, i.e., 
the area under the curve (AUC). 
  15.  In order for the one-pot assay to work, both nanoprobes must 
aggregate at similar minimum salt concentration. If the mini-
mum salt concentration for aggregation varies slightly between 
nanoprobes, use the highest determined concentration of salt 
for the one-pot assay. 
 Fig. 5.  SPR absorption band peak of alloy-nanoparticles as function of the gold:silver ratio. 
 Dashed line represents a linear  fi t of the experimental data points. 
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ABSTRACT   
Cancer is a multigenic complex disease where multiple gene loci contribute to the phenotype. The ability to 
simultaneously monitor differential expression originating from each locus results in a more accurate indicator of degree 
of cancerous activity than either locus alone. Metal nanoparticles have been thoroughly used as labels for in vitro 
identification and quantification of target sequences. We have synthesized nanoparticles with assorted noble metal 
compositions in an alloy format and functionalized them with thiol-modified ssDNA (nanoprobes). These nanoprobes 
were then used for the simultaneous specific identification of several mRNA targets involved in cancer development - 
one pot multicolor detection of cancer expression. The different metal composition in the alloy yield different "colors" 
that can be used as tags for identification of a given target. Following a non-cross-linking hybridization procedure 
previously developed in our group for gold nanoprobes, these multicolor nanoprobes were used for the molecular 
recognition of several different targets including differently spliced variants of relevant genes (e.g. gene products 
involved in chronic myeloid leukemia BCR, ABL, BCR-ABL fusion product). Based on the spectral signature of 
mixtures, before and after induced aggregation of metal nanoparticles, the correct identification could be made. Further 
application to differentially quantify expression of each locus in relation to another will be presented. The differences in 
nanoparticle stability and labeling efficiency for each metal combination composing the colloids, as well as detection 
capability for each nanoprobe will be discussed. Additional studies will be conducted towards allele specific expression 
studies.  
Keywords: gold nanoparticles, alloy nanoparticles, gene expression, cancer, splice variants, multicolor nanoparticles, 
gene characterization, chronic myeloid leukemia, mRNA 
 
1. INTRODUCTION  
Cancer cells exhibit deregulation of the cell cycle resulting in uncontrolled growth and they are resistant to programmed 
death as result of abnormalities in one or more proteins that inhibit apoptosis. Moreover, alternatively and abnormally 
expressed mRNAs (e.g. alternatively spliced mRNAs, fusion gene products) are considered as triggers of tumor 
development. The National Cancer Institute envisions that over the next years, nanotechnology will result in significant 
advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of 
cancer1. Among these advances, nanodiagnostics has been providing for improved techniques for clinical diagnostics 
with increased sensitivity at lower costs2-10. Due to their optical properties, gold nanoparticles (AuNPs) have been used 
for DNA/RNA screening approaches, namely via functionalization with thiolated oligonucleotides (Au-nanoprobes), 
capable of specifically hybridizing with a complementary oligonucleotide sequence. These optical properties derive from 
the characteristic surface plasmon resonance (SPR) band that can be easily tailored through the synthesis of nanoparticles 
(NPs) with different metal composition, either in an alloy or core-shell structure, e.g. different gold:silver ratios11,12.  
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For the past years we have been developing nanodiagnostics systems based on noble metal NPs in a non-cross linking 
approach, where an increase of the ionic strength of the surrounding media leads to selective aggregation of nanoprobes: 
absence of complementary target allows extensive aggregation with concomitant spectral change of the colloidal 
solution, whereas presence of a complementary target stabilizes the nanoprobe, thus preventing aggregation and 
colorimetric changes6-9. We have recently reported on a highly selective colorimetric detection method for DNA 
sequences based on AuAg-alloy-NPs functionalized with thiol-modified oligonucleotides, i.e. AuAg-alloy-nanoprobes, 
and the use of these alloy-nanoprobes together with more common Au-nanoprobes in a one-pot colorimetric assay for the 
simultaneous differential detection of two gene sequences13. Simultaneously, we have shown that the Au-nanoprobe 
assay could be used for mRNA quantification and used this strategy to quantify gene expression of an aberrant BCR-
ABL fusion gene involved in the development of chronic myeloid leukemia14. 
Chronic myeloid leukemia (CML) is a clonal neoplastic disease of the hematopoietic stem cell, whose hallmark 
molecular event is the genetic t(9;22)(q34;q11) translocation known as the Philadelphia (Ph) chromosome. This 
translocation - ABL gene (chromosome 9) and BCR gene (chromosome 22) - originates a BCR-ABL fusion gene, 
leading to the expression of a chimeric BCR-ABL protein with tyrosine-kinase activity15-20. Because the translocation 
can result in distinct breakpoints and, thus, fusion genes, these constitute an interesting model to study splice variants and 
their expression in cancer development. Furthermore, several other genes may be implicated in the development of the 
cancer, such as tumor suppressor genes whose expression prevents cell transformation (e.g. p53) or proto-oncogenes, 
which tend to be upregulated and promote neoplastic events (e.g. C-MYC). 
Here, we report the synthesis of AuAg-alloy-NPs with different noble metal molar fractions, and their derivatization with 
thiol-modified ssDNA oligonucleotides for application in molecular diagnostics. Using the BCR-ABL fusion products as 
a model, we demonstrate the use of these AuAg-alloy nanoprobes for the quantitative analysis of targets in complex 
mixtures, and for the differential expression analysis of two genes in relation to each other. Because the assay is 
performed on total RNA, this approach avoids the need for retrotranscription and/or nucleic acid amplification. 
 
2. MATERIALS AND METHODS 
 
All chemicals were from Sigma-Aldrich and of the highest purity available. All thiol-modified oligonucleotides were 
purchased from STAB Vida, Lda (Portugal). 
 
2.1 Au- and AuAg-alloy nanoparticles syntheses 
AuNPs were prepared by the citrate reduction method described by Lee and Meisel21. The AuAg-alloy-NPs were 
prepared following a similar method by co-reducing AgNO3 and HAuCl4 with sodium citrate described in [13]. Briefly, 
12.5 mg of HAuCl4•3H2O and 16.2 mg of AgNO3 (for a 25:75 Au:Ag ratio); or 25 mg of HAuCl4•3H2O and 10.8 mg of 
AgNO3 (for Au:Ag ratio 50:50); or 37.5 mg of HAuCl4•3H2O and 5.4 mg of AgNO3 (for Au:Ag 75:25 ratio) - were 
dissolved in 250 mL of milli-Q H2O and brought to a boil while stirring in a 500 ml round-bottom flask. Twenty-five 
millilitres of sodium citrate 34 mM were quickly added and the mixture was refluxed for 15 min with continuous stirring. 
The flask was left to cool down to room temperature and the solution was later centrifuged at 233 g for 20 minutes to 
remove any silver precipitate, and further filtered using 0.2 µm nylon filters (Whatman, UK). Both Au- and AuAg-alloy-
NPs were characterized by Transmission Electron Microscopy (TEM) and UV-visible spectroscopy. The elemental 
composition (i.e. Au:Ag ratio) of AuAg-alloy-NPs was determined by Inductively Coupled Plasma (ICP) upon 
dissolving the nanoparticles in freshly prepared aqua regia. Solutions containing NPs were kept in the dark at room 
temperature until further use. 
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2.2 Au- and AuAg-alloy-nanoprobes syntheses 
The sequence of the thiolated oligonucleotides sued for nanoparticle functionalization are indicated in Table 1 together 
with the synthetic oligos used as complementary and non-complementary targets. 
 
Oligo 
# 
Probe/target Sequence 5’-3’ Modification 
1p ABL probe CGCTGAAGGGCTTCTTCCAG 5’-(CH2)6-SH 
1t ABL target CTCCAGCTGTTATCTGGAAGAAGCCCTTCAGCGGCCAGTA  
2p C-MYC probe GATTGCTCAGGACATTTCTG 5’-(CH2)6-SH 
2t C-MYC target TTCCTTCTAACAGAAATGTCCTGAGCAATCACCTATGAAC  
3p BCR-ABL_e1a2 probe CGCTGAAGGGCTTCTGCGTC 5’-(CH2)6-SH 
3t BCR-ABL_e1a2 target TCCATGGAGACGCAGAAGCCCTTCAGCGGCCAGTAGCATC  
4 Non-complementary 
target 
GGCCGCTGCGGCGGGGCTCAGGGCACAAATTGGAACGTTC  
  
Both Au- and AuAg-alloy-nanoprobes were synthesized following a previously described protocol13. The Au-NPs were 
functionalized with a thiol-modified 20mer oligonucleotide derived from the junction of exon 1 and 2 of ABL gene (i.e. 
oligo#1p) or a 20mer oligonucleotide derived from human v-myc myelocytomatosis viral oncogene homolog (C-MYC) 
gene (i.e. oligo#2p). The AuAg-alloy-NPs (25%Au:75%Ag) were functionalized with a thiol-modified 20mer 
oligonucleotide derived from the BCR-ABL fusion gene involving the isoform e1a2 (oligo#3p). Briefly, 10µM thiol-
modified oligonucleotide was added to NPs in a ratio of 1:200 Au-NPs or 1:3500 AuAg-alloy-NPs per oligonucleotide, 
in phosphate buffer 10 mM (pH8) with 0.01% sodium dodecyl sulfate (SDS). The solution was incubated at room 
temperature for 20 min and the concentration of NaCl increased to 0.05 M using phosphate buffer 10 mM (pH8), 1.5 M 
NaCl, 0.01% SDS. The solution was then submitted to ultrasounds for 10 sec. This salt aging process was repeated three 
times with increments of 0.1 M NaCl until a concentration of 0.3 M NaCl was reached. After a final incubation over-
night at room temperature, the solution was washed three times and ressuspended in phosphate buffer 10 mM (pH8), 0.1 
M NaCl. Functionalization was assessed by evaluation of the UV/visible spectra upon increasing concentrations of 
MgCl2. 
 
 
2.3 Total RNA purification 
Escherichia coli cells were grown in standard Luria-Bertani (LB) broth overnight at 37°C. Isolation of total RNA was 
performed using a High Pure RNA Isolation Kit (Roche Applied Science) or GeneJET™ RNA Purification Kit 
(Fermentas) according to the manufacturer’s protocol for the human cell lines and for E. coli, respectively. Total RNA 
concentration was determined by UV photometry and its integrity evaluated on a 2% agarose gel stained with GelRed™ 
dye (Biotium, USA), and it was stored at -80 ºC until further use. 
 
2.4 Detection/quantification assay 
Target detection was carried out via the previously described non-cross-linking protocol13. Hybridizations were carried 
out in 10 mM phosphate buffer (pH 8) by mixing up to 2µM target with either 2.5 nM Au-nanoprobe or 72 pM AuAg-
alloy-nanoprobe. Forty-mer ssDNA oligonucleotides were used as targets: complementary to the BCR-ABL_e1a2 
AuAg-alloy-nanoprobe (probe’s oligo#3p) - oligo#3t derived from BCR-ABL fusion gene, isoform e1a2; complementary 
to the ABL Au-nanoprobe (probe’s oligo#1p) – oligo#1t, derived from ABL gene; complementary to the C-MYC Au-
nanoprobe (probe’s oligo#2p)– oligo#2t derived from C-MYC gene; non-complementary to either nanoprobes – oligo#4 
harboring an unrelated sequence. For each probe assay, at least three solutions were prepared: one with the 
complementary target (Comp), one with the unrelated sequence (Non-comp) and a Blank to confirm aggregation. 
Following 10 min of denaturation at 95 ºC, solutions were allowed to stand for 30 min at room temperature, and then 
MgCl2 was added to a final concentration of 20 mM (for BCR-ABL_e1a2 AuAg-alloy-nanoprobe) or 40 mM (for ABL 
Au-nanoprobe and One-pot assay), or 0.95M of NaCl for the C-MYC probe. UV/visible spectra of solutions were 
registered 15 minutes upon salt addition using a UV-Vis Spectrophotometer Evolution 300 (Thermo, USA) and an Ultra-
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Micro quartz cell (Hëllma, Germany). Digital photographs were taken using a Canon Rebel Xsi SLR digital camera 
(Canon, USA). 
For the differential quantification assays, the final concentration of BCR-ABL_e1a2 target varied between 0 and 2 µM; 
ABL target was set at a fixed concentration of 2 µM; the final total ssDNA concentration was kept at 4 µM and total 
RNA at 20 ng/µL. The c-MYC spike in assays were achieved as a function of specific target concentration in mixtures of 
20 ng/μl total RNA from E.coli spiked in with increasing concentrations of the synthetic c-MYC oligonucleotide, with 
final concentration from 33 to 133 nM. For c-MYC quantification the final concentrations of total RNA from a c-MYC 
positive cell line (HL-60) differed between 10 and 80 ng/μl. All experiments were done with c-MYC-nanoprobe at a 
final concentration of 2.5 nM. 
For the one-pot spiking assay, both nanoprobes were mixed - 72 pM BCR-ABL_e1a2 AuAg-alloy-nanoprobe and 2.5 
nM ABL Au-nanoprobe, and the assay carried out as above setting the ABL target (oligo#1t) concentration at 0.2µM and 
varying the concentration of BCR-ABL_e1a2 target (oligo#3t) between 0 and 2µM, always in a fixed final concentration 
of 20 ng/µL of E.coli total RNA.   
 
 
3. RESULTS AND DISCUSSION 
 
Regulation of gene expression is fundamental in all living organisms and is essential for the correct development and for 
the tight control over cell proliferation and physiology. Alterations to the expression of certain genes have strong 
implications on the development of aberrant phenotypes that can lead to cell cycle deregulation and to cancer. Most of 
these alterations involve sequence mutations to DNA (e.g. single point mutations, translocations, inversions, etc.) and/or 
to the way RNA is processed and its expression levels (e.g. splicing, multiple isoforms, etc.). As an example, Chronic 
myeloid leukemia (CML) is generally associated with the genetic t(9;22)(q34;q11) translocation, originating an aberrant 
BCR-ABL fusion gene that can differ from one another by the exact localization of the beak-point and which exons are 
involved in the fusion transcript. As mentioned earlier, other genes may also be deregulated and implicated in disease 
development, such as p53 and C-MYC. The most commonly used procedures for the initial diagnosis and management 
of CML patients are expensive and time consuming, e.g. karyotype analysis, reverse transcriptase polymerase chain 
reaction analyses (RT-PCR) and fluorescence in-situ hybridization (FISH)20,22. Molecular methods able to detect and 
quantify the BCR-ABL fusion transcripts are of paramount relevance when monitoring minimal residual disease and 
genetic recurrence in patients known to harbor the translocation. There is, therefore, a strong demand for new and 
improved strategies for the detection of these alterations with increased sensitivity and specificity. 
Metal nanoparticles that differ in size and composition can be fabricated to scatter light of different wavelengths 
according to their distinct SPR. The optical properties from noble metal NPs with different sizes, shapes and composition 
has been extensively explored, with focus on application to biomolecular detection and characterization. Gold-silver 
alloy NPs can be synthesized with different ratios of each metal, where increasing molar fractions of silver leads to a 
typical blue-shift of the SPR absorption band peak. We have previously demonstrated that the use of AuAg-alloy-NPs 
(50%Au:50%Ag) allowed to modulate the characteristic SPR band of silver NPs, while retaining the ease of 
functionalization via thiol-modified oligonucleotides conferred by the gold surface13. The alloy-nanoprobes thus created 
were used in a two color one-pot detection scheme based on the non-cross-linking systems developed for Au-
nanoprobes. Here, we tuned the SPR band of the alloy-NPs so as to allow better discrimination from the typical AuNPs’ 
SPR band, and evaluated their use as nanoprobes for the differential quantification of specific gene sequences. 
 
3.1 Au and AuAg-alloy-nanoprobes syntheses and characterization 
First, we synthesized Au-NPs with 13 nm diameter and functionalized them with the suitable thiol-ssDNA 
oligonucleotide according to a well-established protocol. Then, we also effectively synthesized stable gold:silver alloy 
nanoparticles with varying ratios of each metal. Because we aim at using these NPs in conjunction with the AuNPs, the 
proportion of each metal was chosen so as to allow for an increased difference between the peak of non-aggregated 
nanoprobes, which, once aggregation takes place, would allow better color discrimination between alloys and gold NPs. 
AuAg-alloy-NPs with 25% gold and 75% silver were selected due to their SPR peak being located farther away from the 
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typical peak for pure AuNPs (Figure 1 – inlet). This way, better spectral discrimination can be attained and the 
simultaneous use of the respective nanoprobes in a one-pot is more effective. So, 29±13 nm AuAg-alloy NPs 
(25%Au:75%Ag) showing a SPR band peak circa 442 nm were synthesized. Similarly to what is observed with AuNPs, 
aggregation of the NPs can be achieved by increasing ionic strength, i.e. salt addition. These novel alloy NPs were then 
successfully functionalized with thiol-modified oligonucleotides via a similar procedure of that described for the 
synthesis of Au-nanoprobes. These AuAg-alloy-nanoprobes presented an increased stability to salt-induced aggregation 
when compared to the AuAg-alloy-NPs alone, withstanding a saline concentration up to 20mM MgCl2. In the presence 
of 20 mM MgCl2, the AuAg-alloy-nanoprobes aggregated and their initial yellow color changed to blue due to a red-shift 
from 442 nm to >600 nm of the SPR absorbance band (see Figure 1). 
 
 
Figure 1 - UV/visible spectrum of AuAg-alloy-nanoprobes (25%Au:75%Ag) alone and in presence of 20mM MgCl2 (dashed 
line). Inlet: UV/vis spectrum and digital photography of pure Au- and AuAg-alloy-NPs with different metal ratios. 
 
These nanoprobes were assessed in terms of specificity via hybridization to a specific synthetic oligonucleotide 
complementary to the sequence of the nanoprobe. A non-complementary target in the same conditions was also used to 
confirm specificity of the reaction. In the case of BCR-ABL fusion product (corresponding to e1a2 fusion product), it 
should be noted that, in reality, patients may only harbor one copy of the fusion gene and the remaining copies of normal 
ABL and BCR should be still functional, thus expressing the normal mRNA sequence. Therefore, an oligonucleotide 
harboring the normal sequence of ABL genes was used to evaluate the probe’s capability to discriminate from similar 
sequences. Following salt addition, the presence of the respective complementary synthesized target, protected the 
AuAg-alloy-nanoprobes from aggregation and the solution remained yellow; whereas the presence of non-
complementary targets did not prevent aggregation and the solution changed color to blue – Figure 2. 
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Figure 2 - UV/visible spectrum of BCR-ABL_e1a2 AuAg-alloy-nanoprobe alone (Blank) and in presence of a complementary 
target (BCR-ABL_e1a2); a semi-complementary target harboring the ABL gene sequence (ABL) and a non-complementary 
target with a non-related sequence. Inlet shows the ratio Abs442nm/Abs600nm with a dashed line positioned at a ratio equal to 1. 
 
Absence of any target results in extensive aggregation (Blank). Only full hybridization of the AuAg-alloy-nanoprobe to a 
fully complementary synthetic sequence (BCR-ABL fusion sequence) avoids aggregation, whereas a semi-
complementary target (normal ABL gene sequence) did not show the same capability. Based on the UV/Vis spectra, the 
extension of AuAg-alloy-nanoprobe aggregation was evaluated in terms of SPR variation, i.e. a ratio between the free 
and aggregated fractions after 15 min incubation with MgCl2. The ratio between the peaks of the SPR characteristic of 
non-aggregated (Abs442nm) and aggregated (Abs600nm) nanoprobe was calculated. A ratio of 1 was considered as the point 
of equilibrium between non-aggregated and aggregated nanoprobe, hence the threshold to respectively consider the 
positive and negative discrimination of sequences (i.e. positive identification of complementary target for ratios greater 
than 1). 
 
3.2 Au-nanoprobes for quantification of gene expression 
Once the specific identification of the target sequence was achieved, the Au-nanoprobes were used to evaluate the 
quantification potential using an ABL gene specific sequence – Figure 3A. For this purpose, a complementary synthetic 
target was used in a spike in experiment using a non-complementary target to keep a constant total concentration of 
nucleic acids in solution. Aggregation of the Au-nanoprobe varied linearly for complementary target concentrations 
between 0.1 and 0.8 µM. Below 0.1 µM, full aggregation occurred. Above 0.8 µM of ABL target, the stability of ABL 
Au-nanoprobe remained unaltered. Additionally, a parallel experiment using different concentrations of the specific 
synthetic oligonucleotide target was performed by spiking in 20 ng/µl of total RNA extracted from an unrelated organism 
(i.e. E. coli). In this case, the ABL Au-nanoprobe no longer fully aggregated although a linear variation in Au-nanoprobe 
stability could still be observed for different concentrations of complementary target (see Figure 3A inlet). This residual 
stability could be due to some stabilization derived from partial sequence homology between the human ABL gene and 
an E.coli transposase.  
Because C-MYC overexpression has been implicated in CML development23, we then assessed whether the Au-
nanoprobes were suitable for C-MYC expression analysis. Following the same approach as before, and using a C-MYC 
Au-nanoprobe, our data indicate a linear correlation (R2 = 0.96) between the Abs526nm/Abs600nmfor target concentration 
range between 33 and 133 nM (Figure 3B).  Then, to show that this nanoprobe approach was suitable for mRNA 
quantitation in cells, we quantified the amount of C-MYC in total RNA extracted from a HL-60 cell line (an acute 
myeloid leukemia cell line where C-MYC is over expressed, where a similar linearity was attained (see Figure 3B inlet). 
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These results show that gene expression analysis is possible directly on total RNA extracted from cells, without the need 
for retrotranscription and/or amplification via PCR. 
 
 
Figure 3 - Absorption ratios of (A) ABL and (B) C-MYC Au-nanoprobes for different concentrations of 
complementary targets. For (A), (B) and inlet (A) the absorption ratio - Abs526nm/Abs600nm – was considered. 
In the case of (B) and inlet (A) the complementary targets were spiked in total RNA E.coli (20ng/µL). Inlet (B) 
represents quantification (AUC500nm-560nm/AUC570nm-630nm) of C-MYC mRNA in total RNA extracted from HL-60 
cell lines. Dashed lines represent a ratio equal to 1 and solid lines represent the trendline for ratios above 1 and up 
to a saturation point.  
3.3 AuAg-alloy-nanoprobes for quantification of gene expression 
A similar approach to that described above was followed to assess the potential of AuAg-alloy-nanoprobes 
(25%Au:75%Ag) for quantification purposes. Total RNA mixtures spiked in with synthetic oligonucleotides harboring 
the fusion site BCR-ABL_e1a2 – Figure 4. 
 
 
Figure 4 – Absorption ratio (Abs442nm/Abs600nm) of BCR-ABL_e1a2 AuAg-alloy-nanoprobe for different concentrations of 
complementary target. Total oligonucleotide concentration was kept constant at 4µM. Dashed line represents a ratio equal 
to1 and the solid line represent a trendline for data points with a ratio greater than 1. 
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The level of aggregation can be given by the absorption ratio Abs442nm/Abs600nm. Data show a linear correlation between 
the amount of specific target in the mixture and stability of the alloy-nanoprobe for target concentration range of 125 nM 
and 2 µM. This quantification capability is in good agreement with what has been demonstrated for Au-nanoprobes.  
 
3.3 Au- and AuAg-alloy-nanoprobes for differential gene expression analysis – proof-of-concept 
The analysis of differential gene expression is of utmost importance to assess the involvement of a specific gene product 
in a given phenotype. In CML, it is expected that the normal gene (i.e. ABL) maintains its levels of expression while the 
BCR-ABL fusion product, because it functions as an oncogene, sees its expression increased. To evaluate the potential of 
Au- and AuAg-alloy-nanoprobes for the quantification of two sequences in relation to each other, total RNA was spiked 
in with both targets - ABL and BCR-ABL_e1a2. Keeping the concentration of ABL constant, we added increasing 
amounts of the BCR-ABL_e1a2 target sequence and quantified it via the nanoprobe system – Figure 5. Despite the 
overall stabilization effect of the fragments in total RNA, it is clearly visible a concentration dependence of the level of 
aggregation of the alloy nanoprobe (complementary to the BCR-ABL fusion sequence) while the Au-nanoprobe shows 
that the levels of its complementary sequence (ABL) are constant. 
 
 
Figure 5- Absorption ratios (Abs526nm/Abs600nm and Abs442nm/Abs600nm, respectively) of ABL Au- and BCR-ABL_e1a2 AuAg-
alloy-nanoprobes for different concentrations of BCR-ABL_e1a2 target, keeping the concentration of ABL target (2µM) and 
total RNA (20ng/µL) constant. Dashed black line represents a ratio equal to 1. Solid lines represent trendline for data points 
with a ratio greater than1. 
 
The next step was to evaluate the possibility to quantify the BCR-ABL fusion product in a mixture containing constant 
concentrations of ABL in a one-pot assay – Figure 6. As seen above, aggregation of the AuAg-alloy-nanoprobe causes a 
red-shift of the SPR peak, with concomitant decrease of the peak intensity at 442 nm that can be easily observed and 
used for quantitation. Additionally, when the AuAg-alloy-nanoprobe and the Au-nanoprobe are joined together in the 
same solution, aggregation of the alloy nanoprobe leads to an increase of absorbance in the 500-600 nm region. This 
originates a small change of the SPR peak of the Au-nanoprobe. To facilitate analysis of the spectral changes as function 
of target concentration, the UV/visible spectra were normalized. Similarly to what is observed for each nanoprobe in 
separate, results show that it is possible to quantify the specific BCR-ABL target in solution, whilst keeping ABL 
constant. In fact, this is exactly what is observed in CML patients, where the BCR-ABL gene expression is induced 
while the normal ABL gene is under normal regulation and, thus, with constant levels of mRNA expression. 
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Figure 6 - Normalized UV/visible spectra of binary mixture (one-pot assay) of ABL Au- and BCR-ABL_e1a2 AuAg-alloy-
nanoprobes for different concentrations of BCR-ABL_e1a2 target, keeping the concentration of ABL target (2µM) and total 
RNA (20ng/µL) constant. Dashed lines represent the characteristic SPR peak of each nanoprobe in a non-aggregated state. 
Inlet: Absorption ratio (Abs442nm/Abs526nm) of normalized data. Solid lines represents trendlines for data points. 
 
 
4. CONCLUSIONS 
 
We have demonstrated the functionalization of AuAg-alloy-NPs with ssDNA and the use of the resulting alloy 
nanoprobes for the specific detection of a target of interest. The attained AuAg-alloy-nanoprobes show a combination of 
the optical properties of Ag nanoparticles (high extinction coefficient) with the ease of functionalization via a thiol bond 
provided by the gold. Similarly to what is observed for Au-nanoprobes alone, these alloy nanoprobes are sensitive to 
variations in the quantity of target in solution and can, thus, be used for quantification assays. AuAg-alloy-nanoprobes 
with 25% gold and 75% silver were successfully synthesized and functionalized to produce nanoprobes that exhibit an 
SPR peak away from that of the Au-nanoprobes. This way, it is possible to better discriminate the aggregation profiles of 
both types of nanoprobes once they are used in a one-pot assay. Based on the combination of AuAg-alloy- and Au-
nanoprobes, it was possible to develop a differential gene expression assay using the BCR-ABL fusion product involved 
in chronic myeloid leukemia as a model. We further demonstrated that this dual-color nanoparticle approach can be used 
as sensitive, selective, one-pot multicolor method for the simultaneous quantification of multiple RNA targets in a single 
reaction. The simultaneous differential quantification of two (or more) sequences is of utmost importance when 
performing genome based screening, where there is a mandatory need to assess whether a given transcript is present in a 
homo- or heterozygous form. This approach should be easily extendable to additional colors using the remarkable optical 
properties of nanoparticles of different sizes and compositions, i.e. different Au:Ag ratios, other metals may provide a 
multicolor homogenous system for application in array strategies and to rival fluorescence based assays. 
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OVERVIEW 
 
This section presents 5 articles related to the studies on gold nanoparticles as nanovectors for 
therapy applications, using several strategies of biofunctionalization. 
Article D describes the development of a dual pathway silencing of gene expression via 
ssDNA functionalized gold nanoparticles. In this study, gold nanoparticles modified with 
single-stranded thiolated-oligonucleotides have been evaluated as a two-way inhibition 
system that operates towards the suppression of in vitro transcription and translation. AuNPs 
functionalized with thiolated oligonucleotides to specifically inhibit transcription in vitro, 
demonstrating the synergetic effect between AuNP and a specific antisense sequence that 
blocks the T7 promoter region. In addition, we demonstrate that AuNPs functionalized with a 
thiolated oligonucleotide complementary to the ribosome binding site and the start codon, 
effectively shuts down in vitro translation. In this important study we also demonstrated that 
AuNPs efficiently protect the antisense oligonucleotide against nuclease degradation, which 
can thus retain its inhibitory potential.  
Article E and F describes several strategies for functionalizing AuNPs with different 
biomolecules, such as proteins, peptides, polymers and RNA molecules. Article E describes 
the synergetic effect of Poly(ethylene glycol) biofunctional spacers and a peptide in dsRNA 
loading on the surface of AuNPs. This effect was found to be spatially and charged specific 
once the RNA loading was shaped by the electrostatic interactions between the peptide and 
the different charged PEG spacers. The peptide could approach the RNA to the gold surface 
arranging the entry of the oligo through the polyethyleneglycol layer with a positively 
polarized behaviour enhancing the oligo loading on the nanoparticle. In Article F we study the 
interaction between AuNPs functionalized with a protein (histone like) and circular DNA 
molecules. Our aim was to investigate whether or not these AuNP conjugates modified DNA 
condensation, altering plasmid DNA conformation and inducing structural changes.  
These studies from Articles E and F were an important background for the development of 
the following studies. Article G describes the development of smart multifunctional gold 
nanoparticles for gene silencing. This study intends to develop an innovative kind of 
multifunctional gold nanoparticles loaded with polymers, cell penetrating and cell adhesion 
peptides and RNAi complementary to the proto-oncogene myc. The c-myc gene encodes a 
transcription factor that is critical for progression through the cell cycle, and mutations that 
misregulate c-Myc are frequently found in human and animal cancers. Thus the main rationale 
for selecting c-Myc as a target for cancer therapy is twofold; (i) the gene is involved in a wide 
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variety of human tumours and thus therapies could potentially have an impact on the 
treatment of a broader range of malignancies; (ii) c-Myc is involved in both proliferation and 
apoptosis, thus strategies aimed at targeting c-Myc might lead to either inhibition of tumour 
cell proliferation and/or increase in cell apoptosis. c-Myc could be targeted at different 
biological levels using various techniques, however using specifically designed cell targeting 
nanoparticles as a mean of intracellular delivery and self-tracking will provide a novel end 
product.  
This biofunctionalization allowed the interaction between NPs and biological systems, 
ranging from in vitro cultured human cells (HeLa cells) to in vivo animal models (primitive 
Hydra and complex vertebrate mouse – C57BL/6j mice).  
These studies were extended to the evaluation of the inflammatory response and therapeutic 
siRNA silencing via RGD-nanoparticles (the most efficient NPs produced in Article G) in a 
lung cancer mouse model – Article H. This article reported the use of siRNA/RGD gold 
nanoparticles capable of targeting tumour cells in two lung cancer xenograft mouse models, 
resulting in successful and significant c-Myc oncogene downregulation followed by tumour 
growth inhibition and prolonged survival of the animals.  
 
All these studies were performed at the Research Centre for Human Molecular Genetics, 
Dept. of Life Sciences at Science and Technology Faculty, New University of Lisbon; IUI of 
Nanoscience of Aragon at the University of Zaragoza (Zaragoza, Spain); Centre for Cell 
Engineering (University of Glasgow, UK); Instituto di Cibernetica “E. Caianiello” (Pozzuoli, 
Italy); and Helmholtz Zentrum München (München, Germany). 
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(2012), Vol. 7, pp. 1657-1666. Research article (IF=5.260) 
 
Article G 
“Design of Multifunctional Gold Nanoparticles for In vitro and In vivo Gene Silencing.” João 
Conde*, A. Ambrosone*, V. Sanz, Y. Hernández, V. Marchesano, F. Tian, H. Child, C.C. 
Berry, M.R. Ibarra, P.V. Baptista, C. Tortiglione and J.M. de la Fuente. (* Co-first authors). 
ACS Nano (2012), Vol. 6, pp. 8316–8324. Research article (IF=12.062) 
 
Article H 
“In vivo tumour targeting via nanoparticle-mediated therapeutic siRNA coupled to 
inflammatory response in lung cancer mouse models.” João Conde*, F. Tian*, Y. Hernández, 
C. Bao, D. Cui, K.P. Janssene, M.R. Ibarra, P.V. Baptista, T. Stoëger and J.M. de la Fuente. 
(* Co-first authors). Biomaterials (2013), Vol. 34, pp. 7744–7753. Research article 
(IF=7.604) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
172
Articles D, E, F, G and H 
 
Declaration of authorship 
 
I, João Diogo Osório de Castro Conde, declare that the manuscripts preparation and writing 
was carried out by me, Prof. Pedro V. Baptista, Prof. Jesus M. de la Fuente, and all the 
associated co-authors. 
 
João Conde contributions:  
Article D – JC designed all the methods, generated the ssDNA-AuNPs, and calibrated, 
carried out characterization and performed the in vitro assays. JC also drafted the manuscript 
protocols and all the figures. 
Article E – JC carried out the characterization and quantification assays concerning the 
functionalization of AuNPs with the polymers, peptide and dsRNA molecules. JC also drafted 
some of the manuscript sections and figures. 
Article F – JC conceived the project. JC designed the plasmid-AuNPs interaction and kinetic 
assays. JC also drafted the manuscript protocols and all the figures. 
Article G – JC carried out all the synthesis and functionalization methods regarding the 
production of all nanoformulations in this study. JC also performed all cell studies. JC also 
drafted some of the manuscript sections and figures. 
Article H – JC carried out all the synthesis and functionalization methods regarding the 
production of all nanoformulations in this study. JC analysed all the data and wrote the 
manuscript. 
 
We, Pedro V. Baptista and Jesus M. De la Fuente, as supervisors of João Conde hereby 
acknowledge and confirm that the information above is correct. 
 
 
     
João Conde        Pedro V. Baptista 
 
 
 
Jesus M. de la Fuente 
IOP PUBLISHING NANOTECHNOLOGY
Nanotechnology 21 (2010) 505101 (6pp) doi:10.1088/0957-4484/21/50/505101
In vitro transcription and translation
inhibition via DNA functionalized gold
nanoparticles
J Conde1,2, J M de la Fuente2 and P V Baptista1
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Abstract
The use of gold nanoparticles (AuNPs) has been gaining momentum as vectors for gene
silencing strategies, combining the AuNPs’ ease of functionalization with DNA and/or siRNA,
high loading capacity and fast uptake by target cells. Here, we used AuNP functionalized with
thiolated oligonucleotides to specifically inhibit transcription in vitro, demonstrating the
synergetic effect between AuNPs and a specific antisense sequence that blocks the T7 promoter
region. Also, AuNPs efficiently protect the antisense oligonucleotide against nuclease
degradation, which can thus retain its inhibitory potential. In addition, we demonstrate that
AuNPs functionalized with a thiolated oligonucleotide complementary to the ribosome binding
site and the start codon, effectively shut down in vitro translation. Together, these two
approaches can provide for a simple yet robust experimental set up to test for efficient gene
silencing of AuNP–DNA conjugates. What is more, these results show that appropriate
functionalization of AuNPs can be used as a dual targeting approach to an enhanced control of
gene expression—inhibition of both transcription and translation.
S Online supplementary data available from stacks.iop.org/Nano/21/505101/mmedia
(Some figures in this article are in colour only in the electronic version)
1. Introduction
The unique physico-chemical properties of metal nanoparticles
(NPs), and in particular gold NPs, show great potential of
application in biomedicine for the development of sensing plat-
forms and therapeutics [1, 2]. Recent advances in approaches
using AuNPs functionalized with oligonucleotides have made
them an attractive tool for DNA based therapy [3–7], where
antisense DNA technology in particular shows a significant
potential for gene regulation in therapeutics [8–11]. These
approaches rely on the use of nucleic acids that bind to
specific targets following cellular uptake, either by blocking
the RNA polymerase promoter preventing transcription into
mRNA and/or of protein production via impediment of
association of the protein production facilities—the ribosome.
However, a major problem is the poor stability of nucleic
acids in biological media, as unmodified phosphodiester
oligonucleotides are rapidly degraded in most biological
systems [12]. Protection against degradation by nucleases can
be circumvented through the use of AuNPs [13, 14]. Also,
AuNPs have been shown to interfere with protein binding, thus
strongly modulating the resulting effect [15]. Recently, the
effect of non-specific binding of AuNP–DNA nanoconjugates
in protein production has been elegantly demonstrated [16].
Therefore, precise assessment of the selected sequence on gene
silencing mediated by AuNP–DNA conjugates is of utmost
importance when developing efficient antisense therapeutic
vectors.
0957-4484/10/505101+06$30.00 © 2010 IOP Publishing Ltd Printed in the UK & the USA1
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Figure 1. Silencing gene expression using targeted AuNP–DNA conjugates. AuNP–DNA conjugates specifically block (1) in vitro
transcription via binding to the T7 RNA polymerase promoter, and (2) in vitro translation by suppressing the ribosome binding site (RBS).
We used in vitro transcription and in vitro translation
assays to demonstrate the potential use of specific AuNP–
DNA conjugates to silence gene expression. These in vitro
approaches show some advantages over in vivo gene expression
as there is no need to support processes required for cell
viability, or when the over-expressed product is toxic or
insoluble [17, 18]. As a result we can produce a two-way
inhibition system (see figure 1) using AuNP–DNA conjugates
to specifically block in vitro transcription by binding the RNA
polymerase promoter and in vitro translation by suppressing
the ribosome.
We evaluate the use of AuNPs functionalized with
thiol-modified single-stranded oligonucleotides to block the
transcriptional machinery at the specific promoter site and
to repress gene translation by blocking the ribosome binding
site. We also evaluate the protection conveyed by the AuNPs
against the destructive effect of cellular nucleases on naked
oligonucleotides. As the DNA bound to AuNP is efficiently
protected from nuclease digestion it is thus expected that these
AuNP conjugates might also provide a shield for the entrapped
DNA during gene delivery. The proposed system could be of
great interest when assessing the gene therapy potential of a
given AuNP–DNA conjugate.
2. Experimental procedure
All synthesized unmodified and thiol-modified oligonu-
cleotides were purchased from STAB Vida, Lda. (Portugal).
All chemicals were from Sigma-Aldrich and of the highest
purity available.
2.1. AuNP synthesis
Gold NPs were prepared by the citrate reduction method
described by Lee and Meisel [19]. Briefly, 250 ml of 1 mM
HAuCl4 was brought to a boil while stirring in a 500 ml round-
bottom flask. Twenty-five milliliters of 38.8 mM sodium citrate
was quickly added and the mixture was refluxed for 15 min
with continuous stirring. The flask was left to cool to room
temperature and stored in the dark until use. The average size
of the particles was obtained by analysis of TEM images.
2.2. AuNP–DNA conjugate synthesis
All oligonucleotides used are listed in table 1. Thiolated
oligonucleotides were suspended in 1 ml of 0.1 M dithiothreitol
(DTT), extracted three times with ethyl acetate and further
purified through a desalting NAP-5 column (Pharmacia
Biotech, Sweden).
AuNP–DNA conjugates were prepared as previously
described [20, 21]. Briefly, an appropriate volume of 10 μM
thiol-modified T7 or antisense oligonucleotide was initially
incubated with 6 ml of an aqueous solution of AuNPs
(≈8.55 nM) for at least 16 h. After centrifugation (20 min at
14 500g), the oily precipitate was washed with 5 ml of 10 mM
phosphate buffer (pH 8.0), 0.1 M NaCl, recentrifuged and
redispersed in 5 ml of the same buffer to a final concentration
in AuNPs of 8.5 nM. The resulting AuNP–DNA conjugate was
stored in the dark at 4 ◦C.
2.3. Quantitation of thiol-oligonucleotides loaded on AuNPs
Coverage (average number of ssDNA strands per particle) was
measured by completely displacing the DNA from the AuNPs
2
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Table 1. ssDNA sequences used for in vitro transcription and translation assays.
Assay Oligonucleotide Sequence
In vitro transcription AuNP–T7 5′-HS-(CH2)6-TCTCCCTATAGTGAGTCGTATTA-3′
T7 oligo 5′-TCTCCCTATAGTGAGTCGTATTA-3′
In vitro translation AuNP–antisense 5′-HS-(CH2)6-CATGGTATATCTCCTTCTTA-3′
AuNP–nonsense 5′-HS-(CH2)6-CGCTGAAGGGCTTTTGAACT-3′
in 1 M DTT for 48 h. After 48 h at room temperature,
the solutions containing the displaced oligonucleotides were
removed from the AuNPs by centrifugation at 14 500g
for 20 min. The concentration of oligonucleotides in
the supernatant was measured using an OliGreen ssDNA
Quantitation Kit® (Molecular Probes) according to the
manufacturer’s guidelines in a PerkinElmer LS45 Fluorescence
Spectrometer (USA) using an Ultra-Micro quartz cell (Hëllma,
Germany). The concentration of DNA was calculated
from fluorescence intensity of DNA solutions with known
concentration. All the AuNPs samples and the standard
solutions of the thiol-oligonucleotide were kept at the same
pH and ionic strength and calibration for all measurements
due to the sensitivity of the optical properties of the
OliGreen® to these conditions. Fluorescence emission
was converted to molar concentrations of the thiol-modified
oligonucleotide by interpolation from a standard linear
calibration curve. Standard curves were prepared with known
concentrations of thiol-oligonucleotide using the same buffer
pH, salt, and DTT concentrations. The average number of
oligonucleotides per particle was obtained by dividing the
measured oligonucleotide molar concentration by the original
Au nanoparticle concentration.
2.4. Reverse transcription and PCR amplification
The total RNA extracted from HL-60 cells was subjected
to reverse transcription (RT) for cDNA synthesis. The RT
reaction was performed with Revert-AidTM M-MuLV Reverse
Transcriptase (Fermentas, Vilnius, Lithuania) according to the
manufacturer’s specifications, using 20 μM of MYCreverse
primer, annealing at 42 ◦C for 1 h and 70 ◦C for 10 min to
reverse transcriptase inactivation. The resulting 229 bp frag-
ment of the human v-myc myelocytomatosis viral oncogene
homolog (MYC) gene was PCR amplified using the primers
MYCforward: 5′-GCTCATTTCTGAAGAGGACTTGT-3′ and
MYCreverse: 5′-AGGCAGTTTACATTATGGCTAAATC-3′.
PCR amplification was performed in duplicate on a My-
Cycler Thermocycler (Biorad) in 25 μl using 1 μM of
primers, 2.5 mM dNTPs with 1 U Taq DNA Polymerase
(GE Healthcare Europe GmbH, Freiburg, Germany), with
the following thermal cycling conditions: initial 5 min
denaturation at 95 ◦C, followed by 30 amplification cycles
of denaturation at 95 ◦C for 30 s, annealing at 62 ◦C for
30 s, elongation at 72 ◦C for 30 s, and a final elonga-
tion at 72 ◦C for 5 min. The RT-PCR product was re-
amplified using a T7 promoter–MYCforward primer (5′-
TAATACGACTCACTATAGGGAGAGCTCATTTCTGAAGA
GGACTTGT-3′). The resulting 252 bp T7-cMYC-fusion
fragment was PCR amplified using the primers MYCreverse
and T7 primer (5′-TAATACGACTCACTATAGGGAGA-3′) as
described above and purified through an NZYGelpure purifica-
tion kit (NZYtech genes & enzymes, Portugal). Confirmation
of correct PCR products was performed by 2% agarose gel
electrophoresis stained with GelRed™. This product was used
as template for in vitro transcription reactions.
2.5. In vitro transcription
Standard in vitro transcription was performed in a volume
of 50 μl containing in vitro transcription buffer, 10 mM of
each NTP, 500 ng of the 252 bp DNA template and with
30 U of T7 RNA polymerase (Fermentas, Vilnius, Lithuania)
according to the manufacturer’s protocol. Reactions were
incubated for 2 h at 37 ◦C, followed by heat inactivation of
enzyme for 15 min at 75 ◦C and cooling to −20 ◦C. All
transcription reaction products were centrifuged at 14 500g
for 20 min to pellet the AuNPs and 27 μl of the supernatant
was evaluated on a 3% agarose gel electrophoresis with
GelRed™ staining. Product quantity determination was
performed by pixel intensity/counting using ImageJ™ imaging
software as previously described [22, 23]. Determination of
the degree of inhibition was performed after normalizing to
the intensity of the positive control (100%) of the in vitro
transcription reaction.
2.6. Nuclease digestion
In order to evaluate nuclease resistance the functionalized
AuNP–DNA conjugate and the naked T7 oligonucleotide
were subjected to DNase I digestion, performed with 10 U
of DNase I (Invitrogen, Karlsbad, CA, USA) in DNase I
buffer (100 mM Tris-HCl, 25 mM MgCl2, 1 mM CaCl2,
pH 7.5 at 25 ◦C) for 30, 90 and 180 min at 37 ◦C, which
was subsequently heat inactivated for 10 min at 65 ◦C. The
molar concentration of the naked T7 oligonucleotide was
the matched to that of the number of oligonucleotides per
particle. The molar concentration of the oligonucleotide bound
to AuNP was determined as previously described and the
naked T7 oligonucleotide quantified by optical absorbance
at 260 nm. Samples containing the AuNP–DNA conjugates
were centrifuged at 14 500g for 20 min, and those containing
the naked T7 oligonucleotide were ethanol precipitated. The
resulting pellets were resuspended in DEPC–H2O and used in
transcription reactions as described above.
2.7. In vitro translation
The pGFP vector (4235 bp), which encodes the native (i.e.,
non-fusion) GFP protein, was transformed into E. coli DH5α
as described previously [24]. The pGFP (5Prime, GmbH,
3
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VWR International) used as template for in vitro protein
synthesis reactions contains the GFP gene under control of T7
promoter (TAATACGACTCACTATAGGGAGA) upstream of
the ribosome binding site (RBS) with the ‘epsilon sequence’
(TTAACTTTA) derived from gene 10 of bacteriophage
T7 [25] followed by a Shine–Dalgarno sequence (AAGGAG)
and a T7 terminator (TAGCATAACCCCTTGGGGCCTC-
TAAACGGGTCTTGAGGGGTTTTTTG) at the 3′ end of the
GFP gene.
The coupled in vitro transcription/translation reactions
were performed in a Rapid Translation System RTS 100 E. coli
HY Kit (5Prime, GmbH, VWR International). GFP protein
was synthesized for 6 h at 30 ◦C followed by incubation at 4 ◦C
for 24 h to GFP maturation. GFP protein levels were measured
using fluorescence spectroscopy (λ excitation = 395 nm,
λ emission = 510 nm) in a PerkinElmer LS45 Fluorescence
Spectrometer (USA) using an Ultra-Micro quartz cell (Hëllma,
Germany). Assessment of AuNP–DNA conjugate influence
in translation was performed by adding 1 μg of GFP vector
and crescent concentrations of the AuNP–DNA conjugates to
the standard reaction mixture. After 24 h storage at 4 ◦C,
the reactions were centrifuged at 14 500g for 20 min to pellet
AuNP–DNA conjugates. The translation levels were measured
as fluorescence of GFP.
3. Results and discussion
AuNPs of 14 nm (D = 14.07 nm, see supplementary
information S1 available at stacks.iop.org/Nano/21/505101/
mmedia) were synthesized via the citrate reduction method
and, in a first set of experiments, functionalized with
a thiol-modified 23-mer complementary to the promoter
region recognized by T7 RNA polymerase (T7 oligo). We
report that the affinity between specific T7 promoter gold
nanoparticles and DNA is strong enough to completely inhibit
transcription of DNA by T7 RNA polymerase and, as a
consequence, decrease the levels of mRNA produced. These
AuNP–T7 conjugates, together with the naked AuNPs and
oligonucleotide, were used in standard in vitro transcription
assays, and the level of transcription determined. Direct
comparison between T7 oligo and AuNP–T7 conjugates is
feasible via utilization of naked T7 at the same concentration
as the T7 concentration calculated to be covering the AuNP.
When the T7 oligo was added to the reaction, 27% inhibition
of transcription was attained, at 0.06 nM (figure 2). Addition
of the AuNP–T7 conjugates (70 ± 3 oligos/NP) originated
a decrease in the level of transcription of 60%. For higher
concentrations of the AuNP–DNA conjugates, the level of
transcription quickly reached background levels (>0.64 nM).
However, those levels of transcription were impossible to attain
with free T7. It should be noted that naked AuNPs can achieve
almost total inhibition of transcription at concentrations higher
that 2.5 nM, i.e. four times the concentration of AuNP–DNA
conjugates needed for comparable inhibition. Results also
show that the inhibitory effect of AuNP–DNA conjugates
strongly depends on concentration, being exceptionally
effective for very low amounts of these conjugates. AuNP–
DNA conjugates with half the amount of oligonucleotides
Figure 2. Inhibition of in vitro transcription via AuNP–DNA
conjugates. (A) Agarose gel electrophoresis of in vitro transcription
reactions in the presence of increasing AuNP–DNA conjugate
concentration. The bands in the gel represent the mRNA product
produced by in vitro transcription. Increasing concentrations of
AuNP–DNA conjugates correspond to decreasing amounts of
mRNA. (B) Transcription levels as function of increasing
AuNP–DNA conjugates. Determination of the degree of inhibition
was performed after normalizing to the intensity of the positive
control (100%) of the in vitro transcription reaction. Error bars
correspond to average and standard deviation of two independent
assays. ∗ Direct comparison between free T7 oligonucleotide and
AuNP–T7 conjugates is feasible via utilization of naked T7 at the
same concentration as the T7 concentration determined at the surface
of the AuNP–DNA conjugate.
at the NPs’ surface (44 ± 2 oligos/NP), showed comparable
inhibitory effect (see supplementary information S2 available
at stacks.iop.org/Nano/21/505101/mmedia). Naked AuNPs
also demonstrate an inhibitory effect on transcription, maybe
due to unspecific adsorption of proteins (i.e. polymerase) to
the AuNPs’ surface [26, 27]. These results seem to indicate
the existence of a synergic effect between the AuNP and the
T7 oligonucleotide sequence. Specific sequence inhibition of
the promoter region is achieved via the T7 oligonucleotide and
localization of the AuNP on the same recognition sequence
seriously hampers enzymatic activity, probably due to steric
hindrance [28]. In fact, the T7 RNA polymerase exhibits
extreme specificity for its own promoter and will only
transcribe the DNA harboring the T7 promoter sequence.
The steric block is caused by the T7 oligo hybridization to
the promoter region compromising the recognition by the
polymerase [29].
DNA vectorization into cells is frequently hampered by
the degradation of the DNA load by cell nucleases and,
therefore, on the inhibition potential of a gene therapy vector.
To assess the protective effect of AuNP against nuclease
digestion and its repercussion in the inhibition potential of
the AuNP–DNA conjugates, we submitted the AuNP–T7
4
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Figure 3. AuNP–DNA conjugates’ resistance to nuclease attack.
(A) Agarose gel electrophoresis of in vitro transcription reactions
after 90 min nuclease digestion for AuNP–T7 and free T7
oligonucleotide. The bands in the gel represent the mRNA product
produced by in vitro transcription. (B) Product quantification
performed as described above. Error bars correspond to average and
standard deviation of two independent assays. ∗ Direct comparison
between T7 oligo alone and AuNP–T7 conjugates is feasible via
utilization of naked T7 at the same concentration as the T7
concentration calculated to be covering the AuNP–DNA conjugate.
conjugates and the naked T7 oligonucleotide to digestion with
DNase I. We then assessed the effect on in vitro transcription
of the ‘digested’ AuNP–T7 and naked T7 in a similar way
as described above. After 90 min of DNase I digestion,
the naked T7 oligonucleotide had minimal influence on the
rate of transcription, showing that it had been completely
degraded. Conversely, the AuNP–T7 conjugates showed that,
even after extensive nuclease activity, they retain the capability
to inhibit transcription (figure 3). When compared to the results
attained without digestion, where only 0.64 nM of AuNP–
DNA conjugate was needed to completely inhibit transcription
(see figure 2), following nuclease action the same effect is
only attained at 1 nM, i.e. nuclease activity is responsible for
a 56% loss of inhibition potential. These results demonstrate
the greatly enhanced stability to nuclease attack of single-
stranded oligonucleotides functionalized on the surface of gold
nanoparticles. The extent of DNA degradation on the AuNP
surface was also evaluated through the aggregation profiles of
the AuNP–DNA conjugates to increasing salt concentrations,
as cleavage of DNA strands in the surface of nanoparticles by
DNase I ought to decrease stability to increasing ionic strength
and cause AuNP to aggregate. In fact, the ‘digested’ AuNP–T7
showed only a slight shift in surface plasmon band peak from
520 to 550 nm (see supplementary information S3 available at
stacks.iop.org/Nano/21/505101/mmedia) whereas the ‘naked’
AuNPs show extensive aggregation (red-shift to 700 nm), upon
addition of 30 mM MgCl2. The protection provided by the
Figure 4. Inhibition of in vitro translation by AuNP–DNA
conjugates. In vitro translation levels, measured as fluorescence of
GFP, after incubation with AuNP–antisense conjugates (red
triangles), AuNP–nonsense (filled squares) and unmodified AuNPs
(filled circles). Error bars correspond to average and standard
deviation of two independent assays.
AuNPs also depends on the time of exposure to nucleases
(see supplementary information S4 available at stacks.iop.org/
Nano/21/505101/mmedia). These results suggest that the
AuNP–DNA conjugates’ resistance to nuclease degradation
ought to increase the lifetime of the oligonucleotide within the
cell and, therefore, constitutes a great advantage for antisense
oligonucleotide delivery.
We then evaluated the efficiency of AuNP–DNA
conjugates to suppress in vitro translation. The same AuNPs
used for the in vitro transcription assays were functionalized
with a thiolated 20-mer oligonucleotide (AuNP–antisense)
whose sequence is complementary to the Shine–Dalgarno
sequence (i.e. the ribosome binding site) and to the start
codon. In this way, effective silencing of expression is achieved
by simultaneously blocking ribosome access and initiation of
translation. Fluorescence measured from green fluorescent
protein (GFP) decreased by about 80% after incubation with
the AuNP–antisense conjugates—red triangles in figure 4. No
significant change to fluorescence measurements was noted
for naked AuNPs or AuNP functionalized with an unrelated
sequence to that of the target mRNA (AuNP–nonsense)—filled
circles and filled squares in figure 4, respectively. Antisense
inhibition by AuNP–DNA conjugates has been previously
reported [30], even though the antisense mechanism is not
clearly understood [31–33]. Recently, enhancement of in vitro
translation by AuNP–DNA conjugates was demonstrated
to occur via a combination of non-specific adsorption of
translation-related molecules and the ribosome to the AuNP–
DNA conjugate and specific binding to the mRNA of interest;
whereas strong binding of AuNP–DNA to mRNA results
only in inhibition, as it probably sterically hinders the
ribosome from reading the mRNA [15]. Here we showed
that combination of AuNP with a specific oligonucleotide that
simultaneously blocks the ribosome binding site and the start
codon strongly inhibits in vitro translation, probably due to
the synergetic effect of the sequence unavailability due to the
5
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antisense oligonucleotide and steric hindrance of the binding
site essential for recognition by the ribosome.
4. Conclusions
Here we show that gold nanoparticles functionalized with
promoter specific oligonucleotides strongly disrupt transcrip-
tion even after extensive nuclease digestion, indicating the
proficiency of these AuNP–DNA conjugates for application
as gene silencing vectors. We also demonstrate that enhanced
specific in vitro translation inhibition is achieved by means of
the antisense oligonucleotides on the AuNP surface. These
AuNP–DNA conjugates seem to profit from the synergy be-
tween the specific sequence blocking and the steric hindrance
provided by the AuNPs.
The described experimental setup can provide researchers
with a simple yet robust means to assess the gene silencing
potential of nanoparticle–DNA conjugates being developed for
gene expression silencing purposes. These results show that a
dual targeting approach for gene silencing could be explored—
blocking transcription and translation, which can be achieved
via combination of different oligonucleotide sequences on one
or more nanoparticle vectors.
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Figure S1. Gold nanoparticles size distribution. TEM images (Left, scale bar = 50 nm) and sizing histogram 
(Right, average diameter = 14.07 nm) of AuNPs. 
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Figure S2. Inhibition of in vitro transcription via AuNP-DNA conjugates. Influence of DNA coverage of 
AuNPs, AuNP-T7 (44 ± 2) and (70 ± 3) oligonucleotides/particle. (A) Agarose gel electrophoresis of in vitro 
transcription reactions in the presence of increasing AuNP-DNA conjugates concentration. (B) Transcription levels 
as function of increasing AuNP-DNA conjugates. Determination of the degree of inhibition was performed after 
normalizing to the intensity of the positive control (100%) of the in vitro transcription reaction. Error bars 
correspond to average and standard deviation of two independent assays. 
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Figure S3. (A) Stability of AuNP-T7 conjugates against salt-induced aggregation. AuNP-T7 conjugates 
aggregation as measured by the ratio A520nm/A600nm for increasing concentrations of MgCl2. (B) Stability of AuNP-
T7 after nuclease digestion. DNase I effect on the stability of the AuNP-T7 conjugate and AuNPs after salt (30 
mM MgCl2) addition. Error bars correspond to average and standard deviation of two independent assays. 
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Figure S4. AuNP-DNA conjugates resistance to nuclease activity at several times of exposure. (A) Agarose gel 
electrophoresis of the nuclease digestion for 30, 90 and 180 min of the free T7 oligonucleotide and the AuNP-T7. 
Transcription product quantification of (B) free T7 oligonucleotide and (C) AuNP-T7 conjugate at 30 (red 
squares), 90 (green triangles) and 180 min (purple circles) of digestion. Error bars correspond to average and 
standard deviation of two independent assays.  
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Abstract The surface chemistry of gold nanoparti-
cles (AuNPs) plays a critical role in the self-assembly
of thiolated molecules and in retaining the biological
function of the conjugated biomolecules. According to
the well-established gold–thiol interaction the unde-
fined ionic species on citrate-reduced gold nanoparti-
cle surface can be replaced with a self-assembled
monolayer of certain thiolate derivatives and other
biomolecules. Understanding the effect of such deriv-
atives in the functionalization of several types of
biomolecules, such as PEGs, peptides or nucleic acids,
has become a significant challenge. Here, an approach
to attach specific biomolecules to the AuNPs
(*14 nm) surface is presented together with a study
of their effect in the functionalization with other
specific derivatives. The effect of biofunctional spac-
ers such as thiolated poly(ethylene glycol) (PEG)
chains and a positive peptide, TAT, in dsRNA loading
on AuNPs is reported. Based on the obtained data, we
hypothesize that loading of oligonucleotides onto the
AuNP surface may be controlled by ionic and weak
interactions positioning the entry of the oligo through
the PEG layer. We demonstrate that there is a
synergistic effect of the TAT peptide and PEG chains
with specific functional groups on the enhancement of
dsRNA loading onto AuNPs.
Keywords Gold nanoparticles  PEG biofunctional
spacers  TAT peptide  dsRNA oligonucleotide 
Surface science
Introduction
Nanotechnology has entered the fray in the techno-
logical leap of controlling materials at nanoscale and
offering a ‘‘big revolution’’ in medical and healthcare
treatments and therapies (Sanvicens and Marco 2008).
Nanotechnology offers a wealth of tools to diagnose
and treat cancer—new imaging agents; multifunc-
tional, targeted devices capable of bypassing biolog-
ical barriers to deliver therapeutic agents directly to
cells and tissues involved in cancer growth and
metastasis; monitor predictive molecular changes
allowing preventive action against precancerous cells;
minimizing costs (Baptista 2009).
AuNPs have gained increasing interest due to
their special features, such as extraordinary optical
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and electronic properties, high stability and biolog-
ical compatibility, controllable morphology and size
dispersion, and easy surface functionalization (El-
Sayed 2001; Daniel and Astruc 2004). The unique
characteristics of these particles, such as high
surface-to-volume ratio or size-dependent optical
properties, are drastically different from those of
their bulk materials and hold pledge in the clinical
field for therapy (Kim 2007). This has encouraged
the development of new forms and modifications of
AuNPs for biomedical applications, as well as the
use of these nanoparticles in self-assembly of
biomolecules such as DNA/RNA, oligonucleotides,
PEGs, and various proteins, that are easily attached
to the AuNP surface (Sperling and Parak 2010;
Han et al. 2007). On the surface of an AuNP the
presence of negative electronic shielding provides a
Coulomb force sufficient to bind different mole-
cules, and constitutes a suitable system to adjust the
surface properties (El-Sayed 2001; Link and El-
Sayed 2003).
In recent years, biodegradable polymeric nanopar-
ticles, particularly those coated with hydrophilic
polymer such as PEG, have been used as potential
delivery devices. These complexes have the ability to
avoid the immune system and circulate for a prolonged
time in the blood stream and target a particular organ,
consequently they may act as carriers of DNA in gene
therapy and to deliver proteins, peptides, and drugs
(Kommareddy et al. 2005). For systemic applications
the development of surface functionalized and long-
circulating AuNPs as cellular probes and delivery
agents are desired for passive targeting to tumors and
inflammatory sites. PEG-modification of nanoparti-
cles affords long-circulating property by evading
macrophage-mediated uptake and removal from the
systemic circulation. Owing to its simple structure and
chemical stability, it is a prototype of an inert,
biocompatible polymer (Sperling and Parak 2010;
Verma and Stellacci 2010). Surface modification of
AuNPs through the PEG spacers would, therefore,
allow the modified nanoparticles to remain in the
systemic circulation for the prolonged period and
provide flexibility to the attached ligand for efficient
interaction with its target (Yu et al. 2007). Using the
PEG spacer, gold nano-platform can be conjugated
with a variety of biologically-relevant ligands such as
peptides and RNAs.
When bound to surfaces, PEG prevents other
molecules to bind by steric effects. In fact, the
molecules are not attracted by electrostatic forces and
cannot penetrate the hydrated PEG layer, producing
an inert hydrophilic surface. Nanoparticles modified
by PEGs are more stable at high salt concentrations
and in biological environments, avoiding non-spe-
cific binding to proteins and cells (Liu et al. 2007).
On the other hand, the activation of PEG with
appropriate functional groups (such as carboxyl and
azide) which specifically react with other functional
groups (amino and cysteine) of protein can be
achieved by 1-ethyl-3-(3-dimethylaminopropyl)-car-
bodiimide (EDC) reactions. EDC is a zero-length
crosslinking agent used to couple carboxyl groups to
primary amines. This crosslinker has been used in
diverse applications, such as forming amide bonds in
peptide synthesis, attaching haptens to carrier pro-
teins to form immunogens, labeling nucleic acids
through 5’ phosphate groups, and creating amine-
reactive NHS-esters of biomolecules (Grabarek and
Gergely 1990).
In order to study the self-assembly of certain
thiolated components (thiol-PEG and thiol-dsRNA)
and positive peptides on the surface of AuNPs we
conducted a bioconjugation study of the surface-
modified AuNPs with different PEG layer composi-
tion and several amounts of TAT peptide and dsRNA.
We developed an effective strategy to combine, in a
highly controlled way, specific biomolecules to the
surface of AuNPs and study their synergetic or
antagonistic effect in the functionalization of the
specific components. Here, we present the effect of
biofunctional spacers such as PEG spacers (with a
thiol end to bond covalently to the gold nanoparticle
and carboxylic acid (SH–EG(7)–CH2–COOH) and
azide (SH–(CH2)3–CONH–EG(6)–CH2–N3) func-
tional groups in the other end) and TAT peptide in
the efficiency of RNA loading into the surface of
AuNPs (see Scheme 1).
Materials and methods
Synthesis of citrate-AuNPs
The citrate capped AuNPs were synthesized by the
reduction of tetrachloroaurate (III) trihydrate with
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sodium citrate described elsewhere (Lee and Meisel
1982). In brief, in this method a mixture of the gold
salt (0.2 mg) and sodium citrate (0.57 g) in 500 mL of
distilled water is heated under reflux. The pale yellow-
colored solution turned to deep red as the AuNPs were
formed and stabilized by adsorbed citrate ions. The
nanoparticles suspension was observed with a trans-
mission electron microscope (TEM) obtaining an
average diameter of 14.47 nm (see Fig. S1, electronic
supplementary material).
Scheme 1 EDC functionalized polyvalent gold nanoparticles.
a EDC coupling reaction. 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC), a zero-length crosslinking agent, was used
to couple carboxyl groups from PEG to the primary amines of the
TAT peptide. In the presence of N-hydroxysulfosuccinimide
(sulfo-NHS), EDC can be used to convert carboxyl groups to
amine-reactive sulfo-NHS esters. The addition of sulfo-NHS
stabilizes the amine-reactive intermediate by converting it to an
amine-reactive sulfo-NHS ester, thus increasing the efficiency of
EDC-mediated coupling reactions. The amine-reactive sulfo-
NHS ester intermediate has sufficient stability to permit two-step
crosslinking procedures, which allows the PEG with carboxyl
groups on one peptide to remain unaltered. b Polyvalent gold
nanoparticles. Bioconjugation of the surface-modified gold
nanoparticles with different thiol-PEG layer composition (SH–
EG(7)–CH2–COOH and SH–(CH2)3–CONH–EG(6)–CH2–N3),
TAT peptide and thiol-dsRNA oligonucleotide
J Nanopart Res (2012) 14:917 Page 3 of 9
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Synthesis of PEG heterofunctional surfaces
on citrate-AuNPs
The synthesis of heterofunctional surfaces was accom-
plished with bifunctional spacers (PEG) with a thiol end
to bond covalently to the AuNP and other functional
group in the other end (azide and carboxylic acid
groups) which can act as a flexible spacer and as
substrates for EDC/NHS coupling reactions. Two kinds
of nanoparticles with distinct PEG surfaces were
synthesized—one functionalized with only PEG with
carboxylic groups (SH–EG(7)–CH2–COOH) and other
with both PEG-azide and PEG with carboxylic groups
(SH–(CH2)3–CONH–EG(6)–CH2–N3 and SH–EG(7)–
CH2–COOH, respectively). Both kinds of the nanopar-
ticles were functionalized with 15 % of saturated PEG
layer to allow the incorporation of other thiolated
components such as the thiolated RNA. Thereafter
AuNPs@COOH were functionalized with 100 % of
SH–EG(7)–CH2–COOH and the AuNPs@COOH@N3
with a mixture of 50 % of SH–EG(7)–CH2–COOH and
50 % of SH–(CH2)3–CONH–EG(6)–CH2–N3 (see
Determination of the degree of saturation of gold
nanoparticles functionalized with thiolated polyethyl-
ene glycol chains, in Supplementary Information).
TAT functionalization by EDC/NHS coupling
reaction
The synthesis of AuNPs functionalized with increasing
amounts of TAT peptide was based on an EDC/NHS
coupling reaction (Grabarek and Gergely 1990)
between the amine-containing peptide and carboxyl-
functionalized AuNPs. In the presence of N-hydrox-
ysulfosuccinimide (sulfo-NHS), 1-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide (EDC) can be used to
convert carboxyl groups to amine-reactive sulfo-NHS
esters (Staros et al. 1986). In brief, 1 mg/mL AuN-
Ps@PEG were incubated in 1.25 mg/mL sulfo-NHS
and in 25 mM MES (2-(N-morpholino)ethanesulfonic
acid) buffer pH 6.1. Then, TAT peptide was added to
the mixture at a final concentration from 0.1 to 0.8 lg/
mL and allowed to stabilize for 5 min. After this period
of time, EDC was added at a final concentration of
150 lg/mL and the mixture was incubated at room
temperature for 16 h. Then, AuNP@PEGs were cen-
trifuged at 14.000 rpm for 30 min at 4 C to remove the
excess of peptide, the supernatants were recovered and
tested for protein concentration by the Bradford assay.
AuNPs functionalization with RNA
Thiolated dsRNA (Quiagen) was dissolved in 1 mL of
0.1 M DTT, extracted three times with ethyl acetate,
and further purified through a desalting NAP-5 column
(Pharmacia Biotech) according to the manufacturer’s
instructions. The purified dsRNAs, at a constant
concentration of 0.035 nmol, in with RNase-free
solution were incubated with the AuNP@PEG@TAT
(0.45 mg/mL) and sonicated to increase the coverage
of oligoribonucleotides on the surface. After incuba-
tion during 16 h at 4 C, the particles were purified by
centrifugation at 13.000 rpm for 20 min at 4 C, and
re-suspended in DEPC-water. This process was
repeated 3 times. The number of dsRNA per AuNP
was determined using the nucleic acid intercalator
GelRed. In this procedure, the supernatants were
incubated with GelRed 9100 and TBE 90.5, the
fluorescence was measured using a fluorimeter Perkin
Elmer LS50B (excitation and emission slits 7.5 nm)
and interpolated in the calibration curve.
Characterization of the functionalized AuNPs
Characterization of the nanoparticles was performed
by Dynamic Light Scatter (DLS) and UV/Vis Spec-
troscopy. Size increase shown by DLS and shifts in
UV/Vis spectra also confirmed the peptide and the
dsRNA functionalization (see Fig. 6). Zeta-potential
studies were also carried out for the AuNPs@COOH
and AuNPs@COOH@N3 with increasing amounts of
the TAT peptide and with a constant concentration of
dsRNA (see Fig. 5).
Results and discussion
The most common and efficient method in terms of
stability and strength of the interaction for the binding
of oligonucleotides to AuNPs is the use of the bond
gold–thiol—a quasi-covalent bond between the thiol
group and the gold surface. When other groups or
molecules are or have to be attached to the AuNP
depending on the final application of the complex it is
important that the availability of the gold surface for
the effectiveness of the binding of the thiolated
oligonucleotide. In this situation, a non-saturated
AuNP with available and enough binding points for
the interaction gold–thiol is needed. In this work, we
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study the effect of other groups or molecules
co-immobilized with thiolated dsRNA on AuNPs on
the loading yield of these oligos. For this purpose, we
first studied the effect of the degree of saturation of a
thiolated layer already attached to the AuNP on the
binding of other thiolated molecules, in our case the
thiolated PEG and dsRNA, respectively. In this way, it
is possible to obtain the conditions at which it is
feasible for the approach and binding of a thiolated
molecule to an AuNP already functionalized with a
layer of thiolated chains. The AuNPs show an average
diameter of 14.47 nm (Fig. S1, electronic supplemen-
tary material). These nanoparticles were functional-
ized with two kinds of thiolated PEG chains: a) a PEG
chain containing a carboxylic group (SH–EG(7)–
CH2–COOH), and b) a PEG chain containing an azide
group (SH–(CH2)3–CONH–EG(6)–CH2–N3). As it
will be shown below, both carboxyl and azide groups
make possible a chemical functionality to the AuNP to
be able to bind other molecules to the nanoparticle
through common coupling reactions. The best condi-
tions for obtaining AuNPs with a non-saturated
thiolated PEG layer were obtained (see Supplemen-
tary Information). It was observed that AuNPs are able
to bind around 5,000 thiolated chains until their
complete saturation with a thiolated PEG layer. It was
also observed that it is possible to control the degree of
saturation of the thiolated layer (see Figs. S3 and S4,
electronic supplementary material). Thiolated layers
with a degree of saturation below 10 % lead to non-
stable nanoparticles that tend to aggregate, whereas
AuNPs with thiolated layers with a degree of satura-
tion above 10 % are stable and allow further studies
for the purposes of this work: first, they allow the
modeling of the entrance and binding of another
thiolated molecule, and second, they are stable enough
to perform coupling reactions for the binding of other
molecules. As it was stated above, the purpose of this
work is to study the binding of thiolated oligonucle-
otides to AuNPs carrying different groups and mole-
cules. For this study, AuNP@COOH and AuNP@
COOH@N3 complexes were prepared from a starting
thiolated PEG layer of around 15 % of saturation.
Under these conditions, it is possible to allow the
entrance and binding of thiolated oligonucleotides on
the non-saturated surface of the AuNPs and to perform
coupling reactions, thanks to the chemical function-
ality imparted by the pegylated chains. This will allow
us to investigate the effect that other molecules bound
to the AuNPs have on the further loading of the
oligonucleotides. The binding of thiolated oligonu-
cleotides to these non-saturated AuNPs was confirmed
to be the proof of concept of the described model. A
constant amount of thiolated oligonucleotide was
incubated with the same concentration of the two
kinds of AuNPs, AuNP@COOH, and AuNP@COOH
@N3. It was observed that the thiolated oligonucleo-
tide was able to bind to both functionalized AuNPs, as
expected. However, the degree of binding was about
twice for AuNP@COOH@N3 (19 ± 0.4 oligonucle-
otides per AuNP) than for AuNP@COOH (9 ± 2
oligonucleotides per AuNP) showing that the spacer
plays an important role on the loading yield of the
thiolated oligonucleotide (see Fig. S6, electronic
supplementary material). AuNP@N3 are not stable
enough in suspension after synthesis. In fact, follow-
ing functionalization with only the azide-containing
PEG, nanoparticles aggregate, making it impossible to
study the effect on dsRNA loading.
At this point, we have created AuNPs with a non-
saturated thiolated layer composed of two kinds of
spacers that allow the binding of thiolated oligonu-
cleotides. Furthermore, the two kinds of thiolated PEG
chains produce a chemically functional surface around
the AuNP. As it was stated above, the loading of
thiolated oligonucleotide was different depending on
the composition of the PEG layer on the non-saturated
AuNPs. The functional groups that the thiolated chains
carry, allow the binding of other molecules or groups
to the AuNPs given their chemical reactivity. The
question that arises now is what would be the role of a
further binding of other molecules on the oligonu-
cleotide loading yield.
As a model example we have bound amine-
containing molecules to carboxyl groups by the EDC
coupling reaction. This methodology makes possible
to bind other molecules to the carboxyl groups and
study the effect of these molecules on the oligonu-
cleotide loading yield. With this aim in mind we
selected a cationic peptide (TAT). The optimal
conditions for the binding of this peptide through the
EDC reaction were obtained. The procedure used was
based on the stability assays of the AuNPs that were
carried out to determine the range of peptide concen-
trations available for the EDC reaction. In Fig. 1, the
stability of AuNP@COOH and AuNP@COOH@N3
nanoparticles as a function of the peptide concentra-
tion in the EDC reaction conditions is represented. It
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can be seen that a slight aggregation of the AuNPs is
observed only for TAT concentrations higher than
2 lg/mL, which is more pronounced for AuNP@-
COOH@N3 nanoparticles than for AuNP@COOH.
This decrease in stability can be explained by the ionic
interaction between the peptide, which is cationic, and
the nanoparticles which are negatively charged
because of their functionalization with the carboxyl-
ated chain. As the peptide concentration increases, this
ionic interaction takes place in a higher extent
triggering the aggregation of the nanoparticles.
AuNP@COOH@N3 nanoparticles showed a slightly
lower stability owing to the fact that they are a bit less
stable themselves because of the azide-containing
chain which is nonionic and impairs a lower stability
to the nanoparticles (Fig. 1). Peptide concentrations
lower than 3 lg/mL lead to the covalent coupling of
the peptide to the carboxylated chain without causing
any aggregation of the nanoparticles. For this reason,
the TAT concentration in the EDC coupling reaction
was varied between 0.1 and 0.8 lg/mL. In the optimal
conditions for the binding, a method for the quanti-
fication of the bound peptide was developed (see Fig.
S5, electronic supplementary material). In Fig. 2, the
number of TAT chains bound to AuNP as a function of
the initial concentration of peptide in the reaction
mixture is shown. As it can be seen, the amount of
bound peptide is proportional to the initial concentra-
tion of peptide and, therefore, it is possible to control
the number of peptide chains per AuNP. As expected,
the amount of peptide bound to the nanoparticles is
higher for AuNP@COOH@N3 than for AuNP@-
COOH because of the higher amount of carboxylated
chains available for the EDC reaction. From these
coupling reactions, two other kinds of functionalized
AuNPs were obtained, both AuNP@COOH and
AuNP@COOH@N3 carrying the peptide: AuNP@-
COOH@TAT and AuNP@COOH@N3@TAT, respec-
tively. For all kinds of nanoparticles the loading of the
peptide can be varied and controlled.
Once the procedure for the binding of the TAT to
the functionalized AuNPs had been optimized, a study
of the thiolated oligonucleotide loading was carried
out. Interestingly, as it can be seen in Fig. 3, the
loading yield of the oligonucleotide was much higher
for AuNP@COOH@N3@TAT than AuNP@COOH
@TAT as the peptide concentration increases. The
dsRNA loading on AuNP@COOH@TAT remains
constant, while there is an increase on the RNA
loading on AuNP@COOH@N3@TAT with increas-
ing concentration of bound peptide. This is very
important, as it establishes the conditions at which the
loading yield of thiolated oligonucleotides shows a
clear enhancement. The explanation for this phenom-
enon cannot be understood by the pure effect of
the peptide chain itself. As we can see in Fig. 3,
AuNP@COOH@TAT and AuNP@COOH@N3@TAT
nanoparticles (containing the same number of peptide
chains—see Fig. 2) do not lead to the same oligonu-
cleotide loading. Therefore, just an increase on the
peptide loading on the AuNP does not lead to an increase
on the oligonucleotide loading. As a consequence, an
increase of the thiolated oligonucleotide loading because
Fig. 1 Stability of AuNPs as a function of TAT concentration
in the EDC coupling reaction conditions. The stability is given
as the ratio between the absorbance values at 520 and 600 nm. A
ratio Abs520/Abs600 of 1 may be considered as the point of
equilibrium between non-aggregated and aggregated nanopar-
ticles. Black points AuNP@COOH and gray points AuNP@
COOH@N3
Fig. 2 Determination of the number of TAT chains bound to
AuNPs by the EDC reaction as a function of the initial peptide
concentration in the reaction mixture. Black bars AuNP@-
COOH@N3 and grey bars AuNP@COOH
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of an ionic interaction and not by the expected thiol–gold
interaction should be discarded. To confirm this hypoth-
esis, AuNPs already loaded with the thiolated oligonu-
cleotide were incubated with sodium chloride at a final
concentration of 0.3 M to detach any oligonucleotide
that would have been bound by an ionic interaction. The
addition of salt do not cause any release of the bound
thiolated oligonucleotide (data not shown). Therefore, it
is confirmed the quasi-covalent bound of the thiolated
oligonucleotide to the functionalized AuNPs and that a
pure ionic interaction of the oligo with the peptide is not
responsible for the enhancement of the oligo loading on
the nanoparticles. Our hypothesis is that there is a
synergetic effect of the peptide and the azide-containing
chain on the enhancement of the oligonucleotide loading.
This synergistic effect can be explained by the approach-
ing effect of the azide-containing chain to the gold
surface. The azide group has a resonant structure with a
positively polarized behavior. This structure can attach
the negatively charged thiolated oligo to the gold surface.
On the other hand, the azide-containing chain contains
an amide group near the gold surface that could play a
role in approaching the thiol group of the oligonucleotide
to the gold surface. This amide group could form a
hydrogen bond with one of the hydroxyl groups of the
ribose group near the thiol group on the oligo. This
hydrogen bond could approach the oligo to the gold
surface steering its entry through the PEG layer enhanc-
ing the oligo loading on the nanoparticle (see Fig. 4).
For the complete characterization of the function-
alized AuNPs Z potential studies were carried out. In
Fig. 5a, b, the Z potential values for AuNP@COOH
and AuNP@COOH@N3 nanoparticles as a function of
peptide and oligonucleotide loading is represented. It
can be observed that for AuNP@COOH@TAT and
AuNP@COOH@N3@TAT the Z potential values
change toward more positive values as the load of
Fig. 3 Loading of thiolated oligonucleotide (HS-dsRNA) on
AuNPs functionalized with TAT peptide and with both PEG-
azide and PEG–COOH and only with PEG–COOH. Black bars
AuNP@COOH@N3@TAT, and gray bars AuNP@COOH
@TAT
Fig. 4 Mechanism for the
enhancement of the dsRNA
loading on AuNP
functionalized with PEG
chains and TAT peptide.
The azide group has a
resonant structure with a
positively polarized
behavior that can attach the
negatively charged thiolated
oligo to the gold surface.
The azide-containing chain
also encloses an amide
group near the gold surface
that could play a role in
approaching the thiol group
of the oligonucleotide to the
gold surface. This amide
group could form a
hydrogen bond with one of
the hydroxyl groups of the
ribose group near the thiol
group on the oligo
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the peptide increases. This is expected for the nega-
tively charged nanoparticles AuNP@COOH and
AuNP@COOH@N3 that after increasing the amount
of the cationic peptide bound to the nanoparticle they
become more positively charged. Besides, the binding
of the thiolated oligonucleotide to the AuNP@-
COOH@TAT and AuNP@COOH@N3@TAT nano-
particles shifts again the Z potentials toward more
negative values, as expected. DLS measurements were
also performed on the functionalized AuNPs. As it can
be seen in Fig. 6, the binding of the peptide and the
oligonucleotide produces a shift on the size of the
nanoparticles toward higher values as expected. This
is a confirmation of the binding of the peptide and the
oligonucleotide on the AuNPs. This binding was also
confirmed by the shift in the SPR of the AuNPs when
functionalized with the PEG chains, the TAT peptide
and the dsRNA. As it can be seen in Fig. 7, there is a
3 nm shift of the SPR when the peptide is bound to the
nanoparticles whereas the shift is higher (5 nm) after
RNA binding.
Conclusions
In this study, an approach to bind specific biomole-
cules to the surface of AuNPs and study the effects in
the combined functionalization is developed. The
effect of thiolated PEG (PEG) spacers carrying
different functional groups (carboxyl and azide) and
the positively charged TAT peptide on the dsRNA
loading into the surface of AuNPs was studied. We
demonstrated that there is a synergetic effect of the
TAT peptide and the azide-containing PEG chain on
Fig. 5 Zeta-Potential measurements for AuNPs@COOH
a (gray points AuNP@COOH@TAT, black points AuNP@-
COOH@TAT@dsRNA), and AuNPs@COOH@N3 b (gray
points AuNP@COOH@N3@TAT, black points AuNP@-
COOH@N3@TAT@dsRNA) incubated with increasing amounts
of the TAT and with a constant concentration of dsRNA
Fig. 6 Dynamic light scattering (DLS) measurements with
diameter distribution of AuNPs@COOH@N3, AuNPs@COOH
@N3@TAT and AuNPs@COOH@N3@TAT@dsRNA
Fig. 7 Surface plasmon resonance (SPR) shift for the func-
tionalization of PEG chains, TAT peptide, and dsRNA. The
spatial arrangement of gold nanoparticles can be inferred by
measuring the shift of a characteristic surface plasmon band that
is influenced by their size, shape, aggregation state, and
surrounding medium polarity
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the enhancement of the dsRNA loading into AuNPs.
Based on the obtained data, we hypothesize that
loading of oligonucleotides onto the AuNP surface
may be controlled by ionic and weak interactions, such
as the TAT peptide and the polarized azide group on
one of the PEG chains, thus positioning the entry of the
oligo through the PEG layer,. It was also demonstrated
that the weak interactions, e.g., hydrogen bounds,
between PEG chains spacers and dsRNA enhance the
loading of the dsRNA onto the AuNPs by steering its
entry through the PEG layer.
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Figure S1 – Citrate-Gold nanoparticle characterization. TEM images (left, scale bar = 100 nm), 
size distribution histogram (right) showing an average diameter of 14.47 nm. 
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Figure S2 – A. TEM image of AuNPs@COOH (scale bar: 100 nm). B. TEM image of 
AuNPs@COOH/N3 (scale bar: 100 nm). C. UV/Vis Spectroscopy of AuNPs@COOH/N3, 
AuNPs@COOH/N3@TAT and AuNPs@COOH/N3@TAT@dsRNA. 
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1. Determination of the degree of saturation of gold nanoparticles functionalized with thiolated 
polyethyleneglycol chains.  
 
For the determination of the degree of saturation of gold nanoparticles functionalized with thiolated 
polyethyleneglycol chains we developed and optimized a procedure based on the Ellman’s assay. 
With this procedure it is possible to determine the number of thiolated chains that have been bound 
to gold nanoparticles. After the incubation of the gold nanoparticles with the thiolated chains, the 
nanoparticles are functionalized with a defined number of chains being the excess of thiolated chains  
free in solution. In order to determine the number of bound chains, this suspension is centrifuged and 
the supernatant with the excess of thiolated chains is kept to perform the quantification assay. The 
number of exchanged chains is given by the difference between the amount determined by this assay 
and the initial amount of chains in the incubation mixture with the nanoparticles. As it was stated 
above, the free thiolated chains are determined by a procedure based on the Ellman’s assay. In this 
assay, the supernatant, containing the spacer with thiol groups on its structure, reacts with DTNB 
(5,5’-dithio-bis(2-nitrobenzoic) acid) to give a colored product that can be measured 
spectrophotometrically. In the optimal conditions, 200 μL of stock solution of the thiolated chain or 
the sample containing the supernatant are mixed with 100 μL of phosphate buffer 0.5 M pH 7 and 7 
μL of DTNB 5 mg/mL in phosphate buffer 0.5 M pH 7. The mixture is made to react for 10 minutes 
and the absorbance at 412 nm is measured. The linear range for the thiolated chain is 0.5-30 μg/mL 
(Abs412 = 0.0229[chain, µg/mL] + 0.0587).  
The total number of thiolated chains that can be attached per gold nanoparticle were calculated. As it 
is shown in Figure S3, the excess of thiolated chain versus the initial concentration of thiolated chain 
in an incubation mixture with a constant concentration of gold nanoparticles is represented. As the 
initial concentration of thiolated chain increases, the excess of free chain increases in an equilibrium 
dependent way (equilibrium constant [bound chain]/[free chain]=0.76). There is a point at which the 
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nanoparticle becomes saturated with a thiolated layer and is not able to uptake more thiolated chains. 
At this point it is possible to calculate the maximum number of thiolated chains that it is possible to 
bind per gold nanoparticle being estimated a number of around 5000 chains per nanoparticle. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Variation of the excess of thiolated chain as a function of the initial concentration in the 
incubation mixture with gold nanoparticles. Initial concentration of gold nanoparticles 0.5 mg/mL. 
 
Therefore, it is possible to prepare gold nanoparticles with a controlled degree of saturation if an 
initial thiolated chain concentration below the saturation conditions is used (below 0.05 mg/mL of 
thiolated chain per 0.5 mg/mL of gold nanoparticles). In order to determine the degree of saturation 
at which gold nanoparticles are stable enough and allow the binding of additional thiolated chains we 
performed the following assay. Gold nanoparticles were functionalized with a controlled amount of 
thiolated chains in order to obtain nanoparticles with different degrees of saturation. After this, a 
fixed amount of a thiolated chain was added and incubated with the gold nanoparticles. The 
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concentration of thiolated chain that was bound to the non-saturated gold nanoparticles was 
determined by the Ellman’s assay. As it is shown in Figure S4, as the initial percentage of saturation 
of the thiolated layer decreases the gold nanoparticles are able to bind a higher amount of thiolated 
chain added on this second addition. The best conditions for the binding by a second addition of a 
thiolated molecule are to work with gold nanoparticles with a degree of saturation be low 35 %. 
However, gold nanoparticles with a degree of saturation below 10 % are less stable. For these 
reasons, the best conditions for study the binding of thiolated molecules on gold nanoparticles 
functionalized with a non-saturated thiolated chain layer is between 10 and 35 %.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Determination of the amount of thiolated chain bound to gold nanoparticles already 
functionalized with a thiolated chain layer with different degree of saturation. The initial 
concentration of gold nanoparticles is 0.5 mg/mL. 
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2. Procedure for the determination of the bound TAT peptide by the EDC coupling reaction to 
functionalized gold nanoparticles. 
 
As it was stated in method section, a procedure for the determination of the peptide that was bound 
to gold nanoparticles through the EDC coupling reaction was developed. This assay was based on the 
Bradford method. Given that the reagents for the EDC reaction (sulfo-NHS, EDC) interferes with the 
assay an standard addition calibration curve for the TAT peptide in the EDC reaction conditions was 
obtained (see Figure S5). This calibration curve was used for the interpolation of the samples 
containing the excess of peptide that was not bound to gold nanoparticles.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5. Standard addition calibration curve for the TAT peptide in the conditions of the EDC 
coupling reaction. In the linear range the calibration curve is given by the following equation  
Abs570 = 0.071[peptide, μg/mL] + 0.24. 
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3. Quantification of the dsRNA strand loaded into gold nanoparticles 
 
In order to carry out the dsRNA quantification we used the GelRed™ dye as a nucleic acid 
intercalator. The GelRed™ is a sensitive, stable fluorescent nucleic acid dye commonly designed to 
stain dsDNA, ssDNA as well as ds and ssRNA. Here, we had developed an analytical method to 
quantify the amount of dsRNA that was lost during the functionalization. We measured the dsRNA 
concentration in the supernatants after incubation, which is measuring the dsRNA in excess, that 
hadn’t bound to gold surface. Briefly, the supernatants were incubated with GelRed 100× and TBE 
0.5× and fluorescence was measured with emission at 602 nm. A Correlation to a standard curve of 
known dsRNA concentrations allows accurate measurement of dsRNA in unknown samples. In 
Figure S6A we can see the fluorescence spectra of the GelRed only and when it is bound to dsRNA. 
Figure S6B presents the calibration curve for the thiolated dsRNA used in the experiments.  
 
Figure S6. A. Fluorescence spectra of the GelRed only and dsRNA-GelRed.  B. Calibration curve 
for the thiolated dsRNA. In the linear range the calibration curve is given by the following equation: 
Emission at 602nm = 439.96[dsRNA, nmol] + 32.697. 
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Modification of plasmid DNA topology by  
‘histone-mimetic’ gold nanoparticles
Nanotechnology-based systems have shown 
the potential to provide effective therapies with 
minimal side effects and high specificity [1–3], 
where the use of gold (Au) nanoparticles (NPs) 
as nontoxic carriers for drug and gene delivery 
[4–6] has been widely reported. Gold nanopar-
ticles (AuNPs) have emerged as an attractive 
tool for biomedical applications due to their 
unique features, such as quantum properties, 
biocompatibility, high stability and a relatively 
large functional surface [2,7–10]. Many of these 
platforms rely on the functionalization and/or 
interaction of a particular biomolecule of inter-
est and the surface of the NP, and in particular 
several studies of DNA and protein interactions 
with NPs by noncovalent interactions have been 
reported [11–14]. Despite the wide application of 
these nanosystems, the effect on DNA structure 
and topology of interactions between the dielec-
tric environment of AuNPs and DNA has not 
been extensively studied.
Watson and Crick first described DNA to be 
composed of two helical chains each coiled round 
the same axis, consisting of simple and repeating 
units called nucleotides, with backbones made 
of sugars and phosphate groups joined by ester 
bonds that run in opposite directions to each 
other [15]. It was initially believed that all DNAs 
were linear with two free ends, but the existence 
of closed-circular duplex structures were soon 
confirmed by naturally occurring circular DNAs, 
such as plasmids [16,17]. Plasmids are small auto-
nomous replicating genetic elements that provide 
a means for horizontal genetic transfer and can 
be used for transient or sustained expression of 
foreign genes in a given cell, and are often applied 
to gene therapy. Histones and protamine can 
improve the intranuclear disposition of plasmid 
DNA and are capable of modulating transgene 
expression. These DNA complexes are expected 
to penetrate the cell membrane by a nonendo-
cytotic pathway and enter the nucleus through 
nuclear pores. Furthermore, plasmids provide 
excellent molecular models to study DNA topol-
ogy. In solution, plasmids adopt three main types 
of circular molecules – relaxed, supercoiled (Sc) 
and nicked circle (Nc). Although the relaxed and 
Sc forms are not restricted to plasmid DNA, it 
provides the best model to study DNA molecules 
with different levels of topology and conden-
sation [18]. The flexible structure of DNA is a 
function of both the surrounding ionic environ-
ment and the nature of DNA-binding proteins 
[17,19]. Changes to DNA topology are of utmost 
importance as they mediate gene expression and 
silencing, while allowing packaging into the cell 
nucleus, which is mediated by histones that coil 
the DNA into small nucleosomal units organized 
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in chromatin fibers [20,21]. Histones are relatively 
small proteins, whose high content of lysine and 
arginine provides a strong cationic effect, capa-
ble of stabilizing the DNA by ionic/electrostatic 
bonds. Condensation of rigid and highly charged 
DNA molecules into compact structures can also 
be achieved by small cationic proteins such as 
protamine [22–24]. In gametogenesis, these small 
arginine-rich proteins bind to the entire length 
of the haploid genome in sperm cells, causing 
the DNA to coil into toroidal (50-60 kb of 
DNA) structures, thus inactivating the entire 
genome [25]. Protamine’s arginine-rich anchoring 
domains bind to the negatively charged phospho-
diester backbone of DNA in a base sequence-
independent fashion leading to neutralization of 
the negative charge, inducing both condensation 
and decondensation of sperm chromatin during 
fertilization [26]. Protamine is the histone sub-
stitute in sperm chromatin during the haploid 
phase of spermatogenesis [27], where the proper 
replacement of histones by transition proteins fol-
lowed by the more basic protamine, constitutes 
the main event in sperm maturation that affects 
chromatin structure [28]. Several studies have 
shown that male factor infertility patients pos-
sess anomalies in the composition of their sperm 
nuclei, displaying damaged DNA and higher lev-
els of loosely packaged chromatin, probably due 
to protamine deficiency [29–31]. Also, it has been 
shown that approximately 85% of the DNA in 
the sperm nucleus is associated with protamines 
and that 15% remains associated with histones 
or other proteins [32].
Owing to their ultra small size and unique 
physico-chemical properties, AuNPs are capable 
of permeating easily inside the cell and nucleus 
and interacting with DNA, which may induce 
changes to chromatin condensation and/or 
decondensation processes and nuclear structure. 
This interaction can be strongly enhanced via 
conjugation with protamine. Free protamine 
molecules have been used for gene and macro-
molecule delivery into cells [33] due to their cell 
penetrating activity [34]. Changes to DNA con-
formation and topology can produce important 
effects on the transfection efficiency, as they can 
promote or disrupt the expression of the genes 
encoded by the plasmid. The efficiency and 
strength of plasmid DNA binding to AuNPs can 
also be affected by DNA conformation on the 
NP surface. This binding has important impli-
cations in gene delivery as it will determine the 
ability of the NP to carry and deliver the plasmid 
(i.e., binding has to be strong enough to carry 
the plasmid to the target, yet loose enough to 
deliver it with efficiency into the cell for effective 
expression).
Recently, functionalized AuNPs were used 
as novel markers for sex-sorting of mamma-
lian sperm and for the selection of sperm with 
heritable DNA sequences interesting for animal 
breeding [35]. However, protamine’s role in con-
trolling plasmid DNA structure, topology and 
levels of condensation and decondensation when 
complexed with polyethylene glycol (PEG)ylated 
AuNPs has not been described.
Here, we report the use of AuNPs function-
alized with PEG carboxylated and protamine 
(AuNP@PEG@Prot) to modulate plasmid DNA 
topology in a histone-mimetic way. Our main goal 
is to study the influence of AuNP@PEG@Prot 
conjugates on plasmid DNA condensation, and 
to develop a method to control plasmid DNA 
topology for downstream cellular applications 
that avoids the use of histones (Figure 1).
Materials & methods
n Synthesis of citrate-AuNPs
The citrate-AuNPs were synthesized by the 
reduction of tetrachloroaurate (HAuCl
4
) with 
sodium citrate, described elsewhere [36]. Briefly, 
hydrogen tetrachloroaurate (III) hydrate (Strem 
Chemicals, MA, USA; 0.2 g; 0.589 mmol) was 
dissolved in 500 ml of distilled water, heated and 
stirred under reflux. Upon boiling, the sodium 
citrate dihydrate (0.57 g; 1.94 mmol) is added 
and the solution is kept under reflux for 30 min, 
turning the color of the solution to red due to the 
synthesis of the NPs. In this process, the Au3+ 
ions are reduced by citrate to neutral Au atoms. 
When the solution becomes saturated with Au 
atoms, they start to precipitate in the form of 
NPs. The citrate acts as a stabilizing agent that 
sticks to the NP surface avoiding the aggrega-
tion of the NPs. When the process finished, we 
cooled the reaction mixture and kept it protected 
from light. The NP suspension was observed 
with a transmission electron microscope (TEM) 
(T20, 200 KeV; FEI) to determine Au core size, 
dynamic light scattering (DLS; Brookhaven 
ZetaPALS) and Fourier transform infrared 
spectroscopy (FTIR; JASCO FT/IR 4100).
n Synthesis of PEGylated AuNPs 
(AuNP@PEG)
Functionalization of PEGylated AuNPs was 
carried out using commercial hetero-functional 
PEG functionalized with a thiol and a carboxyl-
ated group (SH-EG(8)-COOH, 450 Da; Iris-
Biotech). 0.5 mg/ml of the citrate-AuNPs was 
mixed with 0.03 mg/ml of SH-EG(8)-COOH 
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in an aqueous solution of SDS (0.028%). 
Following this, NaOH was added to a final 
concentration of 25 mM and the mixture was 
incubated for 16 h at room temperature.
Excess PEG was removed by centrifugation 
(14,000 rpm, 30 min, 4°C) and quantified by the 
Ellman’s Assay. The Ellman’s Assay is suitable for 
sulfhydryl group determination. 0.05 mg/ml of 
5,5́ -dithio-bis-(2-nitrobenzoic acid) reacts with 
sulfhydryls under slightly alkaline conditions 
(0.5 M phosphate buffer, pH 7–8), to release the 
highly cromogenic compound (412 nm) 5-thio-
2-nitrobenzoic acid after 15 min at room tem-
perature. A linear standard curve was prepared 
in the range of 0.5-30 µg/ml of SH-EG(8)-
COOH. The excess SH-EG(8)-COOH was 
determined after interpolation in this curve 
(Supplementary Figure 1a; see online www.future-
medicine.com/doi/suppl/10.2217/nnm.12.21). 
The linear range for the thiolated chain is 
0.5-30 µg/ml (Abs
412
 = 0.0248 × [SH-EG(8)-
COOH, µg/ml] + 0.0645). The total number 
of thiolated-PEG chains that can be attached per 
AuNP was determined to be 5624.4 ± 456.8 chains 
per NP (Supplementary Figure 1).
AuNP@PEG were analyzed by TEM, DLS 
and FTIR confirming the presence of PEG on 
the NPs.
n Functionalization of histone-mimetic 
AuNPs (AuNP@PEG@Prot)
The process for producing the histone-
mimetic AuNPs was based on a carbodiimide 
(EDC)/N-hydroxysuccinimide (NHS) cou-
pling reaction [37] of protamine and carboxyl-
functionalized AuNPs. A commercial hetero-
functional PEG with a thiol group on one 
terminus and a carboxylic acid functional group 
on the other (SH-EG(8)-COOH) was used 
for the carboxyl functionalization of AuNPs. 
Briefly, 1 mg/ml Au@PEG and 1.25 mg/ml 
N-hydroxysulfosuccinimide (sulfo-NHS) were 
incubated in 25 mM MES (2-(N-morpholino)
ethanesulfonic acid) at pH 6.1. After this, prot-
amine sulfate from salmon sperm (SIGMA; 
molecular weight of 5000–10000 Da) was 
added to the mixture at a final concentration 
of 0.5 µg/ml and allowed to stabilize for 5 min. 
After this period of time, EDC was added at a 
final concentration of 150 µg/ml and the mixture 
Figure 1. The effect of protamine on dNA topology. (A) Formation of toroidal structures (50-60 kb DNA) by free Prot.  
(B) Conformational changes of plasmid DNA mediated by AuNP@PEG@Prot. (C) Electrostatic interactions between AuNP@PEG@Prot 
and plasmid DNA. Prot possesses large tracts of positively charged arginine residues that neutralize the negative phosphodiester 
backbone of the DNA. 
AuNP: Gold nanoparticle; PEG: Polyethylene glycol; Prot: Protamine.
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incubated at room temperature for 16 h. Then, 
the AuNP@PEG@Prot were centrifuged at 
14,000 rpm for 30 min at 4ºC to remove the 
excess protamine, and supernatants were recov-
ered and tested for protein concentration by the 
Bradford assay. The Bradford assay, a colorimet-
ric protein assay, is based on an absorbance shift 
of the dye Coomassie Brilliant Blue in which 
under acidic conditions the red form of the dye 
is converted into its bluer form to bind to the 
protein being assayed. After interpolation in 
a standard curve for protamine concentration 
(Supplementary Figure 2) AuNP@PEG@Prot were 
determined to have 4.8 ± 0.34 molecules of 
protamine per AuNP.
Characterization of the NPs was performed 
by DLS z-potential (Brookhaven ZetaPALS), 
UV/Vis Spectroscopy (Varian Cary50 Probe) 
and FTIR. Size increase shown by DLS and 
z-potential values also confirmed protamine 
functionalization.
n Plasmid DNA conformation studies
Evaluation of plasmid (psiCHECK™-2; 
Promega) conformations (Supplementary Figure 3) was 
confirmed by linearizing the plasmid with 20 U 
of HindIII (Fermentas), incubating at 37°C for 
1 h and 80ºC for 20 min for inactivation. The 
plasmid was also nicked with 10U of S1 nucle-
ase (Fermentas), incubating the mixture at room 
temperature for 30 min. To stop the reaction, 
2 µl of 0.5 M EDTA was added and the reac-
tion heated at 70°C for 10 min. Confirmation 
of proper conformations was performed by 0.8% 
agarose gel, at 70 V during 100 min.
Plasmid DNA conformation quantification 
was performed by pixel intensity/counting using 
ImageJ™ imaging software.
n Atomic force microscopy studies
For atomic force microscopy (AFM) analysis, an 
atomic force microscope (Nanotec) and noncon-
tact cantilever (SuperSharpSilicon; Nanosensors) 
(fo = 190 kHz) probes were used to image the 
DNA topology when incubated with AuNPs 
functionalized with protamine. Samples were 
deposited from water solution. Samples were 
deposited onto freshly cleaved mica sheets, left for 
20 min and then air dried. Images were collected 
in air at room temperature. The raw data images 
were rendered using Nanotec WSxM software 
(version v5.0 Develop 3.1).
Results & discussion
AuNPs were synthesized by the reduction of 
tetrachloroaurate acid with sodium citrate. NPs 
were 14.47 nm in size as determined by TEM 
(Supplementary Figure 4). Chemical functionalization 
was incorporated into the NPs by substitution 
of citrate with a hetero-functional octa(ethylene 
glycol) (SH-EG(8)-COOH) with a thiol group 
at one end to be linked to the Au core and a 
carbo xylic group at the other end to incorporate 
chemical functionality onto the NPs. AuNPs 
were covered with a dense layer of SH-EG(8)-
COOH and functionalized NPs (AuNP@PEG) 
were obtained. The excess SH-EG(8)-COOH 
was removed by centrifugation at 4°C, and eval-
uated by the Ellman’s method (see Material & 
methods section), retrieving a PEG:AuNP ratio 
of 5624:1. Conjugation of protamine to AuNP@
PEG was achieved by taking advantage of the car-
boxylated surface previously generated on the NP 
and the remaining amino groups from the prot-
amine. Using EDC and sulfo-NHS, protamine 
was covalently conjugated to the NP surface 
yielding AuNP@PEG@Prot. Determination of 
the amount of protamine per NP was achieved 
by quantification of supernatants using the 
Bradford assay, and a final protamine:AuNP 
ratio of 4.8 ± 0.34 was obtained. UV/Vis and 
DLS were also used to confirm protamine con-
jugation (Figure 2) as well as FTIR (Supplementary 
Figure 5). z-potential values are -29.10 ± 0.83 for 
AuNP@PEG and -17.24 ± 0.64 for AuNP@
PEG@Prot. Au@PEG is negatively charged, 
whereas AuNP@PEG@Prot is slightly more posi-
tive, which could be explained by the differences 
in ratio of PEGs (5624:1) and protamine (5:1) per 
AuNP. Interaction between AuNP@PEG@Prot 
and DNA is driven by the nature of the ligand 
protamine, which is selective for DNA binding, 
when bound to AuNPs. Alteration of DNA con-
formation is driven by the specific binding to 
protamine molecules arranged on the surface of 
AuNPs, associated with a local ionic interaction 
between the DNA-binding site on protamine and 
the DNA itself.
After functionalization of the Au conjugates, 
we performed the plasmid DNA conforma-
tion studies. The free plasmid DNA (control) 
presents several distinct conformations that 
can be identified through the electrophoretic 
profile of the uncut plasmid in an agarose gel 
(0.6% - TBE 1x, 70 V for 100 min) (Figure 3B). 
Plasmid DNA shows two distinct conforma-
tions: Sc, where DNA is wound up into a com-
pact structure; and Nc, where one strand is a 
covalently continuous circle and the other has 
been cut; either in the form of monomers or 
dimers. In the Sc structure (or covalently closed-
circular structure), DNA is fully intact with 
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both strands uncut with a built in twist, result-
ing in a twisted compact form where the strands 
may become more tightly or more loosely wound 
together accommodating one too many or one 
too few helical twists. Once one of the strands 
has been cut, the superhelical tension relaxes 
and the tightly wound ball becomes a floppy 
circle. This Nc form is one of the most relaxed 
and unstressed states of a closed-circular DNA 
and shows the slowest electrophoretic mobility 
for uncut plasmid DNA. The Sc DNA shows 
the highest electrophoretic mobility in an 
agarose gel and represents 95% of all plasmid 
DNA conformations. The Sc and Nc conforma-
tions are the two main conformational struc-
tures of a single plasmid molecule (monomer). 
Nevertheless, two plasmid molecules can join to 
form a dimer with twice the molecular weight 
of that of the monomer. This way, a dimer will 
show a decreased electrophoretic mobility and 
becomes visible in the gel above the monomeric 
form. As for the monomeric plasmid, Sc shows 
the highest mobility and Nc the lowest.
Regarding the effect of free protamine in 
plasmid conformation, we demonstrate that 
protamine allows plasmid DNA condensation 
(Supplementary Figure 6). The quantity of unbound 
plasmid DNA could easily be assayed by a gel 
shift assay, and shows plasmid binding to prot-
amine at a range of 10-4-0.1 mg/ml at a constant 
plasmid concentration (4.4 ng/µl). The binding 
of plasmid to protamine is apparent at protamine 
concentrations from 2 × 10-3 to 0.1 mg/ml. The 
significant decrease in DNA mobility is asso-
ciated with the formation of extremely dense 
clumps of plasmid DNA and protein. For lower 
concentrations of protamine, it is still possible to 
observe the monomeric and dimeric, both Sc and 
Nc, forms of the plasmid. In fact, no change in 
Sc and Nc conformations is observed for 10-4 to 
2 × 10-3 mg/ml of protamine.
Following demonstration of the potential for 
DNA condensation and complexation, we then 
evaluated protamine function when functional-
ized on AuNP@PEG. Protamine effect on plas-
mid conformation when bound to AuNP@PEG 
Figure 2. Characterization of gold nanoparticle conjugates by (A) transmission electron 
microscopy, (B) UV/Vis and (C) dynamic light scattering. The polydispersity index is 0.265 for 
AuNP@PEG and 0.091 for AuNP@PEG@Prot. The size increase shown by dynamic light scattering 
confirmed Prot functionalization. 
AuNP: Gold nanoparticle; PEG: Polyethylene glycol; Prot: Protamine.
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can easily be observed in Figure 3a. In contrast to 
the effect of AuNP@PEG, AuNP@PEG@Prot 
(Figure 3B) greatly influences plasmid DNA topol-
ogy. In a concentration-dependent manner, for 
higher concentrations of the AuNP conjugates, 
the quantity of the Sc conformation of the mono-
mer decreases at the same time the Nc confor-
mation of the dimer increases. Also, for higher 
concentrations of AuNP conjugates more than 
two plasmid molecules join together and create 
high-molecular-weight multimers. It is usually 
difficult to distinguish conformations of mul-
timers but, in Figure 3B, the three conformations 
of the multimers can be easily seen. Similar to 
the Nc conformation of the dimer, with a high 
concentration of AuNP conjugates an increase 
in multimer quantity can be seen. As revealed in 
Figure 3B, DNA condensation by AuNP@PEG@
Prot results in the formation of DNA conden-
sates with a wider diversity of plasmid morpholo-
gies and with great potential for formation of 
greater quantity of dimers and multimers. The 
Nc conformations of plasmid dimers were still 
the predominant morphology; however, the mul-
timers (probably representing toroidal conden-
sates of 50–60 kb of DNA) were also observed. 
For higher AuNP@PEG@Prot concentrations, 
there is an increase in the Nc conformation and 
a decrease in Sc form, both for monomers and 
dimers. It seems that when protamine is asso-
ciated with AuNPs, it favors the most relaxed 
forms of plasmid DNA, instead of supporting 
the most condensed conformations. Conversely, 
there is an increasing formation of DNA mul-
timers, most likely toroidal structures, with 
increasing concentrations of Au@PEG@Prot. 
This proves that protamine is capable of inducing 
both condensation and decondensation of DNA. 
In fact, protamine, when complexed to AuNPs, 
plays an active role in controlling plasmid DNA 
structure and quantity, not only for condensation 
but also for decondensation of DNA, as demon-
strated by the increase in the Nc conformation, 
the most relaxed and unstressed state of plasmid 
DNA. Furthermore, this behavior was observed 
to be general and not dependent on plasmid 
Figure 3. Comparison of dNA topology changes between gold nanoparticles functionalized 
with (A) polyethylene glycol or (B) polyethylene glycol and protamine. AuNP@PEG@Prot 
concentration varies from 2.5 to 0.2 mg/ml and plasmid concentration was kept constant (2.5 ng/µl). 
The stoichiometric ratio between Prot and DNA molecules to obtain different topologies are shown. 
The quantity of the Sc conformation of the monomer decreases at the same time the Nc 
conformation of the dimer increases in an AuNP@PEG@Prot concentration-dependent manner. 
AuNP@PEG did not show the same effect as AuNP@PEG@Prot in changing plasmid conformation. 
Both Sc and Nc conformations maintain almost the same quantities as the control (plasmid DNA 
only). Agarose gel electrophoresis was carried out at 70 V for 100 min.  
AuNP: Gold nanoparticle; Nc: Nicked circle; PEG: Polyethylene glycol; Prot: Protamine; 
Sc: Supercoiled.
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size. The pattern of the conformational changes 
mediated by AuNP@PEG@Prot on plasmids of 
different sizes presents a similar tendency (data 
not shown). AFM was also carried out to con-
firm the results obtained by gel electrophoresis 
(Figure 4). Figure 4a depicts the AFM images of the 
DNA alone (plasmid with 6273 bp) with con-
densed and decondensed strands. The condensed 
DNA molecules have significantly more nodes 
(the number of visible crossover points in AFM 
images) than the relaxed forms. Figure 4C shows 
the effect of AuNP@PEG without protamine on 
DNA condensation: the NPs are present with 
circular semi-decondensed DNA in their vicin-
ity. In the case of AuNP@PEG@Prot (Figure 4D), 
the DNA structures are even less condensed 
(i.e., decondensed). We can see that AuNP@
PEG@Prot binds to DNA, stretching the plas-
mid strands. This effect is due to the conjugated 
effect of AuNPs and protamine, as protamine 
alone induces the high level of condensation 
seen in Figure 4B. DNA condenses into distinct 
toroid structures and highly condensed particles 
when protamine alone is added. In fact, the posi-
tively charged guanidinium groups of arginine 
residues of the protamine bind electrostatically 
to the negatively charged phosphate groups of 
DNA. These effects are observed in gel electro-
phoresis (Supplementary Figure 1) and in the band gel 
quantification (Figure 5).
A time-dependence study of plasmid confor-
mation changes mediated by AuNP@PEG@
Prot was also performed in order to calculate 
the kinetic constants for DNA topology modi-
fication via histone-mimetic AuNPs. The con-
centration of Sc monomers and dimers decreases 
in a similar fashion, with Nc dimers being the 
conformational product of the former species 
(Supplementary Figure 7). A theoretical equation that 
relates the variation of the conformational species 
as a function of time was developed (Supplementary 
material 1, theoretical model for kinetic constant 
calculation):
0
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The main conformation transitions are from 
Sc for monomer and dimer forms to Nc for dimer 
forms. The relative concentration of the Sc con-
formations (Sm: Sc monomer; Sd: Sc dimer) 
decrease as a function of time with a similar 
tendency. Therefore, both species decrease in 
concentration with the same kinetic constant 
(kinetic constant of formation of Nc dimer, kf). 
From adjustment of the theoretical equation, a 
kinetic constant (kf) of 1152 M/s was calculated.
Conclusion
We successfully report the use of AuNPs func-
tionalized with PEG-carboxylated and protamine 
to modify plasmid DNA topology. We demon-
strate that AuNP@PEG@Prot plays an active role 
in controlling plasmid DNA structure, topology 
and levels of condensation and decondensation. 
Conversely to what occurs when using free prot-
amine, AuNP@PEG@Prot may allow control of 
the levels of condensation and decondensation of 
DNA molecules in a stable and organized manner. 
By means of a theoretical equation, it is possible 
to exert control over the amount of each plasmid 
DNA conformation by constraining the initial 
conditions and the incubation time of AuNPs 
with plasmid DNA. Although the functional-
ized AuNPs show an opposite effect on DNA 
structure, plasmid DNA conformations could 
be selectively extracted to shift the equilibrium 
of the reaction towards the desired conformation.
We hypothesize that the effect of AuNP@
PEG@Prot on plasmid DNA conformations prob-
ably mimics the interactions between AuNPs and 
600 nm 600 nm
600 nm 600 nm
Figure 4. Atomic force microscopy images. (A) Plasmid DNA, (B) protamine–DNA 
complex, (C) gold nanoparticles functionalized with a carboxylated polyethylene 
glycol plus plasmid DNA and (d) gold nanoparticles functionalized with polyethylene 
glycol and protamine–DNA complex, showing an increase in diameter to 
approximately 54 nm confirming PEG and protamine functionalization. The 14-nm 
particles refer to the citrate-gold nanoparticles without any functionalization.
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the DNA double helix in sperm chromatin. This 
hypothesis is supported by the fact that protamine 
proteins play an important role in condensation 
and stabilization of spermatic nuclear chroma-
tin and that when combined with AuNPs of this 
particular size they may locate within the wide 
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Figure 5. Relative quantification of the main plasmid conformations for the (A) monomers, 
(B) dimers and (C) multimers after incubation of 2.5 ng/µl of plasmid dNA with increasing 
amounts of gold nanoparticles functionalized with polyethylene glycol and protamine. 
Error bars correspond to the average and standard deviation of three independent measurements. 
AuNP: Gold nanoparticle; PEG: Polyethylene glycol; Prot: Protamine.
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groove of the DNA molecule, thus disturbing the 
structure of liquid crystals of DNA, changing its 
topology [38]. Although plasmid DNA is different 
from genomic and sperm DNA, it can be used as 
a valuable model to study DNA topology.
Several studies have shown that aberrant prot-
amine content results in human male infertility 
due to diminished parameters of semen quality, 
such as sperm count, motility and morphology 
[30,39]. In fact, sperm chromatin/DNA integrity 
is essential for the accurate transmission of pater-
nal genetic information. In addition, a deficient 
function in protamine may also predispose DNA 
to damages and fragmentation characterized by 
both single and double DNA strand breaks, 
and this characteristic is particularly frequent 
in infertile men. With this in mind, the pres-
ent report may constitute a good model study 
and to evaluate application of histone-mimetic 
AuNPs - AuNP@PEG@Prot. If proven effec-
tive in cell models and on genomic DNA, such 
a system may be considered for therapy and/or 
infertility procedures, for example, in protamine-
deficient sperm individuals. For this, further 
studies of in vitro experiments with intact nuclear 
membrane and nuclear core complexes, and with 
a relevant in vivo model of spermatogenesis will 
be needed to support this hypothesis.
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executive summary
Synthesis of gold nanoconjugates
  Gold nanoparticles (AuNPs; ~14 nm) were synthesized by the reduction of tetrachloroaurate acid 
with sodium citrate.
  Chemical functionalization was incorporated into the nanoparticles by substitution of citrate by a 
hetero-functional octa(ethylene glycol) with a thiol group at one end to be linked to the gold core 
and a carboxylic group at the other end to incorporate chemical functionality onto the nanoparticles.
  Using carbodiimide and N-hydroxysulfosuccinimide, protamine was covalently conjugated to the 
nanoparticles’ surface, yielding AuNP@PEG@Prot.
Effect of free protamine on DNA topology
  We demonstrate that the significant decrease of DNA mobility is associated with the formation of 
extremely dense clumps of plasmid DNA and protein.
  Protamine alone induces high levels of condensation of DNA (formation of toroidal structures:  
50-60 kb of DNA).
Effect of AuNP@PEG & AuNP@PEG@Prot on DNA topology
  In contrast to the effect of AuNP@PEG, AuNP@PEG@Prot greatly influences plasmid DNA topology.
  DNA condensation by AuNP@PEG@Prot results in the formation of DNA condensates with a wider 
diversity of plasmid morphologies and with a great potential for formation of higher quantities of 
dimers and multimers.
  When protamine is associated with gold nanoparticles, it favors the most relaxed forms of plasmid 
DNA, instead of supporting the most condensed conformations.
Conclusion
  Protamine, when complexed to AuNPs, plays an active role in controlling plasmid DNA structure and 
quantity, not only for condensation of DNA, but also for decondensation of DNA as demonstrated 
by the increase in the nicked circular conformation, the most relaxed and unstressed state of 
plasmid DNA.
  AuNP@PEG@Prot presents a tool to control, in a stable and organized approach, the levels of 
condensation and decondensation of DNA molecules.
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Supplementary figure 1. Determination of the degree of saturation of gold nanoparticles 
functionalized with hetero-functional octa(ethylene glycol) (SH-EG(8)-COOH). 
For the determination of the degree of saturation of gold nanoparticles functionalized with 
thiolatedpoly(ethylene glycol) chains, we developed and optimized a procedure based on the 
Ellman’s assay. With this procedure it is possible to determine the number of thiolated chains 
that bound to the gold nanoparticles. Following incubation of the AuNPs with the thiolated 
chains the thiolated PEG chains bind to the nanoparticle surface. The excess of thiolated 
chains not bound to the AuNP surface, i.e. free in solution, can then be experimentally 
determined via the optimized protocol described.  
In order to determine the number of bound chains, the suspension is centrifuged and the 
supernatant with the excess of thiolated chains is used for the quantification assay. The free 
thiolated chains are quantified by a procedure based on the Ellman’s assay, where the 
supernatant, containing the spacer with thiol groups on its structure, reacts with DTNB (5,5’-
dithio-bis(2-nitrobenzoic) acid) to give a coloured product that can be measured 
spectrophotometrically. A stock solution of the thiolated chain is used for constructing a 
calibration curve from which the number of chains of any given sample can be interpolated. 
The number of bound chains to the AuNPs’ surface is given by the difference between the 
amount determined by this assay and the initial amount of chains in the incubation mixture.  
In the present case, 200 μL of stock solution (of different concentrations) and of the sample 
containing the supernatant are mixed with 100 μL of phosphate buffer 0.5 M pH 7 and 7 μL 
of DTNB 5 mg/mL in phosphate buffer 0.5 M pH 7. The mixture is made to react for 10 
minutes and the absorbance at 412 nm is measured. A linear standard curve was prepared in 
the range of 0.530 μg/mL of SH-EG(8)-COOH (see Figure S1A). The excess of SH-EG(8)-
COOH was determined after interpolation in this curve. The linear range for the PEG 
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thiolated chain is given by the Abs412nm = 0.0248×[SH-EG(8)-COOH chain, µg/mL] + 
0.0645. 
 
Following experimental determination of the total number of SH-EG(8)-COOH chains 
attached per gold nanoparticle via interpolation of a calibration curve, the level of saturation 
on the surface of the NP can also be calculated. Figure S1Bshows the excess of SH-EG(8)-
COOH chains versus the initial concentration of SH-EG(8)-COOH chains in an incubation 
mixture with a constant concentration of gold nanoparticles is represented. As the initial 
concentration of SH-EG(8)-COOH chains increases, the excess of free SH-EG(8)-COOH 
chains increases in an equilibrium dependent way (equilibrium constant [bound chain]/[free 
chain]=0.76). There is a point at which the nanoparticle becomes saturated with a SH-EG(8)-
COOH layer and is not able to uptake more PEG chains. It is then possible to calculate the 
average number of SH-EG(8)-COOH chains bound to each gold nanoparticle, which was 
5624.4±456.8 chains per nanoparticle. 
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(A) Standard addition calibration curve for the SH-EG(8)-COOH chains. In the linear range 
the calibration curve is given by the following equation Abs412nm = 0.0248×[SH-EG(8)-
COOH, μg/mL] + 0.0645. (B) Variation of the excess of thiolated SH-EG(8)-COOH chains as 
a function of the initial concentration in the incubation mixture with gold nanoparticles. Initial 
concentration of gold nanoparticles is0.5 mg/mL. 
214
5 
 
Supplementary figure 2. Determination of the Protamine peptide bound by the EDC 
coupling reaction to functionalized gold nanoparticles. 
As it was stated in materials and methods section, a procedure for the determination of the 
Protamine peptide that was bound to gold nanoparticles through the EDC coupling reaction 
was developed. This assay was based on the Bradford method. Given that the reagents for the 
EDC reaction (sulfo-NHS, EDC) interferes with the assay an standard addition calibration 
curve for the Protamine peptide in the EDC reaction conditions was obtained (see Figure S2). 
This calibration curve was used for the interpolation of the samples containing the excess of 
peptide that was not bound to gold nanoparticles.  
 
 
 
 
 
 
 
 
 
 
 
Standard addition calibration curve for the Protamine peptide in the conditions of the 
EDC/NHS coupling reaction. In the linear range the calibration curve is given by the 
following equation Abs570nm = 0.0496×[Protamine peptide, μg/mL] + 0.2441. 
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Supplementary figure 3.Plasmid DNA conformations. 
Plasmid DNA conformations: circular, linear (digested with Hind III) and nicked (digested 
with nuclease S1). 
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Supplementary figure 4: Citrate-Gold Nanoparticle Characterization. 
Citrate-Gold nanoparticle characterization.(A) TEM images (scale bar = 100 nm). (B) Size 
distribution histogram showing an average diameter of 14.47 nm. (C) TEM micrograph of 
AuNP@PEG@Prot, where PEG and protamine layer can be observed. 
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 Supplementary figure 5: Infra-red (FT-IR) spectra of AuNP’s conjugates. 
 
Infra-red (FT-IR) spectra of PEG, Protamine, AuNP@PEG and AuNP@PEG@Prot. PEG 
FT-IR peaks: 3456 cm
-1
 (OH st), 2871 cm
-1
 (-CH st), 2739 cm
-1
, 2599 cm
-1
, 1734 cm
-1
, 1648 
cm
-1 
(C=O st), 1458 cm
-1
; Protamine FT-IR peaks: 3352 cm
-1
, 3269 cm
-1
, 2962 cm
-1
, 2873 
cm
-1 
(-CH st), 1656 cm
-1
 (amide I, -helix), 1543 cm
-1 
(Amide II vibration C–N–H), 1458 cm
-
1 
(amide II), 1258 cm
-1 
(amide III band), 1112 cm
-1
, 1069 cm
-1
; AuNP@PEG FT-IR peaks: 
3449 cm
-1
 (NH st), 2855 cm
-1
 (-CH st), 1636 cm
-1
 (C=O st); AuNP@PEG@Prot FT-IR 
peaks: 3455 cm
-1
 (NH st), 2860 cm
-1
 (-CH st), 1655 cm
-1
 (amide I, -helix), 1461 cm
-1
 
(amide II). 
The characteristic amide I and II peaks of protamine is found on AuNP@PEG@Prot showing 
that protamine is conjugated to gold nanoparticles. The Amide I band is due to carbonyl 
stretching vibrations while the Amide II is due primarily to NH bending vibrations. 
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Supplementary figure 6. Effect of free protamine in plasmid conformation. 
Effect of free protamine in plasmid conformation. Free protamine shows plasmid binding at a 
range of 10
-4
0.1 mg/mL), with a constant plasmid concentration (4.4 ng/µL). The binding of 
plasmid to the protamine is apparent at protamine concentrations from 2×10
-3
 to 0.1 mg/mL. 
For lower concentrations of protamine it is still possible to observe the monomeric and 
dimeric, both Sc and Nc, forms of the plasmid DNA. No change in Sc and Nc conformations 
is observed for 10
-4
 to 2×10
-3
 mg/mL of protamine. 
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Supplementary figure 7.Kinetic study of plasmid conformation changes. 
Kinetic study of plasmid conformation changes mediated by AuNP@PEG@Prot.(A) 
Variation of relative quantification of the main plasmid conformation for the monomers and 
dimers in a time dependence way. (B) Adjustment by the theoretical model for kinetic 
constant calculations (ln (1[Nd]/[P]0 – [Nm]0)= -0.0036t – 0.4855, R
2
= 0.99) 
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Supplementary material 8. Theoretical model for kinetic constant calculation 
 
The kinetics data was obtained from the line scans of the bands in the gel mobility shifts (see 
Figure 3 from the manuscript). From Figure S7A the main conformation transitions are from 
Supercoiled for monomer and dimer forms to the Nicked circle for dimer (Nd). The relative 
concentration of the Sc conformations (Sm – supercoiled for monomer; Sd – supercoiled for 
dimer) decrease as a function of time with a similar tendency. Therefore both species decrease 
in concentration with the same kinetic constant (kinetic constant of formation of Nc dimer, 
kf). From this hypothesis the kinetic equation for the formation of the Nc dimer form is as 
follows: 
 
 
The mass balance for total plasmid concentration ([P]0) is given by equation 2: 
 
 
 
From Figure S7A it is possible to see that the concentration of the supercoiled for dimer [Sd] 
and for multimers [M] are negligible and remain as constant during the kinetic process. 
Consequently can be group as a constant: 
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From equation 1 to 3 the follow deferential equation has to be solved: 
 
 
 
Where [Nd]0 is the initial concentration of the nicked circle form for dimer and [Nd]t is the 
nicked circle form for dimer at t time. 
The equation 4 solution is: 
 
 
As the concentration of plasmid conformations is proportional to gel band intensity (I) it leads 
to: 
 
 
As the experimental data fit the equation 6 (see Figure S7B) it confirms the proposed 
hypothesis validating the theoretical model presented. 
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N
anoparticles exhibit excellent phys-
icochemical properties for applica-
tion in drug delivery, namely, their
reduced sizes, rendering them capable of
interacting with biomolecules in a one-
to-one scale, and the high surface-to-volume
ratio allowing for surface functionalization
with a plethora of molecules for specific
targeting and drug payloads.1,2 Among
the numerous nanoparticle formulations
designed to improve siRNA3,4 delivery and
efficiency, those based ongoldnanoparticles
(AuNPs) have been extensively investigated
without undesirable immune response or
off-target effects.515 To our knowledge, with
the exception of one report on AuNPs for
systemic administration of siRNA in humans,16
over the last 6 years, formulations using
AuNP-siRNA have solely been tested in cell
cultures targeting reporter genes, such as
luciferase or green fluorescence protein.17
However, as with any drug treatment, gene
therapy vehicles need extensive testing in
archetypal animal models before translation
into the clinics, and this requires the coordi-
nated effort of interdisciplinary research
groups.18
Here we used a functional comparative
approach to assist the smart design, synth-
esis, and testing of a library of multifunc-
tional nanodevices for RNAi, resulting in a
nanocarrier based on AuNPs as the delivery
system, with demonstrated functionality
both in vitro and in vivo for RNAi-based
therapy. Several biochemical moieties, cell
penetrating and cell adhesionpeptideswere
selected to enhance cellular recognition and
uptake and confer specific downregulation
of gene expression. The c-myc protoonco-
gene, a key gene playing a pivotal role in cell
cycle and tissue homeostasis,19 was selected
as RNAi target; poly(ethylene glycol) (PEG)
molecules were incorporated to guarantee
nanoparticle stability and avoid unspecific
interactions, and three in vitro/in vivomodel
systems were selected: human cells (HeLa),
freshwater polyps (Hydra vulgaris), and
* Address correspondence to
c.tortiglione@cib.na.cnr.it,
jmfuente@unizar.es.
Received for review July 6, 2012
and accepted August 12, 2012.
Published online
10.1021/nn3030223
ABSTRACT Over the past decade, the
capability of double-stranded RNAs to
interfere with gene expression has driven
new therapeutic approaches. Since small
interfering RNA (siRNAs, 21 base pair
double-stranded RNA) was shown to be
able to elicit RNA interference (RNAi),
efforts were directed toward the devel-
opment of efficient delivery systems to
preserve siRNA bioactivity throughout the
delivery route, from the administration
site to the target cell. Here we provide evidence of RNAi triggering, specifically silencing c-myc
protooncogene, via the synthesis of a library of novel multifunctional gold nanoparticles (AuNPs).
The efficiency of the AuNPs is demonstrated using a hierarchical approach including three
biological systems of increasing complexity: in vitro cultured human cells, in vivo invertebrate
(freshwater polyp, Hydra), and in vivo vertebrate (mouse) models. Our synthetic methodology
involved fine-tuning of multiple structural and functional moieties. Selection of the most active
functionalities was assisted step-by-step through functional testing that adopted this hierarchical
strategy. Merging these chemical and biological approaches led to a safe, nonpathogenic, self-
tracking, and universally valid nanocarrier that could be exploited for therapeutic RNAi.
KEYWORDS: gold nanoparticles . RNA interference . animal models .
biofunctionalization . c-myc . cancer
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mouse (C57BL/6j) (Figure 1). This chemical and biological
strategy allowed us to compare the effect of the siRNA
linkage to the NPs and the effect of cell penetration and
adhesion peptides, finally leading to an optimally de-
signed nanocarrier for RNAi therapeutic purposes.
RESULTS AND DISCUSSION
Stable AuNPswith an average diameter of 14( 1 nm
were synthesized by reduction of sodium tetra-
chloroaurate(III) hydrate with sodium citrate dehydrate
(Figure S1 of Supporting Information). To increase the
stability, biocompatibility, and grant chemical func-
tionality, AuNPs were functionalized with two types
of thiolated poly(ethylene glycol) (PEG) spacers: a com-
mercial carboxylated spacer, SH-EG(8)-(CH2)2-COOH,
and an azide-containing spacer custom synthesized
in our lab, SH-(CH2)3-CONH-EG(6)-(CH2)2-N3. The car-
boxylated spacer provides the anchoring moieties for
the covalent binding of amine-containing molecules
through carbodiimide chemistry, while the azide-
containing spacer confers positive Z-potential values,
which is a crucial factor for cell uptake. Combined
functionalization of the AuNPs with both spacers was
finely tuned by controlling both specific spacer com-
position and degree of saturation (Figure S2). In order
to elucidate the most efficient strategy to bond siRNA
to AuNPs, two types of AuNPs stabilized by different
degrees of PEG saturationwere selected: (i) NP-ionwith
100% coverage (25% azide-containing spacer and 75%
carboxylated spacer); (ii) NP-cov with 25% coverage
(50% of either spacer). These AuNP formulations re-
presented the basic nanoparticles for downstream
functionalization with c-myc siRNA, using either ionic
interaction (ION) or covalent binding (COV). Both were
initially tested for biocompatibility and toxicity in two
human cancer cell lines (MCF-7 and HeLa). Cell survival
rates following AuNP exposure were determined via
MTT, with no cytotoxicity detected up to 48 h of
incubation with either NP-ion or NP-cov (Figure S5).
Further functionalization of these nontoxic AuNPs with
c-myc siRNA and the HIV-derived TAT peptide was
performed.20 In the ION method, quaternary ammo-
nium groups (R4N
þ) were bound to AuNPs through
carbodiimide chemistry between the carboxylated
spacer and (2-aminoethyl)trimethylammonium hydro-
chloride. Ionic interactions between the negatively
charged siRNA backbone and both the azide and
quaternary ammonium positively charged groups en-
sured binding of siRNA onto the NP surface for the
whole pH range. In the COV method, thiolated
siRNA was bound via a thiol bond to AuNPs with a
nonsaturated PEG layer. The TAT peptide was bound
to NP-ion and NP-cov by EDC/NHS coupling between
the carboxylated spacer and the amine terminal
group of the KKKGRKKRRQRRR (KKK-TAT) peptide.
The binding efficiency of each functional group was
determined by Bradford assay, alongside detailed
Figure 1. In vivo gene silencing through nanoparticle-mediated RNAi. The nanocarrier is a AuNP functionalized withmultiple
biomolecules: PEG, cell penetration and cell adhesion peptides, and siRNA. Two different approaches were employed to
conjugate the siRNA to the AuNP: (1) covalent approach, use of thiolated siRNA for goldthiol binding to the nanoparticle;
(2) ionic approach, interactionof thenegatively charged siRNA to themodified surface of theAuNP through ionic interactions.
A hierarchical scheme employed three biological systems of increasing complexity: cultured cells (HeLa), freshwater polyp
(Hydra vulgaris), andmouse (C57BL/6j) to screen the synthesized nanocarrier library and select the ideal engineeredAuNP for
the delivery of siRNA to block gene function.
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AuNP assay characterization (Supporting Information).
All AuNP bioconjugates presenting at the surface
siRNA and/or TAT/RGD and/or quaternary ammonium
groups (R4N
þ) in various combinations were chara-
cterized by transmission electron microscopy (TEM),
UV/vis spectroscopy, surface plasmon resonance
(SPR) shift, and zeta-potential (see Figure 2). To deter-
mine cell uptake and intracellular fate, HeLa cells
were incubated with the functionalized AuNPs for
18 h and processed for TEM analysis. Results show
that both NP-ion and NP-cov conjugates were found
isolated or as small aggregates in the cytoplasm
(Figure 3b,c).
To permit rapid screening of the large variety of
functionalized AuNPs in terms of c-myc RNAi, the
c-myc gene sequence was cloned into a psiCHECK-2
vector downstream of the Renilla luciferase reporter
(Figure S4). This construct was stably expressed in HeLa
cells, and the decrease in luciferase activity, as conse-
quence of RNAi, was quantified by a luminescence
assay. Figure 3d shows normalized luciferase activity
of each AuNP conjugate, where both synthetic ap-
proaches used to bind siRNA onto the AuNP (ION
versus COV) show comparable silencing efficiency,
matching that attained via the transfection of naked
siRNA with lipofectamine. Control experiments utilized
Figure 2. Physicochemical characterization of AuNPs. TEM analysis of (a) NP-cov@myc-siRNA, (b) NP-cov@TAT@myc-siRNA,
(c) NP-ion@R4N
þ@myc-siRNA, (d) NP-ion@R4N
þ@TAT@myc-siRNA. The stabilization effect of the different functional groups
on the multifunctional AuNPs can be observed via examination of the optical properties by UVvis spectroscopy (e,f):
absorption band of the resulting AuNPs appeared at(520 nm due to the surface plasmon resonance (SPR) of the AuNPs. The
spatial arrangement of AuNP can be inferred bymeasuring the shift of a characteristic SPR band dependent from size, shape,
aggregation state, and medium polarity. The SPR of the AuNPs shown in e and f insets exhibited a red shift from 520 to
525 nm: a 3 nm shift for TAT/RGDpeptides binding and a 5 nm shift for siRNA binding indicating successful binding of several
groups. (g) Quantification of the PEG chains, TAT and RGD peptides, and siRNA strands is shown for all bioconjugates,
together with the Z-potential measurements.
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a nonrelated siRNA (cont-siRNA) that does not induce
downregulation of luciferase or c-myc. These results
clearly show the effective capability of the functiona-
lized AuNPs to specifically and selectively silence
c-myc gene expression. With regard to NP-ion design,
Figure 3d depicts the importance of including R4N
þ
moiety to introduce ionic interactions between the
positively charged NPs and the negatively charged
siRNA. Absence of R4N
þ did not induce any silencing,
suggesting a possible proton-sponge effect played
by the carboxylic and quaternary ammonium groups,
which could be responsible for endosome rupture
and release of the trapped materials (siRNA) into
the cytoplasm.21 Also, addition of the TAT peptide
branched on NP-ion@R4N
þ@myc-siRNA showed neg-
ligible effects when compared to the same NP with-
out TAT, probably due to steric hindrance of siRNA.
Concerning the NP-cov@myc-siRNA, their efficiency in
achieving RNAi might result from increased stability of
the siRNA covalently bound to the gold core compared
to their stability when adsorbed by electrostatic inter-
action on the NP surface. However, the possibility that
the strong efficiency of this adduct might depend
on cytoplasmic release of the siRNA (due to the redu-
cing environment of the cytoplasm acting on the thiol
bonds) and prompt availability to trigger the RNAi
machinery cannot be excluded. When branched on
NP-cov@myc-siRNA, the TAT peptide again decreased
the RNAi efficiency from 73 ( 11 to 43 ( 7%. These
data support the hypothesis that the TAT peptide may
act as a suppressor of the RNAi response, as previously
reported,22 which might be related to the fact that this
virally derived peptide has evolved to naturally bypass
cell defense mechanisms. In summary, despite the low
AuNP concentration used (2.1 nM AuNPs, 2 pM siRNA),
following confirmed cell uptake via TEM (Figure 3b,c),
it was able to trigger a very efficient RNAi, likely due to
the amplification of the siRNA signal in vivo, as else-
where reported.23
Prior to testing the efficiency of the multifunctional
nanocarrier for c-myc RNAi on an archetypal animal
model, we used a simpler and more singular inverte-
brate model, Hydra vulgaris (Cnidaria, Hydrozoa), to
allow for further fine-tuning of the nanocarrier. Thus,
following successful silencing in the cell model, the
efficiency of both NP-ion andNP-covwere evaluated in
the Hydra in vivomodel. The increase in complexity of
the animal model, in fact, could enable us to select the
more appropriate nanocarrier to test inmouse.Hydra is
a freshwater polyp whose structural anatomy reflects
a tissue grade of organization (body composed of two
cell layers; absence of either proper organs, or central
Figure 3. Internalization and efficiency of c-myc RNAi induced by functionalized AuNP in HeLa cells. (a) Renilla luciferase was
used as the primary reporter gene, and the c-myc gene was cloned into a multiple cloning region located downstream of the
Renilla gene. Initiation of the RNAi process by synthetic myc-siRNAs results in cleavage and subsequent degradation of the
fusion mRNA. Measuring decreases in Renilla activity provides a convenient way of monitoring the RNAi effect. This vector
also contains a second reporter gene, Firefly luciferase, which functions as an internal control for reporter gene activity
(scheme adapted from Promega psiCHECK vectors). (b,c) TEM images of cells treated with NP-cov@myc-siRNA (b) and NP-
ion@myc-siRNA (c) show NPs present in the cytoplasm as single units, supporting the correct delivery of siRNA to initiate
RNAi. (d) Quantitative assessment of RNAi efficiency. HeLa cells were transfected with the recombinant vector psiCHECK-2,
encoding for the fusion protein Renilla luciferase-myc. Decrease of Renilla luciferase activity induced by c-myc-siRNA was
expressed as percentage of normal luciferase activity. Unrelated siRNA (cont-siRNA) bound on the AuNPs; naked or
lipofectamine delivered siRNA were included as negative and positive RNAi controls, respectively. Data marked with
asterisks are statistically significant relative to the corresponding NP-ion/cov with control siRNA as calculated by paired
Sample t test (**, P e 0.0001; *, P e 0.001).
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nervous system), but exhibiting behavior and physiol-
ogy proper of animals (Figure 4a and Figure S6 of
Supporting Information). Reliable methods have been
developed for a comprehensive analysis of nanoparti-
cle impact in Hydra, spanning from in vivo analysis
induced by nanoparticle treatments (structural mor-
phological changes, impact on reproductive rate, effi-
ciency of regeneration) to in vitro approaches of cell
biology, microscopy, and molecular biology to investi-
gate the internalization routes and the genotoxic
effects.24,25
Moreover, the Hydra c-myc (Hymyc) homologue
gene function has been recently identified,26,27 allow-
ing to functionally test the RNAi efficiency. NP-ion
and NP-cov were initially tested for biocompatibility
and toxicity by measuring the impact on population
growth rate,25 showing the absence of toxic effects
(Figure S7). Optical microscopy showed that both
NP-ion and NP-cov were internalized at low rate by
ectodermal cells, facing the animal outer plane
(Figure 4b and Figure S3), and TEM analysis was
necessary for subcellular localization of AuNPs. In
Figure 4c, TEM images on thin sections from animals
incubated 30minwithNP-cov@myc-siRNA shownano-
particles bound to the membrane glycocalix, as
single units or small clusters passing through the
bilayer structure of the cell membrane. After 24 h of
incubation, AuNPs were found in the cytoplasm, clus-
tered or monodispersed, demonstrating their capabil-
ity to cross biological membranes and shuttle siRNA
into the cytoplasm (Figure 4d). Hymyc silencing effi-
ciency was assessed using the AuNPs recommended
following HeLa silencing (NP-ion@R4N
þ@myc-siRNA,
NP-ion@R4N
þ@TAT@myc-siRNA, NP-cov@TAT@myc-
siRNA, NP-cov@myc-siRNA). The qRT-PCR results in
Hydra further restricted the selection of bioactive AuNP
conjugates previously identified in HeLa cells: only two
of those nanoparticles induced Hymyc gene silencing,
NP-ion@R4N
þ@myc-siRNA and NP-cov@myc-siRNA,
which rise up to 80% of gene downregulation in the
case of the covalent conjugate (Figure 4e). TAT peptide
(initially employed to enhance the cell permeability),
but causing a decrease in the RNAi efficiency of the
NP-cov conjugates in HeLa cells, completely inhibited
Figure 4. Hymyc RNAi in Hydra vulgaris. (a) Representative images of living polyps of Hydra vulgaris (scale bar 0.5 mm).
(b) Bright-field image of Hydra treated 24 h with NP-cov@myc-siRNA (scale bar 200 μm). Nanoparticles appear as dark spots
on the Hydra ectodermal cells. Same uptake was observed for NP-ion@myc-siRNA (Supporting Information Figure S3). (c,d)
TEM images of Hydra tissues, prepared from polyps treated with 15 nM of NP-cov@myc-siRNA for 30min (c) and 24 h (d). NPs
are detected as single unit or small clusters into the cytoplasm for correct delivery of siRNA. Scale bar: 0.2 μm (c) and 0.5 μm
(d). (e) Molecular assessment of RNAi efficiency by qRT-PCR using 15 nM AuNPs and 25 polyps in 100 μL of Hydra medium.
Hymyc relative expression upon incubation with NP-ion and NP-covwas compared to naked siRNA. Relative gene expression
changes fromNPs not carrying c-myc siRNA are shown as gray bars, while those induced by Hymyc siRNA functionalized NPs
are colored red. Data aremeans of three independent experiments from three biological replicates; error bars show standard
deviation. Data marked with asterisk are statistically significant relative to the corresponding NP-ion/cov without siRNA as
calculated by paired sample t test (*, P e 0.005).
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the RNAi process in Hydra, further suggesting that TAT
RNAi suppressor activitymay be conserved throughout
the animal kingdom.22 Those AuNPs unable to induce
gene silencing in cells were also ineffective in Hydra,
confirmed by analysis of gene expression (Figure 4e).
Finally, the two AuNPs identified as inducing c-myc
silencing in both HeLa and Hydra, NP-ion@R4N
þ@myc-
siRNA and NP-cov@myc-siRNA, were tested in the
more complex in vivo mouse model. Both AuNPs
were administered to 1012 week aged female mice
(n = 68 animals) by intratracheal instillation. While
intravenous administration is themostpopular choice in
clinical studies, an oral route inhalation or intratracheal
instillation mode, together with intranasal drug deliv-
ery, convection-enhanced diffusion, and intrathecal/
intraventricular drug delivery systems has been gain-
ing considerable attention. Intratracheal instillation
of nanoparticles becomes an important criterion of
consideration to overcome the physiological barriers
of the lung and to achieve locally high drug concentra-
tions for pulmonary diseases. In our case, the choice
was also dictated by the siRNA loaded on the AuNP,
targeting the c-myc gene. As this oncogene is deregu-
lated in lung cancer, in a future study of lung cancer
treatment, this administrationmodemight allow prop-
er deliver of therapeutic siRNA to the target organ.
After 7 days from instillation, mice were dissected
for bronchoalveolar lavage (BAL cells) and lung
tissue extraction. In general, NPs of size <100 nm and
different zeta-potential display toxic effects, due to
trade-off between drug potency and immunologic
surveillance.28,29 In fact, the influence of size, solubility,
and surface modification on the biocompatibility of
nanoparticles and their use in biological applications is
well-known. NPs have a proclivity in vivo and in vitro to
bioaccumulate within various types of cells with a
special affinity for macrophage-type cells and reticu-
loendothelial cells throughout the body. In order to
select safe material for drug delivery, toxicity studies of
both NP-cov and NP-ion sets were performed in mice
following 1, 3, and 14 days of treatment by the evalua-
tion of the number of macrophages, neutrophils,
and lymphocytes, in which an increase indicates an
inflammation process. Results showed negligible ad-
verse effects using a low instillation dose (16 nM)
(Supporting Information, Figure S8). However, the
qRT-PCR performed on four lung samples of each
groups, instilled with this dose of NPs, showed very
low gene downregulation (Figure 5c), probably due to
a lack of NPs' selectivity to the target cells. The func-
tional studies performed in in vitro cell culture and in
living Hydra provided feedback for improving the de-
sign and synthesis of AuNPs@siRNA targeting mouse.
To this aim, the cell adhesion peptide RGD was incor-
porated on the AuNP to reinforce cellNP interaction
and drive lung-specific uptake. RGD integrin ligand is
well-known for its capability to bind to the integrin
Rvβ3 receptor family,30 involved in a wide range of
cellextracellular matrix and cellcell interactions. Pre-
vious studies have demonstrated RGD efficiency to
promote NPcell adhesion events.31 RGD-containing
peptides were conjugated to both NP-ion and NP-cov,
Figure 5. c-myc RNAi inmouse. (a,b) TEM images of lung epithelial cells. Mice (C57BL/6j strain)were treatedwith 16 nMof NP-
cov@RGD@myc-siRNA by intratracheal instillation. At 4 h (a) after instillation, NPs are located in ruffles of lung epithelial cell
membranes and a fewNPs are in the vesicles. At 18 h (b), huge amounts of NPs are found in vesicles or free in cytoplasm (scale
bars 500 nm). (c) Molecular assessment of RNAi efficiency. To quantify efficiency of silencing, total RNAs from lung tissue (four
mice treated with each NP type) were extracted after 48 h and analyzed by qRT-PCR. The c-myc expression levels were
determined using β-actin as reference gene. Data marked with asterisks are statistically significant relative to the
corresponding NP-ion/cov without siRNA as calculated by paired sample t test (*, Pe 0.001; **, Pe 0.01). (d,e) c-myc protein
expression on alveolar epithelial cells in lung tissue after 48 h treatment. (d)Mice instillatedwith 16 nMNP-cov@RGD, (e)mice
instillated with 16 nM NP-cov@RGD@myc-siRNA. The c-myc protein was detected by Alexa-488-conjugated anti-c-myc
antibody (green), and cell nuclei were DAPI stained (blue). Scale bars 200 μm.
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in the presence or absence of c-myc siRNA, by EDC/
NHS coupling between the carboxylated spacer and
the primary amine in the RGD peptide (Supporting
Information). Mice were treated as previously indi-
cated. TEM analysis on lung epithelial cells revealed
the efficient uptake of NPs conjugated with RGD
with sufficient cytoplasmic availability (Figure 5a,b) to
initiate RNAi. The qRT-PCR results showed a 65.2 (
6.7% c-mycdownregulation inducedbyNP-cov@RGD@
myc-siRNA and 34.9 ( 19% c-myc silencing by NP-
ion@R4N
þ@RGD@myc-siRNA. These results confirm the
specificity of the RNAi approach. Immunolocalization of
the MYC protein on alveolar epithelial cells in lung
tissue from mice treated with NP-cov@RGD@myc-siR-
NA confirmed decreased MYC protein accumulation in
lung tissue, unequivocally demonstrating the bioactiv-
ity of the multifunctional NP (Figure 5d,e).
Remarkably, the same NP-cov@siRNA adduct was
shown to elicit highest RNAi in HeLa cells, Hydra
vulgaris, and mouse, with the only exception of the
RGD presence when testing on mouse, as it is not
expressed in Hydra. From an evolutionary point of
view, having found that gene silencing in this primitive
animal is accomplished by the same nanocarrier work-
ing on human cell cultures and mouse, underlines not
only the conservation of key molecular pathways
throughout animal evolution but also the conservation
of the basic chemicophysical interactions between
nanoparticle and the living world, Hydra bridging the
gap between cell cultures and complex models.
CONCLUSION
In this study, we show that two balanced formula-
tions (ionic and covalent approaches), in terms of
stability/electrostatic interactions, designed to pro-
duce smart multifunctional nanostructures succeeded
to generate new innovative and versatile tools for
efficient RNA interference in eukaryotic systems. Using
three biological models of increasing complexity
(cultured cells, invertebrate, and mammal), both de-
sign and validation of multifunctional nanocarriers
capable of selectively and specifically delivering siRNA
in vivo were demonstrated. This functional screening
approach allowed us to finely tune concentrations,
bonding, and the combination of different chemical
groups on the nanoparticle surface, addressing current
ethical issues on unnecessary, cost-effective, and time-
consuming vertebrate testing. These multifunctional
nanocarriers are robust enough to preserve stability
without showing acute toxicity or cell viability impair-
ment while simultaneously able to bypass biological
barriers to perform RNAi activity without off-target
effects. Our universal nanocarrier represents a valid
gene delivery platform that can be exploited for clinical
application in the near future. While treatment of a
lung cancer mouse model might represent the first
therapeutic test of the nanocarrier developed here, the
simple change of the siRNA sequence might target the
same device to a huge range of diseases, strengthen-
ing the way to clinical application of RNAi.
METHODS
We divided the methods into similar parts for each system
(except for the synthesis). Full description of methods can be
found in Supporting Information.
Synthesis and Functionalization of Gold Nanoparticles. AuNPswith a
diameter of 14( 1 nmwere synthesized by the citrate reduction
method described by Lee and Meisel.32 A mixture of AuNPs,
0.028% SDS, and SH-EG(8)-(CH2)2-COOH (Iris-Biotech) and
SH-(CH2)3-CONH-EG(6)-(CH2)2-N3 in the adequate ratio for NP-
ion and NP-cov was mixed under basic conditions for 16 h.
PEGylated AuNPs were obtained after purification by centrifuga-
tion. Number of PEG molecules was carried out by Ellman's
method. Further chemical functionalization with quaternary
ammonium ((2-aminoethyl)trimethylammonium chloride hy-
drochloride), TAT, and RGD peptides was carried out by EDC
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (Sigma) and
sulfo-NHS (sulfo-hydroxysuccinimide) (Sigma) chemistry at pH
6.1 (25mMMES). Quantificationof TATpeptideswasobtainedby
Bradford assay (CA). AuNP functionalization with siRNA (Thermo
Scientific Dharmacon) was taking place using unmodified siRNA
for NP-ion by mixing them with NP-ion@R4N
þ@TAT during 16 h
at 4 C. For NP-cov, thiolated siRNA was incubated with NP-
cov@TAT containing 0.028% SDS and 0.1 M NaCl. Excess siRNA
was removed by centrifugation at 4 C. siRNA quantification was
carried out by fluorescence measurement (Perkin-Elmer LS55)
using a GelRed (Biotium) acid nucleic intercalator (see Support-
ing Information, Table 1, for siRNA sequences).
Hydra Culturing. Hydra vulgaris (strain Zurich, originally ob-
tained by P. Tardent) were asexually cultured in Hydra medium
(1 mM CaCl2, 0.1 mM NaHCO3, pH 7). The animals were kept at
18 ( 1 C and fed three times per week with freshly hatched
Artemia salina nauplii. In vivo imaging was accomplished at
several magnifications by using both a stereomicroscope and
an inverted microscope (Axiovert 100, Zeiss).
Transmission Electron Microscopy. To visualize the cellular up-
take of NPs, HeLa cells were incubatedwith all NPs for 18 h. Mice
were treated with NPs for 4 and 18 h. Mice were sacrificed and
mice lungs fixed in 2.5% glutaraldehyde for TEM. For Hydra,
polyps were treated with 2% urethane in Hydra medium and
then fixed for 2 h in 2% glutaraldehyde in Hydra medium.
Samples were postfixed in 1% buffered OsO4 followed by 0.5%
uranyl acetate for 1 h and then taken through alcohol dehydra-
tion increments and left in resin (propylene oxide Epon 812
resin mix (1:1) for cells and propylene oxide/Epon 12 resin mix
(1:1) forHydra) overnight. Cell layers were captured in pure resin
and cured overnight in an oven. Hydra were incubated 2  2 h
in Epon 12 resin. Blocks were then cut into ultrathin sections,
stained with 2% methanolic uranyl acetate and Reynolds lead
citrate, and viewed under a Leo 912 AB TEM (120 kV for cells and
80 kV for Hydra).
Toxicity. Cellular cytotoxicity was assessed by standard MTT
assay (Invitrogen). Hydra growth rate was calculated to monitor
NP toxicity, as previously described.25 Toxicity in mice was
assessed by enumeration of total differential cells in bronch-
oalveolar lavage cells. Several nanomaterials studied in the size
range from ca. 5 to 20 nm (TiO2, Fe, Cu, Ag) induced higher
neutrophil recruitment in BAL fluid, compared to control.33 Low
amounts of neutrophiles and lymphocytes indicate minimal
inflammatory response or toxicity.
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Assessment of RNAi in HeLa Cells. c-myc RNAi was evaluated by
using the psiCHECK Vector system (Promega), which allows one
to monitor change in expression of a reporter gene (Luciferase)
fused to a target gene. MYC-Luciferase vector construction:
the whole human v-myc myelocytomatosis viral oncogene
homologue (c-myc) gene was PCR amplified from cDNA retro-
transcribed from HeLa cells total RNA (see Supporting
Information) and the resulting product cloned in frame with
Luciferase reporter gene contained into the vector psiCHECK-2,
and maintained in Escherichia coli DH5R strains. Cell culture:
HeLa cells were grown in Dulbecco's modified Eagle's medium
(DMEM, Lonza) with 10% heat inactivated fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL strepto-
mycin and maintained at 37 C in 5% CO2. Cells were seeded
at a density of 5  103 cells/well in 96-well plates and grown
for 1 day prior to transfection of the MYC-Luciferase vector
(0.125 μg per well) using Lipofectamine 2000 (Invitrogen) and
Opti-MEM reduced serum medium (Invitrogen) according to
the manufacturer's recommendations. RNAi efficiency of differ-
ent NP conjugates (2.1 nM AuNPs, 2 nM siRNA) was tested by
treating the cells for 48 h and by quantification of luciferase
expression using a dual-luciferase reporter assay (Promega)
assay according to the manufacturer's protocols. Data are
average ((SD) of three experiments.
RNAi Experiments in Hydra. Groups of 10 animals, collected in
plastic multiwells, were incubated in 100 μL of Hydramedium in
the presence of AuNPs (15 nM), and the treatment was renewed
after 24 h to account for possible siRNA degradation. At 48 h,
animals were washed and processed for RNA extraction and
qRT-PCR. Animals interfered by naked siRNA, nonfunctionalized
NP, or untreated were used as controls. Briefly, total RNAs were
purified using Trizol (Invitrogen), retrotranscribed using Super-
Script II retrotranscriptase (Invitrogen), and used for qRT-PCR
analysis (see Supporting Information for detailed methods and
primers employed).
RNAi Experiments in Mouse. C57BL/6J mice were anesthetised
by intraperitoneal injection of a mixture of Medetomidin
(0.5 mg/kg body mass), Midazolam (5.0 mg/kg body mass),
and Fentanyl (0.05 mg/kg body mass). The animals were then
intubated by a nonsurgical technique. Using a cannula inserted
10mm into the trachea, a suspension containing 16 nMAuNP in
50 μL of pyrogene-free distilled water was instilled, followed by
100 μL of air. After instillation, animals were antagonized by
subcutaneous injection of a mixture of Atipamezol (2.5 mg/kg
body mass), Flumazenil (0.5 mg/kg body mass), and Naloxon
(1.2 mg/kg body mass) to guarantee their awakening and well-
being. Animals were treated humanely and with regard for
alleviation of suffering; experimental protocols were reviewed
and approved by the Bavarian Animal Research Authority.
Preparation of BAL Cells/Fluid. BAL fluid was obtained by inject-
ing and recovering of two 0.5 mL aliquots of PBS via a tracheal
cannula. Cells in the lavage fluids were counted using a hemo-
cytometer, and the differentials were determined by utilizing
light microscopy to count 200 cells on cytospin preparations.
Molecular Analyses of Gene Expression in Mouse. Immunolocaliza-
tion: Lung tissues were sliced and blocked by adding 1% BSA in
PBS for 30min.Mouse anti-c-myc (Molecular Probes) was added
(dilution 1:1000) for 1 h, washed in PBS with agitation for 5 min
three times, and incubated with goat anti-mouse IgG coupled
with Alexa-488 (Molecular Probes) at 2 μg/mL for 30min. Nuclei
were DAPI stained before slide mounting with 50 μL of fluor-
mount mounting medium. Total RNAs were extracted from
mouse lungs, retrotranscribed, and analyzed by qRT-PCR (see
Supporting Information for detailed methods and primers
employed).
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S1: Synthesis, physicochemical characterisation and functionalisation of AuNPs 
Synthesis of citrate-gold nanoparticles  
Gold nanoparticles with an average diameter of ~14 nm were synthesised by the citrate reduction method 
described by Lee and Meisel
1
. Briefly, hydrogen tetrachloroaureate (III) hydrate (Strem Chemicals) (0.2 g; 
0.589 mmol) was solved in 500 ml of distilled water, heated and stirred under reflux. When the solution boils, 
sodium citrate dihydrate (0.57 g; 1.94 mmol) was added resulting in a red solution. The solution is kept under 
ebullition and protected from light for 30 min, whereby it is cooled down and kept protected from light.  
Synthesis of PEG heterofunctional surfaces in citrate-gold nanoparticles 
Two types of NPs with distinct surfaces were prepared 1) 100% saturated PEG layer (NP-ion) functionalised 
with 75% carboxylic groups (SH-EG(8)-(CH2)2-COOH) and 25% of azide groups (SH-(CH2)3-CONH-EG(6)-
(CH2)2-N3); 2) 25% saturated PEG layer (NP-cov) functionalised with 50% carboxylic groups (SH-EG(8)-
(CH2)2-COOH) and 50% of azide groups (SH-(CH2)3-CONH-EG(6)-(CH2)2-N3). This PEG saturation allows 
the incorporation of further thiolated components, such as the SH-siRNA.  
Briefly, a mixture of 10 nM of the citrate-gold nanoparticles, 0.028 % SDS and 39 µM SH-EG(8)-(CH2)2-
COOH (Iris-Biotech) and 13 µM SH-(CH2)3-CONH-EG(6)-(CH2)2-N3 for NP-ion and 7 µM SH-EG(8)-
(CH2)2-COOH (Iris-Biotech) and 7 µM SH-(CH2)3-CONH-EG(6)-(CH2)2-N3 for NP-cov were prepared. 
NaOH was further added to a final concentration of 25 mM and the mixture was incubated for 16 hr at room 
temperature. The excess PEG chains were removed by centrifugation at 14.000 rpm for 30 min at 4°C and the 
supernatant was discarded. This washing process was repeated three times and the pellet with AuNPs was 
dissolved in pure water.  
AuNP functionalisation with TAT peptides and Quaternary Ammonium groups by EDC/NHS coupling 
reactions 
For NP-ion AuNPs 26 nM were incubated in 13 mM sulfo-NHS and 50 mM MES (2-(N-
morpholino)ethanesulfonic acid) buffer pH 6.1. Then, 38 mM of (2-aminoethyl)trimethylammonium chloride 
hydrochloride (R4N
+) were added to the mixture, EDC (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide) 
was added at a final concentration of 3 mM and the mixture incubated for 20 min. TAT peptide (H-KKK-
GRKKRRQRRR-OH) was added at a final concentration of 1 µM. For NP-cov AuNPs 20 nM were incubated 
233
3 
 
in 6 mM sulfo-NHS and 25 mM MES buffer pH 6.1. Then TAT peptide was added to a final concentration of 
0.5 µM followed by 0.8 mM of EDC. In both approaches, the mixture was incubated at room temperature for 
16 hr, at which point the AuNP were centrifuged at 14000 rpm for 30 min at 4ºC to remove excess TAT 
peptide and the supernatants were recovered and tested for protein concentration by the Bradford assay 
(BioRad, CA). 
 
AuNP functionalisation with RGD peptides. 
The Arginine-Glycine-Aspartic Acid (G-RGD-S)-Peptide (Sigma, MW 490.47 Da) functionalisation was done 
in the same step as for the TAT and R4N
+
.
 
 Briefly, all the reagents were used in the same conditions 
previously described and the RGD was added at a final concentration of 0.5 µM for NP-cov and 2 µM for NP-
ion. The mixture was incubated at room temperature for 16 hr. Then the AuNPs were centrifuged at 14000 
rpm for 30 min at 4ºC to remove excess RGD peptide and the supernatants were recovered and tested for 
protein concentration using a BCA Protein Assay Kit (Thermo Scientific). 
 
Characterisation of citrate-gold nanoparticles 
AuNPs were characterised by different techniques (Figure S1). The high monodispersity of the gold core was 
confirmed by Transmission Electron Microscopy (TEM, T20 200KeV; FEI) showing an average size of 14 
nm. Infrared spectra (FTIR, JASCO FT/IR 4100) confirmed the presence of the citrate groups covering the 
gold cores. The UV-Vis molecular absorption spectra of the AuNPs show the characteristic surface plasmon 
resonant peak at 519 nm. They present at pH 7 with a negative Z-potential value of -12.32 mV. 
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Figure S1. Characterisation of citrate-AuNPs A) Infrared spectra, peaks appear at 3422.06 cm-1,  
2957.30 cm
-1
, 2925.48 cm
-1
, 2854.13 cm
-1
, 1584.23 cm
-1
, 1400.07 cm
-1
, 1253.50 cm
-1
, 1080.90 cm
-1
; B) UV-
Vis molecular absorption spectra (Absorbance peak at 520 nm) C) Transmission Electron Microscopy, scale 
bar 100 nm. 
 
Synthesis of N-(20-azido-3,6,9,12,15,18-hexaoxoicosane)-4-mercaptobutanamide (HS-(CH2)3-CONH-
EG(6)-(CH2)2-N3)  
For the synthesis, 0.6 mmoles of α-Amine-ω-azido hepta(ethylene glycol) were added to 12.5 mL of 
dimethylsulfoxide under argon atmosphere in a poly(ethylene glycol) bath at 50
°
C and under continuous 
stirring. Subsequently, 0.63 mmol of γ-tiobutirolactone and 5.7 mmol of triethylamine were added. After 5 hr, 
the mixture was cooled down and lyophilised obtaining a yellow oil. The yield of the reaction was  
93%, without any further purification step. The product was characterised by: FT-IR: 3301 cm-1 (NH st), 2870 
cm-1 (-CH st), 2530 cm-1 (SH st), 2106 cm-1 (N3 st), 1663 cm
-1 (C=O st); 1H-RMN 300 MHz (δ): 2,00 (m, 2H); 
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2,25 (t, 2H, J=7,30 Hz); 2,65 (t, 2H, J=7,00 Hz); 3,01 (s, 1H, SH); 3,32 (t, 4H, J = 5,00 Hz); 3,37 (t, 2H, J = 
5,22 Hz); 3,59 (s, 22H); 6,60 (t, 1H, J = 4,76 Hz) and mass spectroscopy [M-H+] 451.1. 
 
Quantification of SH-EG(8)-(CH2)2-COOH bound to AuNPs 
To estimate the degree of saturation of AuNPs functionalised with thiolated PEG chains (SH-EG(8)-(CH2)2-
COOH)  we developed and optimised a procedure based on the Ellman’s assay. In this assay, the supernatant, 
containing the spacer with thiol groups on its structure, reacts with 5,5’-dithio-bis(2-nitrobenzoic) acid 
(DTNB) to give a coloured product that can be measured by spectrometry. With this procedure it is possible to 
determine the number of thiolated chains that have bound to the AuNP. After the incubation of the AuNP with 
the thiolated chains, the suspension was centrifuged at 14000 rpm for 30 min at 4oC and the supernatant 
retained for quantification assay: 400 µL of either the stock solution of PEG-COOH or the supernatant are 
mixed with 100 µL of TRIS buffer 1M pH 8 and 50 µL of DTNB 2 mM in sodium acetate (NaAc) buffer 50 
mM. After 10 min of incubation the absorbance at 412 nm is measured. The linear range for the PEG-COOH 
chain obtained by this method is 1-100 µM (Abs412 = 0.006·[PEG-COOH, µM] + 0.1764)). The number of 
exchanged chains is given by the difference between the amount determined by this assay and the initial 
amount of chains in the incubation mixture with the NPs. 
 
Quantification of SH-(CH2)3-CONH-EG(6)-(CH2)2-N3 bound to AuNPs 
At the end of SH-(CH2)3-CONH-EG(6)-(CH2)2-N3 synthesis, the compound was obtained as a disulphide (N3-
(CH2)2-EG(6)-NHCO-(CH2)3-S-S-(CH2)3-CONH-EG(6)-(CH2)2-N3). In order to determine the number of 
azide-containing chains bound to the AuNPs by the Ellman’s assay, a reduction step of the disulphide 
compound was necessary. One of the simplest methods to reduce disulphide groups is the use of sodium 
borohydride (NaBH4) under anaerobic conditions. This common reducing agent is able to specifically reduce 
disulphides to free thiols without affecting any of the other major functional groups and without any 
secondary reactions with Ellman’s reagent. Briefly, the sample containing the disulphide was dissolved in 
phosphate buffer 0.05M pH 8. Sodium borohydride was added at final concentration of 0.12M and incubated 
90 min. The pH of the reaction was acidified using HCl 3M:Acetone (1:1) (v/v) and incubated 10 min to 
guarantee the complete elimination of excess borohydride. NaOH 3M was added in order to neutralize the 
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reaction. The neutralised solution was buffered at pH 7 with phosphate buffer 0.2M and immediately analysed 
by the Ellman’s assay to prevent re-oxidation of the thiols to disulphides. The linear range was 0.022-2.2 mM 
(Abs412 = 0.5 [PEG-N3, nM] + 0.1215).  
As the sensitivity of this method was shown low for the quantification of PEG-N3 bound to AuNPs an indirect 
method using a second addition of PEG-COOH (see below) was employed, while  the presence of PEG-N3 
chain on the AuNPs was confirmed by FTIR (2106 cm
-1
, N3 st). 
The PEG chains loaded on the AuNPs were quantified by using the PEG-COOH chain as a model. PEG-
COOH was added to AuNPs until a complete saturation (0.1 mM of thiolated chain per 10 nM of gold 
nanoparticles). AuNPs were functionalised with a controlled amount of thiolated chains in order to obtain NPs 
with different degrees of saturation – Figure S2A (increasing amount of PEG-N3 at a constant PEG-COOH 
chains bound to AuNPs) and Figure S2B (increasing amount of PEG-COOH at a constant PEG-N3 chains 
bound to AuNPs). After this, a fixed amount of a PEG-COOH chain was added and incubated with the 
AuNPs. The concentration of thiolated chains bound to non-saturated AuNPs was determined by the Ellman’s 
assay. As illustrated in Figure S2A-B, when the initial percentage of saturation of the thiolated layer decreases 
the AuNPs are able to bind a higher amount of thiolated chains further added. The best condition to bind 
further thiolated molecules was to work with AuNPs with a degree of saturation below 47%, but higher than 
20% to guarantee stability, corresponding to a range from 37 µM to 11 µM of total PEG chains per 10 nM
 
of 
gold (see Figure S2C). This model was used to determine the optimum degree of saturation of AuNPs for the 
loading of thiolated siRNA by the covalent approach. 
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Figure S2. Quantification of degree of saturation for the PEG chains. A) Increasing amount of PEG-N3 at a 
constant PEG-COOH chains bound to AuNPs. B) Increasing amount of PEG-COOH at a constant PEG-N3 
chains bound to AuNPs. C) Optimum degree of saturation of AuNPs for the entrance of a third thiolated 
chain. 
 
Determination of the bound TAT peptide by the EDC coupling reaction to functionalised AuNPs 
As was stated in the methods section, a procedure for the determination of the bound TAT peptide was 
developed based on Bradford method. Given that the reagents for the EDC reaction (sulfo-NHS, EDC) 
interfere with the assay a standard addition calibration curve for the TAT peptide in the EDC reaction 
conditions was obtained (Abs570 = 0.1265 [TAT peptide, µM] + 0.24). This calibration curve was used for 
the interpolation of the samples containing the excess peptide that was not bound to AuNPs.  
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Quantification of the RGD peptide 
The RGD quantification was achieved using the BCA Protein Assay (Thermo Scientific) according to 
manufactures’ instructions. This assay is a detergent-compatible formulation based on bicinchoninic acid 
(BCA) for the colorimetric detection and quantification of total protein. This method combines the well-
known reduction of Cu
+2
 to Cu
+1
 by protein in an alkaline medium (the biuret reaction) with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu+1) using a unique reagent containing 
bicinchoninic acid. The purple-colored reaction product of this assay is formed by the chelation of two 
molecules of BCA with one cuprous ion. This water-soluble complex exhibits a strong absorbance at 562 nm 
in a near linear relationship with increasing protein concentrations. Briefly, 0.1 mL of each standard and 
unknown sample (the supernatants) was mixed with 2.0 mL of the BCA™ Working Reagent to each tube. The 
reaction mixture was incubated at 60°C for 2 hr. After this period the tubes were cooled down to room 
temperature and the absorbance measured at 562 nm. The standard curve was used to determine the RGD 
concentration of each unknown sample (supernatant). The calibration curve for a working range (0−18 µg/ml) 
is given by the following equation Abs562nm = -0.0001x2 + 0.0081x + 0.0017. 
 
 
 
Quantification of the siRNA strands loaded onto AuNPs 
In order to carry out the siRNA duplexes quantification, we used the GelRed™ (Biotium) dye as a nucleic 
acid intercalator. An analytical method to quantify the amount of siRNA in excess during the functionalisation 
was developed. Briefly, the supernatants were incubated with GelRed 100× and TBE 0.5× and fluorescence 
was measured with emission at 602 nm. A Correlation to a standard curve of known siRNA concentrations 
allowed accurate measurement of siRNA in unknown samples (Emission at 602nm = 439.96·[siRNA, nmol] + 
32.697). 
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siRNAs used for NP functionalisation 
Thiolated siRNA (Thermo Scientific Dharmacon) was dissolved in 1 ml of 0.1 M DTT, extracted three times 
with ethyl acetate, and further purified through a desalting NAP-5 column (Pharmacia Biotech) according to 
the manufacturer’s instructions. The unmodified siRNA used for the ionic approach was only resuspended in 
DEPC-water. The sequences of human, mouse and hydra c-myc siRNAs (Thermo Scientific, Dharmacon) are 
depicted in table 1.  
c-myc 
siRNA 
siRNA sequence 
Human 
Sense: 5’-Thiol-GCGAGGAUAUCUGGAAGAAAUUU-3’ 
Antisense: 5’-AUUUCUUCCAGAUAUCCUCGCUU-3’ 
Mouse 
Sense: 5’-Thiol-GUGAGGAUAUCUGGAAGAAAUUU-3’ 
Antisense: 5’-AUUUCUUCCAGAUAUCCUCACUU-3’ 
Hydra 
Sense: 5’-Thiol-AAGAUGCUCACGCGUCAAGAAUU-3’ 
Antisense: 5’-UUCUUGACGCGUGAGCAUCUU-3’ 
Nonsense 
control 
Sense: 5’-Thiol-AAUUCUCCGAACGUGUCACGUUU-3’ 
Antisense: 5’- ACGUGACACGUUCGGAGAAUUUU -3’ 
 
Table 1. The siRNA sequences designed on human, mouse and hydra c-myc genes.   
 
For NP-ion, the unmodified siRNAs, at a constant concentration of 5 nmol/mL, were incubated with RNase-
free solution of the NP-ion@R4N
+@TAT (10 nM) for 16 hr at 4ºC. With regards non-saturated AuNPs, the 
purified SH-siRNAs, at a constant concentration of 5 nmol/mL, were incubated with RNase-free solution of 
the NP-ion@TAT (10 nM) containing 0.028 % SDS. Subsequently, the salt concentration was increased to 
0.1M NaCl with brief ultrasonication following each addition to increase the coverage of oligonucleotides on 
the nanoparticle surface. 
Following 16 hr incubation at 4ºC, the particles were purified by centrifugation at 14000 rpm, 20 min at 4°C, 
and re-suspended in DEPC-water. This process was repeated 3 times.  
The number of siRNA per gold nanoparticle was determined by using an acid nucleic intercalator – GelRed. 
Briefly, the supernatants were incubated with GelRed 100× and TBE 0.5× and fluorescence was measured 
using a fluorometer Perkin Elmer LS55 with emission at 602 nm and compared to a standard curve.  
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S2: Internalisation of AuNPs conjugates 
 
Uptake of AuNP by living Hydra polyps 
Polyps were incubated for 24 h with NP-ion and NP-cov and their corresponding siRNA functionalised NP, at 
15 nM, and the uptake of AuNP monitored by optical microscopy.  
 
Figure S3. AuNP uptake in Hydra vulgaris.  
In vivo imaging of Hydra vulgaris treated with NP-ion@myc-siRNA. Low level of uptake was observed with 
both NP-cov@myc-siRNA and NP-ion@myc-siRNA. The image (a) shows NP-ion@myc-siRNA as small 
violet vesicle-like structures present over the tentacles (b) and the body. This lower rate of internalisation 
compared to AuNPs coated with 100% PEG azide (data not shown) is due to the siRNA functionalisation, 
which causes a decrease of the Zeta Potential value. Scale bars: A, 200 µm; B, 100 µm. 
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S3: Evaluation of RNAi efficiency by functional reporter gene assay 
 
1. MYC-Luciferase vector construction 
Total RNA extracted from HeLa cells was subjected to Reverse Transcriptase (RT) for cDNA synthesis.  
Isolation of total RNA was performed using Trisure (Bioline) according to the manufacturer’s protocol. The 
total RNA was subjected to DNase I digestion to ensure absence of DNA after the extraction and was 
performed with 2U of DNase I (Fermentas) for 1 h at 37ºC, which was subsequently  inactivated by adding 50 
mM EDTA and incubated for 10 min at 65ºC. The RNA concentration was determined by measurement of the 
optical density at 260nm and the RNA was stored at -80ºC until use. The quality of each RNA sample was 
controlled on a 1% agarose gel (TBE) stained by GelRedTM. The RT reaction was performed with  
200 U of Revert-AidTM M-MuLV Reverse Transcriptase (Fermentas) according to the manufacturer’s 
specifications, using 500 ng of total RNA, 20 µM of MYCreverse primer, 1mM of dNTPs, annealing at 42°C 
for 1 h and 70°C for 10 min to reverse transcriptase inactivation.  
The 1458-bp product, which corresponds to the whole human v-myc myelocytomatosis viral oncogene 
homolog (MYC) gene, was PCR amplified using primers MYCforward: 5’–CTTCTCTGAAAGGCTCTCC–
3´ and MYCreverse: 5’–TCATAGGTGATTGCTCAGGA–3´. PCR amplification were performed in a 
MasterCycler Personal (Eppendorf) in 50 µl using 0.2 µM of primers, 0.2 mM dNTPs with 2U Taq DNA 
Polymerase (Fermentas), with the following thermal cycling conditions: initial 5 min denaturation at 95°C, 
followed by 35 amplification cycles of denaturation at 95 °C for 30 s, annealing at 62 °C for 30 s, elongation 
at 72 °C for 120 s, and a final elongation at 72 °C for 10 min.  
The RT-PCR product was re-amplified using primers containing the specific restriction sites for the multiple 
cloning region located downstream of the Renilla luciferase translational stop codon of the psiCHECK™-2 
Vector (Promega) with 6273bp. The MYC gene was re-amplified with primers for the XhoI (5’–
GTTCTCGAGCTCCTTCTCTGAAAGGCTCTCC–3’) and NotI (5’–
GATGCGGCCGCTCATAGGTGATTGCTCAGGA–3’) restriction enzymes as described above and purified 
through QIAquick PCR Purification Kit (Quiagen). Confirmation of correct PCR products was performed by 
2% agarose gel electrophoresis stained with GelRedTM.  
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The Ligation between the MYC insert (with sticky ends) and the Luciferase vector was carried out in a 
ligation buffer containing 2U of T4 DNA ligase (Fermentas) at 22ºC for 1 h and at 4ºC overnight. 
Confirmation of proper ligation products was performed by 2% agarose gel. The ligation mixture was used for 
transformation of competent E. coli DH5α strains (plated on nutrient agar containing ampicillin (100 µg/ml) 
as described previously2. Confirmation of the correct cloning was performed by sequencing. 
 
 
2. Myc-psiCHECK2 recombinant vector for assessment of RNAi efficiency in HeLa cells  
The whole human v-myc myelocytomatosis viral oncogene homolog (c-myc) gene (NCBI Reference 
Sequence: NM_002467.4) was cloned into a psiCHECK™-2 Vector from Promega as described above. 
Confirmation of the correct cloning vector was performed by DNA sequencing (see Figure S4). This vector 
was designed to provide a quantitative and rapid approach for optimisation of RNAi enabling to monitor 
changes in expression of a target gene (c-myc) fused to a reporter gene (Luciferase). The c-myc PCR product 
was cloned downstream the Renilla luciferase primary reporter gene. As initiation of the RNAi process by 
siRNAs results in cleavage and subsequent degradation of the fusion mRNA measuring decreases in Renilla 
activity provides a quantitative evaluation of RNAi effect. A second reporter gene, the Firefly luciferase, 
under a different promoter, is present into the cloning vector psiCHECK™-2 as internal control, allowing 
normalisation of Renilla luciferase expression, robust and reproducible results.  
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Figure S4. A) Map of the cloning vector psiCHECK™-2 (Promega). In orange the multiple cloning site used 
for c-myc cloning is shown. A c-myc PCR product (1457 bp) was cloned into the NotI site of the psiCHECK-
2 vector (image adapted from Promega psiCHECK™ vectors). B) Sequence chromatographs obtained from 
the Fused Renilla Luciferase-MYC vector are illustrated to confirm the fusion between c-myc and Renilla 
luciferase genes, and to show the mRNA region targeted by myc-siRNA (yellow squared, siRNA sequence). 
C) Agarose gel electrophoresis (0.8% agarose in TBE 1×) of the luciferase vectors. Lane 1 - psiCHECK™-2 
vector (supercoiled); Lane 2 – psiCHECK™-2 (6273 bp), linearised by BamHI digestion; Lane 3 – 
Recombinant Renilla Luciferase-MYC vector (supercoiled); Lane 4 – recombinant Renilla Luciferase-MYC 
vector (7730 bp),  BamHI digested . The higher molecular weight of the bands on lanes 3 and 4 demonstrate 
c-myc gene cloning. 
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3. Molecular analysis of gene expression in Hydra 
Quantitative Real-Time polymerase chain reaction (qRT-PCR) was performed in 25 µl of reaction mixture 
consisting of 1x Platinum SYBR green qPCR SuperMix-UDG with ROX (Invitrogen), serial cDNA dilutions 
and 0.5 µM each primer. The reactions were processed using the StepOne Real-Time PCR system (Applied 
Biosystem) under the following cycling steps: 10 min at 94°C; 40 cycles at 
94°C for 15 s; 58°C for 30 s; 72°C for 30 s, and a 20 min gradient from 55°C to 90°C to obtain a melting 
curve. To normalize RNA levels, Hydra Elongation factor 1alfa gene (HyEf-1α, GenBank Accession no. 
Z68181.1) was employed as internal calibrator. Gene-specific primers were: HyEf-1α: forward, 
5’CCAGGAGACAATGTCGGTTT 3’; reverse, 5’GCTTCAATGGCAGGATCATT 3’; Hymyc1: forward, 5’ 
TACAGAAAGCGAGGACGAAGTT 3’; reverse, 5’GCGAAGCAACTTTCAGTATTGTTAC 3’). At least 
three independent repeats for each experiment were carried out. Herein, the delta–delta Ct (2-∆∆CT) method, for 
comparing relative expression results between treatments, was applied
3
. 
 
4. Molecular analysis of gene expression in mouse lung 
PCR was amplified from cDNAs retrotranscribed from mice lung total RNA using the following primers: 5’ 
ATCTGCGACGAGGAAGAGA 3’ and 5’ AGCGACCGCAACATAGGAT 3’. Quantitative Real-Time 
polymerase chain reaction (qRT-PCR) was performed in 25 µl of reaction mixture consisting of 1x Platinum 
SYBR green qPCR SuperMix-UDG with ROX (Invitrogen), serial cDNA dilutions and 0.5 µM each primer. 
The reactions were processed using the StepOne Real-Time PCR system (Applied Biosystem) under the 
following cycling steps: 10 min at 94°C; 35 cycles at 94°C for 15 s; 56°C for 30 s; 72°C for 30 s. and a final 
elongation at 72 °C for 10 min. At least three independent repeats for each experiment were carried out. The 
delta–delta Ct (2-∆∆CT) method, for comparing relative expression results between treatments, was applied3. 
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S4: Evaluation of Toxicity 
 
1. Toxicity tests on human cell cultures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5. Cytotoxicity of NP-cov and NP-ion in Human cancer cell lines (MCF-7 and HeLa) via the MTT 
assay following 48 hr AuNP exposure. The tetrazolium salts (present in the MTT reagent) are cleaved to 
formazan by cellular enzymes. An expansion in the number of viable cells results in an increase in the overall 
activity of mitochondrial dehydrogenases in the sample. This augmentation in enzyme activity leads to an 
increase in the amount of formazan dye formed, which directly correlates to the number of metabolically 
active cells in the culture. 
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2. Acute and long term toxicity effects of AuNP on Hydra vulgaris 
At the base of metazoan evolution the freshwater polyp Hydra vulgaris (Cnidaria; Hydrozoa) has been shown 
an amenable system to study the interaction between nanoparticles and living systems
4
. Reliable methods have 
been developed for a comprehensive analysis of the NP impact in Hydra, spanning from in vivo analysis 
induced by NP treatments (structural morphological changes, impact on reproductive rate, efficiency of 
regeneration), to in vitro approaches of cell and molecular biology
5,6
. The animal is composed of just two 
epithelial cell layers (an inner endoderm and an outer ectoderm) with few interspersed specialised cell types 
and a neuronal net controlling functions and physiology. 
 
Figure S6. Structural anatomy of Hydra vulgaris. a) In vivo imaging of an adult polyp, showing the simple 
anatomical structure, shaped as a hollow tube, with a mouth surrounded by crown of 6-8 tentacles, and a foot 
to anchor to a substrate. The bud on the left side of the animal shows the animal asexual reproduction. b) 
Scheme showing a longitudinal section of the animal. The body is composed of two cell layers, an outer single 
cell layer, the ectoderm (ec) is separated by an acellular matrix, the mesoglea (me) from the inner cell layer, 
the endoderm (en) lining the gastric cavity. The bilayered structure is shown in c) by confocal and in d) by 
TEM microscopy analysis. Scale bars are 500µm, 50µm and 10 µm, respectively in a, c and d. 
 
We have previously optimised standard toxicity protocols, developed for testing environmental pollutants, for 
NP toxicity evaluation
7
. With regards identifying potential toxicity of AuNP on Hydra, groups of 20 living 
animals were soaked in culture medium supplemented with increasing doses of NP-ion and NP-cov (10 nM to 
80 nM) and monitored for acute and chronic toxicity by using three different approaches, i.e. presence of 
morphological changes, impact on regeneration and reproductive rates. No changes in the animal morphology 
were detected at 24, 48 and 72 h of continuous incubation, neither animals treated 24 h with nanoparticles and 
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then bisected, were impaired in the capability to regenerate body missing parts. The long term effect was 
analysed by monitoring the population growth rate, which is an indirect measure of the Hydra tissue growth 
rate and cell viability (see Figure S7). A group of founder animals (n°) either untreated or incubated for 24 h 
with 80 nM NP-ion or NP-cov, were monitored over two weeks, and the total number of individuals (n) used 
to calculate the growth rate constant (k) over the duration of the experiment (t), was defined by the equation 
ln(n/n°) = kt. Control animals at the same developmental stage were not treated. Both experimental and 
control Hydra were fed once daily and monitored for bud formation and detachment. For n/n0 = 2, t = T2, the 
doubling time of the population. T2 was determined by linear regression
8. No significant differences were 
observed between growth parameters of treated or untreated animals, showing the absence of toxic effects of 
these NP on Hydra survival and reproductive capabilities. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Impact of AuNP treatment on the population growth rate. The ratio between the number n of 
polyps present at a given day and the number n° of the founder individuals is reported. 80 nM was the highest 
possible concentration tested. 
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3. Toxicity of NP-cov@RGD@myc-siRNA in mice 
 
 
 
Figure S8.  Toxicity study of NP-cov@RGD@myc-siRNA in mice during 1, 3 and 14 days of treatment. 
Evaluation of the number of Macrophages (A), Neutrophils (B) and Lymphocytes (C) was used to detect 
inflammation
9
. The increased number of Neutrophils with 53 nM of NP-cov@RGD@myc-siRNA represents 
inflammation, whereas for 16 nM of NP-cov@RGD@myc-siRNA (concentration used in the mouse silencing 
studies) the activation of neutrophils is negligible.  
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Up to now, functionalized gold nanoparticles have been optimized as an effective intracellular in vitro
delivery vehicle for siRNAs to interfere with the expression of specific genes by selective targeting, and
provide protection against nucleases. Few examples however of suchlike in vivo applications have been
described so far.
In this study, we report the use of siRNA/RGD gold nanoparticles capable of targeting tumor cells in a
lung cancer syngeneic orthotopic murine model. Therapeutic RGD-nanoparticle treatment resulted in
successful targeting evident from significant c-myc oncogene down-regulation followed by tumor
growth inhibition and prolonged survival of lung tumor bearing mice, possibly via avb3 integrin inter-
action. Our results suggest that RGD gold nanoparticles-mediated delivery of siRNA by intratracheal
instillation in mice leads to successful suppression of tumor cell proliferation and respective tumor size
reduction. These results reiterate the capability of functionalized gold nanoparticles for targeted delivery
of siRNA to cancer cells towards effective silencing of the specific target oncogene. What is more, we
demonstrate that the gold-nanoconjugates trigger a complex inflammatory and immune response that
might promote the therapeutic effect of the RNAi to reduce tumor size with low doses of siRNA.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
RNA interference via the use of small-interfering RNA (siRNA)
[1,2] is a powerful and useful tool to block gene function through
sequence-specific post-transcriptional gene silencing, playing an
important role in the down-regulation of gene expression. siRNAs
can be transfected into mammalian cells by a variety of methods
[3e5] that influence the strength and duration of the silencing
response, which in turn is affected by the amount of siRNA effec-
tively delivered and by the potential of each siRNA to suppress itsuenchen.de (T. Stoeger),
All rights reserved.
25target. Nevertheless, naked siRNAs show extremely short half-lives
due to RNases activity, poor chemical stability, and dissociation
from the vector [2]. In fact, the major obstacle to clinical application
is the uncertainty about how to deliver siRNA with maximal ther-
apeutic impact.
Nanotechnology in general, and nanoparticles in particular, offer
unprecedented opportunities towards effective cancer therapy [6],
as multifunctional devices capable of bypassing biological barriers
for the specific delivery of therapeutic agents, reducing systemic
toxicity and severe adverse side effects avoiding the undesirable
distribution to healthy organs and tissues [7,8]. Nowadays the main
challenge in therapy is to develop a delivery system capable of
circulating in the blood stream undetected by the immune system
and capable to recognize a desirable target and signal it for effective
drug delivery or gene silencing. Due to their chemical properties
and ease of surface modification with a variety of ligands (e.g.1
J. Conde et al. / Biomaterials 34 (2013) 7744e7753 7745targeting moieties, therapeutic loads), gold nanoparticles (AuNPs)
are optimal non-toxic carriers for gene therapy [9,10]. In fact,
numerous studies using engineered AuNPs modified with siRNA
have demonstrated cytoplasmic delivery of siRNA and efficient
gene silencing [11e18]. However, almost all nanoconjugates using
siRNA have exclusively been tested in cell cultures targeting only
reporter genes.
Recently, we provided evidence of a proof-of-concept in vitro
and in vivo RNAi triggering via the synthesis of a library of multi-
functional AuNPs. Using a hierarchical approach including three
biological systems of increasing complexity: in vitro cultured hu-
man cells, in vivo freshwater polyp (Hydra vulgaris), and in vivo
healthy nude mice, we could identify the most adequate nano-
particles to efficiently transport siRNAs [19]. These previous results
evidenced the importance of a correct design in the functionali-
zation of nanoparticles for biological applications, mainly for
complex animal systems such asmice. The ionic linkage of siRNA on
the AuNPs showed efficiency in cells and in Hydra, however only a
covalent bond ensured an active RNAi release in mice. This effi-
ciency was reinforced by the addition of RGD peptide to the surface
of the nanoparticles. RGD has been extensively investigated as cell
adhesion peptide that is recognized by cell-surface receptors, such
as integrins, known to mediate cell adhesion and proliferation [20].
These adhesion molecules play a key role in tumor angiogenesis
and metastasis, being considerably up-regulated on the endothe-
lium during angiogenesis. The avb3 integrin receptor is expressed
specifically on proliferating endothelial cells such as those present
in tumors, representing a marker for malignancy [21].
Here, we set out for the treatment of lung cancer in two
orthograft mouse tumor models. We used female C57BL/6 mice,
tumor induced with LA-4 adenocarcinoma cells and to monitoringFig. 1. Inflammatory response and therapeutic siRNA silencing through RGD-nanoparticle
modified with RGD and siRNA can represent a delivery system of siRNA and a useful tool for
AuNPs@PEG@RGD@siRNA are administered by intratracheal instillation and directly deliver
passively accumulate or anchor through targeting RGD receptors, such as avb3 integrins, e
252tumor size a female C57BL/6 albino mice tumor induced with
luciferase expressing CMT/167 adenocarcinoma cells. For therapy
we used the previously as most active identified AuNPs to drive
RNAi release into the cytoplasm of the target cell: AuNP-
s@PEG@RGD@siRNA. Our results suggest a synergistic effect
resulting in delayed tumor growth, and increased tumor mouse
survival related to an enhanced inflammatory response in lung
tumor tissue when compared to healthy lungs (see Fig. 1).
2. Materials and methods
2.1. Synthesis of RGD/siRNA gold nanoparticles
All gold nanoconjugates used in this study were synthesized and extensively
describe elsewhere (Supplementary Information, Figure S1) [19]. Briefly, gold
nanoparticles with an average diameter ofw14 nm, were synthesized by the citrate
reduction method and functionalized with 25% saturated PEG layer, functionalized
with 50% carboxylic groups (SH-EG(8)e(CH2)2eCOOH) and 50% of azide groups
(SHe(CH2)3eCONH-EG(6)e(CH2)2eN3). A mixture of 10 nM of the citrate-gold
nanoparticles, 0.028% SDS and 7 mM SH-EG(8)e(CH2)2eCOOH (Iris-Biotech) and
7 mM SHe(CH2)3eCONH-EG(6)e(CH2)2eN3, AuNPs@COOH/N3 was prepared. Then,
NaOH was added to a final concentration of 25 mM and the mixture was incubated
for 16 h at room temperature. The excess of PEG chains was removed by centrifu-
gation at 14,000 rpm for 30 min at 4 C and the supernatant was discarded. For
functionalization with the ArginineeGlycineeAspartic Acid (G-RGD-S)-Peptide
(Sigma, MW490.47 Da), 20 nM of AuNPs@COOH/N3 were incubated in 6 mM sulfo-N-
hydroxysulfosuccinimide sodium salt and 25 mM MES buffer pH 6.1 followed by the
addition of the peptide at a final concentration of 0.5 mM. The mixture was incubated
at room temperature for 16 h. Then the AuNPs were centrifuged at 14,000 rpm for
30 min at 4 C to remove excess RGD peptide and the supernatants were recovered
and tested for protein concentration using a BCA Protein Assay Kit (Thermo Scien-
tific). Purified thiolated siRNA (Thermo Scientific Dharmacon) for mouse c-myc
(Sense strand: 50-Thiol GUGAGGAUAUCUGGAAGAAAUUU-30; Antisense strand: 30-
AUUUCUUCCAGAUAUCCUCACUU-50) at a constant concentration of 5 nmol/mL,
were incubated with RNase-free solution of the AuNPs@COOH/N3@RGD (10 nM)
containing 0.028% SDS. Subsequently, the salt concentration was increased to 0.1 Ms in a lung cancer syngeneic orthotopic mouse model. (A) Engineered nanoparticles
sequence-specific post-transcriptional gene silencing in a lung cancer mouse model. (B)
ed to bronchial airways, where the can efficiently target tumor cells. Nanoparticles can
xpressed in lung tumor cells.
J. Conde et al. / Biomaterials 34 (2013) 7744e77537746NaCl with brief ultrasonication following each addition to increase the coverage of
oligonucleotides on the nanoparticle surface. After functionalization during 16 h at
4 C, the particles were purified by centrifugation at 14,000 rpm (20min) at 4 C, and
re-suspended in DEPC-water.
Full characterization for AuNPs@PEG@RGD@siRNA has been reported elsewere
[19]. For brief characterization see Supplementary Information S1.
2.2. Inflammatory response in bronchoalveolar lavage (BAL) cells
BAL fluid was obtained by 4 times injecting and recovering 1 mL PBS via a
tracheal cannula. Cells recovered with the lavage fluid (lymphocytes and neutrophils
accompanying the predominant population of alveolar macrophages) were deter-
mined utilizing light microscopic counting of 200 cells on cytospin preparations.
Details of the bronchoalveolar lavage (BAL) procedure were described elsewhere
[22].
2.3. Assessment of c-myc downregulation
Total RNAs were extracted using the RNA Purification Kit PP-210L (Jena Biosci-
ence) from lung tissue treated for 48 h with 0.3 pmol of different nanoparticles
(AuNP@PEG, AuNP@PEG@RGD, AuNP@PEG@siRNA and AuNP@PEG@RGD@siRNA),
or dissected lungs, reverse transcribed and analyzed by qRT-PCR. qPCR was per-
formed using the following primers for the amplification of 165 bp c-myc gene
(GenBank: BC138931.1): 50-ATCTGCGACGAGGAAGAGA-30 and 50-AGCGACCGCAA-
CATAGGAT-30 . Quantitative Real-Time polymerase chain reaction (qRT-PCR) was
performed in 25 mL of reaction mixture consisting of 1 Platinum SYBR green qPCR
SuperMix-UDGwith ROX (Invitrogen), serial cDNA dilutions and 0.5 mM each primer.
The reactions were processed using the StepOne Real-Time PCR system (Applied
Biosystem) under the following cycling steps: 10 min at 94 C; 35 cycles at 94 C for
15 s; 56 C for 30 s; 72 C for 30 s and a final elongation at 72 C for 10 min. At least
three independent repeats for each experiment were carried out. The deltaedelta Ct
(2DDCT) method, for comparing relative expression results between treatments, was
applied.
2.4. Cell lines and flow cytometry
Lung fibroblasts (ATCC CCL-206), and two alveolar epithelial type II like
adenocarcinoma cell lines LA-4 (ATCC CCL-196) and MLE12 (ATCC CRL-2110)
were grown under standardized conditions as recommended by the manufacturer.
10,000 Cells were used for flow cytometrical analysis of integrin expression using
anti avb3-integrin antibody (BD Bioscience) and fixed cells were analyzed in BD
FACSDiva Software (BD Biosciences) as described by Schiller et al. [23].
2.5. RNAi and tumor targeting experiments in mice
Prior to instillation, mice were anesthetized by intraperitoneal injection of a
mixture of Medetomidin (0.5 mg/kg body mass), Midazolam (5.0 mg/kg body mass)
and Fentanyl (0.05 mg/kg body mass). The animals were then intubated by a
nonsurgical technique. Using a cannula inserted 10 mm into the trachea, a sus-
pension containing 1  105 cancer cells in 50 ml pyrogene-free distilled water was
instilled, followed by 100 ml of air, at week 8. Four weeks after the lung cancer in-
duction 0.3 pmol AuNPs (at weeks 12, 13, 14 and 15), in 50 ml pyrogene-free distilled
water was intratracheally instilled into the mice, followed by 100 ml of air. After
instillation animals were antagonized by subcutaneous injection of a mixture of
Atipamezol (2.5 mg/kg body mass), Flumazenil (0.5 mg/kg body mass) and Naloxon
(1.2 mg/kg body mass) for antagonization and to control awakening of the mice.
Animal experiments were carried out according to the German law of protection of
animal life and were approved by an external review committee for laboratory an-
imal care (animal approval number: 55.2-1-54-2532-20-11).
2.6. Molecular analyses of MYC expression in mouse
The lung cancer tissues (from C57BL/6 female mice induced with LA-4 adeno-
carcinoma cells) were embedded and sliced into 3 mm section. A normal Hema-
toxylin and Eosin (H&E) staining were employed for cancer morphology
observation. For immunolocalisation, standard immunohistochemical staining
method was employed. The tissue slide was incubated with anti-mouse c-myc and
anti-rabbit caspase-3 (Invitrogen) (1:1000) in PBS containing 1% BSA for 60min, and
was washed three times in Tris-buffered saline (TBS). The slide was incubated with
560 nm anti-mouse and FITC anti-rabbit as the secondary antibody (Invitrogen), at
the recommended dilution, in TBS containing 1% BSA, for 30 min, and then was
washed for three times in PBS. The slides were mounted with 50 ml of mounting
medium. The images were taken by Olympus microscopy and the fluorescent den-
sity per cell was analyzed by ImageJ. The percentages of MYC expression in each
groupwere comparedwith cancer cell without treatment. To visualize the particle in
cancer cell, mice were treated with 1  105 cancer cells and with 0.3 pmol AuNPs.
Mice were sacrificed and mice lungs fixed in 2.5% glutaraldehyde for TEM as
described elsewhere [19].252.7. Bioluminescence imaging
Stable clones of CMT64/61 cells, originally derived from a spontaneous lung
adenocarcinoma of a C57Bl/ICRF mouse [24] were generated by transfection with
pGL3-Control vector (Promega GmbH), and co-transfection for selection with a
linear Hygromycin resistance marker (Clontech). A stable clone (CMT/167-luc)
expressing high levels of firefly luciferase, constitutively driven by the SV40 pro-
moter and enhancer, was instilled into female C57BL/6 albino mice. Prior to instil-
lation, mice were anesthetized by intraperitoneal injection of a mixture of
Medetomidin (0.5 mg/kg body mass), Midazolam (5.0 mg/kg body mass) and Fen-
tanyl (0.05 mg/kg body mass). The animals were then intubated by a nonsurgical
technique. Using a cannula inserted 10mm into the trachea, a suspension containing
1  105 CMT/167-luc cells in 50 ml pyrogene-free distilled water was instilled, fol-
lowed by 100 ml of air, at week 8. Four weeks after orthotropic lung cancer induction
mice were treated by instillation of 0.3 pmol AuNP (at weeks 12, 13, 14 and 15),
respectively, in 50 ml pyrogene-free distilled water, followed by 100 ml of air. After
instillation animals were antagonized by subcutaneous injection of a mixture of
Atipamezol (2.5 mg/kg body mass), Flumazenil (0.5 mg/kg body mass) and Naloxon
(1.2 mg/kg body mass). Luciferase expression was monitored applying the IVIS
imaging system (Lumina, PerkinElmer) from mice bearing tumors from luciferase-
CMT/167 cells (n ¼ 8 animals per treated group).
2.8. Statistical analysis
All statistical analysis was performed with SPSS statistical package (version 15,
SPSS Inc., Chicago, IL) using a Paired-Sample t-test. All experiments, unless other-
wise stated, were performed in triplicate. All error bars used in this report ares.d of
at least three independent experiments.
3. Results and discussion
3.1. Inflammatory response in bronchoalveolar lavage cells
AuNPs have been shown in vivo and in vitro to accumulate
within various types of cells with a special affinity for macrophage-
like and reticuloendothelial cells throughout the body, where they
bioaccumulate in lymph nodes, bone marrow, spleen, adrenals,
liver and kidneys [25]. On the other hand, the influence of size,
solubility and surface chemistry on the biocompatibility of nano-
particles is well known and thus impacts their use in biomedical
applications [26].
In order to evaluate off-target effects, the inflammatory response
to the assembled gold-nanoconjugates (see Supplementary
Information S1 for characterization of siRNA/RGD AuNPs) was eval-
uated as a known sensitive readout for local toxicity by bron-
choalveolar lavage (BAL). Analysis of BAL cell counts provides
insights into immunologic, inflammatory, neoplastic, and infectious
processes occurring at the pulmonary level. BAL may also be helpful
to identify alveolar hemorrhage, malignancy, or opportunistic
infection. The method represents a valid diagnostic procedure also
used to assess interstitial lung disease and the detection of lung
tumor infiltrates by washing resident or inflammatory leukocytes as
well as mediators from the alveolar and bronchial airspaces. Under
healthy conditions alveolar macrophages represent the most
frequent cell type recovered in BAL fluid (>95%), but lymphocyte and
neutrophil numbers rapidly increase upon inflammation. Conse-
quently, evaluation of the number of macrophages, lymphocytes and
neutrophils was used to characterize the inflammatory response
(Fig. 2AeC) upon treatment with AuNPs@PEG@RGD@siRNA in
healthy mice during 1, 3 and 14 days. As expected, BAL from sham
treated lungs reveals healthy conditions with normal alveolar
macrophage numbers without any sign for an infection (Fig. 2A).
Significant inflammatory neutrophil infiltration is noted for the high
dose,1 pmol AuNPs@PEG@RGD@siRNA treated groups on days 1 and
3 (Fig. 2AeB). In contrast for 0.3 pmol of AuNPs@PEG@RGD@siRNA
the neutrophil influx seems negligible (Fig. 2C). During the acute
phase of inflammation neutrophils are one of the first-responders to
migrate towards the site of inflammation, and transient and over two
weeks resolving increases of neutrophils in the lower respiratory
tract were observed for AuNP treated mice thus characterizing a3
Fig. 2. Inflammatory response assessed by bronchoalveolar lavage (BAL) cell analysis. Inflammatory response to different doses of intratracheal instilled AuNPs@PEG@RGD@siRNA in the lungs of mice after 1, 3 and 14 days of treatment.
Evaluation of the number of Macrophages (A), Lymphocytes (B) and Neutrophils (C) was used to characterize the inflammatory response. (D) Representative microscope images of BAL cells (scale bars, 50 mm) at days 1 and 3 for 1 pmol
of AuNPs@PEG@RGD@siRNA and upon treatment with 0.3 pmol of AuNPs@PEG@RGD@siRNA in mice during 1, 3 and 14 days after AuNPs instillation.
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J. Conde et al. / Biomaterials 34 (2013) 7744e77537748typical moderate, acute inflammatory response. No significant in-
creases in BAL lymphocyte numbers have been observed except with
1 pmol of AuNPs@PEG@RGD@siRNA 14 days after exposure to NPs
(Fig. 2B). Fig. 2D shows representative light microscope images of
cytospin preparations from BAL cells at days 1 and 3 for 1 pmol of
AuNPs@PEG@RGD@siRNA and upon treatment with 0.3 pmol of
AuNPs@PEG@RGD@siRNA in mice during 1, 3 and 14 days. No
multinucleated macrophages were detected in all conditions, indi-
cating biocompatibility of the nanomaterials over time.
Based on these data and considering that at a concentration of
0.3 pmol of AuNPs@PEG@RGD@siRNA caused no significant in-
flammatory response, this concentration was used for subsequent
siRNA delivery studies.
3.2. siRNA silencing via RGD/siRNAeAuNPs in murine cell lines
Several reports have shown that therapeutic siRNA silencing is
prone to off-target effects leading to cellular and systemic toxicity,
which depends on the type of delivery system and commonly
associated with lack of siRNA specificity and/or high doses of
therapeutic agent. Specific gene knockdown activity is only
attained when siRNA binding, internalization, and cytoplasmic
release are achieved [2]. Previouslywe had observed an appreciable
effect in the silencing of endogenous c-myc in healthy nude mice
[19], which showed some variation between cell types and be-
tween different organisms. For that reason, the silencing efficiency
was evaluated with other cell lines, and adenocarcinoma cells were
selected to act as a proof of concept for subsequent studies and
cancer treatment using this strategy.
Consequently, we conducted the molecular assessment of RNAi
efficiency in three different murine cell lines (CCL-206 lung fibro-
blasts, and two alveolar epithelial type II like adenocarcinoma cell
lines LA-4 and MLE12). To quantify efficiency of silencing, total
RNAs from the three murine cell lines were extracted after 48 h of
treating the cells with 0.3 pmol of all AuNPs conjugates and
analyzed by qRT-PCR (Fig. 3A). The c-myc expression levels were
determined using b-actin as reference gene. Treatment with naked
siRNA alone was also analyzed for comparison, once does not freely
cross the cell membrane, is relatively unstable in blood and serum
and it is rapidly degraded by endo- and exo-nucleases.
Data show that steady state expression of c-myc was substan-
tially inhibited by the specific AuNPs@PEG@RGD@siRNA at 48 h
only for alveolar epithelial type II like adenocarcinoma LA-4 cells
(78.7  6.5% c-myc downregulation) (Fig. 3A). No significant
silencing effect was observed for AuNPs@PEG only, AuNP-
s@PEG@RGD and AuNPs@PEG@siRNA, probably due to a lack of
selectivity of the NPs towards the target cells. These results
demonstrate that AuNPs@PEG@RGD@siRNA are potent and specific
in c-myc expression silencing.
RGD integrin ligand is well-known for its capability to bind to
the integrin avb3 receptor family, involved in a wide range of cell
extracellular matrix and cellecell interactions. The cell adhesion
molecule avb3 integrin is a specific marker of angiogenesis and the
expression of avb3 integrin correlates with tumor grade [27],
suggesting a possible role as marker of malignancy. Therefore, the
ability to target tumor cells via avb3 integrin in living subjects
would allow a better tumor targeting and regression in regions
with higher aggressiveness. This might be valuable to improve
other anti-angiogenic and noninvasive antitumor therapies. In or-
der to evaluate whether AuNPs@PEG@RGD@siRNA promote siRNA
targeting in lung cancer cells via avb3 integrin interaction, flow
cytometry analysis was performed in CCL-206 lung fibroblasts, LA-
4 and MLE12 cells. Flow cytometry analysis (Fig. 3B) revealed
highest levels of the RGD motive binding integrin avb3 expressed
on LA4 cells (P < 0.05) compared to CCL-206 and MLE-12 cells. LA425cells show 84.5% of positive cells for avb3 integrin antibody stain-
ing, showing that AuNPs@PEG@RGD@siRNA promotes siRNA tar-
geting in LA-4 cancer cell and c-myc downregulation (Fig. 3A) via
avb3 integrin interaction. The multifunctional arrangement of RGD
on AuNPs may enhance the binding affinity to endothelial cells,
promoting the delivery of c-myc siRNA to suppress tumor growth
and angiogenesis. Moreover, direct conjugate of RGD ligands pre-
sent in AuNPs@PEG@RGD@siRNA possibly saturates integrin re-
ceptors, resulting in inefficient receptor-mediated endocytosis,
allowing enhanced cellular uptake. Actually, RGD-surface-modified
nanoparticles, including polyplexes and liposomes, have been
extensively used to deliver therapeutic genes, confirming the
involvement of integrins in transfection [28]. Moreover, cellular
uptake efficiency and intracellular distribution of the RGD/siRNAe
AuNPs have been evaluated using transmission electron micro-
scopy (see Supplementary Information S2).
These results validated RGD-directed stealth-based siRNAe
AuNPs as an effective systemic nucleic acid delivery system. It
should be pointed out that delivery targeting via avb3 integrin
interaction could achieve therapeutic siRNA silencing delivery of
nucleic acids to avb3 positive lung tumor cells.
3.3. Lung tumor targeting and therapeutic siRNA silencing via RGD/
siRNA-AuNPs
Lung cancer is the most common cause of cancer-related death
in men and women in the modern world [29] and the selectively
reactivated expression of developmental regulator genes, such as c-
myc have frequently been associated with lung tumor development
and progression, and inhibition of c-myc expression may be suffi-
cient to permanently stop tumor growth and induce regression of
tumors [30]. However, ubiquitous inhibition of c-myc expression
unavoidable leads to side effects, since regenerating tissue com-
partments require endogenous expression levels to sustain normal
activity. Conversely, Soucek et al. show that c-myc inhibition trig-
gers rapid regression of incipient and established lung tumors,
defining an unexpected role for endogenous c-myc function in the
maintenance of Ras-dependent tumors in vivo. Although systemic
suppression of c-myc activity has profound effects on proliferating
somatic tissues, these effects are well tolerated, without any
discernible negative impact on animal well being and they are
completely reversible. Thus, the authors demonstrate the feasibility
of targeting c-myc, a common downstream conduit for many
oncogenic signals, as an effective, efficient and tumor-specific
cancer therapy [30].
With the attempt to translate the concept of gene therapy to
clinical cancer therapeutics, the engineering of delivery systems
that could achieve translocation of siRNA duplexes directly into the
tumor cell cytoplasm and accomplish successful silencing has
become essential. To ascertain whether the targeted delivery sys-
tem can provide effective in vivo delivery of functional siRNA to
tumors, a lung cancer tumor model in nude mice was established
and treated with AuNPs@PEG@RGD@siRNA. Cancer model was
achieved by intratracheal instillation of induction LA-4 adenocar-
cinoma cells (1  105 cells) into C57BL/6 mice lung for 4 weeks.
After this period, 0.3 pmol of NPs (AuNPs@PEG@RGD and AuNP-
s@PEG@RGD@siRNA) and Sham (mice without induction of LA-4
adenocarcinoma cells and treated with water) were adminis-
trated by intratracheal instillation. After 72 h mice lungs were
dissected and prepared for Hematoxylin and Eosin staining (H&E)
to verify the extents of tumorigenesis by tissue sections. As ex-
pected, Sham tissue staining reveals healthy and normal alveolar
architecture without any tumor (Fig. 4A). AuNPs@PEG@RGD
treated group demonstrates a cancer lung tissue characterized by
hypercellularity and thickened alveolar septa (Fig. 4B). Severe5
Fig. 3. siRNA mediated c-myc silencing via AuNPs@PEG@RGD@siRNA in murine cell lines. (A) Molecular assessment of RNAi efficiency. To quantify the efficiency of silencing, total
RNAs from three different murine cell lines (CCL-206 lung fibroblasts, and two alveolar epithelial type II like adenocarcinoma cell lines LA-4 and MLE12), treated with various NP
types was extracted after 48 h and analyzed by qRT-PCR. The c-myc mRNA expression levels were determined using b-actin as reference gene. Data marked with asterisks indicate
statistically significant changes relative to the corresponding NP without RGD and siRNA (AuNPs@PEG) as calculated by paired sample t test (*, P < 0.001). (B) Flow cytometric
profiling of avb3 integrin surface expression in the three different murine cell lines (CCL-206, LA-4 and MLE12). Within the dot-plots the upper right quadrant (P3) illustrates the
fraction of avb3 integrin positive cells (84.5% for LA-4 cells, 1.4% for CCL-206 cells and 1.0% for MLE12 cells).
J. Conde et al. / Biomaterials 34 (2013) 7744e7753 7749interstitial inflammatory cells infiltration is noted, with predomi-
nance of mononuclear cells and perivascular and peribronchiolar
edemas as indicated by arrows. In the AuNPs@PEG@RGD-treated
groups, no significant effect on tumor regression was obtained
when compared to AuNPs@PEG@RGD@siRNA treated group.
Essentially, in cancer lung AuNPs@PEG@RGD@siRNA (Fig. 4C)
treatment group, there was a significant decrease in the incidence
and severity of tumor clones in lung, revealing the capacity of
AuNPs@PEG@RGD@siRNA in reducing tumor cells in a lung cancer
mice model.
Previous studies with nanosized gold vectors have also proved
successful results in lung tumor targeting. Lippard and Mirkin have
exploited the rapid intracellular uptake of AuNPs to deliver and
activate cisplatin and achieve efficient cytosolic delivery of this
prodrug to lung cancer cells [31]. Similarly efficiency has also been
demonstrated from AuNP conjugates of oxyplatin [32]. Furthermore,256Chen et al. have also studied AuNPs conjugates of methotrexate, a
dihydrofolate reductase inhibitor for the treatment of primary lung
tumors [33].
However, the AuNPs@PEG@RGD@siRNA described here as tar-
geted therapeutic approach for lung cancer therapy in murine cell
lines and in this lung cancer syngenic orthotopic mouse model has
not been described so far. In fact, our data suggests that intra-
tracheal administration of AuNPs@PEG@RGD@siRNA leads to suc-
cessful and statistically significant suppression of tumor cells in
lung tissue.
Having determined that AuNPs@PEG@RGD@siRNA is delivered
efficiently to cancer mice, we conducted the molecular assessment
of c-myc silencing efficiency in the same lung tumor model (C57BL/
6 mice induced with LA-4 adenocarcinoma cells). AuNP-
s@PEG@RGD and AuNPs@PEG@RGD@siRNA were administered
(0.3 pmol) to 10e12 week aged mice (n ¼ 6e8 animals) by
Fig. 4. Lung tumor treatment via AuNPs@PEG@RGD@siRNA. Hematoxylin and eosin (H&E) stains of (A) the Sham treated group (healthy lung tissue from untreated mice), (B)
AuNPs@PEG@RGD treated group (LA4 induced lung cancer tissue) and (C) AuNPs@PEG@RGD@siRNA-treated group (LA4 induced lung cancer tissue). Severe interstitial infiltration of
inflammatory cells is noted in the AuNPs@PEG@RGD treated group, with a predominance of mononuclear cells and perivascular and peribronchiolar edema (arrows). The lung
cancer tissue is characterized by hypercellularity and thickened alveolar septa. In cancer lungs the AuNPs@PEG@RGD@siRNA treatment group, shows a significant decrease in the
incidence and severity of inflammation, revealing the capacity of AuNPs@PEG@RGD@siRNA in reducing tumor cells in a lung cancer model on C57BL/6 mice induced with LA-4
adenocarcinoma cells.
J. Conde et al. / Biomaterials 34 (2013) 7744e77537750intratracheal instillation. Since tumor cell apoptosis is an important
indicator of treatment success, tumor cells were also stained for
Caspase 3 detection. Fig. 5A,C shows high expression of MYC pro-
tein and positive staining of Caspase 3 in cytoplasm of tumor cellsFig. 5. Therapeutic siRNA silencing in murine lung cancer tissue. (AeD) Immunolocalization
cells) after 48 h of AuNPs@PEG@RGD (A,C) and AuNPs@PEG@RGD@siRNA (B,D) treatment.
50 mm). (E) Time course of tumor model induction, therapy and analysis as well as Kaplane
AuNPs@PEG@RGD@siRNA after lung cancer induction. Sham mice were also inoculated wit
interpretation of the references to color in this figure legend, the reader is referred to the
25after exposure to AuNPs@PEG@RGD. Whereas, Fig. 5B,D illustrate
tumor cells treated with AuNPs@PEG@RGD@siRNA and shows
downregulation of local MYC expression and high expression of
Caspase 3, probably leading tumor cells to apoptosis. On day 27of MYC protein in tumor cells from C57BL/6 mice (induced with LA-4 adenocarcinoma
Tumor cells in lung tissue stained for Caspase 3 (green) and c-myc (red) (Scale bars,
Meier survival rates for mice (n ¼ 30 animals) treated with to AuNPs@PEG@RGD and
h LA-4 adenocarcinoma cells but were not exposed to any type of nanoparticles. (For
web version of this article.)
7
Fig. 6. Bioluminescent imaging of B6 albino mice injected with luciferase-CMT/167 adenocarcinoma cells (n ¼ 8 animals per treated group). Bioluminescence imaging was performed to serially assed tumor size in each mouse, with
luciferase activity as a measure for the tumor burden. Images show lung cancer mice and respective control lungs with no treatment (A), or with AuNPs@PEG@RGD (B) and AuNPs@PEG@RGD@siRNA (C) treatment. These biolumi-
nescence images clearly depict a tumor regression (decrease of 80e90% related to fluorescence signal) in AuNPs@PEG@RGD@siRNA treated group.
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J. Conde et al. / Biomaterials 34 (2013) 7744e77537752after cancer induction the therapeutic outcome of AuNP-
s@PEG@RGD and AuNPs@PEG@RGD@siRNA was analyzed in terms
of animal survival in a KaplaneMeier curve (Fig. 5E) (n ¼ 30 ani-
mals). Animals in the AuNPs@PEG@RGD@siRNA treated group
demonstrated tumor growth inhibition, which resulted in signifi-
cant increase in survival (approximately 80% increase) compared to
AuNPs@PEG@RGD and sham mice without nanoparticle treatment
(Fig. 5E). AuNPs@PEG@RGD@siRNA leads to a concomitant main-
tenance of survival of lung tumor-bearing animals. There was no
significant increase in survival seen in animals treated only with
AuNPs@PEG@RGD.
In order to test changes of lung tumor size in mice, biolumi-
nescence imaging was carried out in a second model to serially
assess lung tumor in each mouse (B6 albino female mice injected
with luciferase-CMT/167 adenocarcinoma cells), treated with
0.3 pmol of AuNPs@PEG@RGD and 0.3 pmol of AuNP-
s@PEG@RGD@siRNA, with luciferase activity as a measure for tu-
mor burden (Fig. 6). Briefly, stable clones of CMT/167 cells, derived
from a spontaneous lung adenocarcinoma in B6 albino mice
expressing high levels of firefly luciferase constitutively driven by
an SV40 promoter (CMT/167-luc) as previously described [34].
Representative imaging of individual mice from each treated group
(n ¼ 8 animals) is shown, with the same scale of photon flux
indicating luciferase activity. Fig. 6 shown images of lung cancer
mouse with no NP treatment (Fig. 6A), with exposure to AuNP-
s@PEG@RGD (Fig. 6B) and AuNPs@PEG@RGD@siRNA (Fig. 6C).
These bioluminescence images clearly depict tumor size regression
(decrease of 80e90%) in AuNPs@PEG@RGD@siRNA treated group.
Exposure to AuNPs@PEG@RGD without siRNA shows a negligible
decrease of 1e5%.
Based on this data, the systemically delivery of AuNP-
s@PEG@RGD@siRNA was the only treatment condition that resul-
ted in successful tumor growth inhibition and prolonged survival of
the animals, in two lung cancer mice models (C57BL/6 female mice
inducedwith LA-4 adenocarcinoma cells and B6 albino female mice
injected with luciferase-CMT/167 adenocarcinoma cells). Using
siRNA/RGD gold nanoparticles, targeted gene delivery based on
selective expression of avb3 integrin in the tumor vasculature
might become applicable to lung cancer gene therapy. In reality, the
observed in vivo gene silencing and tumor regression by siRNA/RGD
AuNPs suggests its possible use as a therapeutic agent for lung
cancer, as well as opening a new translational avenue to approach
the many diseases driven by deregulation of c-myc gene
expression.
4. Conclusions
In summary, we report that RGD-functionalization of thera-
peutic nanoparticles can promote siRNA targeting in LA-4 cancer
cell likely via avb3 integrin interaction leading to downregulation
of c-myc oncogene expression. Moreover we show that, siRNA/RGD
gold nanoparticles are capable of targeting tumor cells in two
different orthotopic mouse models, resulting in successful and
significant c-myc oncogene down-regulation and subsequent by
tumor growth inhibition, as well as extended survival of mice
bearing tumors.
Our findings pave the way for clinical cancer therapeutics via
engineered and fine-tuned AuNPs@PEG@RGD@siRNA capable to
deliver siRNA into lung tumor cells and effectively silence a proto-
oncogene without side effects or toxicity.
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S1. Preparation and characterization of RGD/siRNA-gold nanoparticles 
 
Spherical citrate-AuNPs with an average diameter of 14±1 nm (Figure S1A Inset) were 
functionalized with two kinds of poly(ethylene glycol) (PEG) spacers, a RGD peptide and an 
siRNA molecule to c-myc gene. The high monodispersity of the gold core was confirmed by 
Transmission Electron Microscopy (TEM) (Figure S1A). The diameter of citrate-AuNPs 
observed by TEM was in good agreement with the DLS measurement, showing an average 
diameter of 14.7 nm with relatively narrow distribution (polydispersity index 0.197±1.529). 
The UV-Vis molecular absorption spectra of the citrate-AuNPs show the characteristic 
surface plasmon resonant peak at 519 nm, presenting at pH 7 a negative Zeta potential value 
of -12.32 mV.  
PEGylated AuNPs with 15% saturated PEG layer, were functionalized with 50% carboxylic 
groups (SH-EG(8)-(CH2)2-COOH) and 50% of azide groups (SH-(CH2)3-CONH-EG(6)-
(CH2)2-N3). The 15% of saturated PEG layer (1250.5±279.8 PEG chains per nanoparticle) 
allows the incorporation of further thiolated components, such as the thiolated siRNA. The 
carboxylated spacer provides the anchoring moieties for the covalent binding of amine-
containing molecules through carbodiimide chemistry. Besides, PEG-carboxylic and PEG-
azide were used as opposite polyelectrolytes in order to improve nanoparticle transfection and 
gene silencing efficiency. PEGylated AuNPs (AuNP@COOH/N3) were then functionalized 
with Arg-Gly-Asp (RGD peptide) amino acid sequence by EDC/NHS coupling reaction 
between the carboxylated spacer and the amine terminal group of the RGD peptide (20.6±0.7 
RGD peptides per nanoparticle). Consequently, AuNPs@COOH/N3@RGD were 
functionalized with a siRNA molecule (62.9±0.7 RGD peptides per nanoparticle) 
complementary to a master regulator gene, the proto-oncogene c-myc. 
It is known that the solubility of the coated AuNPs is largely affected by size and surface 
charges. Therefore, the process of AuNPs functionalization was monitored by Dynamic Light 
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Scattering (DLS) (Figure S1B) and Zeta potential (Figure S1C) measurements of all AuNPs 
conjugates. Additionally, the spatial arrangement of AuNPs can be inferred by measuring the 
shift of a characteristic surface plasmon band. In fact, the Surface Plasmon Resonance (SPR) 
of the AuNPs shown in Figure S1B exhibited a red shift from 519 to 525nm when PEG, RGD 
and siRNA were bound. SPR peaks showed a 3 nm shift of the SPR when the RGD peptide is 
bound to the nanoparticles whereas the shift is higher (5 nm) after siRNA binding. 
The determination of the degree of saturation of AuNPs functionalized with thiolated 
poly(ethylene glycol) chains and quantification of RGD peptides and siRNA strands per 
nanoparticle was extensively described elsewhere [19]. 
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Figure S1. Physical characterization of AuNPs conjugates. (A) Transmission Electron 
Microscopy (TEM) of citrate-AuNPs, Inset: size distribution histogram showing an average 
diameter of 14±1 nm. (B) Dynamic Light Scattering (DLS) showing average diameter of 
AuNPs conjugates and Surface Plasmon Resonance (SPR) shift peaks. (C) Surface charge 
measurements by Zeta Potential at each functionalization step. 
264
5 
 
 
S2. RGD/siRNA-gold nanoparticles internalization in lung cells 
 
In order to assess the effectiveness of gene silencing in lung tumor cells, cellular uptake 
efficiency and intracellular distribution of the RGD/siRNA–AuNPs have been evaluated using 
transmission electron microscopy (TEM) (see Figure S2A,B). TEM images of LA-4 lung 
epithelial cells treated with 0.3 pmol of RGD/siRNA–AuNPs (AuNP@PEG@RGD@siRNA) 
show NPs in the cytoplasm as single units, supporting the correct delivery of siRNA to initiate 
RNAi. LA-4 induced tumor mice were treated with 0.3 pmol of RGD/siRNA–AuNPs by 
intratracheal instillation. At 24 hours (Figure S2A) after instillation, some NPs are located 
outside of tumor cell membranes and a few NPs are inside vesicles. At 48 hours (Figure 
S2B), bigger amounts of NPs are found in vesicles or free in cytoplasm. RGD/siRNA–AuNPs 
were exclusively localized in the cytoplasm where siRNA mediates its function, thus 
demonstrating that these RGD/siRNA capped-AuNPs facilitate the intracellular distribution of 
siRNA to cytoplasm.  
 
 
Figure S2. RGD/siRNA-gold nanoparticles internalization in lung cancer cells (A, B) 
TEM images of lung cancer cells. Mice implanted with LA-4 cancer cells were treated with 
0.3 pmol of AuNP@PEG@RGD@siRNA by intratracheal instillation. At 24 hours (A) after 
instillation, TEM images show NPs located outside of the cell but a few NPs also located 
inside cellular vesicles. After 48 hours (B), bigger amounts of NPs are found in vesicles or 
also free in cytoplasm (scale bars, 500 nm). 
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OVERVIEW 
 
This section presents 3 articles related to the studies on gold nanoparticles as nanovectors for 
both diagnostics and therapy applications – Theranostics. 
Article I describes the development of a direct method to follow RNA synthesis in real time 
based on gold nanoparticles (AuNPs) functionalized with a fluorophore labeled hairpin-DNA, 
i.e. gold-nanobeacon (Au-nanobeacon). With a reporter Au-nanobeacon we were able to 
measure the rate of in vitro RNA synthesis. At the same time, we designed a second Au-
nanobeacon targeting the promoter sequence (inhibitor) so as to inhibit transcription whilst 
simultaneously monitor the number of promoters being silenced. Using the two Au-
nanobeacons in the same reaction mixture, we are capable of quantitatively assess in real time 
the synthesis of RNA and the level of inhibition. This strategy defines the way of using these 
gold nanoconjugates for the detection (diagnostic) and at the same time for the inhibition of 
specific genes (therapy). 
This gold-nanobeacon concept was extended and adapted to a universal tool for RNAi, from 
gene specific silencing to silence-the-silencers (Article J). For the first time, we reported the 
potential of a single molecular nanoconjugate to intersect all RNA pathways: from gene 
specific downregulation to silencing the silencers, i.e. siRNA and miRNA pathways. Gold-
nanobeacons were capable of efficiently silencing single gene expression, exogenous siRNA 
and endogenous miRNAs while yielding a quantifiable fluorescence signal directly 
proportional to the level of silencing.  
In Article K we evaluate the genotoxicity, cell toxicity and proteome profiling analysis of the 
previous gold-nanobeacons system for gene therapy. An integrated toxicology evaluation was 
performed based on acute cell toxicity, genomic DNA damage and proteome profiling 
showing that the proposed strategy does not exhibit significant toxicity, which is extremely 
relevant when translating into in vivo systems. 
 
All these studies were performed at the Research Centre for Human Molecular Genetics, 
Dept. of Life Sciences at Science and Technology Faculty, New University of Lisbon. 
 
Article I 
“Gold-Nanobeacons for Real-Time Monitoring of RNA Synthesis.” J. Rosa*, João Conde*, 
J.M. de la Fuente, J.C. Lima and P.V. Baptista. (* Co-first authors). Biosensors & 
Bioelectronics (2012), Vol. 36, pp. 161-167.  Research article (IF=5.437) 
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Article J 
“Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the 
silencing events.” João Conde, J. Rosa, J.M. de la Fuente and P.V. Baptista. Biomaterials 
(2013), Vol. 34, pp. 2516–2523. Research article (IF=7.604) 
 
Article K 
“A Gold-nanobeacon system for Gene therapy: evaluation of Genotoxicity, Cell toxicity and 
Proteome profiling analysis” João Conde, M. Larguinho, A. Cordeiro, L.R. Raposo, P.M. 
Costa, S. Santos, M.S. Diniz, A.R. Fernandes and P.V. Baptista. Nanotoxicology (2013). 
Research article (IF=7.844) 
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Measuring RNA synthesis and, when required, the level of inhibition, is crucial towards the develop-
ment of practical strategies to evaluate silencing efficiency of gene silencing approaches. We developed
a direct method to follow RNA synthesis in real time based on gold nanoparticles (AuNPs)
functionalized with a fluorophore labeled hairpin-DNA, i.e. gold-nanobeacon (Au-nanobeacon). Under
hairpin configuration, proximity to gold nanoparticles leads to fluorescence quenching; hybridization
to a complementary target restores fluorescence emission due to the Au-nanobeacons’ conformational
reorganization that causes the fluorophore and the AuNP to part from each other, yielding a
quantitative response. With this reporter Au-nanobeacon we were able to measure the rate of in vitro
RNA synthesis (10.3 fmol of RNA per minute). Then, we designed a second Au-nanobeacon targeting
the promoter sequence (inhibitor) so as to inhibit transcription whilst simultaneously monitor the
number of promoters being silenced. Using the two Au-nanobeacons in the same reaction mixture, we
are capable of quantitatively assess in real time the synthesis of RNA and the level of inhibition.
The biosensor concept can easily be extended and adapted to situations when real-time quantitative
assessment of RNA synthesis and determination of the level of inhibition are required. In fact, this
biosensor may assist the in vitro evaluation of silencing potential of a given sequence to be later used
for in vivo gene silencing.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Monitoring and controlling RNA synthesis is of great relevance
for understanding the cell (and the organism) homeostasis. The
ability to scrutinize cellular processes in vitro has become an
important tool for novel approaches to gene studies and for
molecular therapeutics (Agrawal, 1996; Fichou and Ferec, 2006;
Tamm et al., 2001; Toub et al., 2006). Several techniques to analyze
RNA synthesis in vitro have been described, e.g. Northern Blot (Bor
et al., 2006), RT-PCR (Freeman et al., 1999; Weis et al., 1992) and
cDNA microarrays (Schena et al., 1995). In addition, molecular
beacons have provided a rapid and sensitive system capable of
efficient quantitative monitoring of RNA synthesis and/or inhibition
in real-time. A molecular beacon is a stem–loop DNA single-
stranded-oligonucleotide that carries a fluorophore and a quencher
at both ends: in absence of target, the stem–loop structure is closed
forcing the fluorophore and the quencher to close proximity,
resulting in fluorescence quenching; upon hybridization to a com-
plementary target the stem–loop sequence opens, the fluorophorell rights reserved.
.
.
270and quencher are spatially separated and the fluorescence is restored
(Tan et al., 2004; Tyagi and Kramer, 1996). Fluorescence monitoring
allows quantitative kinetic analysis of the conformation changes
occurring in the molecular beacon under various situations such as
real-time monitoring of DNA cleavage caused by enzymes (Li et al.,
2000a, 2000b), protein–DNA interaction studies (Li et al., 2000a,
2000b), real-time in vitro transcription monitoring (Liu et al., 2002;
Marras et al., 2004) and real-time PCR detection (Waltz et al., 2005).
Although robust, traditional molecular beacons can be easily
degraded by nucleases that are often residually present in reac-
tion mixtures and/or in cellular extracts, rendering the beacons
ineffective. Gold nanoparticles (AuNPs) can overcome this pro-
blem by conferring protection against nucleases (Conde et al.,
2010; Rosi et al., 2006) whilst maintaining the quenching and
sensing properties of the beacon (Baptista et al., 2008; Baptista,
2009; Lakowicz, 2006; Paciotti et al., 2004; Quarta et al., 2007;
Saha et al., 2012; Seferos et al., 2007). The combination of the
optical properties of AuNPs with fluorophores in a molecular
beacon conformation (Au-nanobeacon) have been used to detect
sequence-specific DNA targets (Song et al., 2009) and even be
more sensitive in detecting single-mismatch than regular mole-
cular beacons (Dubertret et al., 2001).
Recently, we have assisted to a renewed interest in gene
silencing strategies that aim to decrease the effective capability
J. Rosa et al. / Biosensors and Bioelectronics 36 (2012) 161–167162of a given gene to express itself, either by an inhibition of
transcription or via an increased specific degradation. In fact,
ssDNA-functionalized AuNPs have already been used in modula-
tion of in vitro transcription and translation (Agbasi-Porter et al.,
2006; Conde et al., 2010). Evaluation of transcription inhibition is
usually assessed mainly by end-point quantification of RNA
synthesis and comparison to transcription levels without silen-
cing. However, when evaluating the effectiveness of inhibition, it
is of utmost relevance to ascertain the number of molecules being
de facto silenced, and correlating the level of inhibition to that of
product production (i.e. RNA). Doing so in real-time would also
provide information on the kinetics involved, thus yielding
important information towards optimization of silencing strategy,
re-design of target and effector sequences, etc (Rayburn and
Zhang, 2008).
Here, we present a two-gold-nanobeacon system for the real-
time monitorization of RNA transcription and inhibition: one
Au-nanobeacon monitors the transcription level (reporter), and a
second Au-nanobeacon acts as inhibitor of transcription (inhibitor)
that quantitatively assesses the number of sequences being
inhibited. Because the inhibitor reports on the number of targets
it binds to, we attain real time quantification of the number of
sequences being silenced at one time, and the consequent effect
on transcription is provided by the reporter Au-nanobeacon—
Fig. 1. This dual-biosensing system may be a practical andFig. 1. Gold-nanobeacons for monitoring and inhibition of real-time RNA synthesis. An Au-
and a fluorophore at 30 . When the hairpin has its stem–loop structure formed, the fluoro
quenched due to gold nanoparticles modulation properties on standard organic fluorop
loop sequence of the hairpin the stem–loop structure is opened and the fluorophore is
labeled Au-nanobeacon hybridizes with the RNA transcript as it is formed in an in vitro
labeled Au-nanobeacon is used to hybridize with the T7 promoter region of the dsDNA
both Au-nanobeacons is measured and quantification of both as to how many T7 pro
retrieved.
27straightforward tool for kinetics and mechanistic studies in gene
silencing approaches.2. Experimental details
2.1. Materials
All chemicals were purchased from Sigma Aldrich in the
highest purity available and used without further purification.
T7 RNA Polymerase and Revert-AidTM M-MuLV Reverse Tran-
scriptase were purchased from Fermentas. DNase I and SYBRs
GreenER Real-Time PCR Kit purchased from Invitrogen. All oligo-
nucleotides were purchased from STAB Vida, Portugal.
2.2. Synthesis of citrate–gold nanoparticle
Gold nanoparticles with an average diameter of 14 nm were
synthesized by the citrate reduction method described by Lee and
Meisel (1982). Briefly, 1 mM hydrogen tetrachloroaureate (III)
hydrate (88.61 mg) was dissolved in 500 ml of distilled water, heated
and stirred under reflux. Then, 38.8 mM sodium citrate tribasic
dihydrate (285 mg) was added resulting in a red solution. The
solution is kept under ebullition and protected from light for
30 min. After this, the solution is cooled down to room temperaturenanobeacon is composed of a hairpin DNA structure with a gold nanoparticle at 50
phore is forced to be in close proximity with gold nanoparticles and fluorescence is
hores. On the other hand, in the presence of a target that can hybridize with the
parted from the gold nanoparticles resulting in restoration of fluorescence. A cy3-
reaction acting as a reporter of the levels of transcription. Simultaneously, a FAM-
template which results in inhibition of in vitro transcription. The fluorescence of
moter sites are being blocked and how many RNA products are being formed is
1
J. Rosa et al. / Biosensors and Bioelectronics 36 (2012) 161–167 163and kept protected from light. Citrate–gold nanoparticles were
characterized by Transmission Electron Microscopy (TEM) and
UV–vis spectroscopy (see Figure S1 in Supplementary Information).
2.3. Gold-nanobeacons syntheses
We prepared two gold-nanobeacons: the inhibitor, a stem–
looped oligonucleotide double labeled with 30-FAM and 50-Thiol-
C6 (50-TTTGCATCTCCCTATAGTGAGTCGTATTATGCAAA-30) com-
plementary to the promoter region recognized by T7-RNA
polymerase, thus capable of blocking the transcriptional machin-
ery at the specific promoter site; the reporter, a stem–looped
oligonucleotide double labeled with 30-Cy3 and 50-Thiol-C6
(50-TTTGCATAGCTGTTCAAGTTTGTGTTTCATGCAAA-30) complemen-
tary to the c-MYC transcript produced by in vitro transcription—
see below. Briefly, the thiolated oligonucleotides (STAB Vida,
Portugal) were suspended in 1 mL of 0.1 M dithiothreitol (DTT),
extracted three times with ethyl acetate and further purified
through a desalting NAP-5 column (Pharmacia Biotech, Sweden)
using 10 mM phosphate buffer (pH 8) as eluent. Following
oligonucleotide quantification via UV/Vis spectroscopy, each oli-
gomer was added to the AuNP solution in a 50:1 ratio. AGE I
solution (2% (w/v) SDS, 10 mM phosphate buffer (pH 8)) was
added to the mixture to achieve a final concentration of 10 mM
phosphate buffer (pH 8), 0.01% (w/v) SDS. The solution was
sonicated for 10 s using an ultrasound bath and incubated at
room temperature for 20 min. After this period, 0.045 mg/mL of
O-(2-Mercaptoethyl)-O0-methyl-hexa(ethylene glycol), C15H32O7S
was added to the mixture and incubated for another 20 min at
room temperature. Afterwards, the ionic strength of the solution
was increased sequentially in 50 mM NaCl increments by adding
the required volume of AGE II solution (1.5 M NaCl, 0.01% (w/v)
SDS, 10 mM phosphate buffer (pH 8)) up to a final concentration
of 10 mM phosphate buffer (pH 8), 0.3 M NaCl, 0.01% (w/v) SDS.
After each increment, the solution was sonicated for 10 s and
incubated at room temperature for 20 min before the next
increment. Following the last addition, the solution was left to
rest for additional 16 h at room temperature. Then, the functio-
nalized Au-nanobeacons were centrifuged for 20 min at
21,460 g, the oily precipitate washed three times with DEPC-
treated H2O, and redispersed in the same buffer to a final
concentration in Au-nanobeacons of 15 nM. The resulting Au-
nanobeacons were stored in the dark at 4 1C until further use.
2.4. Quantitation of beacon coverage on AuNPs
Coverage, i.e. average number of labeled beacons per nano-
particle was assessed following complete displacement of the
thiolated oligonucleotides (beacons) from the AuNP by means of
0.12 mM b-Mercapthoethanol incubation for 48 h. After 48 h at
room temperature, the solutions were centrifuged at 14500g for
20 min. The concentration of beacon in the supernatant was
measured by monitoring the emission spectra of FAM
(Exc¼490 nm) or Cy3 (Exc¼530 nm) dyes in a Cary Eclipse
(Varian, USA) using an Ultra-Micro quartz cell (Hëllma, Germany).
All the AuNPs samples and the standard solutions of the thiol-
oligonucleotide beacon were kept at the same pH and ionic
strength and calibration for all measurements. Fluorescence
emission was converted to molar concentrations of the thiol
modified oligonucleotide by interpolation from a standard linear
calibration curve. Standard curves were prepared with known
concentrations of beacon using the same buffer pH, salt, and
b-Mercapthoethanol concentrations. The average number of molecu-
lar beacon strands per particle was obtained by dividing the
oligonucleotide molar concentration by the AuNP concentration.2722.5. RNA extraction and cDNA production
Total RNA extracted from HL-60 cells was subjected to RT for
cDNA synthesis with Revert-AidTM M-MuLV Reverse Transcrip-
tase (Fermentas, Vilnius, Lithuania) according to the man-
ufacturer0s specifications, using 20 mM of MYCreverse primer,
annealing at 42 1C for 1 h and 70 1C for 10 min to reverse tra-
nscriptase inactivation. Gene specific primers MYCforward:
50-GCTCATTTCTGAAGAGGACTTGT-3 and MYCreverse: 5r-AGG-
CAGTTTACATTATGGCTAAATC-30 can then be used to PCR amplify
a 229-bp fragment of the human v-myc myelocytomatosis viral
oncogene homolog (c-MYC) gene (Gene-Bank accession no.
NM_002467.4).
2.6. Transcription template preparation and purification
PCR amplification of the c-MYC specific fragment was per-
formed in duplicate on a MyCycler Thermocycler (Biorad) in 25 mL
using 1 mM of primers, 2.5 mM dNTPs with 1 U Taq DNA Poly-
merase (Amersham Biosciences, GE Healthcare, Europe, GmbH),
with the following thermal cycling conditions: initial 5 min dena-
turation at 95 1C, followed by 30 amplification cycles of denatura-
tion at 95 1C for 30 s, annealing at 62 1C for 30 s, elongation at 72 1C
for 30 s, and a final elongation at 72 1C for 5 min. This amplification
product was re-amplified under the same reaction conditions and
thermal cycling as above using a T7 promoterMYCforward
primer (50-TAATACGACTCACTATAGGGAGAGCTCATTTCTGAAGAG-
GACTTGT-30). The resulting 252-bp T7-MYC-fusion fragment
was then PCR amplified using primers MYCreverse and T7 primer
(50-TAATACGACTCACTATAGGGAGA-30) as described above and
purified through band gel extraction. Confirmation of correct PCR
products was performed by 2% agarose gel electrophoresis stained
with GelRed
TM
. This amplification product was used as template for
in vitro transcription reactions.
2.7. Real-time RT-PCR
To evaluate the expression of the c-MYC transcript, Real-time
RT-PCR was performed. Real-Time PCR amplification was per-
formed in a Corbett Research Rotor-Gene RG3000 using SYBR
GreenER Real-Time PCR Kit (Invitrogen) according to manufac-
turer’s specifications in 50 ml reactions containing 6 ml of cDNA
from HCT-116 cells, 1 SYBR Green SuperMix and 200 nM of
primers (STAB Vida)—MYCforward and MYCreverse. The amplifi-
cation conditions consisted of 50 1C for 2 min hold, 95 1C during
10 min hold, followed by 50 cycles consisting of denaturation at
95 1C for 30 s, annealing at 60 1C for 30 s, extension at 72 1C for
30 s, with a final extension step at 72 1C for 10 min. Data were
collected from three independent experiments.
2.8. Monitoring RNA synthesis
Standard in vitro transcription was performed in 100 mL reaction
containing in vitro transcription buffer (200 mM Tris-HCl (pH 7.9),
30 mM MgCl2, 50 mM NaCl, 10 mM spermidine), 10 mM of each
NTP, 0.6 mg of DNA template, and 30 U of T7 RNA polymerase
(Fermentas, Vilnius, Lithuania) according to the manufacturer’s
protocol. For the real time quantification experiments, 1 nM of
the reporter Au-nanobeacon (labeled with Cy3) was added to each
transcription reaction. When using the inhibitor Au-nanobeacon
(labeled with FAM), 1 nM was also added to the reaction mixture.
All measurements were performed in a PerkinElmer LS45 Fluores-
cence Spectrometer (USA) using an Ultra-Micro quartz cell (Hëllma,
Germany) programmed to incubate the reactions for 120 min at
37 1C while recording the fluorescence intensity of the Au-nano-
beacon every 2 min at an excitation wavelength of 490 nm or
J. Rosa et al. / Biosensors and Bioelectronics 36 (2012) 161–167164530 nm for FAM-labeled or Cy3-labeled Au-nanobeacon, respec-
tively. After the measurements, the enzyme was heat inactivated
for 15 min at 75 1C.
All transcription reaction products were also evaluated on a 3%
agarose gel electrophoresis with GelRedTM staining. Product
quantity determination was performed by pixel intensity/count-
ing using ImageJTM imaging software as previously described
(Luhtala and Parker, 2009).3. Results and discussion
3.1. Au-nanobeacon design
We demonstrate the use of Au-nanoparticle based molecular
beacon structures (Au-nanobeacons) for real time monitoring of
RNA synthesis. First, we designed Au-nanobeacons constituted by
AuNPs with an average diameter of 14 nm (see Figure S1 in
Supplementary Information) that work both as support structure
for the thiolated DNA hairpin structure labeled with Cy3 or FAM
and as a quencher to these fluorophores. Much like standard
molecular beacons, in the native conformation the hairpin struc-
ture is closed and the fluorophore (Cy3 or FAM) and AuNP are
brought together, and fluorescence is quenched. In one
Au-nanobeacon, the loop in the hairpin structure is complemen-
tary to a fragment of the c-MYC proto-oncogene mRNA produced
by in vitro transcription (reporter); as transcription occurs, theFig. 2. Au-nanobeacon calibration. (A) – Reporter Au-nanobeacon normalized emission
(gray diamonds, y¼0.8482xþ0.0719; and black triangles, y¼1.2634xþ0.1614, respe
squares, y¼0.1076xþ0.0539, respectively) RNA products for increasing transcription te
corresponding to the transcript for higher template mass. (B) – Inhibitor Au-nano
Transcription inhibition with increasing amounts of inhibitor Au-nanobeacon. (C) – R
increasing concentrations of total RNA (0 ng/mL – white circles, 6.7 ng/mL – black diamo
at least 3 independent assays. (D) – Real-time PCR of the total RNA samples tested with
13.3 ng/mL – black dashed line, 26.7 ng/mL – black full line). Inset: Plot of Cycle Thr
represents the cycle number at which the fluorescence produced within a reaction cro
27presence of mRNA target induces the opening of the reporter’s
structure with concomitant fluorescence intensity increment.
Transcription of a gene into mRNA is highly regulated and can
be elegantly switched on and off by blocking the respective
promoter. The RNA promoter determines the maximal rate of
RNA synthesis and is the site of binding or ‘‘initiation’’ for RNA
polymerase. To silence gene transcription, we constructed an
inhibitor Au-nanobeacon complementary to the promoter region
recognized by the T7-RNA polymerase, thus capable of blocking
the transcriptional machinery at the specific promoter site and
impede transcription. However, the same rationale may be used
to target any specific gene sequence of choice, thus blocking a
specific gene from being transcribed.
3.2. Au-nanobeacon calibration
First, we calibrated the response of the reporter Au-nanobea-
con to the complementary target using the DNA template that
was subsequently used for in vitro transcription (see Fig. 2A).
A 10-fold increase in fluorescence was detected upon hybridiza-
tion of the Au-nanobeacon to the complementary target at 37 1C
when compared to hybridization to non-related target, showing
that the nanobeacon is capable of specific sequence recognition.
To ensure that, during transcription, the Au-nanobeacon in solu-
tion would not be totally hybridized to the DNA template alone
before transcription started, a fixed amount of Au-nanobeacon
was added to crescent target concentrations, heated and cooled-
down to induce maximum hybridization before transcription.before and after transcription of dsDNA templates that generate complementary
ctively) and non-complementary (black crosses, y¼0.0618xþ0.0018; and white
mplate. Inset: Agarose gel demonstrating an increase in the intensity of the band
beacon normalized emission in presence of increasing dsDNA template. Inset:
eporter Au-Nanobeacon normalized emission for 120 min at 37 1C in presence of
nds, 13.3 ng/mL – black triangles, 26.7 ng/mL – white squares). Error bars represent
the reporter Au-nanobeacon (0 ng/mL – gray dashed line, 6.7 ng/mL – gray full line,
eshold vs. [total RNA], y¼0.8721xþ54.1, R2¼0.9948. The Threshold Cycle (Ct)
sses the threshold line (horizontal dotted line at Intensity¼2).
3
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after transcription was measured. The fluorescence intensity
consistently increases after transcription indicating that, although
higher quantities of template correspond to higher fluorescent
intensities, there are still hairpin-structures available for specific
hybridization to the newly formed transcript. It should be noted
that, when compared to traditional molecular beacons, we have
more than one hairpin-oligonucleotide per nanoparticle, which
results in better signal to background noise, i.e. better capability
to detect complementary targets that has also been previously
reported by others (Cheng et al., 2011). From these calibrating
experiments, a working concentration of 0.6 mg of template for
the real-time assay was selected. The reporting signal obtained
from the reporter Au-nanobeacon was further validated by
(i) hybridization to total RNA containing complementary target
– Fig. 2C; and (ii) real-time quantitative PCR, the gold standard for
transcript quantification – Fig. 2D. Results corroborate the quan-
tification capability of the reporter Au-nanobeacon.
The inhibitor Au-nanobeacon presents an average of 4.957
0.66 oligomer per AuNP (see Figure S4 in Supplementary Informa-
tion). We first calibrated the inhibitor Au-nanobeacon as
described above for the reporter Au-nanobeacon, showing its
capability to specifically detect its complementary target
sequence inducing a 4.3-fold increase in fluorescence, while not
hybridizing to a non-complementary target (Figure S5 in Supple-
mentary Information). In a typical inhibition assay, the dsDNA
template (T7-MYC) is incubated with increasing concentrations of
inhibitor Au-nanobeacon and then the transcription reaction is
carried out. Following agarose gel electrophoresis, quantification
of the amount of mRNA produced in each transcription showed a
steady decrease with increasing amount of inhibitor Au-nanobea-
con, as expected – Fig. 2B. It is clear that the inhibitor Au-
nanobeacon can effectively compete with the template DNA
sequence for RNA polymerase and drastically reduce the level of
transcription. This is in clear agreement with previous reportsFig. 3. Au-nanobeacon effect on in vitro transcription. In vitro transcription in the
presence of the reporter Au-nanobeacon (black bars) and in the presence of both
reporter (1 nM) and inhibitor (1 nM) Au-nanobeacons (white bars) with increasing
amounts of DNA template, measuring the fluorescent intensity of cy3 (l¼530 nm)
for two independent assays (n¼2). Full bars correspond to average of the assays
and the error bars to the respective standard deviation.
Table 1
In vitro transcription inhibition vs. inhibited Au-nanobeacon hybridization.
Added template (mol1012) 1.29 (0.2 mg) 2.57 (0.4 mg
Inhibited template (mol1012) 0.23 (17.63%) 0.35 (13.79
Inhibition of transcription (%) 96.14 90.69
Inhibitor saturation (%) 45.34 70.95
274that demonstrate that AuNPs enhance the silencing capability of
oligonucleotides, while conveying protection against nucleases
(Conde et al., 2010). At the same time it blocks transcription, the
inhibitor Au-nanobeacon simultaneously signals out the amount
of target it is binding to, i.e. the fraction of promoters being
blocked at any given time.
3.3. Monitoring of RNA synthesis inhibition
We then used the reporter and the inhibitor Au-nanobeacons
simultaneously in the same reaction vial so as to assess transcrip-
tion and transcription inhibition – Fig. 3. Data show increasing
fluorescence output from the reporter Au-nanobeacon with
increasing concentrations of template that correlates with
increasing levels of transcription. The presence of the inhibitor
Au-nanobeacon (1 nM) can be noted by a decrease in fluorescence
from the reporter (1 nM) Au-nanobeacon, showing that it is
blocking transcription.
As the concentration of template increases, the level of
transcription also increases showing that the same amount of
inhibitor Au-nanobeacon is blocking a smaller percentage of all
the available templates present in the reaction medium. In fact,
considering that each AuNP of the inhibitor Au-nanobeacon
possess an average of five hairpins on its surface, one may assume
that all the hairpins per AuNP are in the open conformation if
each Au-nanobeacon is blocking five promoters. In this situation
the inhibitor Au-nanobeacon is saturated and ceases to respond to
incremental increases in target concentration, which happens
for a concentration of target of about 10 mg (6.431011 mol)
(see Fig. 2B). Taken this into account and retrieving the fluores-
cence of the inhibitor Au-nanobeacon, it is possible to determine
the ratio of promoters being effectively blocked  Table 1. The
percentage of promoters being blocked is lower for the higher
template concentrations, which correlates to lower inhibition and
consequent higher levels of transcription. This way, we demon-
strate that this system can effectively quantify the level of RNA
synthesis and simultaneously assess the ratio of blocked promo-
ters. To the best of our knowledge, this is the first time a DNA-
AuNP conjugate is used to simultaneously silence transcription and
quantify the percentage of promoters being effectively blocked.
3.4. Real-time assessment of transcription and inhibition – a dual
color Au-nanobeacon approach
Based on the previous results, we employed the same
approach to follow the in vitro transcription in real-time –
Fig. 4. We used both Au-nanobeacons in the same RNA synthesis
reaction towards a dual-color system for the real time monitoring
of both RNA synthesis and level of inhibition. We first measured
the fluorescence of the reporter Au-nanobeacon for 120 min
immediately after the addition of T7 enzyme and NTPs to a
previously stabilized solution containing the Au-nanobeacon
and template. The reporter Au-nanobeacon signals the continuous
synthesis of the complementary mRNA, whilst the production of a
non-related transcript induces no changes to the fluorescence
intensity. Because of the calibration of the Au-nanobeacon) 3.86 (0.6 mg) 5.14 (0.8 mg) 6.43 (1 mg)
%) 0.42 (10.79%) 0.36 (6.91%) 0.49 (7.64%)
66.49 62.00 56.39
83.23 71.08 98.28
Fig. 4. Real-time in vitro transcription and inhibition using Au-nanobeacons. In vitro
transcription was measured (excitation wavelength of 530 nm, primary axis) in
real-time in presence of the reporter Au-nanobeacon (black circles) and in
simultaneous presence of the reporter and inhibitor Au-nanobeacons (white
squares). The emission of the inhibitor Au-nanobeacon was also measured through-
out the experience (black stars, secondary axis, and excitation wavelength 490 nm).
J. Rosa et al. / Biosensors and Bioelectronics 36 (2012) 161–167166previously described it is possible at any time point to correlate
directly to the actual amount of RNA being produced (as number
of moles or mass). This is extremely relevant if one is to study the
regulatory and controlling elements of transcription of a given
gene.
We then combined 1 nM of each Au-nanobeacon in one in vitro
transcription reaction and measured the fluorescent intensity of
both fluorophores with excitation at 490 and 530 nm. During the
entire reaction time there was no rise in fluorescence associated
with production of transcript (reporter Au-nanobeacon), showing
that the inhibitor Au-nanobeacon is effectively blocking the
promoter. The inhibitor’s emission is constant throughout the
entire time lapse, and the percentage of blocked promoters can be
easily determined via the procedure described above (7.61%). The
level of inhibition of transcription can be easily calculated for
each time point. What is more, as can be seen in Figure S7B in
Supplementary Information, a normalized intensity curve can be
plotted as function of the resulting transcription product
retrieved from the agarose gel electrophoresis (see Figure S7A in
Supplementary Information).
Real-time monitoring of RNA transcription reactions gave
fluorescence plots with an initial lag phase, followed by a first-
order increase. The initial lag may be due to assay sensitivity and
kinetics of double-helix formation between the Au-nanobeacon
and its RNA target. Comparison between the linear phase of the
RNA synthesis for the reporter Au-nanobeacon (black circles) and
reporterþ inhibitor (white squares) demonstrate that we can
achieve a 14.1-fold decrease in RNA synthesis after 60 min of
transcription (618 fmol of RNA and 43.9 fmol of RNA, respec-
tively). These results were confirmed through quantification of
transcription via agarose gel electrophoresis (see Figure S8 in
Supplementary Information).4. Conclusions
Here, we demonstrate the use of Au-nanobeacons capable of
recognizing specific complementary sequences that can be easily
synthesized by functionalization of gold nanoparticles with thio-
lated DNA hairpin oligonucleotides. One of the Au-nanobeacons
was designed so as to monitor the synthesis of a specific RNA27sequence related to the human proto-oncogene c-MYC – reporter;
whereas the inhibitor was designed to specifically recognize the
c-MYC sequence downstream of the RNA polymerase T7 promo-
ter, thus blocking transcription in a sequence dependent manner.
Because of its beacon conformation, the inhibitor is able to
simultaneously block the promoter and signal out the number
of promoters being effectively blocked. Following Au-nanobea-
cons calibration, we used them to quantitatively monitor
RNA synthesis in real-time and for kinetic quantification of RNA
transcript synthesized by a RNA polymerase (10.3 fmol of RNA
per minute of reaction). We also demonstrate that by combining
the use of a reporter and an inhibitor Au-nanobeacon, we were
able to create a dual color system capable of quantify transcrip-
tion and the level of inhibition in a single reaction vial. It is
possible to quantify the level of inhibition of the RNA synthesis
and relate it to the amount of template being effectively silenced,
i.e. assessing actual silencing capability. Even though some
reports can be found on the use of gold nanoparticles for
detection of gene expression, to the best of our knowledge, this
is the first time an approach for the simultaneous quantitative
monitoring of RNA synthesis and inhibition in real-time is
reported. The proposed Au-nanobeacon biosensor allows for fast,
accurate and sensitive RNA transcript expression profiling.
A unique feature of this sensor, compared to conventional
measurements of polymerase activities using intercalating dyes,
is that the probes do not generate a signal from unrelated nucleic
acids and polymerase activities can be distinguished from pro-
moter-specific RNA polymerization. The simplicity and speed of
the sensor are also great advantages.
This new Au-nanobeacon sensor allows extending quantifica-
tion of gene expression to real-time assessment of transcription
and inhibition, thus providing means to evaluate the potential of a
given sequence to effectively silence a target gene. Also, because
the AuNPs confer resistance to nuclease degradation, these
sensors may be used to follow gene silencing in vivo, thus
providing additional information to assist modeling of actual
gene therapy protocols. Nevertheless, before in vivo utilization,
exhaustive studies need to be conducted in situations of increas-
ing complexity, e.g. complex reaction mixtures, cell extracts and
cell lineages.Acknowledgments
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Figure S1. Gold nanoparticle characterization. TEM images (left, scale bar = 100 
nm), size distribution histogram (right) showing an average diameter of 14.3 nm; UV-
Vis spectra of the synthesized gold nanoparticles (bottom). 
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Figure S2. Two-dimensional structures of the inhibitor and reporter Au-
nanobeacons at 37ºC as predicted by NUPACK (Zadeh, J.N., Steenberg, C.D., Bois, 
J.S., et al., 2011. NUPACK: analysis and design of nucleic acid systems. J. Comput. 
Chem. 32, 170–173.) 
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Figure S3. Absorption and emission spectra of the fluorophores. Absorption (full 
lines) and emission (dashed lines) spectra of FAM (black lines) and cy3 (grey lines). 
Vertical lines represent the excitation wavelength of each fluorophore. Cy3 was excited 
at 530 nm to enhance the full emission spectra.  
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Figure S4. Oligonucleotides density - inhibitor Au-nanobeacon. Calibration curve of 
FAM-labeled oligonucleotide (diamonds, y=36090.0x2+9625.8x+89.7, R2=0.9996) and 
fluorescence intensities measured in the supernatants of Au-nanobeacon (circles). A 
ratio of 4.96±0.66 oligonucleotides per gold nanoparticle was calculated. 
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Figure S5. Inhibitor Au-nanobeacon specificity. Hybridization kinetics of the Au-
nanobeacon inhibitor at 37º C in presence of the complementary target (black 
diamonds) and non-complementary target (white squares). 
282
7 
 
 
 
Figure S6. Real-time monitorization with the reporter Au-nanobeacon. Real-time 
measurement of in vitro transcription of RNA products showing complementarity to the 
reporter (black circles) and without any complementarity to the reporter (white 
squares). The complementary RNA product caused a linear response 
(y=0.1066x0.1336) corresponding to the formation of 10.6 fmol of RNA/min. 
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Figure S7. A. Agarose gel electrophoresis of the transcription product as function of 
time. B. Normalized intensity curve plotted as function of the resulting transcription 
product retrieved from the agarose gel electrophoresis (white triangles) and with the 
fluorescence intensity measurements of the reporter Au-nanobeacon (black circles) for 
120 minutes immediately after the addition of T7 enzyme and NTPs to a previously 
stabilized solution containing the Au-nanobeacon and template. All transcription 
reaction products were also evaluated on a 3% agarose gel electrophoresis with 
GelRedTM staining. Product quantity determination was performed by pixel 
intensity/counting using ImageJTM imaging software as previously described (Luhtala 
and Parker, 2009). 
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Figure S8. Agarose gel electrophoresis of end-point measurements of RNA 
synthesis and inhibition using active and non-active (denaturated) T7 RNA 
polymerase. Data show that fluorescence is strictly dependent of transcription of the 
added template. Lane 1 – Reporter + Inhibitor with active T7 Pol., Complementary 
target (T7-MYC); Lane 2 – Reporter with active T7 Pol., Complementary target (T7-
MYC); Lane 3 – Reporter + Inhibitor with non-active T7 Pol., Complementary target 
(T7-MYC); Lane 4 – Reporter with non-active T7 Pol., Complementary target (T7-
MYC); Lane 5 – Reporter with active T7 Pol., Non-complementary target I (X); Lane 6 
– Reporter + Inhibitor with active T7 Pol., Non-complementary target I (X); Lane 7 – 
Reporter with active T7 Pol., Non-complementary target II (T7-Y); Lane 8 – Reporter + 
Inhibitor with active T7 Pol., Non-complementary target II (T7-Y).  
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The potential of a single molecular nanoconjugate to intersect all RNA pathways: from gene specific
downregulation to silencing the silencers, i.e. siRNA and miRNA pathways, is demonstrated. Gold-
nanobeacons are capable of efficiently silencing single gene expression, exogenous siRNA and endoge-
nous miRNAs while yielding a quantifiable fluorescence signal directly proportional to the level of
silencing. The silencing potential is comparable to that of traditional siRNA but the same nanoconjugates
structure is also capable of reversing the effect of an exogenous siRNA. We further demonstrate the Gold-
nanobeacons’ efficiency at targeting and silencing miR-21, an endogenous miRNA involved in cancer
development, which could become a valid nanotheranostics approach. Again, expression of miR-21 was
inhibited with concomitant increase of the Au-nanobeacons’ fluorescence that can be used to assess the
silencing effect. This way, a single nanostructure can be used to intersect all RNA regulatory pathways
while allowing for direct assessment of effective silencing and cell localization via a quantifiable fluo-
rescence signal, making cancer nanotheranostics possible.
 2012 Elsevier Ltd. All rights reserved.́
1. Introduction
Antisense DNA [1,2], small interfering RNA (siRNA) [3e5] or
microRNA [6] technologies have been widely explored to modulate
RNA expression [7e9] and may also be directed towards silencing
endogenous miRNAs, whose deregulation is associated with cancer
development. Within the intricate network of cell regulation, RNA
pathways are key regulatory players of gene expression and cell fate,
where deregulation of endogenous miRNAs has been associated
with tumor progression and differentiation. Particularly, upregu-
lated miRNAs act as endogenous silencers of crucial pathways and
silencing these silencers constitute optimal targets for treatment [8].
The ability of modulating miRNA expression in tumor cells is of
paramount relevance and has been drawing increasing interest from
researchers that require tools capable of silencing these endogenous
silencerswhile signaling out for evaluation. These silencing tools can
be conveyed into mammalian cells by a variety of methods [10e14]
that influence the strength and duration of the silencing response,
which in turn is affected by the amount of therapeutic agent that isAll rights reserved.
28delivered and on the potential of each agent to suppress its target.
Thus, one potential drawback of using naked silencing tools is that
they showextremely short half-lives, weak protection against action
by RNases, poor chemical stability, and common dissociation from
vector [15,16]. In fact, themajor obstacle to clinical application is the
uncertaintyabout how to deliver therapeutic RNAs (e.g.,miRNA and/
or siRNA) with maximal therapeutic impact. Nanotechnology offers
an unprecedented opportunity to overcome these problems, as
nanoscale devices, due to their small size, can readily interact with
biomolecules onboth the surface of cells and inside of cells for longer
periods of time [16].
Gold nanoparticles (AuNPs) are optimal delivery vehicles
for antisense and siRNA therapy because they provide enhanced
protection against RNases and ease of functionalization with moie-
ties for selective targeting [15]. Engineered AuNPs are effortlessly
internalized by cells and they outperform traditional delivery
systems leading to effective gene silencing [17e26]. Previous reports
show that single-stranded DNA functionalized AuNPs represents
a good gene delivery system with greater knockdown of gene
expression and lower cell toxicity than antisense DNA delivered by
Lipofectamine [17]. Additionally, these AuNPs constructs often have
fluorophores on the surface for intra-cellular tracking of the NPs
regardless of being actively hybridizing to the target molecules and
silencing them. Recently, we provided evidence of in vitro and in vivo6
J. Conde et al. / Biomaterials 34 (2013) 2516e2523 2517RNAi triggering via the synthesis of a library of multifunctional
siRNAeAuNPs, using a hierarchical approach including three bio-
logical systems of increasing complexity: in vitro cultured human
cells, in vivo freshwater polyp (Hydra vulgaris), and in vivo mice
models [27]. Nevertheless, a nanoformulation that explores the
capacity of silencing any RNA target, be it gene specific mRNA,
exogenous (siRNA and antisense oligonucleotides) or endogenous
(microRNAs) silencers has not been described so far. To realize the
therapeutic potential of blocking crucial silencing pathways, we
developed a nanoparticle delivery technologyeGold-nanobeacone
to target and promote silencing ofmiRNAs involved in the regulation
of gene expressionwhileprovidingmeans to assess effective binding.
The ubiquitous application of this gold-nanobeacon approach for
gene silencing was further demonstrated by pursuing an antisense,
RNA interference and microRNA approaches and to support the
recovery of gene expression in cancer cells.
Recently, we reported a direct method to follow RNA synthesis
and inhibition in real time based on the use of AuNPs functionalized
with a fluorophore labeled hairpin-DNA, i.e. Gold nanobeacons (Au-
nanobeacon) [28]. In these Au-nanobeacons, the fluorescently
labeled hairpin DNA brings the fluorophore into close proximity
to the AuNP, quenching fluorescence. Hybridization of the Au-
nanobeacon to the complementary target restores fluorescence.
Here, we propose that a strategy based on Au-nanobeacons is
capable of intersecting both pathways of interference RNA regu-
lating gene expression e siRNA and miRNA. Our approach is based
on the use of Au-nanobeacons to directly downregulate a specific
gene (EGFP) and also to silence the silencers allowing for recovery
of previously downregulated gene expression, while simulta-
neously tracking cell internalization and identifying the cells where
silence is occurring. Following proof-of-concept demonstration, we
target for silencing an endogenous microRNA (miR-21) commonly
upregulated in cancer to illustrate the Au-nanobeacons’ potential
for anti-cancer therapeutics via the silencing of the silencers
pathway in colorectal carcinoma cells (HCT-116) (see Fig. 1).
2. Materials and methods
2.1. Gold nanoparticles synthesis and Au-nanobeacon assembly
Gold nanoparticles, with an average diameter of 14.6  1.7 nm, were synthe-
sized by the citrate reduction method described by Lee and Meisel [29]. AuNPs
were then functionalized with polyethylene glycol (PEG) using commercial hetero-
functional PEG modified with a thiol group O-(2-Mercaptoethyl)-O0-methyl-
hexa(ethylene glycol), C15H32O7S, 356.48 Da. Excess PEG was removed by centri-
fugation (21.460  g, 30 min, 4 C), and the level of PEG coverage on the AuNP
evaluated via the Ellman’s Assay to be 190  20 chains per nanoparticle, corre-
sponding to 30% of saturation of the gold’s surface. For Au-nanobeacon assembly,
the stem-looped oligonucleotides modified with 30-Cy3 and 50-Thiol-C6 (STAB-
VIDA) were suspended in 1 ml of 0.1 M dithiothreitol (DTT), extracted three times
with ethyl acetate and further purified through a desalting NAP-5 column (Phar-
macia Biotech) using 10 mM phosphate buffer (pH 8) as eluent. Following oligo-
nucleotide quantification via UV/Vis spectroscopy, each oligomer was added to the
AuNP@PEG in a 100:1 ratio and processed as previously described [28]. Finally, the
resulting Au-nanobeacons were centrifuged for 20 min at 21.460  g, the oily
precipitate washed three times with DEPC-treated H2O, and redispersed in 10 mM
phosphate buffer (pH 8), 0.3 M NaCl, 0.01% (w/v) SDS at a final concentration of
15 nM. The resulting Au-nanobeacons were stored in the dark at 4 C until further
use. Detailed Au-nanobeacons characterization can be found in Supporting
Information Table 1.
2.2. Target specificity of the Au-nanobeacons
The capability to recognize the specific target was evaluated by incubating 1 nM
of each Au-nanobeacon in 10 mM phosphate buffer (pH 7) with 5 nM of a comple-
mentary and a non-complementary target (see Supporting information, Fig. S4). Cy3
fluorescence intensity as function of incubation time was determined at 2 min
intervals in a PerkinElmer LS45 Fluorescence Spectrometer (Cary Eclipse, Varian)
using an Ultra-Micro quartz cell (Hëllma) programmed to incubate the reactions for
120 min at 37 C (excitation/emission, 530 nm/560 nm). Additional information on
target recognition can be found in Supporting Information Fig. S3.2872.3. Cell culture and EGFP vector transfection
HCT-116 cells (from colorectal carcinoma) were grown in Dulbecco’s modified
Eagle’s medium with Glutamax (DMEM, Invitrogen) with 10% heat inactivated fetal
bovine serum (Invitrogen), 100 U/ml penicillin and 100 mg/ml streptomycin (Invi-
trogen) and maintained at 37 C in 5% CO2. Cells were seeded at a density of 1 105
cells/well in 24-well plates and grown for 24 h prior to transfection of the EGFP
vector (pVisionGFP-N vector 4.7 kb, Biovision) encoding for green fluorescent
protein, VisionGFP, optimized for high expression in mammalian cells. On the day of
transfection, EGFP vector (1 mg per well) was added cells at approximately 50%
confluence with 2 mg of Lipofectamine 2000 (Invitrogen) and Opti-MEM Reduced
Serum Medium (Invitrogen) according to the manufacturer’s recommendations.
2.4. EGFP silencing with antisense Au-nanobeacon
After 24 h of EGFP transfection, cells were treated with 30 nM of Antisense Au-
nanobeacons in Opti-MEM Reduced Serum Medium (Invitrogen). After 48 h, cells
were washed with 1  PBS, lysed in water and collected for analysis of EGFP
silencing, RNA extraction and confocal imaging. Fluorescence was measured at least
3 times in a Cary Eclipse spectrofluorimeter (Varian) using an Ultra-Micro quartz cell
(Hëllma) by taking the area under the curve from 495 to 650 nm. EGFP fluorescence
values were normalized to the bulk protein concentration determined via the
Bradford assay (Thermo Scientific), and then normalized against the controls to
determine percent knockdown of EGFP.
2.5. EGFP silencing via siRNA and Au-nanobeacon silencing of siRNA pathway
After 24 h of EGFP transfection, cells were treated with 10 nM of siRNA for EGFP
using 1.5 mg of Lipofectamine 2000 (Invitrogen) and Opti-MEM Reduced Serum
Medium (Invitrogen) according to the manufacturer’s recommendations. EGFP
silencing was evaluated as described above. For Au-nanobeacon silencing of siRNA
evaluation, 10 nM (concentration of beacon on NP) of Anti-siRNA Au-nanobeacon
were added to the media with 10 nM of siRNAwith several delays of incubation (0.5,
1, 3, 6 and 24 h). After 48 h, the cells were washed in 1  PBS, lysed with water and
collected for analysis of EGFP recovery as above.
2.6. Silencing the silencer e Au-nanobeacon for endogenous microRNA-21 silencing
Cells were seeded at a density of 1 105 cells/well in 24-well plates and grown
for 24 h prior to incubation with 10, 30 and 50 nM Anti-miR-21 Au-nanobeacon for
24, 48 and 72 h. After 24, 48 and 72 h, cells were washed with 1  PBS, lysed and
collected for RNA extraction and confocal imaging.
2.7. qRT-PCR
Total RNA was extracted from the cell line using the Trisure reagent (Bioline)
according to the manufacturer’s protocol, and used for qRT-PCR to evaluate
expression of EGFP, miR-21 and b-actin. cDNA was attained by subjecting 1 mg of
total RNA to Reverse Trancriptase with 200U of Revert-AidTM M-MuLV Reverse
Transcriptase (Fermentas) according to the manufacturer’s specifications, using
20 mM of EGFP and b-actin reverse primers and miR-21 loop primer, annealing at
42 C for 1 h and 70 C for 10 min to reverse transcriptase inactivation.
Real-Time PCR amplification was performed in a Corbett Research Rotor-Gene
RG3000 using SYBR GreenER Real-Time PCR Kit (Invitrogen) according to manu-
facturer’s specifications in 50 ml reactions containing 2 ml of cDNA, 1  SYBR Green
SuperMix and 200 nM of primers (STABVIDA, Portugal). Detailed information on
primer sequence, cycling conditions, melting analysis and data processing can be
found in Supporting Information Figs. S5, S6 and Table 3.
2.8. Confocal microscopy
All confocal microscopy samples were prepared as described above for EGFP
silencing and recovery and miR-21 silencing. Cells were fixed with 4% para-
formaldehyde in 1 PBS for 15min at 37 C andmounted in ProLong Gold Antifade
Reagent with DAPI (Invitrogen) to allow for nuclear staining. Images of cells were
taken with a Confocal Laser Point-Scanning Microscope Zeiss LSM 510 META. Once
optimized, the samemicroscope settings were used throughout. The laser lines used
for excitationwere 405 nm for DAPI (nucleus), 480 nm for EGFP, and 561 nm for Cy3
(Au-nanobeacons).
2.9. Cytotoxicity evaluation
Standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide]
reduction assay (Invitrogen) was performed to determine cytotoxicity following
transfection with Au-nanobeacons, siRNA and ssRNA complexes as described above.
After 24 h, 100 ml of Au-nanobeacons were added to the wells and cells further incu-
bated for 48 and72h. Followingmediumremoval, cellswerewashed twicewith sterile
1 PBS and incubated for 2 hwith 300 ml of freshmediumwith serum supplemented
with 16.7 ml of sterile MTT stock solution (5 mg/ml in 1  PBS). Next, medium was
Fig. 1. Au-nanobeacons as multi-targeting tools for RNAi: from specific gene silencing to silencing the silencers. (a) GENE SILENCING e human cancer cells (HCT-116) efficiently
transfected with EGFP expression vector were used for assessing the gene silencing potential of Au-nanobeacons e antisense Au-nanobeacon ( ) and by traditional siRNA
approach ( ). Upon hybridization to the target sequence, the beacons’ conformation change leads to fluorescence emission that signals target recognition and that silencing is
occurring. (b) SILENCING THE SILENCERS e specific Au-nanobeacons are capable of intersecting both pathways e siRNA ( ) and miRNA ( ), leading to recovery of previously
downregulated gene expression while simultaneously discriminating cells where silencing is occurring. The fluorescence signal may allow for tracking cell internalization and sub-
cellular localization. The Au-nanobeacons’ potential for anti-cancer therapeutics via the silencing of the silencers is demonstrated by blocking the endogenous microRNA pathway
via an Anti-miR Au-nanobeacon complementary to the mature microRNA-21 (miR-21), commonly upregulated in cancer phenotypes [31].
J. Conde et al. / Biomaterials 34 (2013) 2516e25232518removed, formazan crystals resuspended in 300 ml of dimethyl sulfoxide (Sigma), and
absorbance measured at 540 nm as a working wavelength and 630 nm as reference
usingaMicroplate reader InfiniteM200withAbsorbancemodule (Tecan). Cell viability
was normalized to that of cells cultured in the culture mediumwith PBS treatment.
2.10. Statistical analysis
All statistical analysis were performed with SPSS statistical package (version 15,
SPSS Inc., Chicago, IL) using a Paired-Sample T-test. All experiments, unless28otherwise stated, were performed in triplicate. All error bars used in this report
are s.d. of at least three independent experiments.
3. Results and discussion
To assess the potential of the Au-nanobeacons for gene silencing,
we transfected HCT-116 cells with EGFP that was then targeted for
silencing by an Au-nanobeacon that contains a stem-looped8
J. Conde et al. / Biomaterials 34 (2013) 2516e2523 2519oligonucleotide double labeled with 30-Cy3 and 50-Thiol-C6
complementary to the Kozak consensus translation initiation site
and start codon of the EGFP expression vector, thus capable of
blocking the transcriptional machinery in the colorectal cell-line.
Stable AuNPs with an average diameter of 14.6  1.7 nm synthe-
sized by reduction of sodium tetrachloroaurate (III) hydrate with
sodium citrate dehydrate were functionalized with poly(ethylene
glycol) (PEG) spacers to increase stability, biocompatibility and grant
chemical functionality as well as avoid opsonization (Supporting
Information Figs. S1 and S2) [27,30]. PEGylated AuNPs were
then functionalized with a Cy3-labeled hairpin-DNA and calibrated
to respond to the specific complementary target (Supporting
Information Fig. S3). A substantial increase in fluorescence was
detected upon hybridization of the Au-nanobeacon to the comple-
mentary target (ssRNA, siRNA and microRNA oligos) at 37 C,
showing that the Au-nanobeacons are capable of specific sequence
recognition. The number of beacons perAuNPwas determined for all
constructs, together with the hydrodynamic diameter by DynamicFig. 2. Au-nanobeacon silencing of specific gene expression in colorectal carcinoma cell lin
expression confirmed by qRT-PCR before and (a) after siRNA and antisense Au-nanobeacon t
fluorescence decrease (**, P  0.005) in bulk cell lysates (as percentage of original EGFP fluo
bound onto AuNPs (Nonsense Au-nanobeacon). Values are means  s.d. from 6 independen
EGFP after transfection with siRNA 10 nM, nonsense siRNA 10 nM, antisense Au-nanobeacon
by the intensity of its fluorescence (green) and Au-nanobeacons in open conformation (re
Relative fluorescence intensity of Au-nanobeacons (Cy3, black bars) and EGFP (white bars) ob
software. (For interpretation of the references to colour in this figure legend, the reader is
289light Scattering (DLS), gold core diameter by Transmission Electron
Microscopy and surface charge by Zeta-potential (Supporting
Information Fig. S2 and Table 2).
We next compared the silencing effect of these antisense Au-
nanobeacons (58  4 beacons per nanoparticle) to that of tradi-
tional siRNA transfection using lipofectamine. All cellular uptake
assays were carried out with serum-free media to avoid unspecific
binding of serum proteins to the Au-nanobeacons and compromise
cell uptake. Results show that both approaches are effective at
blocking EGFP expression. After 24 h of EGFP vector transfection,
cells were treated with 30 nM of antisense Au-nanobeacons or
10 nM of siRNA for optimal EGFP silencing (Supporting Information
Fig. S7). After 48 h of Au-nanobeacons exposure, the cells were
lysed and the bulk fluorescence of the lysate was measured in the
emission range of the EGFP protein (Excitation/Emission, 480/
510 nm) and collected for total RNA extraction.
Quantification of EGFP expression by direct measurement
of EGFP fluorescence levels in bulk cell lysates at 48 h (Fig. 2b)e (HCT-116). HCT-116 cells were transfected with EGFP expression vector and mRNA
ransfection, using b-actin as reference. (b) EGFP silencing was confirmed by significant
rescence levels), using an unrelated siRNA (Nonsense siRNA) or unrelated hairpin DNA
t experiments. (c) Confocal imaging (scale bar, 10 mm) show HCT-116 cells expressing
30 nM and nonsense Au-nanobeacon 30 nM. EGFP expression levels can be evaluated
d, Cy3) can be identified as fine punctuation dispersed throughout the cytoplasm. (d)
tained after individual color channel analysis of the same confocal images using ImageJ
referred to the web version of this article).
J. Conde et al. / Biomaterials 34 (2013) 2516e25232520reveals similar silencing for both approaches: 39.7  12.5% and
37.9  12.6% for antisense Au-nanobeacon and siRNA, respectively.
These data are corroborated by qRT-PCR (Fig. 2a). EGFP expression
is not affected by a nonsense Au-nanobeacon (32  3beacons per
NP) or nonsense siRNA indicating that the knockdown is sequence
specific. No changes in cell viability that would indicate off-target
effects were observed (Supporting Information Fig. S13).
Confocal imaging clearly shows specific EGFP knockdown by
siRNA anti EGFP and antisense Au-nanobeacon (Fig. 2c). Cells show
a punctuate fluorescence pattern indicating that the antisense Au-
nanobeacons are distributed evenly in the cytoplasm (Fig. 2c), and
a closer examination revealed more fluorescence in perinuclear
regions. It should be noted that Au-nanobeacons require no
transfection agent to enter cells. The intensity of fluorescence
signals was broken down by specific channels that show striking
differences for Cy3 and EGFP emissions related to the antisense andFig. 3. Au-nanobeacons silencing of siRNA leads to EGFP expression recovery. HCT-116 cells
anti-EGFP siRNA and 10 nM (concentration of beacon on AuNP) Anti-siRNA Au-nanobeaco
(0.5, 1, 3, 6 and 24 h). (a) EGFP recovery confirmed by qRT-PCR after treatment with Anti-siRN
effect of the Au-nanobeacon on siRNA silencing is attained almost immediately (0.5 h), w
(asterisk, P  0.05) as function of time from incubation with anti-siRNA Au-nanobeacon is
EGFP fluorescence levels), using a nonsense Au-nanobeacon as control. Values are means 
recovery at (d) 0.5 and (e) 24 h delay incubation. Arrows point to Au-nanobeacons (Cy3) onl
silencers effect is corroborated by the relative fluorescence intensity of Au-nanobeacons (Cy
confocal images using ImageJ software.
29nonsense Au-nanobeacons, i.e. silencing occurs upon hairpin
conformational change due to specific hybridization to the target
sequence, which can be identified via the fluorescence emission.
This way, effective silencing can be evaluated by the beacons’
fluorescence (Fig. 2d). Measuring the intensity of the Cy3 and EGFP
channels, we observe a decrease in EGFP fluorescence with an
increase in antisense Au-nanobeacons signal. The opposite occurs
with the respective control, the nonsense Au-nanobeacon. Our data
demonstrate that silencing of the silencers is attained only when
the Au-nanobeacon opens and emits fluorescence that in turn
signals out the localization and effectiveness of silencing
(Supporting Information Fig. S10).
Once EGFP expression had been blocked by siRNA, we reversed
the silencing effect and regained EGFP expression via an anti-siRNA
Au-nanobeacon that blocks siRNA. A specific anti-siRNA Au-nano-
beacon was synthesized with 31  5 anti-siRNA beacons perwere transfected with EGFP expression vector, followed by co-transfection with 10 mM
n or nonsense Au-nanobeacon and points measured with several delays of incubation
A Au-nanobeacon or nonsense Au-nanobeacon using b-actin as reference. (b) maximal
hich then decreases leveling at circa 40% EGFP recovery. (c) significant EGFP recovery
corroborated by fluorescence evaluation in bulk cell lysates (as percentage of original
s.d. from 3 independent experiments. Confocal imaging (scale bar, 10 mm) show EGFP
y observable in the cytoplasm of cells with high levels of EGFP recovery. (f) Silencing of
3, black bars) and EGFP (white bars) after individual color channel analysis of the same
0
J. Conde et al. / Biomaterials 34 (2013) 2516e2523 2521nanoparticle. Quantification of the number of beacons at the NPs’
surface is crucial to match the siRNA being used to silence. There-
fore, 10 nM (beacon concentration on AuNP) of anti-siRNA Au-
nanobeacon were added to the cell media previously incubated
with 10 nM of siRNA at several delays of incubation (0.5 h, 1 h, 3 h,
6 h and 24 h). After 48 h, the cells were lysed and collected for
analysis of EGFP recovery (Fig. 3). Silencing of the silencer, i.e.
blockage of the siRNA, is most effective for the first 3 h of incuba-
tion, where maximum EGFP recovery is accomplished after 0.5 h of
siRNA transfection (80.6  14.8% recovery of EGFP expression) and
barely detected after 24 h. Expression of the EGFP was also
confirmed by qRT-PCR analysis of transfected HCT-116 cells
(Fig. 3a,b). Again, confocal imaging (Fig. 3d,e) clearly shows EGFP
recovery using an anti-siRNA Au-nanobeacon, particularly when
compared with a non-sense Au-nanobeacon for 0.5 and for 24 h.
Surprisingly, EGFP recovery decreases in a time dependent manner
showing almost no recovery at 24 h of incubation after adding the
“silencer”. The high levels of expression recovery by silencing the
silencer with an anti-siRNA Au-nanobeacon, which successfully
blocks the antisense strand of siRNA, together with the persistent
recovery of EGFP may be the result of the stabilization of hairpin-
DNA on nanoparticle. Gold nanobeacons provide significantFig. 4. Au-nanobeacons silencing of endogenous silencers e silencing of miR-21. Confocal im
50 nM and (b) nonsense Au-nanobeacon. Target (mature miR-21) recognition leads to ch
fluorescence signal (red, Cy3) encircling the cell nuclei (blue, DAPI). (c) Specificity of target
reading in the Cy3 channel (black bars). (d) Quantitative assessment of miR-21 silencing i
nanobeacon for 24, 48 and 72 h of incubation using b-actin as reference was confirmed by
control normalized for b-actin expression for the same conditions depicted as in (d), error ba
to colour in this figure legend, the reader is referred to the web version of this article).
291protection from nuclease degradation in an extracellular context,
probably due to the hairpin configuration and to the proximity of
the oligonucleotide to the gold surface, increasing the resistance to
nuclease degradation and the oligonucleotide lifetime in the cell
[18,22]. Our data shows that the Au-nanobeacon approach uses the
beacon’s fluorescence to track the silencing inside the cell whilst
evaluatingwhether the target is effectively being silenced. It is clear
that the beacon’s fluorescence increases for increased levels of
silencing (Fig. 3f). Once again, the fluorescence intensity in each
channel shows an increase (recovery) in EGFP fluorescence when
there is an increase in anti-siRNA Au-nanobeacon signal (Cy3). And
that the reverse is also true, i.e. the nonsense Au-nanobeacon that
does not silence the siRNA, is not capable to promote EGFP recovery
(Fig. 3f, Supporting Information Fig. S11a and b).
We then used ssRNA oligomers to silence the antisense Au-
nanobeacon and a 70.3  15.5% of EGFP recovery was attained.
Interestingly, for the first hour of incubation, the silencing of
the Au-nanobeacon by ssRNA oligomers was more effective than
that of the anti-siRNA Au-nanobeacon (Supporting Information
Figs. S8 and Fig. S11c and d). However, the recovery of EGFP due
to silence of the siRNA seems to last for longer and 10e20% more
than that observed when the antisense Au-nanobeacon is silencedaging (scale bar, 10 mm) shows internalization of 50 nM (a) Anti-miR Au-nanobeacon
ange of Anti-miR Au-nanobeacon conformation in the cytoplasm with concomitant
recognition is corroborated by the relative fluorescence intensity of Au-nanobeacons
n colorectal carcinoma cells (HCT-116) induced by 10, 30 and 50 nM of Anti-miR Au-
RT-PCR followed by agarose gel electrophoresis. (e) qRT-PCR analysis of assay versus
rs indicate  s.d. from 3 independent experiments. (For interpretation of the references
J. Conde et al. / Biomaterials 34 (2013) 2516e25232522by the ssRNA, which might be due to increased degradation of
naked ssRNA by nucleases [17,22].
Finally, we show that this Au-nanobeacon strategy is effective at
targeting and silencing an endogenous miRNA towards modulation
of miRNA pathway in a simple and straightforward way, making the
Au-nanobeacon a valid therapeutic approach against oncomiRs. An
anti-miR-21 Au-nanobeacon (33  3 anti-miR beacons per nano-
particle) was used to block miR-21, which is upregulated in this cell
line. The miR-21, referred as an “oncomiR” has been found to be
over-expressed in most epithelial cancers and therefore, believed to
play a pivotal role in the progression of many malignancies,
including colon cancer and in colorectal carcinoma cells [31].
Quantitative expression and silencing efficiency of miR-21 was
performed by qRT-PCR31 using 10, 30 and 50 nM of anti-miR-21 Au-
nanobeacon during 24, 48 and 72 h of incubation. Data show that
steady state expression of miR-21 was transiently but substantially
inhibited by the specific Au-nanobeacon at 48 h (88.51.4%miR-21
downregulation) and barely reduced at 72 h (Fig. 4d,e). Confocal
microscopy (Fig. 4a,b) shows that miR-21 silencing is associated
with increased Au-nanobeacon fluorescence that can be used to
assess the silencing effect (Supporting Information Fig. S9). Data
from the Cy3 channel show that specific target recognition by anti-
miR-21 Au-nanobeacon leads to higher signal intensity than that of
the nonsense Au-nanobeacon (Fig. 4c), demonstrating that miR-21
silencing is attained only when the anti-miR-21 Au-nanobeacon
opens and emits fluorescence (Supporting Information Fig. S12).
To reassure that the Au-nanobeacon fluorescence emission is
due to the specific recognition of the target inside cells, thus
avoiding false positive signals, the Au-nanobeacons were incubated
with increasing concentrations of dithiothreitol (DTT) or gluta-
thione (GST) to mimic the reductive cell milieu (Supporting
Information Fig. S4). Incubation of anti-miR Au-nanobeacon with
5 mM (physiological concentration), 10 mM and 100 mM of DTT at
37 C during 24 h, showed no increase in fluorescence, which
demonstrates that, at physiological reductive conditions, the Au-
nanobeacons’ emission is due to hybridization to the specific target
sequence. Data show no increase in fluorescence up to 24 h incu-
bation, which demonstrates that, at physiological reductive
conditions, the Au-nanobeacons’ emission is due to hybridization
to the specific target.
For all experiments, cell survival rates upon siRNA and Au-
nanobeacon exposure were determined via the MTT assay on
HCT-116 cells, with the same experimental conditions of both
silencing and recovery of expression. No cell cytotoxicity was
detected up to 48 and 72 h incubation for all Au-nanobeacons and
oligomers (Supporting Information Fig. S13).
These in vitro results open the path for in vivo application in
particular the combination of Au-nanobeacons with other chemical
functionalisations, e.g. targeting moieties, may enhance the thera-
peutic potential of our concept. Simultaneous studies of distinct cell
populations should also be feasible using multicolor labeling.
4. Conclusions
In this paper, we show that Au-nanobeacons are a versatile
concept for gene specific silencing while simultaneously allowing
for intracellular tracking of the silencing events. A significant attri-
bute of these Au-nanobeacons is the ability to inhibit the endoge-
nous and exogenous silencers with noticeably small amounts of
effector molecule and without chemical co-transfectants. Our
approach, combining a fluorescence nanobeacon with silencing
capability is simple, inexpensive and straightforward as adjustment
to any specific target can be easily made, be it a specific mRNA or an
endogenous or exogenous silencing nucleic acid. We demonstrate
such potential by specifically silencing the expression of EGFP and29overturning the knockdown effect of silencers after a first wave of
silencing/delivery. The possibility of silencing the silencers and of
discriminating specific cells, where silencing is occurring, may
provide an useful tool for studying and modulating cellular mech-
anisms involved in cancer.Acknowledgments
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A. Physical characterization of Au-nanobeacons 
 
1. Synthesis of citrate-gold nanoparticles (AuNPs) 
 Gold nanoparticles, with an average diameter of 14.6±1.7 nm, were synthesized by the citrate 
reduction method. Briefly, 225 mL of 1 mM hydrogen tetrachloroaureate (III) hydrate (Sigma) 
(88.61 mg) solved in 500 ml of distilled water were heated to reflux while stirring. Then, 25 mL of 
38.8 mM sodium citrate dihydrate (285 mg) were added and refluxed for additional 30 minutes with 
vigorous stirring and protected from light. The resulting red solution is cooled down and kept 
protected from light. Citrate capped AuNPs were characterized by Transmission Electron 
Microscopy (TEM) and UV-Vis spectroscopy (see Figure S2). 
 
2. Poly(ethylene glycol) functionalization of gold nanoparticles (AuNP@PEG) 
 Briefly, 10 nM of the AuNP solution were mixed with 0.003 mg/mL of a commercial hetero-
functional poly(ethylene glycol) (PEG) [O-(2-Mercaptoethyl)-O’-methyl-hexa(ethylene glycol), 
C15H32O7S, 356.48 Da] in an aqueous solution of SDS (0.028%). Then, NaOH was added to a final 
concentration of 25 mM and the mixture incubated for 16 hours at room temperature. Excess PEG 
was removed by centrifugation (21.460 ×g, 30 min, 4ºC), and quantified by a modification of the 
 ll   ’  Assay [29]. The excess of thiolated chains in the supernatants is quantified by interpolating 
a calibration curve set by reacting 200 μL        k   l          h  O-(2-Mercaptoethyl)-O’-methyl-
hexa(ethylene glycol) in 100 μL     h   h           0.5 M (pH 7) with 7 μL    5 5’-dithio-bis(2-
nitrobenzoic) acid (DTNB) 5 mg/mL in phosphate buffer 0.5 M (pH 7), and measuring the 
absorbance at 412 nm after 10 minutes. The linear range (see Figure S1b) for the O-(2-
Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) chain obtained by this method is 0.00020.035 
mg/mL (Abs412 = 26.034×[PEG, mg/mL] + 0.0627). The number of exchanged chains is given by 
the difference between the amount determined by this assay and the initial amount incubated with the 
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AuNPs. There is a point at which the nanoparticle becomes saturated with a thiolated layer and is not 
able to take up more thiolated chains - maximum coverage per gold nanoparticle, i.e. 0.01 mg/mL of 
O-(2-Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) (Figure S1c). The Au-nanobeacons were 
functionalized with 0.003 mg/mL of O-(2-Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) 
corresponding to 30% of PEG saturation o     P ’ surface (190.29 ± 19.56 chains per 
nanoparticle). 
 
Figure S1. (a) Absorbance spectra of DTNB after reaction with the thiolated PEG. (b) Standard 
calibration curve for PEG chains, whose concentration can be calculated via the following equation 
Abs412nm = 26.034 × [PEG, mg/mL] + 0.0627. (c) Variation of the excess of PEG thiolated chains 
as a function of the initial concentration in the incubation with 10 mM AuNPs. The dashed vertical 
line indicates the 100% saturation, i.e. the PEG concentration above which no more PEG can be 
           h     P ’        . 
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3. Assembly of Au-nanobeacons (AuNP@PEG@Beacon) 
 We prepared four sets of Au-nanobeacons using double modified oligonucleotides, 3’-Cy3 
    5’-Thiol-C6, in an hairpin conformation (see Table 1): antisense Au-nanobeacon, a stem-looped 
oligonucleotide complementary to the Kozak consensus translation initiation site and start codon of 
EGFP (pVisionGFP-N vector 4.7 kb, Biovision), thus capable of blocking the transcriptional 
machinery; anti-siRNA Au-nanobeacon, a stem-looped oligonucleotide complementary to the siRNA 
that silences EGFP; nonsense Au-nanobeacon, an unrelated stem-looped oligonucleotide; and anti-
miR Au-nanobeacon, a stem-looped oligonucleotide complementary to miR-21. Briefly, the thiolated 
beacons (STABVIDA) were suspended in 1mL of 0.1M dithiothreitol (DTT), extracted three times 
with ethyl acetate and further purified through a desalting NAP-5 column (Pharmacia Biotech) using 
10 mM phosphate buffer (pH 8) as eluent. Following oligonucleotide quantification via UV/Vis 
spectroscopy, each beacon was added to the AuNP@PEG in a 100:1 ratio. AGE I solution (2% (w/v) 
SDS, 10 mM phosphate buffer (pH 8)) was added to the mixture to a final concentration of 10 mM 
phosphate buffer (pH 8), 0.01% (w/v) SDS, sonicated for 10 seconds using an ultrasound bath and 
incubated at room temperature for 20 minutes. Afterwards, the ionic strength of the solution was 
increased sequentially in 50 mM NaCl increments by adding the required volume of AGE II solution 
(1.5 M NaCl, 0.01% (w/v) SDS, 10 mM phosphate buffer (pH 8)) up to a final concentration of 10 
mM phosphate buffer (pH 8), 0.3 M NaCl, 0.01% (w/v) SDS. After each increment, the solution was 
sonicated for 10 seconds and incubated at room temperature for 20 minutes. The solution was 
allowed to rest for additional 16 hours at room temperature. Then, the functionalized Au-
nanobeacons were centrifuged for 20 minutes at 21.460 ×g, the oily precipitate washed three times 
with DEPC-treated H2O, and redispersed in the same buffer to a final concentration in Au-
nanobeacons of 15 nM. The resulting Au-nanobeacons were stored in the dark at 4 °C until further 
use. 
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 Physical characterization of the Au-nanobeacons was performed by Dynamic Light Scattering 
(Zetasizer, Malvern), Zeta Potential (Zetasizer, Malvern), UV/Vis Spectroscopy and Transmission 
Electron Microscopy (see Figure S2 and Table 2).  
 
 
 
Table 1. Oligomers sequences used in Au-nanobeacons functionalisation and in target specificity. 
 
Oligomers Sequences 
ΔG (kcal/mol) 
No target 
ΔG (kcal/mol) 
With target 
antisense Au-nanobeacon 5’-TTTGCCTCGTCGCTCTCCATGGTGGGCAAA-3’ -3.38 -27.28 
anti-siRNA Au-nanobeacon 5’-TTTGCCGCATGACCAACAAGATGAAGGCAAA-3’ -4.71 -25.48 
anti-miR Au-nanobeacon 5’-TTTGCCTCAACATCAGTCTGATAAGCTAGGCAAA-3’ -4.74 -27.43 
nonsense Au-nanobeacon 5’-TTTGCCCCGTTACTATTTGCACCACGGCAAA-3’ -3.04 N/A 
Antisense target 5’-CACCAUGGAGAGCGACGA-3’ N/A N/A 
anti EGFP siRNA 
S    : 5’-GCAUGACCAACAAGAUGAAUU-3’ 
         : 3’-UUCAUCUUGUUGGUCAUGCUU-5’ 
N/A N/A 
nonsense siRNA 
S    : 5’-AAUUCUCCGAACGUGUCACGUUU-3’ 
         : 3’-UUUUAAGAGGCUUGCACAGUGCA-5’ 
N/A N/A 
miR-21 target 5’-UAGCUUAUCAGACUGAUGUUGA-3’ N/A N/A 
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Figure S2. Au-nanoparticle characterization. (a) The high monodispersity of the gold cores was 
confirmed by Transmission Electron Microscopy (TEM) (scale bar, 100 nm). Inset: Size distribution 
histogram showing an average diameter of the AuNPs of 14.6±1.7 nm. (b) UV-Vis spectra of the 
synthesized AuNPs, Au@PEG and Au-nanobeacons showing the characteristic surface plasmon 
resonant peak shift from 520 to 525 nm due to surface functionalization. (c) TEM images of all  
Au-nanobeacons. 
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4. Quantitation of Beacon coverage on AuNP@PEG 
 Coverage, i.e. number of beacons per nanoparticle, was determined by quantification of the 
excess beacons in the supernatants collected during synthesis via the emission spectra of Cy3 
(excitation/emission, 530 nm/560 nm) dye in a Cary Eclipse (Varian) using an Ultra-Micro quartz 
cell (Hëllma). All AuNPs samples and standard solutions of the thiolated-beacons were kept at the 
same pH and ionic strength for all measurements. Fluorescence emission was converted to molar 
concentrations by interpolation from a standard linear calibration curve prepared with known 
concentrations of beacon - see Table 2.  
 
 
Table 2. Quantification of the PEG chains and beacon for all Au-nanobeacons, together with DLS 
and Zeta-potential measurements. 
 
 
5. Au-nanobeacon target recognition 
 Each Au-nanobeacon capability to specifically recognize the complementary target was 
assessed by hybridizing 1 nM of Au-nanobeacon to 5 nM of complementary OR non-complementary 
targets in 10 mM of phosphate buffer (pH 7) (see Figure S3). A PerkinElmer LS45 Fluorescence 
Spectrometer (Varian) using an Ultra-Micro quartz cell (Hëllma) programmed to incubate the 
Au-nanobeacons PEG chains/NP 
Hairpin DNA 
(Beacons)/NP 
DLS 
Diameter 
(nm) 
Zeta Potential 
(mV) 
antisense Au-nanobeacon 190.29 ± 19.56 57.87 ± 3.92 33.95 ± 7.10 -36.53 ± 1.24 
anti-siRNA Au-nanobeacon 190.29 ± 19.56 30.78 ± 4.84 40.77 ± 4.42 -37.73 ± 1.34 
anti-miR Au-nanobeacon 190.29 ± 19.56 33.04 ± 2.99 52.65 ± 8.08 -21.87 ± 1.41 
nonsense Au-nanobeacon 190.29 ± 19.56 31.64 ± 3.49 34.86 ± 1.21 -33.76 ± 2.37 
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reactions for 120 min at 37°C recoded the fluorescence intensity of the Au-nanobeacon every 2 
minutes at an excitation wavelength of 530 nm. 
 
 
Figure S3. Au-nanobeacons specificity for target. Fluorescence emission as function of 
hybridization time with (a) the antisense Au-nanobeacon, (b) anti-siRNA Au-nanobeacon, and (c) 
anti-miR Au-nanobeacon at 37ºC in presence of the complementary target (white squares) or a non-
complementary target . Target sequences are depicted in Table 1. 
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6. Au-nanobeacon behaviour in a reductive milieu 
 To evaluate whether the reductive cell environment would cause detachment of the beacon 
      h     P ’           h  Au-nanobeacons resistance to DTT or glutathione (GST) was 
evaluated. To mimic the behaviour in the intra-cellular milieu, 1 nM of the Anti-miR-21 Au-
nanobeacon was incubated with 5, 10 and 100 mM of DTT or GST (Sigma-Aldrich) at 37°C for up 
to 24 h. Fluorescence intensity was measured in a PerkinElmer LS45 Fluorescence Spectrometer 
(Varian) using an Ultra-Micro quartz cell (Hëllma) programmed to incubate the reactions for 1440 
min (24 hours) at 37°C at 15 minutes intervals (excitation/emission, 530 nm/560 nm) (see Figure 
S4). The curves show that for concentrations of reducing agent between 5 and 10 mM, the Au-
nanobeacon remains in its closed conformation, which demonstrate that, under physiologic 
intracellular conditions, observable Au-nanobeacon fluorescence is solely due to hybridization to 
specific target. 
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Figure S4. Au-nanobeacon behaviour in presence of increasing concentration of (a) DTT or (b) 
GST as reducing agent. The anti-miR Au-nanobeacon was incubated with 5 mM (physiological 
millieu), 10 mM and 100 mM of DTT or GST, at 37ºC during 24 hours, and fluorescence plotted as 
function of time.  
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B. Gene expression quantification via Real-time RT-PCR 
 Real-Time PCR was performed in a Corbett Research Rotor-Gene RG3000 using SYBR 
GreenER Real-T    P   K   (          )                         ’                    50 μl 
reactions containing 2 µl of cDNA from HCT-116 cells, 1× SYBR Green SuperMix and 200 nM of 
primers (STABVIDA) - see Table 3 for primer sequences. The amplification conditions consisted of 
50°C for 2 min hold, 95°C during 10 min hold, followed by 40 cycles consisting of denaturation at 
95°C for 30 s, annealing at 52°C for 60 s, extension at 72°C for 45 s, with a final extension step at 
72°C for 10 min. All data originated from three independent experiments. PCR amplification 
products were subjected to agarose gel electrophoresis (2% agarose, TBE 1×, 75 minutes at 90V, 
GelRed staining visualized under UV light)               l     ’  l   l   w   h : 158 bp (-
actin), 792 bp (EGFP) and 75 bp (miR-21) (see Figure S5). As the difference of PCR amplification 
efficiency of EGFP, miR-21 and -actin products was less than 5%, qRT-PCR data were derived 
from 2
-ΔΔ T
 using -actin expression levels as reference [fold-induction was calculated by the Ct 
   h        ll w : ΔΔ T = (    GFP(or miR-21) – Ct -actin)treated for EGFP(or miR-21) - (Ct EGFP(or 
miR-21) – Ct -actin)untreated] [32]. 
 
Table 3. Primer sequences used in qReal-Time PCR. 
 
Primers Sequences 
-actin forward 5´-ATAGCACAGCCTGGATAGCAAC-3´ 
-actin reverse 5´-CACCTTCTACAATGAGCTGCGT-3´ 
EGFP forward 5´-AGCTTCGAATTCTGCAGTCG-3´ 
EGFP reverse 5´-GGCTGATTATGATCTAGAGTC-3´ 
miR-21 loop 5’-TGTTGCCATGAGATTCAACAGTCAACATCAGTCTGATAAGCTACCCGACA-3’ 
miR-21 forward 5’-GCCGCTAGCTTATCAGACTGATGT-3’ 
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Figure S5.  Standard curves for primers in RT-PCR for EGFP (a) and miR-21 (c) expression profiles 
used for calculation of primer efficiency (Efficiency = 10^
(-1/slope)
  1). Agarose gel electrophoresis 
(2% agarose, TBE 1×, 75 minutes at 90V) of the standard curves for primers. The expected sizes of 
the PCR products are 158 bp (-actin) and 792 bp (EGFP) (b) and 75 bp (miR-21) (d). 
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Figure S6. 1
st
 Derivative melting temperature curve of the miR-21, -actin and EGFP Real-
time PCR products. The theoretic melting temperatures of the PCR products were 75.5ºC (miR-21), 
84.8ºC (-actin) and 90.2ºC (EGFP). 
 
 
 
C. Silencing of specific gene expression - Optimization 
Cells were incubated for 48 hours with increasing concentrations of Anti EGFP siRNA and 
Antisense Au-nanobeacon, i.e. 10, 20 and 30 nM, so as to ascertain the best silencing 
conditions for either approach.  
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Figure S7. Silencing of specific gene expression. 
EGFP expression silencing            y              l                    (**  P ≤ 0.005)      lk 
cell lysates (as percentage of original EGFP fluorescence levels), using an unrelated siRNA 
(Nonsense siRNA) (a) or unrelated hairpin DNA bound onto AuNPs (Nonsense Au-nanobeacon) (b). 
Values are means ± s.d. from 3 independent experiments. 
 
D. Recovery of EGFP expression by ssRNA anti-antisense Au-nanobeacon 
 To evaluate EGFP recovery, 30 nM of ssRNA complementary to the Antisense Au-
nanobeacon was added to the media together with 30 nM of the Au-nanobeacon with several delays 
of incubation (0.5, 1, 3, 6 and 24 hours). After 48 hours, EGFP fluorescence was evaluated as for the 
silencing experiments. Expression of the EGFP was confirmed by qRT-PCR analysis of transfected 
HCT-116 cells using -actin as reference. Evaluation of EGFP recovery in bulk cell lysates 
following Antisense Au-nanobeacon silencing was performed by addition of 30 nM of anti-antisense 
ssRNA to the cell media with 30 nM of antisense Au-Nanobeacon at several delays of incubation 
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(0.5, 1, 3, 6 and 24 hours). Bioactivity of anti-antisense ssRNA oligo was compared to that of a 
nonsense ssRNA oligo.  
 
 
Figure S8. Recovery of EGFP expression by ssRNA anti-antisense Au-nanobeacon. Evaluation 
of EGFP recovery by (a,b) qRT-PCR and (c) in bulk cell lysates in presence of ssRNA oligo 
nonsense (grey bars), ssRNA oligo anti-antisense Au-Nanobeacon (black bars) indicating statistically 
significant difference as calculated by Paired-Sample T-test (asterisk  P ≤ 0.05). Values are means ± 
s.d. from 3 independent experiments. Confocal imaging (scale bar, 10 µm) show EGFP recovery at 
(d) 1 and (e) 24 hours delay incubation. (f) blocking of Antisense Au-nanobeacon by ssRNA 
oligomer is corroborated by the relative fluorescence intensity of Au-nanobeacons (Cy3, black bars) 
and EGFP (white bars) after individual colour channel analysis of the same confocal images using 
ImageJ software. 
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E. Intracellular localization of Anti-miR-21 Au-nanobeacon 
 
Figure S9. Intracellular localization of the anti-miR-21 Au-nanobeacon. Cell show a punctuate 
fluorescence pattern indicating that the anti-miR Au-nanobeacons distributed evenly in the 
cytoplasm (white arrows) following hairpin conformational change due to specific hybridization to 
the miR-21 target sequence. A large amount of fluorescence seems to be engulfed in a localized 
compartment above the plan of the nucleus, possibly indicating entrapment in cell vesicle. 
 
F. Individual quantification of Cy3 and EGFP fluorescence signals in confocal images 
Confocal images were processed using ImageJ software to break down fluorescence signals 
into separate channels for Cy3 and EGFP (green), which can be composed into B&W depictions. 
This way, each signal can be observed separately and, therefore, its origin clearly identified. The 
309
17 
 
intensity of each individual signal could then be quantified. This process allowed to confirm that 
only when the Au-nanobeacons are open, due to specific target recognition, their effect on gene 
expression modulation can be felt.  
 
Figure S10. Antisense Au-nanobeacon silencing of EGFP. Striking differences for Cy3 and EGFP 
emissions related to the antisense and nonsense Au-nanobeacon effect can be observed, thus 
confirming that silencing occurs upon hairpin conformational change due to specific hybridization to 
the target sequence. Scale bar, 10 µm. 
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Figure S11. EGFP recovery due to anti-siRNA Au-nanobeacon silencing of siRNA. It can be 
clearly seen that only when the anti-siRNA Au-nanobeacon is emitting fluorescence, thus silencing 
siRNA, EGFP recovery is observed. The nonsense Au-nanobeacon shows no effect. Regarding the 
EGFP recovery by ssRNA oligomers used to silence the antisense Au-nanobeacon, there is no 
difference in Cy3 channel (c) once all cells are incubated with 30 nM of antisense Au-nanobeacon. 
The EGFP channel (d) clear demonstrates that EGFP recovery was attained only by ssRNA 
oligomers anti-antisense Au-nanobeacon, when compared to ssRNA nonsense. Scale bar, 10 µm. 
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Figure S12. Silencing the silencers via anti-miR Au-nanobeacons. Silencing of miR-21 is clearly 
observed when the Anti-miR Au-nanobeacon is open due to hybridization to the target, shown by the 
increased fluorescence intensity in Cy3 channel. These results corroborate what is shown above 
(Figure S9). The nonsense Au-nanobeacon only shows residual fluorescence hardly observable 
above background. Scale bar, 10 µm. 
 
G. Acute cytotoxicity evaluation by the MTT assay 
 Living cell ’ enzymes cleave the tetrazolium salts from the MTT reagent to yield formazan, 
which directly correlates to the number of metabolically active cells in culture. An expansion in the 
number of viable cells results in an increase in the overall activity of mitochondrial dehydrogenases, 
thus increasing the formation of formazan dye.  
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Figure S13. Cytotoxicity evaluation of all biomolecular assemblies administered to human colorectal 
cancer cells (HCT-116 cell line) in the present study via the MTT assay at 48 (a) and 72 hours (b) of 
exposure. Negligible influence in cell viability is observed for all assemblies tested when compared 
to untreated cells (black bar). 
 
Additional references 
(32) Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat 
Protocols 2008; 3:1101-08. 
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Abstract
Antisense therapy is a powerful tool for post-transcriptional
gene silencing suitable for down-regulating target genes
associated to disease. Gold nanoparticles have been described as
effective intracellular delivery vehicles for antisense
oligonucleotides providing increased protection against
nucleases and targeting capability via simple surface
modification. We constructed an antisense gold-nanobeacon
consisting of a stem-looped oligonucleotide double-labelled
with 3¢-Cy3 and 5¢-Thiol-C6 and tested for the effective blocking
of gene expression in colorectal cancer cells. Due to the beacon
conformation, gene silencing was directly detected as fluorescence
increases with hybridisation to target, which can be used to assess
the level of silencing. Moreover, this system was extensively
evaluated for the genotoxic, cytotoxic and proteomic effects of
gold-nanobeacon exposure to cancer cells. The exposure was
evaluated by two-dimensional protein electrophoresis followed by
mass spectrometry to perform a proteomic profile and 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT)
assay, glutathione-S-transferase assay, micronucleus test and
comet assay to assess the genotoxicity. This integrated toxicology
evaluation showed that the proposed nanotheranostics strategy
does not exhibit significant toxicity, which is extremely relevant
when translating into in vivo systems.
Keywords: antisense, gold nanoparticles, gene silencing, DNA
damage, cytotoxicity, proteomics
Introduction
The development of a safe, efficient, specific and non-
pathogenic vehicle for gene delivery is highly attractive
(Kim et al. 2009; Akhtar & Benter 2007). Nanoparticles
(NPs), in particular, are expected to provide a range of
devices for diagnosis and treatment in cancer as their
dimensions are well matched in size to biologic molecules
and structures found inside living cells (Conde et al. 2012b).
Gold nanoparticles (AuNPs) have been extensively investi-
gated and applied in conjunction with biomolecules due to
their ease of synthesis and functionalisation derived from
their large surface-to-volume ratio (Conde et al. 2012a;
Doria et al. 2012; Daniel & Astruc 2004; Jain 2008;
Haglund et al. 2009). This way, several strategies have
been proposed based on AuNPs as intracellular delivery
vehicles for antisense oligonucleotides by providing protec-
tion against intracellular nucleases and ease of functionali-
sation for selective targeting (Whitehead et al. 2009;
Giljohann et al. 2009; Rana et al. 2012; Ghosh et al. 2008a;
Ghosh et al. 2008b; Thomas & Klibanov 2003; McIntosh et al.
2001; Conde et al. 2010; Rosi et al. 2006).
In this study, we used a gold-nanobeacon (Au-nano-
beacon) to target and silence a specific mRNA while pro-
viding means to assess its effectiveness via fluorescence
signalling. The antisense Au-nanobeacon consisting of a
stem-looped oligonucleotide double-labelled with 3¢-
Cy3 and 5¢-Thiol-C6 bonded to the AuNPs’ surface, whose
sequence is capable of blocking enhanced green fluores-
cent protein (EGFP) expression. This nanoconjugate was
tested for the effective blocking of EGFP expression in a
colorectal cancer cell-line (HCT-116). The beacon’s
increase in fluorescence upon hybridisation to the specific
target was used to evaluate the effective silencing as a
higher level of silencing yields a more intense fluorescence
signal from the beacon. Previously, we demonstrated that
Au-nanobeacons could successfully be used for assessing
the effective level of gene silencing in vitro (Rosa et al. 2012;
Conde et al. 2013).
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Despite major advances in nanotechnology-based drug
delivery, the vast majority of studies merely report on the
biocompatibility of nanomaterials relying on cell viability
evaluation and cell counting (van et al. 2011; Dobrovolskaia
& McNeil 2007; Wall & Shi 2003; Ozpolat et al. 2010). Thus far,
little attention has been directed to the detection of genome
damage, such as DNA strand breaks and formation of nuclear
abnormalities (NAs), characterisation of protein markers of
toxicity or measuring the level of oxidative stress. When con-
sidering the toxicity of AuNPs, size, concentration and surface
coating also play a role in triggering cellular and physiologic
response (Alkilany & Murphy 2010). For instance, poly(ethyl-
ene glycol) (PEG)-coated AuNPs have been shown to exhibit
size-dependent in vivo toxicity and PEG alone is known to
trigger cellular stress (Zhang et al. 2011). All thesemarkers are
of great importance when assessing biocompatibility and
safety of the nanomaterials if they are to be used for medical
purposes, and ought to be used as primary screen once
therapeutic effect is demonstrated (Dobrovolskaia & McNeil
2007). Identification of these disease/toxicity biomarkers may
allow improvement of safety assessment of nanomaterials.
Here, following demonstration of the Au-nanobeacons’
gene silencing capability, the system was extensively
evaluated in terms of cellular toxicity, namely at the prote-
omic and genomic level. HCT-116 cells were exposed to
antisense Au-nanobeacons as putative nanotheranostics
tool, and toxicity evaluated using MTT assay, glutathione-
S-transferase assay, NAs and comet assay, and two-
dimensional protein electrophoresis followed by mass spec-
trometry for identification of putative stress markers (see
Figure 1).
Methods
Synthesis of citrate-AuNPs
AuNPs were synthesised by the citrate reduction method
described by Lee and Meisel (1982). Citrate-capped AuNPs
were characterised by transmission electron microscopy
(TEM) and UV-Vis spectroscopy (seeSupplementary Figure
S1A-B).
Synthesis of PEGylated-gold nanoparticles
Functionalisation of PEGylated AuNPs was carried out
using commercial hetero-functional PEG functionalised
with a thiol group O-(2-Mercaptoethyl)-O¢-methyl-hexa(eth-
ylene glycol), C15H32O7S, 356.48 Da (Sigma), as previously
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Figure 1. Antisense Au-nanobeacons for gene therapy: from genotoxicity to proteomics. Gene silencing via antisense Au-nanobeacons; cell
viability (MTT assay); oxidative stress (glutathione-S-transferase activity); genotoxicity assessment (NAs and comet assay); and identifying
protein markers by two-dimensional protein electrophoresis followed by peptide mass fingerprinting.
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described (Rosa et al. 2012; Conde et al. 2013; Sanz et al.
2012). Excess PEGwas removed by centrifugation (21.460 g,
30 min, 4C), and quantified by the Ellman’s Assay suitable
for sulfhydryl group determination.
Synthesis of gold nanobeacons (AuNP@PEG@Beacon)
The antisense Au-nanobeacon contains a stem-looped
oligonucleotide double-labelled with 3¢-Cy3 and 5¢-Thiol-
C6(5¢-TTTGCCTCGTCGCTCTCCATGGTGGGCAAA-3¢)com-
plementary to the Kozak consensus translation initiation site
and start codon of the EGFP (pVisionGFP-N vector 4.7 kb,
Biovision), thus capable of blocking the translational
machinery. The nonsense Au-Nanobeacon contains a
stem-looped oligonucleotide of unrelated sequence dou-
ble-labelled with 3¢-Cy3 and 5¢-Thiol-C6 (5¢-TTTGCC
CCGTTACTATTTGCACCACGGCAAA-3¢). Briefly, the thio-
lated oligonucleotides (STABVIDA) were suspended in
1 mL of 0.1 M dithiothreitol (DTT), extracted three times
with ethyl acetate and further purified through a desalting
NAP-5 column (Pharmacia) using 10 mM phosphate
buffer (pH 8) as eluent. Following oligonucleotide
quantification via UV/Vis spectroscopy, each oligomer
was added to the AuNP@PEG solution in a 100:1 ratio.
AGE I solution [2% (w/v) sodium dodecyl sulphate (SDS),
10 mM phosphate buffer (pH 8)] was added to the mixture
to achieve a final concentration of 10 mM phosphate
buffer (pH 8), 0.01% (w/v) SDS. The solution was soni-
cated for 10 sec using an ultrasound bath and incubated
at room temperature for 20 min. Afterwards, the ionic
strength of the solution was increased sequentially in
50 mM NaCl increments by adding the required volume
of AGE II solution (1.5 M NaCl, 0.01% (w/v) SDS, 10 mM
phosphate buffer (pH 8)) up to a final concentration of
10 mM phosphate buffer (pH 8), 0.3 M NaCl, 0.01% (w/v)
SDS. After each increment, the solution was sonicated for
10 sec and incubated at room temperature for 20 min
before the next increment. Following the last addition, the
solution was left to rest for additional 16 h at room
temperature. Then, the functionalised Au-nanobeacons
were centrifuged for 20 min at 21.460  g, the oily
precipitate washed three times with Diethyl Pyrocarbo-
nate (DEPC)-treated H2O, and redispersed in the same
buffer to a final concentration in Au-nanobeacons of 15 nM.
The resulting Au-nanobeacons were stored in the dark at 4C
until further use. Au-nanobeacons were characterised by
dynamic light scattering (DLS) (Zetasizer, Malvern), Zeta
Potential (Zetasizer, Malvern), UV/Vis Spectroscopy and
TEM (see Supplementary Figure S1C–F).
Quantitation of beacon coverage on AuNP@PEG
Coverage, i.e. average number of labelled beacons per NP
was assessed by quantification of the thiolated oligonucleo-
tides in supernatant from the Au-nanobeacon synthesis. All
the three supernatants containing the unbound oligonucleo-
tides were measured by monitoring the emission spectra of
Cy3 (Exc = 530 nm) dye in a Cary Eclipse (Varian) using an
Ultra-Micro quartz cell (Hëllma). All AuNP samples and
standard solutions of the thiol-oligonucleotide beacon
were kept at the same pH and ionic strength and calibration
for all measurements. Fluorescence emission was converted
to molar concentrations by interpolation from a standard
linear calibration curve, prepared using the same buffer pH
and salt concentrations.
Cell culture and EGFP vector transfection
As a model system, HCT-116 cells (from colorectal carci-
noma) were grown in Dulbecco’s modified Eagle’s medium
with Glutamax (DMEM, Invitrogen) with 10% heat-inacti-
vated fetal bovine serum (Invitrogen), 100 U/mL penicillin
and 100 mg/mL streptomycin (Invitrogen), andmaintained at
37C in 5% CO2. Cells were seeded at a density of 1  105
cells/well in 24-well plates and grown for 24 h prior to
transfection of EGFP vector (pVisionGFP-N vector 4.7 kb,
Biovision) encoding green fluorescent protein optimised for
high expression in mammalian cells. On the day of trans-
fection, cells were approximately 50% confluent. EGFP vector
(1 mg per well) was added with 2 mg of Lipofectamine 2000
(Invitrogen) and Opti-MEM Reduced SerumMedium (Invi-
trogen) according to the manufacturer’s recommendations
(see Supplementary Information S2).
EGFP silencing with antisense Au-nanobeacon
After 24 h of EGFP transfection, cells were treated with 30 nM
of antisense Au-nanobeacons in Opti-MEM reduced serum
medium (Invitrogen). After 48 h, cells were washed with 1
PBS, lysed in ultrapure water and collected for analysis of
EGFP silencing, RNA extraction and confocal imaging. Fluo-
rescence was measured at least three times in a Cary Eclipse
spectrofluorimeter (Varian) using an Ultra-Micro quartz cell
(Hëllma) by taking the area under the curve from 495 to
650 nm. EGFP fluorescence values were normalised to the
bulk protein concentration determined via the Bradford
assay (Thermo Scientific), and then normalised against
the controls to determine percent knockdown of EGFP.
qRT-PCR
Total RNA was extracted from the cell line using the Trisure
reagent (Bioline) according to the manufacturer’s protocol,
and used for quantitative real-time polymerase chain
reaction (qRT-PCR) to evaluate expressions of EGFP and
b-actin. cDNA was obtained by subjecting 1 mg of total
RNA to reverse transcription with 200 U of Revert-AidTM
M-MuLV reverse transcriptase (Fermentas) according to
the manufacturer’s specifications, using 20 mM of EGFP
and b-actin reverse primers, annealing at 42C for 1 h
and 70C for 10 min for reverse transcriptase inactivation.
Real-time PCR amplification was performed in a Corbett
Research Rotor-Gene RG3000 using SYBR GreenER real-
time PCR kit (Invitrogen) according to the manufacturer’s
specifications in 50 mL reactions containing 2 ml of cDNA, 1
SYBR Green SuperMix and 200 nM of primers (STABVIDA).
The following primers were employed: b-actin forward 5-
ATAGCACAGCCTGGATAGCAAC-3; b-actin reverse 5-CACC
TTCTACAATGAGCTGCGT-3; EGFP forward 5-AGCTTCG
AATTCTGCAGTCG-3; EGFP reverse 5-GGCTGATTATGAT
CTAGAGTC-3. The amplification conditions consisted of
50C for 2 min hold, 95C during 10 min hold, followed
by 40 cycles consisting of denaturation at 95C for 30 sec,
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annealing at 52C for 60 sec, extension at 72C for 45 sec,
with a final extension step at 72C for 10 min. All the results
were originated from three independent experiments.
Threshold cycle values were analysed by the DCt method
(Livak & Schmittgen 2001; Pfaffl 2001), once the difference of
PCR amplification efficiency of EGFP and b-actin products
was less than 5% (Efficiency = 10(1/slope)  1). The
b-actin expression levels were used as reference, and fold-
induction was calculated by the Ct method as follows:
DCT = (Ct EGFP – Ct b-actin)treated for EGFP  (Ct EGFP –
Ct b-actin)untreated. The final data were then derived from
2DCT. The expected sizes of the PCR products were 158 bp
(b-actin) and 792 bp (EGFP). The PCR products were sub-
jected to electrophoresis on a 2% agarose gel (TBE 1),
during 75 min at 90 V, stained with GelRed (Biotium) and
visualised under UV light.
Confocal microscopy
HCT-116 cells were seeded at a concentration of 1  105
cells/well in 24-well plates on glass slides in 500 mL of DMEM
(Invitrogen) with 10% heat-inactivated fetal bovine serum
(Invitrogen) and maintained at 37C in 5% CO2. All confocal
microscopy samples were prepared under the same condi-
tions as described above for GFP silencing and recovery.
Cells were fixed with 4% paraformaldehyde in PBS for 15 min
at 37C and mounted in ProLong Gold Antifade Reagent
with DAPI (Invitrogen) to allow for nuclear staining. Images
were acquired with a confocal laser point-scanning micro-
scope Zeiss LSM 510 META, with excitation at 405 nm
for DAPI (nucleus), 480 nm for EGFP and 561 nm for
Cy3 (Au-nanobeacons).
MTT assay
Standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromide] reduction assay (Invitrogen) was per-
formed to determine the cytotoxicity of the functionalised
AuNP complexes. Briefly, cells were seeded at a density of
1  105 cells per well in 24-well culture plates in complete
DMEM (500 ml) with serum. After 24 h, 100 ml of functio-
nalised AuNPs under the same conditions of the EGFP
knockdown/recovery experiments were added and cells
further incubated for 48 and 72 h. The medium was then
removed and cells were washed twice with sterile PBS and
300 ml of fresh medium with serum was added. For the assay,
16.7 ml of sterile MTT stock solution (5 mg/mL in PBS) were
added to each well, incubated for 2 h, the medium removed
and the formazan crystals resuspended in 300 ml of dimethyl
sulphoxide (DMSO) (Sigma). The solution was mixed and its
absorbance was measured at 540 nm as working wavelength
and 630 nm as reference, using a Microplate reader Infinite
M200 with an absorbance module (Tecan). The cell viability
was normalised to that of cells cultured in the culture
medium with PBS treatment. The experiments were
repeated three times.
Genotoxicity assessment
Genotoxic effects were assessed by quantification of DNA
strand breakage, through the alkaline version of comet assay
(Costa et al. 2008; Singh et al. 1988) and frequency of NAs.
Forty-eight hours after treatment with the Au-nanobeacons
(with or without Lipofectamine), HCT-116 cells were cen-
trifuged and the pellet resuspended in 50 mL of 1 PBS. From
this suspension, a drop containing approximately 2.5  105
cells was smeared on glass microscope slides and left to dry
at room temperature for subsequent analysis of NAs. Pre-
parations were methanol-fixed (for 15 min), stained with
0.1 g/L acridine orange and mounted using the non-
fluorescent DPX resin (from BDH) (Costa & Costa 2007).
The frequency of cells with NAs was determined by scoring
1000 cells per preparation, following criteria established
elsewhere (Fenech et al. 2003) (see Supplementary Infor-
mation S3). For the comet assay, glass microscope slides
were previously coated with 1% (w/v) agarose (normal
melting point) in 1 TAE buffer and left to dry for at least
48 h, at 37C. Sample preparation was as follows: 2 mL of the
cell suspension in 1 PBS was diluted in 310 mL of 1% (w/v)
liquid low melting-point agarose (LMPA) in 1 PBS (35–
40C). One hundred and fifty microlitres of cell-containing
LMPA were spotted onto the prepared glass slides (1.1  104
cells per slide) and covered with a coverslip. Upon agarose
solidification, coverslips were removed and the slides dipped
into lysis solution (450 mM NaCl; 3.72% EDTA; 5 mM TRIS;
to which 10% (v/v) DMSO and 1% (v/v) Triton-X were added
just before use) during 1 h at 4C, followed by 40 min into
cold electrophoresis solution (1 mM EDTA; 300 mM NaOH,
pH 13) to ensure DNA unwinding and promote expression
of alkali-labile sites. Electrophoresis was carried out at
4C, for 30 min, at 25 V using a Sub-Cell model 96 apparatus
(Bio-Rad). Afterwards, slides were placed into 0.1M Tris–HCl
buffer (pH 7.5) during 15min for neutralisation. All described
steps were performed under strictly controlled temperature
and light conditions to minimise accessory DNA degradation
and gel lifting from slides. Upon staining with ethidium
bromide (20 mg/mL), an approximated number of 100 intact
nucleoids per slide was analysed, using the CometScore
software v.1.5 (TriTek Corp.). The DNA percentage in the
comets’ tail was employed as metrics for total DNA strand
breakage. Both imaging analyses were performed by epi-
fluorescence microscopy, on a DLMB microscope equipped
with an EL6000 light source (Leica Microsystems), using an
I3 filter (for acridine orange staining) and N2.1 filter (for
ethidium bromide staining).
Measurement of glutathione-S-transferase activity
After the 48-h treatment, cells were washed with 1 PBS,
lysed in ultrapure water and the pellets resuspended in 50 mL
ultrapure water. Briefly, glutathione s-transferase (GST)
activity was determined based on a procedure described
by Habig et al. (1974) by measuring the conjugation of
1-chloro-2,4-dinitro benzene with glutathione (GSH). The
enzyme activity was determined by measuring the absor-
bance at every minute during a maximum of 10 min on a
96-well plate (SPL LifeSciences), using 3 replicas for each
sample. The change in absorbance was measured at 340 nm
using an Infinite 2000 Microplate reader (Tecan) and values
were normalised to total protein concentration determined
by the Bradford assay (Thermo Scientific).
 J. Conde et al.
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Protein sample preparation
To minimise sample degradation, all solutions for sample
preparation contained 1 phosphatase inhibitor (PhosStop,
Roche), 1 protease inhibitor (cOmplete Mini, Roche),
1 mM PMSF and 0.1% (w/v) DTT. After treatment, cells
were collected and concentrated in lysis buffer (150 mM
NaCl; 50mM Tris, pH = 8.0; 5 mM EDTA, 2% (w/v) NP-40) by
centrifugation at 14,000  g for 30 min at 4C. Supernatant
was collected and samples stored at 80C.
Two-dimensional gel electrophoresis
Prior to two-dimensional gel electrophoresis, protein
concentration was determined via the 2-D Quant kit (GE
Healthcare). Isoelectric focusing was performed using
immobilised pH gradient strips (GE Healthcare) in an Etta-
nIPGphor 3 focusing unit (GE Healthcare) according to
Teixeira et al. (2005) (see Supplementary Information S4).
Variation of each protein expression level was calculated as
the ratio of the normalised intensity of each protein spot in
gels corresponding to each condition compared to those
corresponding to control samples. The Mr values for the
identified proteins were determined by comparison with the
relative positions of the proteins included in the molecular
weight protein marker (HyperPAGE, Bioline), which were
run for the second dimension with the samples under study.
Spots with significantly altered intensities between condi-
tions (up- or down-regulated proteins in comparison to
control samples) were selected and picked from gels towards
identification via matrix-assisted laser desorption/ionisa-
tion-time of flight mass spectrometry.
Statistical analysis
All statistical analyses were performed with SPSS statistical
package (version 15, SPSS Inc., Chicago, IL, USA). Data
derived from the comet assay, frequencies of cells with
NAs and GST activity were analysed using non-parametric
statistics, namely the Mann–Whitney U tests for pairwise
comparisons between experimental conditions. A statistical
significance threshold a = 0.05 was set for all analyses.
Results
Synthesis and characterisation of Au-nanobeacons
The synthesised citrate-capped AuNPs were characterised
by: TEM, showing an average diameter of 14.6 ± 1.7 nm, in
good agreement with DLS measurement (average diameter
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Figure 2. Quantitative assessment of EGFP silencing efficiency via antisense Au-nanobeacons, nonsense Au-nanobeacon and naked oligonucleo-
tides. (A,B) EGFP silencing was confirmed by measurement of EGFP intensity in bulk cell lysates (as percentage of original EGFP fluorescence
levels) using an antisense and a nonsense oligonucleotide (without AuNP) (A) and with antisense and nonsense Au-nanobeacons (B). EGFP
silencing was confirmed by significant fluorescence decrease when compared to non-treated cells (**, p £ 0.005) in bulk cell lysates at 30 nM of
antisense Au-nanobeacon only. EGFR mRNA expression confirmed by qRT-PCR for antisense and nonsense oligonucleotides (C); and with
antisense and nonsense Au-nanobeacons (D), using b-actin as reference.
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of 16.7 ± 5.9 nm) with a relatively narrow distribution with a
polydispersity index of 0.294 ± 0.017; a Zeta potential of
28.6 ± 2.4 mV at pH 7; and the characteristic surface
plasmon resonant peak at 519 nm (Supplementary Figure
S1). These AuNPs were then functionalised with a PEG
spacer to increase stability, biocompatibility and grant chem-
ical functionality as well as avoid opsonisation (Liu et al.
2007). The PEGylated AuNPs (AuNP@PEG) showed a 30%
saturated PEG layer (190.29 ± 19.56 PEG chains per NP),
which allows the incorporation of the thiolated fluore-
scence-labelled hairpin oligonucleotide capable of blocking
the transcriptional machinery – antisense Au-nanobeacon
(57.87 ± 3.92 hairpins per NP); or an unrelated stem-looped
oligonucleotide – nonsense Au-nanobeacon (31.64 ± 3.49
hairpins per NP). The determination of the degree of
saturation of AuNPs functionalised with thiolated PEG
chains and quantification of molecular beacon strands per
NP was extensively discussed elsewhere (Rosa et al. 2012;
Conde et al. 2013).
Au-nanobeacon for gene silencing – a nanotheranostics
tool
EGFP knockdown studies were conducted in colorectal
cancer cells (HCT-116 cells) using an EGFP expression
plasmid as a target model. Quantification of EGFP expres-
sion by direct measurement of EGFP fluorescence levels
(Figure 2A and B) reveals that only the antisense Au-
nanobeacon at 30 nM down-regulates EGFP expression
(Figure 2B). The use of Lipofectamine did not result
in EGFP silencing (Figure 2A). These data are corrobo-
rated by qRT-PCR (Figure 2C and D). A significant fluo-
rescence decrease (55.57 ± 13.34% EGFP down-regulation)
was observed at 30 nM of antisense Au-nanobeacon
(Figure 2D).
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Figure 3. Confocal fluorescence imaging of antisense and nonsense Au-nanobeacons effect in HCT-116 cells. Confocal imaging (scale bar,
10 mm) shows HCT-116 cells expressing EGFP after exposure to 30 nM of antisense and nonsense Au-nanobeacons (A). EGFP expression levels
can be evaluated by the intensity of its fluorescence (green, EGFP) (B) and Au-nanobeacons in open conformation (red, Cy3) can be identified
as fine punctuation dispersed throughout the cytoplasm (C). Relative fluorescence intensity of Cy3 and EGFP channels for antisense (black
bars) and nonsense (grey bars) Au-nanobeacons obtained after individual colour channel analysis of the same confocal images using ImageJ
software (D).
 J. Conde et al.
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Confocal fluorescence imaging shows that cells that
internalised the antisense Au-nanobeacon exhibit lower
fluorescence compared to those treated with nonsense
Au-nanobeacon (Figure 3A). Moreover, cellular distribution
of the Au-nanobeacon is observed by the punctuate fluo-
rescence pattern. Data from the Cy3 channel show that
antisense Au-nanobeacon leads to higher signal intensity
than that of the nonsense Au-nanobeacon (Figure 3B and C).
Striking differences for Cy3 and EGFP emissions related to
the antisense and nonsense Au-nanobeacon effect can be
observed in Figure 3D.
Toxicity assessment of Au-nanobeacons
To characterise the system effects in terms of cell viability,
metabolic stress and DNA damage (genotoxicity) and eval-
uate the potential of the antisense Au-nanobeacon as
nanotheranostics tool, we assessed acute toxicity parameters
for all tested conditions: cell survival rates (MTT assay),
oxidative stress (glutathione-S-transferase assay) and geno-
mic DNA damages (comet assay and frequency of NAs).
Regarding the MTT assay, which determines mitochondrial
activity in living cells, no cell viability changes were detected
up to 48 h incubation for both antisense and nonsense
Au-nanobeacons (Figure 4A) and oligonucleotides only at
30 nM (Figure 4B). No major changes in GST activity, which
is often used as an oxidative stress biomarker, were observed
for antisense and nonsense Au-nanobeacons or for the
naked oligonucleotides (Figure 4C) and no significant
differences were observed amongst all samples (p < 0.05).
Genotoxicity was assessed in cells treated with nanobea-
con/oligonucleotide concentrations of 30 nM using two
standard techniques: single-cell gel electrophoresis (comet
assay) and frequency of NAs. According to the % of DNA in
tail, comets were assigned to one of five different classes
(0–4, corresponding to <20%, 20–40%, 40–60%, 60–80% and
>80% total DNA strand breakage). Reference images for the
different classes of comets are shown in Figure 5A. Cells from
the control treatment (i.e. cells expressing EGFP) exhibited
an average of 46.58 ± 10.36% DNA in tail, similar to that
observed in cells treated with AuNP@PEG (45.70 ± 12.58%).
Cells treated with antisense (39.66 ± 3.84%) and nonsense
(32.28 ± 5.13%) Au-nanobeacons failed to yield any signif-
icant differences to that of controls (p < 0.05). Additionally,
the nucleoid distribution per class is uniform amongst these
samples as minor or no alterations are observed (Figure 5B).
Significant differences (p < 0.05) arise, however, in cells
transfected with Lipofectamine and both antisense
(23.09 ± 1.63%) or nonsense (25.26 ± 8.15%) oligonucleo-
tides, when compared with the treatment with Lipofecta-
mine alone (43.93 ± 5.05%). Similarly, differences in class
distribution are denoted (Figure 5B). Despite these differ-
ences, treatment with Lipofectamine alone does not differ
significantly from the control experiment. Comparing anti-
sense with nonsense oligonucleotide treatments (Figure 5C),
no significant differences were found between Au-
nanobeacons or Lipofectamine use for internalisation.
DNA tail percentages above 80% have not been observed
with our approach. Regarding the NA frequency, different
abnormalities, such as micronuclei or nuclear buds, were
surveyed to determine the average frequency of abnormal-
ities for each treatment – see Figure 5J (for reference,
different scored abnormalities are included in Figure 5D–I).
The most frequently observed NAs were micronuclei (>95%).
Data show no significant differences between samples
(p < 0.05): cells expressing EGFP show a frequency of
2.60 ± 1.14%, similar to those treated with AuNP@PEG
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Figure 4. MTT and GST assays in human colorectal cancer cells
(HCT-116). (A) Cell viability (MTT assay) with increasing concentra-
tions of the nanoformulations used in this study. Negligible influence is
observed for all concentrations tested when compared to untreated
cells (black bar). (B) MTT assay for all (nano)biomolecular assemblies
(30 nM) administered in the present study at 48 h of exposure.
Negligible influence in cell viability is observed for all assemblies
tested when compared to untreated cells (PBS). (C) GST activity was
measured for both antisense and nonsense Au-nanobeacons and
naked oligonucleotides at 30 nM.
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(2.08 ± 0.64%), and cells transfected with either the antisense
(1.84 ± 0.69%) or the nonsense (1.93 ± 1.10%) Au-nanobea-
con. Average frequency of cells transfected with and without
Lipofectamine is equivalent (p < 0.05).
Proteome profiling
To have additional insights into the cellular toxicity of
Au-nanobeacons, colorectal cancer cells (HCT-116) previ-
ously transfected with EGFP were used for proteome pro-
filing. Firstly, the effect of Lipofectamine (transfection
vehicle; PBS+Lipo) or AuNPs (as vectors for gene silencing;
AuNP@PEG) in the proteome of HCT-116 cells was evaluated.
A total of five proteins (T-complex protein 1 subunit alpha,
40S ribosomal protein SA and alpha-enolase in Figure 6A-PBS
+Lipo and Ezrin and 40S ribosomal protein SA in Figure 6A-
AuNP@PEG; Supplementary Figure S4B-C and Table S1)
show an increased expression (more than threefold) when
compared to control (Figure 6A-PBS; Supplementary Figure
S4A; Table S1). Protein 40S ribosomal protein SA was over-
expressed (8-fold and 18-fold) in PBS+Lipo and AuNP@
PEG, respectively (Figure 6A; Supplementary Figure S4B-C
and Table S1). In the presence of Lipofectamine, 19 addi-
tional proteins were identified with less than 2-fold over-
expression, most of them acting as molecular chaperones
that assist protein folding (Figure 6A; Supplementary
Figure S3B-C and Table S1). The exposure of EGFP
transfected colorectal cancer cells to naked antisense or
nonsense oligonucleotides revealed no major toxicity
when compared with EGFP transfected cells (PBS+Lipo)
(Figure 6A, Supplementary Figure S4-D-E and Table S1).
Interestingly, protein 40S ribosomal protein SA and alpha-
enolase, which were up-activated in control cells, have an
almost normal level of expression in the presence of both
oligonucleotides. Also, actin cytoplasmatic 2 was slightly
activated (twofold) (Figure 6A, Supplementary Figure
S4-D-E and Table S1).
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Figure 5. Comet assay and NA frequency for evaluation of genotoxic effects in human colorectal cancer cells (HCT-116). (A) Fluorescent
microscopy images of comet classification according to DNA % in tail: class 0 (0–20%); class 1 (20–40%); class 2 (40–60%); class 3 (60–80%);
class 4 (80–100%). (B) Relative frequency profile of comet class distribution according to DNA % in tail. (C) Average DNA % in tail assessed for each
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Significant differences (p < 0.05) marked with *.
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To enquire the cellular toxicity of antisense and non-
sense Au-nanobeacons, protein expression levels in EGFP-
transfected colorectal cancer cell were compared to those
of cells treated with antisense or nonsense Au-nanobea-
cons (Figure 6A, antisense Au-nanobeacon or nonsense
Au-nanobeacon, respectively). No significant differences
were found between cells treated with Au-nanobeacons
and controls. Only one protein alpha-enolase displayed a
higher level of expression (threefold) in both conditions
(Figure 6A, Supplementary Figure S4-D-E and Table S1).
The antisense Au-nanobeacon was responsible for trigger-
ing a sevenfold over-expression of the 40S ribosomal
protein SA and the heat-shock protein 90-beta relative to
the nonsense Au-nanobeacon (Figure 6A, Supplementary
Figure S4-D-E and Table S1).
Discussion
To evaluate the full potential of the antisense Au-
nanobeacon as nanotheranostics tool, we first discuss the
capability of gene silencing via blockage of translation by
conducting EGFP knockdown studies in HCT-116 cells using
an EGFP expression plasmid as a target model, followed by a
characterisation of the system effects in terms of cell viability,
metabolic stress and DNA damage (genotoxicity). Addition-
ally, a proteome profiling, for the same experimental condi-
tions as those of EGFP silencing, is presented so as to identify
putative protein markers of toxicity on HCT-116 cells.
EGFP fluorescence intensity as a direct indicator of EGFP
silencing showed that only the antisense Au-nanobeacon at
30 nMeffectively down-regulates EGFP expression (Figure 2).
EGFP expression is not affected by either the nonsense
Au-nanobeacon or nonsense oligonucleotide indicating
that the knockdown is sequence specific. Interestingly,
EGFP-targeting using the naked antisense oligonucleotide
delivered with or without Lipofectamine did not result in
EGFP silencing (Figure 2A). Confocal fluorescence imaging
allowed for intracellular localisation pattern of the antisense
Au-nanobeacons and direct evaluation of EGFP silencing
associated with an increased Au-nanobeacon fluorescence
that can be used to assess the silencing effect (Figure 3A). It
should be emphasised that Au-nanobeacons require no
transfection agent to enter cells. These results show that
effective and specific gene silencing can be attained by
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Figure 6. Proteome profiling – comparative levels of protein expression in HCT-116 cells previously transfected with EGFP. Incubated with (A) PBS,
PBS + Lipofectamine (PBS + Lipo), AuNPs (AuNP@PEG), antisense Au-nanobeacon, nonsense Au-nanobeacon, naked antisense oligonucleotide,
naked nonsense oligonucleotide; and (B) ratios of antisense Au-nanobeacon/nonsense Au-nanobeacon and nonsense Au-nanobeacon/
antisense Au-nanobeacon.
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means of the proposed antisense Au-nanobeacons. The
specificity and level of silencing can be directly correlated
to the nanobeacon’s fluorescence emission, which de-
monstrates the possibility of using this nanovectorisation
approach as a nanotheranostics tool.
The future use of this system for in vivo models, and for
clinical applications, clearly depends on the evaluation of its
effects in the living system, i.e. toxicity evaluation. Therefore,
we characterised the effects in terms of cell viability and
metabolic stress, DNA damage (genotoxicity) and profiled
the proteome response to the developed gene-silencing
vehicle. In the present study HCT-116 was used as model
but one should be aware that differences between cell lines
do exist and that toxicity may depend on cell types. More-
over, toxicity may be a function of transfection efficiency,
which would show a significant cell type-to-cell type varia-
tion, and therefore extrapolation to other systems is not
straightforward. No cell viability changes and no major
changes in GST activity were detected up to 48 h incubation,
suggesting that no oxidative status changes occur within the
cell following nanobeacon internalisation. These results are
supported by the evidence that GST is inducible and its
expression is directly modulated by the presence of oxidative
radicals that inactivate the Keap repressor, which in turn
releases the Nrf2 transcription factor of GST and other
antioxidant enzymes (Kobayashi & Yamamoto 2005). The
Au-nanobeacon approach may not elicit extensive oxidative
damage, contrarily to what has been previously reported
on internalisation of AuNPs and subsequent intracellular
GSH depletion, promoting oxidative stress in HL7702 cells
and lung fibroblasts (Li et al. 2010; Gao et al. 2011). The
low oxidative stress induced by our approach, and hence
low DNA damage, is in agreement with the genotoxicity
assessment, in particular by the comet assay (see below).
In what comet assay is concerned, cells treated with
antisense (39.66 ± 3.84%) and nonsense (32.28 ± 5.13%)
Au-nanobeacons presented no significant differences to that
of controls (p < 0.05). The uniform nucleoid distribution per
class occurring amongst these samples (Figure 5B) has been
previously reported in cultured cell lines not subjected to
DNA-damage-inducing agents (Costa et al. 2012). These data
show that the proposed antisense Au-nanobeacon strategy
for gene silencing does not appear to significantly exhibit
genotoxicity, which is in accordance with the expected
reduced formation of oxidative radicals, generally regarded
as a major cause of direct DNA strand breakage. Regarding
samples treated with Lipofectamine (alone, and with both
nonsense and antisense oligonucleotides), despite the ver-
ified differences in % of DNA in tail and class distribution
(Figure 5B), Lipofectamine alone does not differ significantly
from the control experiment. It has been previously shown
that these cationic liposome-mediated transfection systems
present toxic effects at concentrations higher than those used
in this study and that liposome:DNA ratio modulates
physicochemical properties of this complex and cytotoxic
consequences upon its internalisation (Sakurai et al. 2000).
Comparing antisense with nonsense oligonucleotide
treatments (Figure 5C), no significant differences were
found between Au-nanobeacons or Lipofectamine use for
internalisation. DNA tail percentages above 80%, indicating
extensive DNA damage and necrotic, apoptotic or nearly
apoptotic cells (Choucroun et al. 2001; Hao et al. 2010), have
not been observed with our approach, suggesting that,
despite the observed variations, no severe genotoxic con-
sequences arise from Au-nanobeacon internalisation. The
rather elevated DNA % in tail value observed for cells
expressing EGFP (46.58 ± 10.36%) might be associated
with high mitotic activity of this cell line or to EGFP expres-
sion as previously reported (Liu et al. 1999; Chalfie & Kain
2006).
NAs usually arise due to errors during mitosis, essentially
consisting of chromosomal aberrations deriving from incor-
rect segregation, and may translate into different observable
abnormalities, such as micronuclei (Fenech et al. 2003). Our
data showed no significant differences (p < 0.05) between
control cells (expressing EGFP, and treated with AuNP@
PEG) and cells transfected with either antisense or nonsense
Au-nanobeacons. Thus far, such comprehensive evaluation
of potential cyto- and/or genotoxic effects to the cell derived
from AuNP-based vectorisation of gene-silencing strategies
has never been presented. Here, effective gene regulation is
attained without significant biological consequences, i.e. no
decrease in cell viability, no perceptible oxidative stress and
no increase of NA frequency and DNA strand breaks support
the idea that the presented methodology bears no critical
genotoxic or mutagenic consequences to the cell.
Regarding the proteome profiling, the effect of Lipofec-
tamine as a transfection vehicle versus AuNPs as vectors for
gene silencing in HCT-116 cells was firstly evaluated. We
highlight the over-expression of protein 40S ribosomal
protein SA that is required for the assembly and/or stability
of the 40S ribosomal subunit and also functions as a cell
surface receptor for laminin, playing a role in cell adhesion to
the basal membrane (Venticinque & Meruelo 2012). More-
over, 19 additional proteins with less than 2-fold over-
expression were identified in the presence of Lipofectamine,
most of them acting as molecular chaperones that assist
protein folding. These results indicate that Lipofectamine
and AuNPs may induce a slight alteration of protein bio-
synthesis and folding, and induce cytoskeletal remodelling.
Nevertheless, no relevant cellular toxicity is observed, which
is in clear agreement with the data from cell viability,
absence of oxidative stress and the lack of DNA strand breaks
and NAs (see previous sections). Tedesco and co-workers
showed similar effects by exposing Mytilus edulis to approx-
imately 15 nm AuNPs (same size of our AuNPs), which lead
to a small decrease in the levels of thiol proteins that they
attributed to light oxidation (Tedesco et al. 2010). However,
in our proteomic study we were not able to observe the
reduction of thiol-containing proteins (Figure 6A and Sup-
plementary Table S1). Interestingly, these authors were also
not able to find lipid peroxidation (as indicator of oxidative
damage) or induction of thioredoxin reductase activity
(Tedesco et al. 2010). Despite no differences in protein
expression levels in EGFP-transfected colorectal cancer
cell to those of cells treated with antisense or nonsense
Au-nanobeacons, the antisense Au-nanobeacon caused a
sevenfold over-expression of the 40S ribosomal protein SA
 J. Conde et al.
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and the heat-shock protein 90-beta relative to the Nonsense
Au-nanobeacon (Figure 6A, Supplementary Figure S4-D-E
and Table S1). These over-expression values may result from
an alteration of cell homeostasis related with EGFP produc-
tion, as EGFP silencing by antisense Au-nanobeacon may
trigger mechanisms of cellular stress response. In support of
this idea, we can observe an increase in the expression levels
of cellular chaperones, namely heat-shock proteins encoded
by HSP90B, HSP71 and HSP7C genes, different T-complex
subunits and calreticulin. Peptidyl-prolylcis-trans isomerase
(a component of non-ligated steroid receptors heterocom-
plexes through interaction with heat-shock protein 90 that
may play a role in the intracellular trafficking of hetero-
oligomeric forms of steroid hormone receptors between
cytoplasm and nuclear compartments) and peptide 35 (no
protein identification) expression levels were reduced
(1.5-fold) in the presence of antisense Au-nanobeacon
relative to nonsense Au-nanobeacon and with similar
expression levels in the other tested conditions (Figure 6A
and B, Supplementary Figure S4-D-E and Table S1).
Conclusions
We developed a robust and versatile system with nanother-
anostics potential capable of blocking specific gene expres-
sion via an antisense Au-nanobeacon. A significant attribute
of these Au-nanobeacons is the ability to attain similar levels
of inhibition of gene expression with lower amounts than
those of free oligonucleotides. This extraordinary efficiency
occurs probably due to the large payload capacity of the NPs.
The nanobeacon conformation allows for detection of
silencing events as it occurs inside cells; thus, our approach
becomes simple, inexpensive and straightforward as
adjustment to any specific target can be easily made.
Evaluating biocompatibility and safety issues of these
nanomaterials is imperative towards its use for medical
purposes. However, the vast majority of studies report
only on the biocompatibility of nanomaterials through
the study of cell viability. Here, we went one step further
and provide for the first time an extensive toxicity study of
NPs for gene therapy. Modulation of gene expression was
successfully attained with 30 nM of antisense Au-nanobea-
con, without decreased cell viability or induction of oxi-
dative stress. Moreover, an assessment of genome-related
toxicity revealed no significant DNA damage increase, as
well as no potential mutagenic or clastogenic conse-
quences to the cell. Proteomics appears to be a relevant
approach for mechanistic studies of cellular responses to
Au-nanobeacons. The proteome profiling, as presented
here, represents a useful tool for systematic analysis of
toxicity of nanoconjugates, not only at the molecular level
but also for the discovery of biomarkers and pathways
towards the understanding of the mechanisms of toxicity.
It must be emphasised that such mechanistic studies must
be ultimately verified on relevant in vivo models. Identi-
fication of response pathways to AuNP internalisation may
assist in gathering relevant information on acute toxicity
so as to optimise systems for translation to in vivo models,
and eventually to clinical applications.
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1. Physical characterization of Au-nanobeacons 
Gold nanoparticles (AuNPs) were synthesized by the citrate reduction method described by Lee and 
Meisel (Lee, 1982).Briefly, 225 mL of 1 mM hydrogen tetrachloroaureate (III) hydrate (Sigma) 
(88.61 mg) was solved in 500 ml of distilled water and heated and stirred under reflux. When the 
solution boils, 25 mL of 38.8 mM sodium citrate dihydrate (285 mg) was added resulting in a red 
solution. The solution is kept under ebullition with vigorous stirring and protected from light for 30 
minutes. Then, the solution is cooled down and kept protected from light. Citrate capped AuNPs 
were characterized by Transmission Electron Microscopy (TEM) and UV-Vis spectroscopy. 
 
Functionalization of PEGylated AuNPs was carried out using commercial hetero-functional 
poly(ethylene glycol) (PEG) functionalized with a thiol group O-(2-Mercaptoethyl)-O’-methyl-
hexa(ethylene glycol), C15H32O7S, 356.48 Da (Sigma) as previously described (Rosa, 2012; Conde, 
2013; Sanz, 2012).Briefly, 10 nM of the AuNPs were mixed with 0.003 mg/mL of O-(2-
Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) in an aqueous solution of SDS (0.028%). Then, 
NaOH was added to a final concentration of 25 mM and the mixture incubated for 16 hours at room 
temperature. Excess PEG was removed by centrifugation (21.460 ×g, 30 min, 4ºC), and quantified 
by the Ellman’s Assay suitable for sulfhydryl group determination. Briefly, 0.05 mg/mL of 5,5’-
dithio-bis-(2-nitrobenzoic acid) (DTNB) (Sigma), reacts with sulfhydryl under slightly alkaline 
conditions (0.5 M phosphate buffer, pH 7-8), to release 5-thio-2-nitrobenzoic acid (TNB) a highly 
chromogenic compound (412 nm), after 15 min at room temperature. The excess of O-(2-
Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) was determined following interpolation in a 
standard curve (Abs412nm = 26.034 × [PEG, mg/mL] + 0.0627). 
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Figure S1. Physical characterisation of Au-nanobeacons. (A) Transmission Electron Microscopy 
(TEM) of citrate-AuNPs, Inset: size distribution histogram showing an average diameter of 14.6±1.7 
nm. (B) UV/Vis Spectroscopy of citrate AuNPs and of Au-nanobeacons.TEM images for antisense 
(C) and nonsense (D) Au-nanobeacons. (E) Surface charge measurements by Zeta Potential. (F) 
Dynamic Light Scattering (DLS) showing average diameter of AuNPs conjugates. 
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2. EGFP vector transfection in HCT-116 cells 
 
Figure S2.Representative images of HCT-116 cells 24 h after transfection with EGFP vector. 
From left to right: bright fieldmicroscopy images, green fluorescence channels corresponding to 
EGFP fluorescence, and nucleus stained with DAPI. 
 
3. Comet class and nuclear abnormality frequency 
 
 
 
 
Figure S3. Average frequencies for (A) scored comets per class, according to % of DNA in tail; 
(B) scored nuclear abnormalities, for each treatment.  
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4. Proteome evaluation – Two-dimensional gel electrophoresis 
Protein samples (200 µg) were transferred onto strip holders along with 7 cm long IPG strips 
covering pH range from 3 to 10. Strips were positioned in the strip holders with gel side down, 
avoiding entrapment of bubbles underneath the strip. Strips were then covered with 3 mL DryStrip 
Cover Fluid (GE Healthcare) and the strip holders lidded. IEF was performed in five steps “step-n-
hold” in the following order: 30 V for 720 minutes, 100 V for 30 minutes, 500 V for 30 minutes, 
1000 V for 30 minutes and 5000 V for 60 minutes. After IEF, the strips were equilibrated 2×15 min 
with a mixture containing 75mM Tris-HCl (Sigma) (pH 8.8), 6 M urea, 2% SDS (Sigma), 30% 
glycerol (Merck) and traces of bromophenol blue. The buffer for the first equilibration step contained 
1% DTT and the second 2.5% iodoacetamide (Sigma). The second dimension was performed in a 
mini-PROTEAN II electrophoresis Cell (Bio-Rad). IPG strips were placed on top of a 12% (w/v) 
acrylamide/bis-acrylamide (37.5:1) gel. The strips were sealed with an agarose solution of 0.5% 
(w/v) with traces of bromophenol blue and the electrophoresis was conducted at 50 V for 30 minutes 
until the proteins were incorporated in the polyacrylamide matrix, followed by 150 V for 90 minutes. 
Gels were soaked in a fixing solution (10% acetic acid; 30% ethanol) for at least 2 h, stained with hot 
Coomassie Brilliant Blue R350 (PhastGelTM Blue R, GE Healthcare) solution in 10% acetic acid for 
30 min and washed overnight in 10% acetic acid. Gels were then dehydrated in a 2% glycerol, 35% 
ethanol solution and dried between two porous cellophane sheets for at least 48 h. All 2-DE gel 
images were digitalized (PIXMA M250, Canon) and analyzed with the Melanie 7.0Software 
(GeneBio). Each one of the conditions studied was evaluated in triplicate. The analysis was 
performed semi-automatically by the software, adhering to the following procedure: (1) spot 
detection; (2) spot matching from different gels; (3) background subtraction; and (4) assessment of 
the normalized intensity of each spot. Normalization was performed as the ratio of the spot intensity 
and the total intensity of the spots with a match in all gels in the experiment.   
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Figure S4. Two-dimensional gel electrophoresis of protein extracts for cells exposed to: (A) PBS, 
(B) PBS + Lipofectamine, (C) Antisense oligonucleotide, (D) Nonsense oligonucleotide, (E) 
AuNP@PEG, (F) Antisense Au-nanobeacon, (G) Nonsense Au-nanobeacon.  
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5. Proteome evaluation – MALDI-TOF Mass Spectrometry analysis 
In-gel digestion and MALDI-TOF Mass Spectrometry analysis  
Selected protein spots were manually excised from 2-DE gels and sent for Peptide Mass 
Fingerprinting analysis at Mass Spectrometry Laboratory in ITQB/IBET (Oeiras, Portugal). Briefly, 
excised gel spots were washed with MilliQ water and 50% acetonitrile (ACN) for Comassie dye 
removal and then dehydrated using 100% ACN. Reduction and alkylation steps followed by 
incubating the samples with agitation, first with 10 mM of DTT, 100 mM ammonium bicarbonate for 
45 minutes at 56 °C followed by 55 mM of iodoacetamide, 100 mM ammonium bicarbonate for 30 
minutes at room temperature in the dark. The spots were once more washed and dried with 100% 
ACN and vacuum centrifuged until completely dry. For in-gel digestion procedure the gel spots were 
rehydrated for 30 min on ice with digestion buffer (50 mM ammonium bicarbonate) a nd overnight 
digestion with 6.7 ng/µL of trypsin at 37 °C. Smaller protein digests were recovered from 
supernatant and larger protein digests were recovered by dehydration of the gels with 5% formic acid 
followed by 100% ACN and supernatant recovery. All samples were then completely dried under 
vacuum and stored at -20 °C. Sample preparation for mass spectrometry analysis was as follows: 
protein digests were resuspended in 5% formic acid, spotted onto the MALDI plate and covered with 
the same volume of matrix solution (α-cyano-4-hydroxycinnamic acid 10 mg/mL; 50% ACN, 5% 
form
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Table 1.Protein identification via MALDI-TOF Mass Spectrometry analysis. 
Spot 
ID 
Protein 
Identi fication 
Acession 
reference 
(HUMAN) 
Protein 
Score 
(Mascot) 
Isoelectric 
point 
MW 
(KDa) 
Description
a
 
3 
Heat shock 
protein HSP 90-
beta 
HS90B 259 4.97 83.212 
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation  
of specific target proteins involved for instance in cell cycle control and signal transduction. 
Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces 
conformat ional changes in the client proteins, thereby causing their activation. Interacts 
dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and 
chaperone function. Homodimer. Interacts with p53/TP53. Forms a complex with CDK6 and 
Hsp90/HSP90AB1. Interacts with UNC45A. Binding to UNC45A involves 2 UNC45A monomers 
per HSP90AB1 dimer. Interacts with CHORDC1 and DNAJC7. Interacts with FKBP4.  
4 
Heat shock 
cognate 71 kDa 
protein 
HSP7C 807 5.37 70.8542 
Acts as a repressor of transcriptional activation. Inhib its the transcriptional coactivator activity of 
CITED1 on Smad-mediated transcription.Chaperone. Component of the PRP19-CDC5L complex 
that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. 
May have a scaffolding role in the spliceosome assembly as it contacts all other components of 
the core complex. Identified in a mRNP granule complex, at least composed of ACTB, ACTN4, 
DHX9, ERG, HNRNPA1, HNRNPA2B1, HNRNPAB, HNRNPD, HNRNPL, HNRNPR, 
HNRNPU, HSPA1, HSPA8, IGF2BP1, ILF2, ILF3, NCBP1, NCL, PABPC1, PABPC4, 
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PABPN1, RPLP0, RPS3, RPS3A, RPS4X, RPS8, RPS9, SYNCRIP, TROVE2, YBX1 and 
untranslated mRNAs. Interacts with PACRG. Interacts with HSPH1/HSP105. Interacts with 
IRAK1BP1 and BAG1. Interacts with DNAJC7. Interacts with CITED1 (v ia N-terminus); the 
interaction suppresses the association of CITED1 to p300/CBP and Smad-mediated transcription 
transactivation. Component of the PRP19-CDC5L splicing complex composed of a core complex 
comprising a homotetramer of PRPF19, CDC5L, PLRG1 and BCAS2, and at least three less 
stably associated proteins CTNNBL1, CW C15 and HSPA8. Interacts with SV40 VP1.  
43 
Eukaryotic 
initiation factor 
4A-I 
IF4A1 588 5.32 46.1246 
ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap 
recognition and is required for mRNA binding to ribosome. In the current model o f translation 
initiat ion, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary 
to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator 
codon. 
69 Prohibitin PHB 629 5.57 29.7859 
Prohibit in inhib its DNA synthesis. It has a role in regulating proliferation. As yet it is unclear if 
the protein or the mRNA exhibits this effect. May play a role in regulat ing mitochondrial 
respiration activity and in aging. Interacts with PHB2.  
9 
Proteasome 
activator 
complex subunit 
1 
PSME1 228 5.78 28.705 
Implicated in immunoproteasome assembly and required for efficient antigen processing. The 
PA28 activator complex enhances the generation of class I binding peptides by altering the 
cleavage pattern of the proteasome. 
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19 Ezrin EZRI 878 5.94 69.3697 
Probably involved in connections of major cytoskeletal structures to the plasma membrane. In 
epithelial cells, required for the format ion of microvilli and membrane ruffles on the apical pole. 
Along with PLEKHG6, required for normal macropinocytosis. Phosphorylated by tyrosine-
protein kinases. Phosphorylation by ROCK2 suppresses the head-to-tail association of the N-
terminal and C-terminal halves resulting in an opened conformation which is capable of act in and 
membrane-binding. 
25 
T-complex 
protein 1 
subunit zeta 
TCPZ 662 6.23 57.9876 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. Known to play a role, 
in vitro, in the fo lding of actin and tubulin. 
33 
Proliferation-
associated 
protein 2G4  
PA2G4 458 6.13 43.7592 
May play a role in a ERBB3-regulated signal transduction pathway. Seems be involved in g rowth 
regulation. Acts a corepressor of the androgen receptor (AR) and is regulated by the ERBB3 
ligand neuregulin-1/heregulin (HRG). Inhib its transcription of some E2F1-regulated promoters, 
probably by recruiting histone acetylase (HAT) act ivity. Binds RNA. Associates with 28S, 18S 
and 5.8S mature rRNAs, several rRNA precursors and probably U3 small nucleolar RNA. May be 
involved in regulation of intermediate and late steps of rRNA processing. May be involved in 
ribosome assembly. Mediates cap-independent translation of specific viral IRESs (internal 
ribosomal entry site). Interacts  with the cytoplasmic domain of non-phosphorylated ERBB3; the 
interaction requires PKC activ ity. Interacts with AR. Treatment with HRG leads to dissociation 
from ERBB3 and increases association with AR. Interacts with NCL/nucleolin. Component of a 
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ribonucleoprotein complex containing at least PA2G4, NCL, TOP1, PABPC2, RPLP0, acetylated 
histone H1 (HIST1H1A or H1F1), h istone H1 2/4, RPL4, RPL8, RPL15, RPL18, RPL18A, 
RPL21, RPL11, RPL12, RPL28, RPL27, RPLP2 and RPL24. Interacts with HDAC2. Interacts 
with RB1; the interaction is enhanced upon PA2G4 dephosphorylation. 
54 Calumenin CALU 231 4.47 37.0835 
Involved in regulation of v itamin K-dependent carboxylat ion of multiple N-terminal g lutamate 
residues. Seems to inhibit gamma-carboxylase GGCX. Binds 7 calcium ions with a low affin ity 
22 Moesin MOES 605 6.08 67.778 
Probably involved in connections of major cytoskeletal structures to the plasma membrane. May 
inhibit herpes simplex virus 1 infection at an early stage. In resting T-cells, part of a PAG1-
SLC9A3R1-MSN complex which is disrupted upon TCR act ivation. Binds SLC9A3R1. Interacts 
with PPP1R16B. Interacts with PDZD8. Interacts with SELPLG and SYK; mediates the activation 
of SYK by SELPLG. 
24 
T-complex 
protein 1 
subunit gamma 
TCPG 177 6.1 60.4953 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin. 
23 
X-ray repair 
cross-
complementing 
protein 6  
XRCC6 511 6.23 69.799 
Single stranded DNA-dependent ATP-dependent helicase. Has a role in chromosome 
translocation. The DNA helicase II complex binds preferentially to fork-like ends of double-
stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' d irection. Binding to DNA 
may be mediated by XRCC6. Involved in DNA non-homologous end joining (NHEJ) required for 
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double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as regulatory 
subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the 
catalytic subunit PRKDC to DNA by 100-fo ld. The XRCC5/6 dimer is probably involved in 
stabilizing broken DNA ends and bringing them together. The assembly of the DNA-PK complex 
to DNA ends is required for the NHEJ ligation step. Required for osteocalcin gene expression. 
Probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalysing the beta-
elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks. 5'-dRP 
lyase activity allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly 
associated with strand breaks, before such broken ends can be joined. The XRCC5/6 dimer 
together with APEX1 acts as a negative regulator of transcription 
17 
T-complex 
protein 1 
subunit gamma 
TCPG 128 6.1 60.4953 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin. 
16 
T-complex 
protein 1 
subunit gamma 
TCPG 132 6.1 
 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin. 
14 T-complex TCPA  597 5.8 60.3056 Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
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protein 1 
subunit alpha 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin. 
37 
Cytochrome b-
c1 complex 
subunit 1, 
mitochondrial  
QCR1 187 5.94 52.6124 
This is a component of the ubiquinol-cytochrome c reductase complex (complex III or 
cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This protein may 
mediate format ion of the complex between cytochromes c and c1.  
38 RuvB-like 2 RUVB2 571 5.49 51.1246 
Possesses single-stranded DNA-stimulated ATPase and ATP-dependent DNA helicase (5' to 3') 
activity; hexamerisation is thought to be critical for ATP hydrolysis and adjacent subunits in the 
ring-like structure contribute to the ATPase activity. Component of the NuA4 histone 
acetyltransferase complex which is involved in transcriptional act ivation of select genes 
principally by acetylation of nucleosomal histones H4 and H2A. This modificat ion may both alter 
nucleosome - DNA interactions and promote interaction of the modified histones with other 
proteins which positively regulate transcription. This complex may be required for the activation 
of transcriptional programs associated with oncogene and proto-oncogene mediated growth 
induction, tumour suppressor mediated growth arrest and replicative senescence, apoptosis, and 
DNA repair. The NuA4 complex ATPase and helicase activit ies seem to be, at least in part, 
contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a 
direct ro le in DNA repair when recruited to sites of DNA damage. Proposed core component of 
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the chromatin remode lling INO80 complex which is involved in t ranscriptional regulat ion, DNA 
replicat ion and probably DNA repair.  
61 
14-3-3 protein 
gamma 
1433G 310 4.8 28.2849 
Adapter protein implicated in the regulation of a large spectrum of both general and specialised 
signalling pathways. Binds to a large number of partners, usually by recognition of a 
phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the 
activity of the binding partner. Interacts with CDK16 and BSPRY. Interacts with W EE1 (C-
terminal). Interacts with SAMSN1. Interacts with MLF1 (phosphorylated form); the interaction 
retains it in the cytoplasm. Interacts with Thr-phosphorylated ITGB2. Interacts with 
BCL2L11.Homodimer. Heterodimerizes with YW HAE. Homo- and hetero-dimerization is 
inhibited by phosphorylation on Ser-58. Interacts with FOXO4, NOXA1, SSH1 and ARHGEF2. 
Interacts with Pseudomonas aeruginosaexoS (unphosphorylated form). Interacts with BAX; the 
interaction occurs in the cytoplasm. Under stress conditions, MAPK8-mediated phosphorylation 
releases BAX to mitochondria. Interacts with phosphorylated RAF1; the interaction is inhibited 
when YWHAZ is phosphorylated on Thr-232. Interacts with TP53; the interaction enhances p53 
transcriptional activity. The Ser-58 phosphorylated form inhibits this interaction and p53 
transcriptional activity. Interacts with ABL1 (phosphorylated form); the interaction retains ABL1 
in the cytoplasm. Interacts with PKA-phosphorylated AANAT; the interaction modulates 
AANAT enzymatic activ ity by increasing affinity for ary lalkylamines and acetyl-CoA and 
protecting the enzyme from dephosphorylation and proteasomal degradation. It may also prevent 
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thiol-dependent inactivation. Interacts with AKT1; the interaction phosphorylates YWHAZ and 
modulates dimerization. Interacts with GAB2 and TLK2.  
50 
Actin, 
cytoplas mic 2 
ACTG 91 5.31 41.7658 
Actins are highly conserved proteins that are involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells. Defects in ACTG1 are the cause of deafness 
autosomal dominant type 20 (DFNA20). DFNA20 is a form of sensorineural hearing loss. 
Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve 
pathways to the brain, or the area of the brain that receives sound informat ion. DFNA20 is a form 
of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors 
of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound 
informat ion. Defects in ACTG1 are the cause of Baraitser-Winter syndrome type 2. A rare 
developmental disorder characterized by the combination of congenital ptosis, high-arched 
eyebrows, hypertelorism, ocular co lobomata, and a brain malformation consisting of anterior-
predominant lissencephaly. Other typical features include postnatal short stature and 
microcephaly, intellectual disability, seizures, and hearing loss. 
51 Secernin-1 SCRN1 162 4.66 46.3525 
Regulates exocytosis in mast cells. Increases both the extent of secretion and the sensitivity of 
mast cells to stimulat ion with calcium 
52 
Ribonuclease 
inhibitor 
RINI 117 4.71 49.9411 
Ribonuclease inhibitor which inhib its RNASE1, RNASE2 and ANG. May play a role in redox 
homeostasis. 
41 Peptidyl- FKBP4 
  
51.7721 Immunophilin protein with PPIase and co-chaperone activities. Component of non-ligated steroid 
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prolylcis-trans 
isomerase 
receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). May p lay a 
role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors 
between cytoplasm and nuclear compartments. The isomerase activity controls neuronal growth 
cones via regulation of TRPC1 channel opening. Acts also as a regulator of microtubule dynamics 
by inhibiting MAPT/TAU ab ility to promote microtubule assembly.  
10 
40S ribosomal 
protein SA 
RSSA 413 4.79 32.8334 
Required for the assembly and/or stability of the 40S ribosomal subunit. Required for the 
processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S 
ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell 
adhesion to the basement membrane and in the consequent activation of signalling transduction 
pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a 
PPP1R16B-dependent substrate of PPP1CA. Also acts as a receptor for several other ligands, 
including the pathogenic prion protein, v iruses, and bacteria. Th is protein appears to have 
acquired a second function as a laminin receptor specifically in the vertebrate lineage. t is thought 
that in vertebrates 37/67 kDalaminin receptor acquired a dual function during evolution. It 
developed from the ribosomal protein SA, playing an essential role in the protein biosynthesis 
lacking any laminin b inding activity, to a cell surface receptor with lamin in binding activity.  
32 no id - - - - - 
31 
T-complex 
protein 1 
TCPB 185 6.01 57.4521 
Molecular chaperone; assists  the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
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subunit beta ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin 
27 no id - - - - - 
15 
Cytosol 
aminopeptidase 
AMPL 350 8.03 56.1308 
Presumably involved in the processing and regular turnover of intracellu lar proteins. Catalyzes the 
removal of unsubstituted N-terminal amino acids from various peptides. 
35 no id - - - - - 
18 
T-complex 
protein 1 
subunit beta 
TCPB 2080 6.01 57.4521 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin 
20 no id - - - - - 
28 
Proteasome 
subunit alpha 
type-1  
PSA1 442 6.15 29.5369 
The proteasome is a mult icatalytic proteinase complex which is  characterized by its ability to 
cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or 
slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Mediates the 
lipopolysaccharide-induced signal transduction in the macrophage proteasome. Might be involved 
in the anti-in flammatory response of macrophages during the interaction with C.albicans heat-
inactivated cells. 
11 
T-complex 
protein 1 
TCPQ 886 5.42 59.5825 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
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subunit theta ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin. 
6 
Glutamate 
dehydrogenase 
1, mitochondrial  
DHE3 166 7.66 61.3592 
May be involved in learn ing and memory reactions by increasing the turnover of the excitatory 
neurotransmitter g lutamate. Defects in GLUD1 are the cause of familial 
hyperinsulinemichypoglycemia type 6 (HHF6) [MIM:606762]; also known as hyperinsulinism-
hyperammonemia syndrome (HHS). Familial hyperinsulinemichypoglycemia [MIM:256450], also 
referred to as congenital hyperinsulinis m, nesidioblastosis, or persistent 
hyperinsulinemichypoglycemia of infancy (PPHI), is the most common cause of persistent 
hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion 
by low glucose levels. In HHF6 elevated oxidation rate of g lutamate to alpha-ketoglutarate 
stimulates insulin secretion in the pancreatic beta cells, while they impair detoxification of 
ammonium in the liver. 
30 
40S ribosomal 
protein SA 
RSSA 198 4.79 44.0791 
Required for the assembly and/or stability of the 40S ribosomal subunit. Required for the 
processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S 
ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell 
adhesion to the basement membrane and in the consequent activation of signalling transduction 
pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a 
PPP1R16B-dependent substrate of PPP1CA. Also acts as a receptor for several other ligands, 
including the pathogenic prion protein, v iruses, and bacteria. Th is protein appears to have 
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acquired a second function as a laminin receptor specifically in the vertebrate lineage. t is thought 
that in vertebrates 37/67 kDalaminin receptor acquired a dual function during evolution. It 
developed from the ribosomal protein SA, playing an essential role in the protein biosynthesis 
lacking any laminin b inding activity, to a cell surface receptor with lamin in binding activity.  
45 no id - - - - - 
34 
Actin, 
cytoplas mic 2 
ACTG 819 5.31 41.7658 
Actins are highly conserved proteins that are involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells. Defects in ACTG1 are the cause of deafness 
autosomal dominant type 20 (DFNA20). DFNA20 is a form of sensorineural hearing  loss. 
Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve 
pathways to the brain, or the area of the brain that receives sound informat ion. DFNA20 is a form 
of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors 
of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound 
informat ion. Defects in ACTG1 are the cause of Baraitser-Winter syndrome type 2. A rare 
developmental disorder characterized by the combination of congenital ptosis, high-arched 
eyebrows, hypertelorism, ocular co lobomata, and a brain malformation consisting of anterior-
predominant lissencephaly. Other typical features include postnatal short stature and 
microcephaly, intellectual disability, seizures, and hearing loss. 
29 
T-complex 
protein 1 
TCPB 874 6.01 57.4521 
Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the 
BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in 
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subunit beta ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in v itro, in the fold ing 
of actin and tubulin 
36 
Tubulin alpha-
1B chain 
TBA1B 1170 4.94 50.1196 
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an 
exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain. 
Undergoes a tyrosination/detyrosination cycle, the cyclic removal and re -addition of a C-terminal 
tyrosine residue by the enzymes tubulin tyrosine carboxypeptidase (TTCP) and tubulin tyrosine 
ligase (TTL), respectively. 
40 Endoplas min ENPL 1330 4.76 92.4113 
Molecular chaperone that functions in the processing and transport of secreted proteins. When 
associated with CNPY3, required for proper fo lding of To ll-like receptors. Functions in 
endoplasmic ret iculum associated degradation (ERAD). Has ATPase activity.  
12 Alpha-enolase ENOA  386 7.01 47.1393 
Multifunctional enzyme that, as well as its ro le in g lycolysis, plays a part in various processes 
such as growth control, hypoxia tolerance and allergic responses. May also function in the 
intravascular and pericellularfibrinolytic system due to its ability to serve as a receptor and 
activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. 
Stimulates immunoglobulin production. MBP1 binds to the myc promoter and acts as a 
transcriptional repressor. May be a tumour suppressor. 
42 Ezrin EZRI 1060 5.94 69.3697 
Probably involved in connections of major cytoskeletal structures to the plasma membrane. In 
epithelial cells, required for the format ion of microvilli and membrane ruffles on the apical pole. 
Along with PLEKHG6, required for normal macropinocytosis. Phosphorylated by tyrosine-
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protein kinases. Phosphorylation by ROCK2 suppresses the head-to-tail association of the N-
terminal and C-terminal halves resulting in an opened conformation which is capable of act in and 
membrane-binding. 
44 
L-lactate 
dehydrogenase 
B chain 
LDHB 443 5.71 36.6151 Responsible for the reaction (S)-lactate + NAD
+
 = pyruvate + NADH. 
53 
Adenine 
phosphoribosylt
ransferase 
APT 162 5.78 19.5954 
Catalyses a salvage reaction resulting in the formation of AMPthat is energically less costly than 
de novo synthesis. Defects in APRT are the cause of adenine phosphoribosyltransferase 
deficiency (APRTD) [MIM:102600]; also known as 2,8-dihydroxyadenine urolithiasis. An 
enzymatic deficiency that can lead to urolithiasis and renal failu re. Patients have 2,8-
dihydroxyadenine (DHA) urinary stones. 
55 
Translationally-
controlled 
tumor protein 
TCTP 332 4.84 19.5826 
Involved in calcium binding and microtubule stabilization. Found in several healthy and tumoral 
cells including erythrocytes, hepatocytes, macrophages, platelets, keratinocytes, erythroleukaemia 
cells, gliomas, melanomas, hepatoblastomas, and lymphomas. It cannot be detected in kidney and 
renal cell carcinoma (RCC). Expressed in placenta and prostate. 
2 
Triosephosphat
eisomerase 
TPIS 152 5.65 30.7717 
Catalytic act ivity D-glyceraldehyde 3-phosphate = glycerone phosphate.Defects in TPI1 are the 
cause of triosephosphateisomerase deficiency (TPI deficiency). TPI deficiency is an autosomal 
recessive disorder. It is the most severe clinical d isorder of glycolysis. It is associated with 
neonatal jaundice, chronic haemolyticanaemia , progressive neuromuscular dysfunction, 
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cardiomyopathy and increased susceptibility to infect ion. 
59 
Rho GDP-
dissociation 
inhibitor 1 
GDIR1 661 5.02 23.1927 
Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibit ing  the dissociation of 
GDP from them, and the subsequent binding of GTP to them. In glioma cells, inhib its cell 
migrat ion and invasion by mediating the signals of SEMA5A and PLXNB3 that lead to 
inactivation of RAC1 
68 
Heat shock 
protein beta-1 
HSPB1 579 5.98 22.7685 
Involved in stress resistance and actin organization. Interacts with TGFB1I1. Associates with 
alpha- and beta-tubulin, microtubules and CRYAB. Interacts with HSPB8 and HSPBAP1 
72 
Phos phoglycera
temutase 1 
PGAM1 573 7.22 28.7858 
Interconversion of 3- and 2-phosphoglycerate with 2,3-b isphosphoglycerate as the primer of the 
reaction. Can also catalyse the reaction of EC 5.4.2.4 (synthase) and EC 3.1.3.13(phosphatase), 
but with a reduced activity..  
57 
14-3-3 protein 
zeta/delta 
1433Z 1030 4.73 27.7277 
Adapter protein implicated in the regulation of a large spectrum of both general and specialised 
signalling pathways. Binds to a large number of partners, usually by recognition of a 
phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the 
activity of the binding partner. Interacts with CDK16 and BSPRY. Interacts with W EE1 (C-
terminal). Interacts with SAMSN1. Interacts with MLF1 (phosphorylated form); the interaction 
retains it in the cytoplasm. Interacts with Thr-phosphorylated ITGB2. Interacts with 
BCL2L11.Homodimer. Heterodimerises with YWHAE. Homo- and hetero-dimerization is 
inhibited by phosphorylation on Ser-58. Interacts with FOXO4, NOXA1, SSH1 and ARHGEF2. 
Interacts with Pseudomonas aeruginosaexoS (unphosphorylated form). Interacts with BAX; the 
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interaction occurs in the cytoplasm. Under stress conditions, MAPK8-mediated phosphorylation 
releases BAX to mitochondria. Interacts with phosphorylated RAF1; the interaction is inhibited 
when YWHAZ is phosphorylated on Thr-232. Interacts with TP53; the interaction enhances p53 
transcriptional activity. The Ser-58 phosphorylated form inhibits this interaction and p53 
transcriptional activity. Interacts with ABL1 (phosphorylated form); the interaction retains ABL1 
in the cytoplasm. Interacts with PKA-phosphorylated AANAT; the interaction modulates 
AANAT enzymatic activ ity by increasing affinity for ary lalkylamines and acetyl-CoA and 
protecting the enzyme from dephosphorylation and proteasomal degradation. It may also prevent 
thiol-dependent inactivation. Interacts with AKT1; the interaction phosphorylates YWHAZ and 
modulates dimerization. Interacts with GAB2 and TLK2.  
56 
14-3-3 protein 
zeta/delta 
1433Z 926 4.73 27.7277 
Adapter protein implicated in the regulation of a large spectrum of both general and specialised 
signalling pathways. Binds to a large number of partners, usually by recognition of a 
phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the 
activity of the binding partner. Interacts with CDK16 and BSPRY. Interacts with W EE1 (C-
terminal). Interacts with SAMSN1. Interacts with MLF1 (phosphorylated form); the interaction 
retains it in the cytoplasm. Interacts with Thr-phosphorylated ITGB2. Interacts with 
BCL2L11.Homodimer. Heterodimerises with YWHAE. Homo- and hetero-dimerization is 
inhibited by phosphorylation on Ser-58. Interacts with FOXO4, NOXA1, SSH1 and ARHGEF2. 
Interacts with Pseudomonas aeruginosaexoS (unphosphorylated form). Interacts with BAX; the 
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interaction occurs in the cytoplasm. Under stress conditions, MAPK8-mediated phosphorylation 
releases BAX to mitochondria. Interacts with phosphorylated RAF1; the interaction is inhibited 
when YWHAZ is phosphorylated on Thr-232. Interacts with TP53; the interaction enhances p53 
transcriptional activity. The Ser-58 phosphorylated form inhibits this interaction and p53 
transcriptional activity. Interacts with ABL1 (phosphorylated form); the interaction retains ABL1 
in the cytoplasm. Interacts with PKA-phosphorylated AANAT; the interaction modulates 
AANAT enzymatic activ ity by increasing affinity for ary lalkylamines and acetyl-CoA and 
protecting the enzyme from dephosphorylation and proteasomal degradation. It may also prevent 
thiol-dependent inactivation. Interacts with AKT1; the interaction phosphorylates YWHAZ and 
modulates dimerization. Interacts with GAB2 and TLK2.  
1 
Proteasome 
activator 
complex subunit 
1 
PSME1 295 5.78 28.705 
Implicated in immunoproteasome assembly and required for efficient antigen processing. The 
PA28 activator co mplex enhances the generation of class I binding peptides by altering the 
cleavage pattern of the proteasome. 
70 
Ran-s pecific 
GTPase-
activating 
protein 
RANG 146 5.19 23.2956 
Inhibits GTP exchange on Ran. Forms a Ran-GTP-RANBP1 trimeric complex. Increase GTP 
hydrolysis induced by the Ran GTPase activating protein RANGAP1. May act in an intracellu lar 
signalling pathway which may control the progression through the cell cycle by regulating the 
transport of protein and nucleic acids across the nuclear membrane. 
63 Proliferating PCNA  502 4.57 28.7503 Auxiliary p rotein of DNA polymerase delta and is involved in the control of eukaryotic DNA 
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cell nuclear 
antigen 
replicat ion by increasing the polymerase's processibility during elongation of the leading strand. 
Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not 
apurinic-apyrimidinic (AP) endonuclease, APEX2 act ivities. Has to be loaded onto DNA in order 
to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being 
conveniently positioned at the replication fork to coordinate DNA replication with DNA repair 
and DNA damage tolerance pathways. Acts as a loading platform to recru it DDR proteins that 
allow complet ion of DNA rep licat ion after DNA damage and promote postreplication repair: 
Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys -63'-
linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination 
mechanis ms to synthesize across the lesion. 
58 Annexin A3  ANXA3 424 5.63 36.3527 
Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic 
bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate. A pair of annexin repeats may 
form one binding site for calcium and phospholipid.  
60 
Small 
glutamine-rich 
tetratricopeptid
e repeat-
containing 
protein alpha 
SGTA  66 4.81 44.0791 Co-chaperone that binds directly to HSC70 and HSP70 and regulates their ATPase activity.  
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13 
Elongation 
factor Tu, 
mitochondrial  
EFTU 317 7.26 49.5102 
This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes 
during protein biosynthesis. Defects in TUFM are the cause of combined oxidative 
phosphorylation deficiency type 4 (COXPD4) [MIM:610678]. COXPD4 is characterized by 
neonatal lactic acidosis, rapidly  progressive encephalopathy, severely decreased mitochondrial 
protein synthesis, and combined deficiency of mtDNA-related mitochondrial respiratory chain 
complexes. 
62 
Actin, 
cytoplas mic 2 
ACTG 886 5.31 41.7658 
Actins are highly conserved proteins that are involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells. Defects in ACTG1 are the cause of deafness 
autosomal dominant type 20 (DFNA20). DFNA20 is a form of sensorineural hearing loss. 
Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve 
pathways to the brain, or the area of the brain that receives sound informat ion. DFNA20 is a form 
of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors 
of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound 
informat ion. efects in ACTG1 are the cause of Baraitser-Winter syndrome type 2. A rare 
developmental disorder characterized by the combination of congenital ptosis, high-arched 
eyebrows, hypertelorism, ocular co lobomata, and a brain malformation consisting of anterior-
predominant lissencephaly. Other typical features include postnatal short s tature and 
microcephaly, intellectual disability, seizures, and hearing loss. 
65 Calreticulin CALR 477 4.29 48.1118 Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the 
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endoplasmic ret iculum (ER) v ia the calreticulin/calnexin cycle. This lectin interacts transiently 
with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts 
with the DNA-binding domain o f NR3C1 and mediates its nuclear export. Involved in maternal 
gene expression regulation. May participate in oocyte maturation via the regulation of calcium 
homeostasis. 
66 
Protein 
disulfide-
isomerase A3  
PDIA3 557 5.98 56.7468 
Catalyzes the rearrangement of -S-S- bonds in proteins. Subunit of the TAP complex, also known 
as the peptide loading complex (PLC). Can form d isulphide-linked heterodimers with TAPBP. 
Interacts with ERP27 and CANX. 
67 
Bifunctional 
purine 
biosynthesis 
protein PURH 
PUR9 247 6.27 64.5753 Bifunctional enzyme that catalyses 2 steps in purine biosynthesis 
5 
Stress-induced-
phosphoprotein 
1 
STIP1 240 6.4 62.5994 Mediates the association of the molecu lar chaperones HSC70 and HSP90 (HSPCA and HSPCB).  
7 
Stress-70 
protein, 
mitochondrial  
GRP75 931 5.87 73.6348 
Implicated in the control of cell proliferation and cellular aging. May also act as a chaperone. 
Interacts with FXN. Interacts with HSCB. Component of the MINOS/MitOS complex that 
includes IMMT, HSPA9 and CHCHD3 and associates with mitochondrial outer membrane 
proteins SAMM50, MTX1 and MTX2. 
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71 
Stress-70 
protein, 
mitochondrial  
GRP75 876 5.87 73.6348 
Implicated in the control of cell proliferation and cellular aging. May also act as a chaperone. 
Interacts with FXN. Interacts with HSCB. Component of the MINOS/MitOS complex that 
includes IMMT, HSPA9 and CHCHD3 and associates with mitochondrial outer membrane 
proteins SAMM50, MTX1 and MTX2. 
73 Ezrin EZRI 734 5.94 69.3697 
Probably involved in connections of major cytoskeletal structures to the plasma membrane. In 
epithelial cells, required for the format ion of microvilli and membrane ruffles on the apical pole. 
Along with PLEKHG6, required for normal macropinocytosis. Phosphorylated by tyrosine-
protein kinases. Phosphorylation by ROCK2 suppresses the head-to-tail association of the N-
terminal and C-terminal halves resulting in an opened conformation which is capable of act in and 
membrane-binding. 
8 
Heat shock 70 
kDa protein 
1A/1B 
HSP71 1020 5.48 70.009 
In cooperation with other chaperones, Hsp70s stabilize pre -existent proteins against aggregation 
and mediate the fo lding of newly translated polypeptides in the cytosol as well as with in 
organelles. These chaperones participate in all these processes through their ability to recognize 
nonnative conformations of other proteins. They bind extended peptide segments with a net 
hydrophobic character exposed by polypeptides during translation and membrane translocation, or 
following stress-induced damage. In case of rotavirus A infection, serves as a post-attachment 
receptor for the virus to facilitate entry into the cell.  Component of the CatSper complex. 
Identified in a mRNP granule complex, at least composed of ACTB, ACTN4, DHX9, ERG, 
HNRNPA1, HNRNPA2B1, HNRNPAB, HNRNPD, HNRNPL, HNRNPR, HNRNPU, HSPA1, 
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HSPA8, IGF2BP1, ILF2, ILF3, NCBP1, NCL, PABPC1, PABPC4, PABPN1, RPLP0, RPS3, 
RPS3A, RPS4X, RPS8, RPS9, SYNCRIP, TROVE2, YBX1 and untranslated mRNAs. Interacts 
with TSC2. Interacts with IRAK1BP1. Interacts with TERT; the interaction occurs in the absence 
of the RNA component, TERC, and dissociates once the TERT complex has formed. Interacts 
with DNAJC7. Interacts with CHCHD3. 
74 
Heat shock 
protein HSP 90-
beta 
HS90B 1470 4.97 83.2121 
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation 
of specific target proteins involved for instance in cell cycle control and signal transduction. 
Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces 
conformat ional changes in the client proteins, thereby causing their activation. Interacts 
dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and 
chaperone function. Homodime r. Interacts with p53/TP53. Forms a complex with CDK6 and 
Hsp90/HSP90AB1. Interacts with UNC45A. Binding to UNC45A involves 2 UNC45A monomers 
per HSP90AB1 dimer. Interacts with CHORDC1 and DNAJC7. Interacts with FKBP4.  
 
ahttp://www.uniprot.org/ 
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 
Final Conclusions 
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This Thesis gathered different points of view regarding the development of smart 
nanosystems to use in both diagnostics and therapy. Throughout this work, we diversified our 
objects of study from simple ssDNA-gold nanoparticles to complex and multifunctional gold 
nanoparticles functionalized with several types of biomolecules, which were tested in both in 
vitro and in vivo models. 
 
All of this came together and allowed us to achieve the following:  
 
i) Establishment of a detection and quantification method of the BCR-ABL gene 
fusion using thiol-modified ssDNA gold nanoparticles;  
 
Here (Article A), we demonstrated the potential of an Au-nanoprobe based assay for the 
specific identification and quantification of aberrant expression of genes involved in cancer 
development. As far as we know, the potential for quantification of mRNA directly from total 
RNA extraction without retro-transcription or amplification was demonstrated here for the 
first time. The assay has a total work-up time of less than 45 minutes with comparable 
sensitivity settled to those demonstrated by traditional molecular biology methodologies. Our 
results show that the technique is quite robust for monitoring gene expression levels. This Au-
nanoprobe strategy allows for detection of less than 100 fmol.μl
-1
 of specific target, with the 
possibility of discriminating between a positive and negative sample from as little as  
10 ng.μl
-1
 of total RNA.  
 
ii) Development of gold-silver alloy nanoparticles for multicolour Cancer 
diagnostics, by simultaneous identified several different mRNA targets using 
colour multiplexing; 
 
Here (Articles B and C), we have demonstrated the functionalization of AuAg-alloy-NPs 
with ssDNA and the use of the resulting alloy nanoprobes for the specific detection of a target 
of interest. The attained AuAg-alloy-nanoprobes show a combination of the optical properties 
of Ag nanoparticles (high extinction coefficient) with the ease of functionalization via a thiol 
bond provided by the gold. Similarly to what is observed for Au-nanoprobes alone, these 
alloy nanoprobes are sensitive to variations in the quantity of target in solution and can, thus, 
be used for quantification assays. AuAg-alloy-nanoprobes with 25% gold and 75% silver 
were successfully synthesized and functionalized to produce nanoprobes that exhibit an SPR 
peak away from that of the Au-nanoprobes. This way, it is possible to better discriminate the 
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aggregation profiles of both types of nanoprobes once they are used in a one-pot assay. Based 
on the combination of AuAg-alloy- and Au-nanoprobes, it was possible to develop a 
differential gene expression assay using the BCR-ABL fusion product involved in chronic 
myeloid leukemia as a model. We further demonstrated that this dual-colour nanoparticle 
approach can be used as sensitive, selective, one-pot multicolour method for the simultaneous 
quantification of multiple RNA targets in a single reaction. The simultaneous differential 
quantification of two (or more) sequences is of utmost importance when performing genome 
based screening, where there is a mandatory need to assess whether a given transcript is 
present in a homo- or heterozygous form. This approach should be easily extendable to 
additional colours using the remarkable optical properties of nanoparticles of different sizes 
and compositions, i.e. different Au:Ag ratios, other metals may provide a multicolour 
homogenous system for application in array strategies and to rival fluorescence based assays. 
 
iii) Clarify the role of ssDNA gold nanoparticles in in vitro Transcription and 
Translation Inhibition;  
 
Here (Article D), we show that gold nanoparticles functionalized with promoter specific 
oligonucleotides strongly disrupts transcription even after extensive nuclease digestion, 
indicating the proficiency of these AuNP-DNA conjugates for application as gene silencing 
vectors. We also demonstrate that enhanced specific in vitro translation inhibition is achieved 
by means of the antisense oligonucleotides on AuNP surface. These AuNP-DNA conjugates 
seem to profit from the synergy between the specific sequence jamming and the steric 
hindrance provided by the AuNPs. 
The described experimental setup can provide researchers with a simple yet robust means to 
assess the gene silencing potential of nanoparticle-DNA conjugates being developed for gene 
expression silencing purposes. These results show that a dual targeting approach for gene 
silencing could be explored - blocking transcription and translation, which can be achieved 
via combination of different oligonucleotide sequences on one or more nanoparticle vector. 
Our experimental results show that we can create a two-way inhibition system using modified 
Au-nanoprobes to specifically block the in vitro transcription by binding the RNA polymerase 
promoter and the in vitro translation by suppressing the ribosome binding site.  
Our results also demonstrate the greatly enhanced stability to nuclease attack of single 
stranded oligonucleotides functionalized at the surface of gold nanoparticles by the recovery 
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of DNA transcription. Surprisingly, the Au- nanoprobe show practically complete protection 
against nuclease-mediated degradation. 
 
iv) Optimization and establishment of efficient methods to functionalized gold 
nanoparticles with several biomolecules like polymers, peptides/proteins and 
DNA/RNA;  
 
v) Study the effect of polymer biofunctional spacers and peptides on dsRNA 
loading on gold nanoparticles;  
 
In this work (Article E), an approach to bind specific biomolecules to the surface of AuNPs 
and study the effects in the combined functionalization was developed. The effect of thiolated 
PEG (PEG) spacers carrying different functional groups (carboxyl and azide) and the 
positively charged TAT peptide, functionalized by EDC reactions, on the dsRNA loading into 
the surface of AuNPs was studied. We demonstrated that there is a synergetic effect of the 
TAT peptide and the azide-containing PEG chain on the enhancement of the dsRNA loading 
into AuNPs. It was found that the loading of the oligonucleotide on the AuNP surface is 
controlled by the presence of ionic interactions between the negatively charged 
oligonucleotides and the positively charged molecules on the nanoparticles, such as the TAT 
peptide and the polarized azide group on one of the PEG chains. It was also demonstrated that 
weak interactions, e.g. hydrogen bounds, between PEG chains spacers and dsRNA enhance 
the loading of the dsRNA onto the AuNPs by steering its entry through the PEG layer. 
 
vi) Demonstrate the implication in DNA Topology by histone-mimetic gold 
nanoparticles;  
 
Here (Article F), we successfully report the use of gold nanoparticles functionalized with 
PEG-carboxylated and protamine to modify plasmid DNA topology. We demonstrated that 
AuNP@PEG@Protamine play an active role in controlling plasmid DNA structure, topology 
and levels of condensation and decondensation. Conversely to what occurs when using free 
protamine, AuNP@PEG@Prot may allow to control the levels of condensation and 
decondensation of DNA molecules in a stable and organized manner. By means of the 
theoretical equation, it is possible to exert control over the amount of each plasmid DNA 
conformation by constraining the initial conditions and the incubation time of AuNPs with 
plasmid DNA. Besides, although the functionalized AuNPs nanoparticles show an opposite 
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effect on DNA structure, plasmid DNA conformations could be selectively extracted to shift 
the equilibrium of the reaction towards the desired conformation. 
We hypothesize that the effect of AuNP@PEG@Prot on plasmid DNA conformations 
probably mimics the interactions between AuNPs and DNA double helix in sperm chromatin. 
This hypothesis is supported by the fact that protamine proteins play an important role in 
condensation and stabilization of spermatic nuclear chromatin and that when combined with 
AuNPs of this particular size they may locate within the wide groove of DNA molecule, thus 
disturbing the structure of liquid crystals of DNA, changing its topology. Although plasmid 
DNA is different from genomic and sperm DNA, it can be used as a valuable model to study 
DNA topology. This study may constitute a good model study and to evaluate application of 
histone-mimetic gold nanoparticles  AuNP@PEG@Prot. If proven effective in cell models 
and on genomic DNA. Such a system may be considered for therapy and/or infertility 
procedures, for example in protamine-deficient sperm individuals. For this, further studies of 
in vitro experiments with intact nuclear membrane and nuclear core complexes, and with a 
relevant in vivo model of spermatogenesis will be needed to support this hypothesis. 
 
vii) Design smart multifunctional gold nanoparticles for in vitro and in vivo gene 
silencing;  
 
In this study (Article G), we show that two balanced formulations (ionic and covalent 
approaches), in terms of stability/electrostatic interactions, designed to produce smart 
multifunctional nanostructures succeeded to generate new innovative and versatile tools for 
efficient RNA interference in eukaryotic systems. Using three biological models of increasing 
complexity (cultured cells, HeLa; invertebrate, Hydra; and mammal, mice), both design and 
validation of multifunctional nanocarrier capable of selectively and specifically delivering 
siRNA in vivo were demonstrated. This functional screening approach allowed to finely tune 
concentrations, bonding and the combination of different chemical groups on the nanoparticle 
surface, addressing current ethical issues on unnecessary, cost-effective and time consuming 
vertebrate testing. These multifunctional nanocarriers are robust enough to preserve stability 
without showing acute toxicity or cell viability impairment, while simultaneously able to 
bypass biological barriers to perform RNAi activity without off-target effects. Our universal 
nanocarrier represents a valid gene delivery platform that can be exploited for clinical 
application in the near future.  
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viii) Development of a tumour targeting system using a nanoparticle-mediated 
therapeutic siRNA coupled to inflammatory response in lung cancer mouse 
models;  
 
Here (Article H), we have developed a novel delivery systems that could achieve 
translocation of siRNA duplexes directly into the tumour cell cytoplasm and accomplish 
successful silencing of an oncogene expression. Our finding pave the way for new concepts, 
that gene therapy can offer to clinical cancer therapeutics. We successfully engineered fine-
tuned RGD/siRNA-AuNPs capable to deliver siRNA into lung tumour cells and effectively to 
silence c-Myc proto-oncogene without side effects or toxicity. These novel AuNPs based 
carriers can both effectively enhance nanoparticle delivery efficiency and regulate gene 
expression in the context of RNA interference. Actually, RGD/siRNA-AuNPs can target 
preferentially and be taken up by tumour cells via integrin αvβ3-receptor-mediated 
endocytosis with no cytotoxicity, showing that can accumulate in tumour tissues 
overexpressing αvβ3 integrins and selectively delivered c-myc siRNA to suppress tumour 
growth and angiogenesis. 
We propose that gene delivery based on selective expression of αvβ3 integrin in the tumour 
vasculature by using RGD/siRNA-AuNPs, might become applicable to lung cancer gene 
therapy. The work reported here, demonstrates the in vivo gene silencing and tumour 
regression by RGD/siRNA-AuNPs in two lung cancer mice models. This finding suggests 
that it is possible to use RGD/siRNA-AuNPs as a therapeutic agent for lung cancer and opens 
a new translational avenue to novel treatments of many diseases driven by deregulation of  
c-Myc gene expression. 
 
ix) Propose an efficient nanotheranostic system – gold nanobeacons – for Real-
Time Monitoring of RNA synthesis and for simultaneous gene specific 
silencing and intracellular tracking of the silencing events. 
 
In this study (Articles I, J, K) we demonstrate the use of gold nanobeacons  
(Au-nanobeacons) capable of recognizing specific complementary sequences that can be 
easily synthesized by functionalization of gold nanoparticles with thiolated DNA hairpin 
oligonucleotides. Following Au-nanobeacons calibration, we used them to quantitatively 
monitor RNA synthesis in real-time and for kinetic quantification of RNA transcript 
synthesized by a RNA polymerase. We also demonstrate that by combining the use of a 
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reporter and an inhibitor Au-nanobeacon, we were able to create a dual colour system capable 
of quantify transcription and the level of inhibition in a single reaction vial. It is possible to 
quantify the level of inhibition of the RNA synthesis and relate it to the amount of template 
being effectively silenced, i.e. assessing actual silencing capability.  
The proposed Au-nanobeacon biosensor allows for fast, accurate and sensitive RNA transcript 
expression profiling. A unique feature of this sensor, compared to conventional measurements 
of polymerase activities using intercalating dyes, is that the probes do not generate a signal 
from unrelated nucleic acids and polymerase activities can be distinguished from promoter-
specific RNA polymerization. The simplicity and speed of the sensor are also great 
advantages. 
Besides this, we also show that Au-nanobeacons are a new and versatile concept for genes 
specific silencing while simultaneously allowing for intra-cellular tracking of the silencing 
events. A significant attribute of these Au-nanobeacons is the ability to inhibit the endogenous 
and exogenous silencers with noticeably small amounts of effector molecule and without 
chemical co-transfectants. Our approach, combining a fluorescence nanobeacon with 
silencing capability is simple, inexpensive and straightforward as adjustment to any specific 
target, be it a specific mRNA or an endogenous or exogenous silencing nucleic acid, can be 
easily made. We demonstrate such potential by specifically silencing the expression of EGFP 
and overturning the knockdown effect of silencers after a first wave of silencing/delivery. 
Simultaneous studies of distinct cell populations should be feasible using multicolour 
labelling. Because the simple beacon-based scaffold of the Au-nanobeacons, our concept can 
be easily directed to any desired target without observable cytotoxicity, opening an important 
route towards tuned packaging and cargo delivery systems. 
Finally, the possibility of silencing the silencers and of discriminating specific cells, where 
silencing is occurring, offers future prospects for studying and modulating cellular 
mechanisms involved in cancer. Combination of gold nanobeacons with other chemical 
functionalizations, e.g. targeting moieties, may enhance the therapeutic potential of our 
concept. 
Moreover, an assessment of genome-related toxicity revealed no significant DNA damage 
increase, as well as no potential mutagenic or clastogenic consequences to the cell. 
Proteomics appears to be a relevant approach for mechanistic studies of cellular responses to 
Au-nanobeacons. The proteome profiling, as presented here, represents a useful tool for 
systematic analysis of toxicity of nanoconjugates, not only at the molecular level but also for 
the discovery of biomarkers and pathways towards the understanding of the mechanisms of 
361
toxicity. It must be emphasised that such mechanistic studies must be ultimately verified on 
relevant in vivo models. Identification of response pathways to AuNP internalisation may 
assist in gathering relevant information on acute toxicity so as to optimise systems for 
translation to in vivo models, and eventually to clinical applications. 
 
The studies presented here pave the way for novel approaches to better understand the 
mechanisms of interaction between multifunctional gold nanoparticles and targets 
(DNA/RNA), cells and tissues in vitro and in vivo biomedical applications.   
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